Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11678955,Peak concentrations,Peak concentrations for i.v. ganciclovir averaged 8.39+/-1.87 microg/mL with minimum concentrations of 0.48+/-0.35 microg/mL.,Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678955/),[μg] / [ml],8.39,407,DB02377,Guanine
,11678955,minimum concentrations,Peak concentrations for i.v. ganciclovir averaged 8.39+/-1.87 microg/mL with minimum concentrations of 0.48+/-0.35 microg/mL.,Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678955/),[μg] / [ml],0.48,408,DB02377,Guanine
,11678955,max,"Plasma concentrations were lower but more sustained during a p.o. dosing interval (max=2.12+/-0.58 microg/mL, min=1.15+/-0.34 microg/mL).",Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678955/),[μg] / [ml],2.12,409,DB02377,Guanine
,11678955,min,"Plasma concentrations were lower but more sustained during a p.o. dosing interval (max=2.12+/-0.58 microg/mL, min=1.15+/-0.34 microg/mL).",Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678955/),[μg] / [ml],1.15,410,DB02377,Guanine
,11678955,concentrations,"Average concentrations (i.v. versus p.o. study period) for TNF-alpha were 40.1+/-17.5 versus 22.1+/-11.2 pg/mL, for IL-8 were 17.1+/-15.6 versus 4.12+/-2.59 pg/mL, and for IL-10 were 7.39+/-5.54 versus 2.64+/-1.06 pg/mL.",Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678955/),[pg] / [ml],40,411,DB02377,Guanine
,11678955,concentrations,"Average concentrations (i.v. versus p.o. study period) for TNF-alpha were 40.1+/-17.5 versus 22.1+/-11.2 pg/mL, for IL-8 were 17.1+/-15.6 versus 4.12+/-2.59 pg/mL, and for IL-10 were 7.39+/-5.54 versus 2.64+/-1.06 pg/mL.",Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678955/),[pg] / [ml],22.1,412,DB02377,Guanine
,11678955,concentrations,"Average concentrations (i.v. versus p.o. study period) for TNF-alpha were 40.1+/-17.5 versus 22.1+/-11.2 pg/mL, for IL-8 were 17.1+/-15.6 versus 4.12+/-2.59 pg/mL, and for IL-10 were 7.39+/-5.54 versus 2.64+/-1.06 pg/mL.",Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678955/),[pg] / [ml],17.1,413,DB02377,Guanine
,11678955,concentrations,"Average concentrations (i.v. versus p.o. study period) for TNF-alpha were 40.1+/-17.5 versus 22.1+/-11.2 pg/mL, for IL-8 were 17.1+/-15.6 versus 4.12+/-2.59 pg/mL, and for IL-10 were 7.39+/-5.54 versus 2.64+/-1.06 pg/mL.",Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678955/),[pg] / [ml],4.12,414,DB02377,Guanine
,11678955,concentrations,"Average concentrations (i.v. versus p.o. study period) for TNF-alpha were 40.1+/-17.5 versus 22.1+/-11.2 pg/mL, for IL-8 were 17.1+/-15.6 versus 4.12+/-2.59 pg/mL, and for IL-10 were 7.39+/-5.54 versus 2.64+/-1.06 pg/mL.",Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678955/),[pg] / [ml],7.39,415,DB02377,Guanine
,11678955,concentrations,"Average concentrations (i.v. versus p.o. study period) for TNF-alpha were 40.1+/-17.5 versus 22.1+/-11.2 pg/mL, for IL-8 were 17.1+/-15.6 versus 4.12+/-2.59 pg/mL, and for IL-10 were 7.39+/-5.54 versus 2.64+/-1.06 pg/mL.",Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678955/),[pg] / [ml],2.64,416,DB02377,Guanine
,11678955,Concentrations,Concentrations were similar for IL-6 during both studies (9.39+/-5.42 versus 14.7+/-14.8 pg/mL).,Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678955/),[pg] / [ml],9.39,417,DB02377,Guanine
,11678955,Concentrations,Concentrations were similar for IL-6 during both studies (9.39+/-5.42 versus 14.7+/-14.8 pg/mL).,Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678955/),[pg] / [ml],14.7,418,DB02377,Guanine
,11076113,percentage,"The percentage acyclovir extraction was 84% and 60% during CVVHD and CVVHDF with F-8 and CA-210 dialyzers, respectively.",Removal of acyclovir during continuous veno-venous hemodialysis and hemodiafiltration with high-efficiency membranes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076113/),%,84,765,DB02377,Guanine
,11076113,percentage,"The percentage acyclovir extraction was 84% and 60% during CVVHD and CVVHDF with F-8 and CA-210 dialyzers, respectively.",Removal of acyclovir during continuous veno-venous hemodialysis and hemodiafiltration with high-efficiency membranes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076113/),%,60,766,DB02377,Guanine
,11076113,clearance,"Acyclovir clearance during CVVHD was 14 ml/min and during CVVHDF was 17 ml/min, with F-8 and CA-210 dialyzers, respectively.",Removal of acyclovir during continuous veno-venous hemodialysis and hemodiafiltration with high-efficiency membranes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076113/),[ml] / [min],14,767,DB02377,Guanine
,11076113,clearance,"Acyclovir clearance during CVVHD was 14 ml/min and during CVVHDF was 17 ml/min, with F-8 and CA-210 dialyzers, respectively.",Removal of acyclovir during continuous veno-venous hemodialysis and hemodiafiltration with high-efficiency membranes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076113/),[ml] / [min],17,768,DB02377,Guanine
,11076113,half-life,"Acyclovir half-life was 22.5 and 25.5 hours in 2 occasions off any type of renal replacement therapy, and it was 19.5 hours during CVVHDF with CA-210 dialyzer.",Removal of acyclovir during continuous veno-venous hemodialysis and hemodiafiltration with high-efficiency membranes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076113/),h,22.5,769,DB02377,Guanine
,11076113,half-life,"Acyclovir half-life was 22.5 and 25.5 hours in 2 occasions off any type of renal replacement therapy, and it was 19.5 hours during CVVHDF with CA-210 dialyzer.",Removal of acyclovir during continuous veno-venous hemodialysis and hemodiafiltration with high-efficiency membranes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076113/),h,25.5,770,DB02377,Guanine
,11076113,half-life,"Acyclovir half-life was 22.5 and 25.5 hours in 2 occasions off any type of renal replacement therapy, and it was 19.5 hours during CVVHDF with CA-210 dialyzer.",Removal of acyclovir during continuous veno-venous hemodialysis and hemodiafiltration with high-efficiency membranes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076113/),h,19.5,771,DB02377,Guanine
,10430061,time to maximum plasma concentration (Tmax),Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2).,A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430061/),h,1.1,2959,DB02377,Guanine
,10430061,time to maximum plasma concentration (Tmax),Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2).,A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430061/),h,1.7,2960,DB02377,Guanine
,10430061,elimination half-life (t1/2),Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2).,A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430061/),h,1.74,2961,DB02377,Guanine
,10430061,elimination half-life (t1/2),Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2).,A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430061/),h,2.35,2962,DB02377,Guanine
,10430061,clearance (Cl(s)/F),Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2).,A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430061/),[ml] / [m2·min],115,2963,DB02377,Guanine
,10430061,clearance (Cl(s)/F),Pharmacokinetic studies of TMZ revealed the following pertinent parameters (mean +/- SD): time to maximum plasma concentration (Tmax) = 1.1+/-0.6 h (day 1) and 1.7+/-0.9 h (day 2); elimination half-life (t1/2) = 1.74+/-0.22 h (day 1) and 2.35+/-0.70 h (day 2); and clearance (Cl(s)/F) = 115+/-27 ml/min/m2 (day 1) and 141+/-109 ml/min/m2 (day 2).,A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430061/),[ml] / [m2·min],141,2964,DB02377,Guanine
,3674844,absorption,"The absorption of DCV was at least 75%, and almost two-thirds of the administered oral dose was recovered in the urine as ACV.","Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674844/),%,75,3568,DB02377,Guanine
,3674844,Peak ACV levels,Peak ACV levels in plasma were about 5 micrograms/ml and were reached in less than 1 h.,"Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674844/),[μg] / [ml],5,3569,DB02377,Guanine
,3674844,half-life,"The half-life of DCV was 0.85 +/- 0.16 h, compared with 2.6 +/- 0.5 h for ACV, indicating rapid conversion of DCV to ACV.","Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674844/),h,0.85,3570,DB02377,Guanine
,3674844,half-life,"The half-life of DCV was 0.85 +/- 0.16 h, compared with 2.6 +/- 0.5 h for ACV, indicating rapid conversion of DCV to ACV.","Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674844/),h,2.6,3571,DB02377,Guanine
,7102710,Binding,Binding of acyclovir to plasma proteins was 36 percent or lower.,Species differences in the disposition of acyclovir. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102710/),%,36,4843,DB02377,Guanine
,7102710,half-life in the elimination phase,"After intravenous bolus dosing (20 mg/kg) in dogs, the plasma acyclovir concentration-time profile, determined by radioimmunoassay, showed a biphasic decline with a half-life in the elimination phase of 2.3 +/- 0.1 hours.",Species differences in the disposition of acyclovir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102710/),h,2.3,4844,DB02377,Guanine
,7102710,volume of distribution (Vd beta),The volume of distribution (Vd beta) of 1.2 +/- 0.2 liters/kg indicated distribution of drug into the tissues.,Species differences in the disposition of acyclovir. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102710/),[l] / [kg],1.2,4845,DB02377,Guanine
,12760851,50% effective concentration,"In vitro, the compound was more potent than ACV against wild-type clinical and laboratory HSV-1 strains and ACV(r) HSV isolates, as determined by a standard plaque reduction assay, with a mean 50% effective concentration of about 0.15 microM.",Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12760851/),μM,0.15,5296,DB02377,Guanine
,12760851,oral bioavailability,"The oral bioavailability of BILS 45 BS in hairless mice was 49%, with a peak concentration in plasma of 31.5 microM after administration of a single dose of 25 mg/kg.",Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12760851/),%,49,5297,DB02377,Guanine
,12760851,peak concentration,"The oral bioavailability of BILS 45 BS in hairless mice was 49%, with a peak concentration in plasma of 31.5 microM after administration of a single dose of 25 mg/kg.",Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12760851/),μM,31.5,5298,DB02377,Guanine
,12760851,50% effective doses,"The 50% effective doses of BILS 45 BS were 56.7 and 61 mg/kg/day against dlsptk- and PAA(r)5-induced infections, respectively.",Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12760851/),[mg] / [d·kg],56.7,5299,DB02377,Guanine
,12760851,50% effective doses,"The 50% effective doses of BILS 45 BS were 56.7 and 61 mg/kg/day against dlsptk- and PAA(r)5-induced infections, respectively.",Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12760851/),[mg] / [d·kg],61,5300,DB02377,Guanine
,34391852,zeta potential,"The optimal formulation (UFGs 6; composed of 600 mg Phosphatidylcholine (PC), 20 mg cholesterol, 0.1:1 weight molar ratio of EA: PC and 1 gm glycerol) possessed nanovesicles (441.70 ± 1.13 nm) that entrapped 69.33 ± 0.28 % of GCV, with zeta potential value of -37.00 ± 0.42 mV and deformability index value of 74.68 ± 0.71.",3D printed ocusert laden with ultra-fluidic glycerosomes of ganciclovir for the management of ocular cytomegalovirus retinitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34391852/),mv,-,6612,DB02377,Guanine
,34391852,zeta potential,"The optimal formulation (UFGs 6; composed of 600 mg Phosphatidylcholine (PC), 20 mg cholesterol, 0.1:1 weight molar ratio of EA: PC and 1 gm glycerol) possessed nanovesicles (441.70 ± 1.13 nm) that entrapped 69.33 ± 0.28 % of GCV, with zeta potential value of -37.00 ± 0.42 mV and deformability index value of 74.68 ± 0.71.",3D printed ocusert laden with ultra-fluidic glycerosomes of ganciclovir for the management of ocular cytomegalovirus retinitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34391852/),mv,37.00,6613,DB02377,Guanine
,34391852,deformability index,"The optimal formulation (UFGs 6; composed of 600 mg Phosphatidylcholine (PC), 20 mg cholesterol, 0.1:1 weight molar ratio of EA: PC and 1 gm glycerol) possessed nanovesicles (441.70 ± 1.13 nm) that entrapped 69.33 ± 0.28 % of GCV, with zeta potential value of -37.00 ± 0.42 mV and deformability index value of 74.68 ± 0.71.",3D printed ocusert laden with ultra-fluidic glycerosomes of ganciclovir for the management of ocular cytomegalovirus retinitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34391852/),,74.68,6614,DB02377,Guanine
,10694549,half-life (t1/2),"The harmonic mean half-life (t1/2) of nelarabine in pediatric and adult patients was 14.1 minutes and 16.5 minutes, respectively.",Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10694549/),min,14.1,7195,DB02377,Guanine
,10694549,half-life (t1/2),"The harmonic mean half-life (t1/2) of nelarabine in pediatric and adult patients was 14.1 minutes and 16.5 minutes, respectively.",Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10694549/),min,16.5,7196,DB02377,Guanine
,10694549,C(max),The C(max) of ara-G ranged from 11.6 micromol/L to 308.7 micromol/L at nelarabine doses of 5 to 75 mg/kg and was linearly related to the nelarabine dose.,Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10694549/),[μM] / [l],11.6,7197,DB02377,Guanine
,10694549,C(max),The C(max) of ara-G ranged from 11.6 micromol/L to 308.7 micromol/L at nelarabine doses of 5 to 75 mg/kg and was linearly related to the nelarabine dose.,Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10694549/),[μM] / [l],308.7,7198,DB02377,Guanine
,10694549,clearance,"However, the clearance of ara-G was higher in pediatric patients (0.312 L.h(-1).kg(-1)) as compared with adult patients (0. 213 L.h(-1).kg(-1)) (P <.001).",Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10694549/),[l] / [h·kg],0.312,7199,DB02377,Guanine
,10694549,clearance,"However, the clearance of ara-G was higher in pediatric patients (0.312 L.h(-1).kg(-1)) as compared with adult patients (0. 213 L.h(-1).kg(-1)) (P <.001).",Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10694549/),[l] / [h·kg],0. 213,7200,DB02377,Guanine
,10694549,t1/2,The t1/2 of ara-G was shorter in pediatric patients as compared with adult patients (2.1 hours v 3.0 hours; P <.01).,Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10694549/),h,2.1,7201,DB02377,Guanine
,10694549,t1/2,The t1/2 of ara-G was shorter in pediatric patients as compared with adult patients (2.1 hours v 3.0 hours; P <.01).,Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10694549/),h,3.0,7202,DB02377,Guanine
,12516939,maximum serum concentration (C(max)),"Valaciclovir pharmacokinetic parameters (mean +/- SD) in children who received tablets and suspension (normalised to 500 mg dose) were: maximum serum concentration (C(max)) 3.16 +/- 1.30 and 2.42 +/- 0.74 mg/L, time to maximum serum concentration (t(max)) 1.88 +/- 0.99 and 1.31 +/- 0.53 hours, half-life (t 1/2) 1.72 +/- 0.41 and 1.94 +/- 0.60 hours, apparent total systemic clearance (CL/F) 20.01 +/- 6.61 and 15.58 +/- 3.34 ml/min/kg, volume of distribution/bioavailability (Vd/F) 3.04 +/- 1.26 and 2.58 +/- 0.81 L/kg, and area under the concentration-time curve (AUC) 10.13 +/- 3.47 and 8.59 +/- 2.52 mg x h/L, respectively.",Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),[mg] / [l],3.16,7590,DB02377,Guanine
,12516939,maximum serum concentration (C(max)),"Valaciclovir pharmacokinetic parameters (mean +/- SD) in children who received tablets and suspension (normalised to 500 mg dose) were: maximum serum concentration (C(max)) 3.16 +/- 1.30 and 2.42 +/- 0.74 mg/L, time to maximum serum concentration (t(max)) 1.88 +/- 0.99 and 1.31 +/- 0.53 hours, half-life (t 1/2) 1.72 +/- 0.41 and 1.94 +/- 0.60 hours, apparent total systemic clearance (CL/F) 20.01 +/- 6.61 and 15.58 +/- 3.34 ml/min/kg, volume of distribution/bioavailability (Vd/F) 3.04 +/- 1.26 and 2.58 +/- 0.81 L/kg, and area under the concentration-time curve (AUC) 10.13 +/- 3.47 and 8.59 +/- 2.52 mg x h/L, respectively.",Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),[mg] / [l],2.42,7591,DB02377,Guanine
,12516939,time to maximum serum concentration (t(max)),"Valaciclovir pharmacokinetic parameters (mean +/- SD) in children who received tablets and suspension (normalised to 500 mg dose) were: maximum serum concentration (C(max)) 3.16 +/- 1.30 and 2.42 +/- 0.74 mg/L, time to maximum serum concentration (t(max)) 1.88 +/- 0.99 and 1.31 +/- 0.53 hours, half-life (t 1/2) 1.72 +/- 0.41 and 1.94 +/- 0.60 hours, apparent total systemic clearance (CL/F) 20.01 +/- 6.61 and 15.58 +/- 3.34 ml/min/kg, volume of distribution/bioavailability (Vd/F) 3.04 +/- 1.26 and 2.58 +/- 0.81 L/kg, and area under the concentration-time curve (AUC) 10.13 +/- 3.47 and 8.59 +/- 2.52 mg x h/L, respectively.",Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),h,1.88,7592,DB02377,Guanine
,12516939,time to maximum serum concentration (t(max)),"Valaciclovir pharmacokinetic parameters (mean +/- SD) in children who received tablets and suspension (normalised to 500 mg dose) were: maximum serum concentration (C(max)) 3.16 +/- 1.30 and 2.42 +/- 0.74 mg/L, time to maximum serum concentration (t(max)) 1.88 +/- 0.99 and 1.31 +/- 0.53 hours, half-life (t 1/2) 1.72 +/- 0.41 and 1.94 +/- 0.60 hours, apparent total systemic clearance (CL/F) 20.01 +/- 6.61 and 15.58 +/- 3.34 ml/min/kg, volume of distribution/bioavailability (Vd/F) 3.04 +/- 1.26 and 2.58 +/- 0.81 L/kg, and area under the concentration-time curve (AUC) 10.13 +/- 3.47 and 8.59 +/- 2.52 mg x h/L, respectively.",Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),h,1.31,7593,DB02377,Guanine
,12516939,half-life (t 1/2),"Valaciclovir pharmacokinetic parameters (mean +/- SD) in children who received tablets and suspension (normalised to 500 mg dose) were: maximum serum concentration (C(max)) 3.16 +/- 1.30 and 2.42 +/- 0.74 mg/L, time to maximum serum concentration (t(max)) 1.88 +/- 0.99 and 1.31 +/- 0.53 hours, half-life (t 1/2) 1.72 +/- 0.41 and 1.94 +/- 0.60 hours, apparent total systemic clearance (CL/F) 20.01 +/- 6.61 and 15.58 +/- 3.34 ml/min/kg, volume of distribution/bioavailability (Vd/F) 3.04 +/- 1.26 and 2.58 +/- 0.81 L/kg, and area under the concentration-time curve (AUC) 10.13 +/- 3.47 and 8.59 +/- 2.52 mg x h/L, respectively.",Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),h,1.72,7594,DB02377,Guanine
,12516939,half-life (t 1/2),"Valaciclovir pharmacokinetic parameters (mean +/- SD) in children who received tablets and suspension (normalised to 500 mg dose) were: maximum serum concentration (C(max)) 3.16 +/- 1.30 and 2.42 +/- 0.74 mg/L, time to maximum serum concentration (t(max)) 1.88 +/- 0.99 and 1.31 +/- 0.53 hours, half-life (t 1/2) 1.72 +/- 0.41 and 1.94 +/- 0.60 hours, apparent total systemic clearance (CL/F) 20.01 +/- 6.61 and 15.58 +/- 3.34 ml/min/kg, volume of distribution/bioavailability (Vd/F) 3.04 +/- 1.26 and 2.58 +/- 0.81 L/kg, and area under the concentration-time curve (AUC) 10.13 +/- 3.47 and 8.59 +/- 2.52 mg x h/L, respectively.",Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),h,1.94,7595,DB02377,Guanine
,12516939,apparent total systemic clearance (CL/F),"Valaciclovir pharmacokinetic parameters (mean +/- SD) in children who received tablets and suspension (normalised to 500 mg dose) were: maximum serum concentration (C(max)) 3.16 +/- 1.30 and 2.42 +/- 0.74 mg/L, time to maximum serum concentration (t(max)) 1.88 +/- 0.99 and 1.31 +/- 0.53 hours, half-life (t 1/2) 1.72 +/- 0.41 and 1.94 +/- 0.60 hours, apparent total systemic clearance (CL/F) 20.01 +/- 6.61 and 15.58 +/- 3.34 ml/min/kg, volume of distribution/bioavailability (Vd/F) 3.04 +/- 1.26 and 2.58 +/- 0.81 L/kg, and area under the concentration-time curve (AUC) 10.13 +/- 3.47 and 8.59 +/- 2.52 mg x h/L, respectively.",Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),[ml] / [kg·min],20.01,7596,DB02377,Guanine
,12516939,apparent total systemic clearance (CL/F),"Valaciclovir pharmacokinetic parameters (mean +/- SD) in children who received tablets and suspension (normalised to 500 mg dose) were: maximum serum concentration (C(max)) 3.16 +/- 1.30 and 2.42 +/- 0.74 mg/L, time to maximum serum concentration (t(max)) 1.88 +/- 0.99 and 1.31 +/- 0.53 hours, half-life (t 1/2) 1.72 +/- 0.41 and 1.94 +/- 0.60 hours, apparent total systemic clearance (CL/F) 20.01 +/- 6.61 and 15.58 +/- 3.34 ml/min/kg, volume of distribution/bioavailability (Vd/F) 3.04 +/- 1.26 and 2.58 +/- 0.81 L/kg, and area under the concentration-time curve (AUC) 10.13 +/- 3.47 and 8.59 +/- 2.52 mg x h/L, respectively.",Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),[ml] / [kg·min],15.58,7597,DB02377,Guanine
,12516939,volume of distribution/bioavailability (Vd/F),"Valaciclovir pharmacokinetic parameters (mean +/- SD) in children who received tablets and suspension (normalised to 500 mg dose) were: maximum serum concentration (C(max)) 3.16 +/- 1.30 and 2.42 +/- 0.74 mg/L, time to maximum serum concentration (t(max)) 1.88 +/- 0.99 and 1.31 +/- 0.53 hours, half-life (t 1/2) 1.72 +/- 0.41 and 1.94 +/- 0.60 hours, apparent total systemic clearance (CL/F) 20.01 +/- 6.61 and 15.58 +/- 3.34 ml/min/kg, volume of distribution/bioavailability (Vd/F) 3.04 +/- 1.26 and 2.58 +/- 0.81 L/kg, and area under the concentration-time curve (AUC) 10.13 +/- 3.47 and 8.59 +/- 2.52 mg x h/L, respectively.",Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),[l] / [kg],3.04,7598,DB02377,Guanine
,12516939,volume of distribution/bioavailability (Vd/F),"Valaciclovir pharmacokinetic parameters (mean +/- SD) in children who received tablets and suspension (normalised to 500 mg dose) were: maximum serum concentration (C(max)) 3.16 +/- 1.30 and 2.42 +/- 0.74 mg/L, time to maximum serum concentration (t(max)) 1.88 +/- 0.99 and 1.31 +/- 0.53 hours, half-life (t 1/2) 1.72 +/- 0.41 and 1.94 +/- 0.60 hours, apparent total systemic clearance (CL/F) 20.01 +/- 6.61 and 15.58 +/- 3.34 ml/min/kg, volume of distribution/bioavailability (Vd/F) 3.04 +/- 1.26 and 2.58 +/- 0.81 L/kg, and area under the concentration-time curve (AUC) 10.13 +/- 3.47 and 8.59 +/- 2.52 mg x h/L, respectively.",Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),[l] / [kg],2.58,7599,DB02377,Guanine
,12516939,area under the concentration-time curve (AUC),"Valaciclovir pharmacokinetic parameters (mean +/- SD) in children who received tablets and suspension (normalised to 500 mg dose) were: maximum serum concentration (C(max)) 3.16 +/- 1.30 and 2.42 +/- 0.74 mg/L, time to maximum serum concentration (t(max)) 1.88 +/- 0.99 and 1.31 +/- 0.53 hours, half-life (t 1/2) 1.72 +/- 0.41 and 1.94 +/- 0.60 hours, apparent total systemic clearance (CL/F) 20.01 +/- 6.61 and 15.58 +/- 3.34 ml/min/kg, volume of distribution/bioavailability (Vd/F) 3.04 +/- 1.26 and 2.58 +/- 0.81 L/kg, and area under the concentration-time curve (AUC) 10.13 +/- 3.47 and 8.59 +/- 2.52 mg x h/L, respectively.",Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),[h·mg] / [l],10.13,7600,DB02377,Guanine
,12516939,area under the concentration-time curve (AUC),"Valaciclovir pharmacokinetic parameters (mean +/- SD) in children who received tablets and suspension (normalised to 500 mg dose) were: maximum serum concentration (C(max)) 3.16 +/- 1.30 and 2.42 +/- 0.74 mg/L, time to maximum serum concentration (t(max)) 1.88 +/- 0.99 and 1.31 +/- 0.53 hours, half-life (t 1/2) 1.72 +/- 0.41 and 1.94 +/- 0.60 hours, apparent total systemic clearance (CL/F) 20.01 +/- 6.61 and 15.58 +/- 3.34 ml/min/kg, volume of distribution/bioavailability (Vd/F) 3.04 +/- 1.26 and 2.58 +/- 0.81 L/kg, and area under the concentration-time curve (AUC) 10.13 +/- 3.47 and 8.59 +/- 2.52 mg x h/L, respectively.",Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),[h·mg] / [l],8.59,7601,DB02377,Guanine
,12516939,relative bioavailability,The relative bioavailability of the valaciclovir tablets compared with the suspension was 115 +/- 32%.,Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516939/),%,115,7602,DB02377,Guanine
,9110063,bioavailability,The bioavailability of oral ganciclovir averages 6-9%.,Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9110063/),%,6-9,8164,DB02377,Guanine
,16734094,Cmax,"The dosage of 20 mg/kg was associated with mean (+/- SD) Cmax of 0.19 +/- 0.10 microg/mL, and bioavailability was 2.8%.",Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16734094/),[μg] / [ml],0.19,8724,DB02377,Guanine
,16734094,bioavailability,"The dosage of 20 mg/kg was associated with mean (+/- SD) Cmax of 0.19 +/- 0.10 microg/mL, and bioavailability was 2.8%.",Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16734094/),%,2.8,8725,DB02377,Guanine
,31847670,Cmax,"Compared with the ETV-N group, the pharmacokinetic parameters of the EF-2 group did not change significantly, but that of the EF-0 group decreased in Cmax to 27.38 μg/L, in AUC0-t from 323.84 to 236.67 μg/h/L, and a delay in Tmax from 0.75 to 6.00 h; that of the EF-0 group presented a decrease in Cmax of 61.92%, delay in t1/2 of 2.45 h and delay in Tmax of 2.92 h.",Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847670/),[μg] / [l],27.38,9540,DB02377,Guanine
,31847670,AUC0-t,"Compared with the ETV-N group, the pharmacokinetic parameters of the EF-2 group did not change significantly, but that of the EF-0 group decreased in Cmax to 27.38 μg/L, in AUC0-t from 323.84 to 236.67 μg/h/L, and a delay in Tmax from 0.75 to 6.00 h; that of the EF-0 group presented a decrease in Cmax of 61.92%, delay in t1/2 of 2.45 h and delay in Tmax of 2.92 h.",Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847670/),[μg] / [h·l],323.84,9541,DB02377,Guanine
,31847670,AUC0-t,"Compared with the ETV-N group, the pharmacokinetic parameters of the EF-2 group did not change significantly, but that of the EF-0 group decreased in Cmax to 27.38 μg/L, in AUC0-t from 323.84 to 236.67 μg/h/L, and a delay in Tmax from 0.75 to 6.00 h; that of the EF-0 group presented a decrease in Cmax of 61.92%, delay in t1/2 of 2.45 h and delay in Tmax of 2.92 h.",Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847670/),[μg] / [h·l],236.67,9542,DB02377,Guanine
,31847670,Tmax,"Compared with the ETV-N group, the pharmacokinetic parameters of the EF-2 group did not change significantly, but that of the EF-0 group decreased in Cmax to 27.38 μg/L, in AUC0-t from 323.84 to 236.67 μg/h/L, and a delay in Tmax from 0.75 to 6.00 h; that of the EF-0 group presented a decrease in Cmax of 61.92%, delay in t1/2 of 2.45 h and delay in Tmax of 2.92 h.",Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847670/),h,0.75,9543,DB02377,Guanine
,31847670,Tmax,"Compared with the ETV-N group, the pharmacokinetic parameters of the EF-2 group did not change significantly, but that of the EF-0 group decreased in Cmax to 27.38 μg/L, in AUC0-t from 323.84 to 236.67 μg/h/L, and a delay in Tmax from 0.75 to 6.00 h; that of the EF-0 group presented a decrease in Cmax of 61.92%, delay in t1/2 of 2.45 h and delay in Tmax of 2.92 h.",Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847670/),h,6.00,9544,DB02377,Guanine
,31847670,t1/2e,The t1/2e and Vd/F of ETV were increased significantly to 8.01 h and 24.38 L/kg in the ETV-M group.,Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847670/),h,8.01,9545,DB02377,Guanine
,31847670,Vd/F,The t1/2e and Vd/F of ETV were increased significantly to 8.01 h and 24.38 L/kg in the ETV-M group.,Effects of Fuzheng Huayu recipe on entecavir pharmacokinetics in normal and dimethylnitrosamine-induced hepatic fibrosis rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31847670/),[l] / [kg],24.38,9546,DB02377,Guanine
,7048912,half-life of its beta phase of elimination,The half-life of its beta phase of elimination is about three hours with normal renal function and increases to about 18 hours with anuria.,Acyclovir clinical pharmacology. An overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7048912/),h,three,10261,DB02377,Guanine
,7048912,half-life of its beta phase of elimination,The half-life of its beta phase of elimination is about three hours with normal renal function and increases to about 18 hours with anuria.,Acyclovir clinical pharmacology. An overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7048912/),h,18,10262,DB02377,Guanine
,11557467,oral clearance,"The mean oral clearance and elimination half-life following oral dosing were 1.47 liters/h/kg and 2.78 h, respectively.",Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557467/),[l] / [h·kg],1.47,12071,DB02377,Guanine
,11557467,elimination half-life,"The mean oral clearance and elimination half-life following oral dosing were 1.47 liters/h/kg and 2.78 h, respectively.",Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557467/),h,2.78,12072,DB02377,Guanine
,11557467,Total clearance,"Total clearance and terminal half-life following intravenous administration were 0.16 liters/h/kg and 3.67 h, respectively.",Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557467/),[l] / [h·kg],0.16,12073,DB02377,Guanine
,11557467,terminal half-life,"Total clearance and terminal half-life following intravenous administration were 0.16 liters/h/kg and 3.67 h, respectively.",Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557467/),h,3.67,12074,DB02377,Guanine
,10602752,bioavailabilities,"The median bioavailabilities of aciclovir after administration of aciclovir and its prodrug valaciclovir were 21.5 and 70.1%, respectively, in 12 patients with malignant hematological diseases with leukopenia after chemotherapy.",Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602752/),%,21.5,12289,DB02377,Guanine
,10602752,bioavailabilities,"The median bioavailabilities of aciclovir after administration of aciclovir and its prodrug valaciclovir were 21.5 and 70.1%, respectively, in 12 patients with malignant hematological diseases with leukopenia after chemotherapy.",Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602752/),%,70.1,12290,DB02377,Guanine
,10602752,bioavailability,"The interindividual variations of the bioavailability were 48.5 and 21.0% after administration of aciclovir and valaciclovir, respectively.",Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602752/),%,48.5,12291,DB02377,Guanine
,10602752,bioavailability,"The interindividual variations of the bioavailability were 48.5 and 21.0% after administration of aciclovir and valaciclovir, respectively.",Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602752/),%,21.0,12292,DB02377,Guanine
,21989766,MTD,"In patients with advanced solid malignancies, the MTD of sunitinib plus 500 mg/m(2) pemetrexed was 37.5 mg/day (CDD schedule) or 50 mg/day (Schedule 2/1).","A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21989766/),mg,37.,12691,DB02377,Guanine
,26547315,Tmax,"Moreover, the extended Tmax value (6h) signifies the potential of the prepared film to prolong acyclovir delivery.",Formulation and evaluation of nano based drug delivery system for the buccal delivery of acyclovir. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26547315/),h,6,13117,DB02377,Guanine
,15167634,half-life,"Steady-state concentrations were reached after 4 weeks, indicating a half-life of approximately 5 days for both 6-TGN and 6-MMPR; the concentrations were 368 (CI95% 284-452) and 2837 (CI95% 2101-3573) pmol/8 x 10 RBCs, respectively.",Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167634/),d,5,13561,DB02377,Guanine
,15167634,half-life,"Steady-state concentrations were reached after 4 weeks, indicating a half-life of approximately 5 days for both 6-TGN and 6-MMPR; the concentrations were 368 (CI95% 284-452) and 2837 (CI95% 2101-3573) pmol/8 x 10 RBCs, respectively.",Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167634/),[pM] / [8],368,13562,DB02377,Guanine
,15167634,half-life,"Steady-state concentrations were reached after 4 weeks, indicating a half-life of approximately 5 days for both 6-TGN and 6-MMPR; the concentrations were 368 (CI95% 284-452) and 2837 (CI95% 2101-3573) pmol/8 x 10 RBCs, respectively.",Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167634/),[pM] / [8],2837,13563,DB02377,Guanine
less,15167634,ratio,A 6-MMPR/6-TGN ratio less than 11 was associated with therapeutic efficacy.,Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167634/),,11,13564,DB02377,Guanine
,26109856,relative bioavailability,"The relative bioavailability of the optimized ACV nanoemulsion hydrogel improved to 535.2% and 244.6% with respect to the raw ACV hydrogel and marketed cream, respectively, confirming improvement of the relative bioavailability of ACV in the formulated nanoemulsion hydrogel.",Utilization of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of herpes simplex viral infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26109856/),%,535.2,13804,DB02377,Guanine
,26109856,relative bioavailability,"The relative bioavailability of the optimized ACV nanoemulsion hydrogel improved to 535.2% and 244.6% with respect to the raw ACV hydrogel and marketed cream, respectively, confirming improvement of the relative bioavailability of ACV in the formulated nanoemulsion hydrogel.",Utilization of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of herpes simplex viral infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26109856/),%,244.6,13805,DB02377,Guanine
,23176429,maximum plasma concentration,Mean maximum plasma concentration of penciclovir was 1.3 μg/mL at 1.1 hours after oral administration of 5 mg/kg.,Estimates of the pharmacokinetics of famciclovir and its active metabolite penciclovir in young Asian elephants (Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23176429/),[μg] / [ml],1.3,14527,DB02377,Guanine
,23176429,maximum plasma concentration,Mean maximum plasma concentration was 3.6 μg/mL at 0.66 hours after rectal administration of 15 mg/kg; this concentration was similar to results reported for humans receiving 7 mg/kg orally.,Estimates of the pharmacokinetics of famciclovir and its active metabolite penciclovir in young Asian elephants (Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23176429/),[μg] / [ml],3.6,14528,DB02377,Guanine
,8185676,AUC,"All of these 5-ethyl-5-halo-6-methoxy-5,6-dihydro compounds, with the exception of (5S,6S)-BMEDU, had higher AUC values (ranging from 0.32 to 1.20 microM.hr.mL-1) and lower plasma clearances (10-36 mL.min-1) relative to the AUC values (0.14 microM.hr.mL-1) and plasma clearance (85 mL.min-1) of EDU.","Synthesis, biotransformation, pharmacokinetics, and antiviral properties of 5-ethyl-5-halo-6-methoxy-5,6-dihydro-2'-deoxyuridine diastereomers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8185676/),[h·μM] / [ml],0.32 to 1.20,14945,DB02377,Guanine
,8185676,plasma clearances,"All of these 5-ethyl-5-halo-6-methoxy-5,6-dihydro compounds, with the exception of (5S,6S)-BMEDU, had higher AUC values (ranging from 0.32 to 1.20 microM.hr.mL-1) and lower plasma clearances (10-36 mL.min-1) relative to the AUC values (0.14 microM.hr.mL-1) and plasma clearance (85 mL.min-1) of EDU.","Synthesis, biotransformation, pharmacokinetics, and antiviral properties of 5-ethyl-5-halo-6-methoxy-5,6-dihydro-2'-deoxyuridine diastereomers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8185676/),[ml] / [min],10-36,14946,DB02377,Guanine
,8185676,AUC,"All of these 5-ethyl-5-halo-6-methoxy-5,6-dihydro compounds, with the exception of (5S,6S)-BMEDU, had higher AUC values (ranging from 0.32 to 1.20 microM.hr.mL-1) and lower plasma clearances (10-36 mL.min-1) relative to the AUC values (0.14 microM.hr.mL-1) and plasma clearance (85 mL.min-1) of EDU.","Synthesis, biotransformation, pharmacokinetics, and antiviral properties of 5-ethyl-5-halo-6-methoxy-5,6-dihydro-2'-deoxyuridine diastereomers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8185676/),[h·μM] / [ml],0.14,14947,DB02377,Guanine
,8185676,plasma clearance,"All of these 5-ethyl-5-halo-6-methoxy-5,6-dihydro compounds, with the exception of (5S,6S)-BMEDU, had higher AUC values (ranging from 0.32 to 1.20 microM.hr.mL-1) and lower plasma clearances (10-36 mL.min-1) relative to the AUC values (0.14 microM.hr.mL-1) and plasma clearance (85 mL.min-1) of EDU.","Synthesis, biotransformation, pharmacokinetics, and antiviral properties of 5-ethyl-5-halo-6-methoxy-5,6-dihydro-2'-deoxyuridine diastereomers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8185676/),[ml] / [min],85,14948,DB02377,Guanine
,24688087,area under the concentration-time curve,Patients received escalated doses of carboplatin at an area under the concentration-time curve of 4 (Level 1) or 5 (Level 2) plus pemetrexed (500 mg/m(2)) every 3 weeks for a maximum of six cycles.,Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688087/),,4,15758,DB02377,Guanine
,24688087,area under the concentration-time curve,Patients received escalated doses of carboplatin at an area under the concentration-time curve of 4 (Level 1) or 5 (Level 2) plus pemetrexed (500 mg/m(2)) every 3 weeks for a maximum of six cycles.,Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688087/),,5,15759,DB02377,Guanine
,24688087,area under the concentration-time curve,"No dose-limiting toxicities were observed in patients at Level 1 or the first six patients at Level 2, and therefore the combination of carboplatin at an area under the concentration-time curve of 5 plus pemetrexed at 500 mg/m(2) was considered to be the recommended dose.",Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688087/),,5,15760,DB02377,Guanine
,24688087,overall response rate,"Six patients showed partial responses, giving the overall response rate of 30%.",Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688087/),%,30,15761,DB02377,Guanine
,24688087,progression-free survival period,The median progression-free survival period was 4.8 months (95% confidence interval 2.9-6.7 months).,Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24688087/),month,4.8,15762,DB02377,Guanine
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,6.28,17149,DB02377,Guanine
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,9.63,17150,DB02377,Guanine
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,3.15,17151,DB02377,Guanine
,18472234,Clast,"Clast (concentration at the last time point) of SACV was observed to be 8+/-2.6microM in aqueous humor which is two and three times higher than VACV and ACV, respectively.",Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18472234/),μM,8,17477,DB02377,Guanine
,8269600,flow rate,O6-mG and the internal standard deoxyguanosine (dGuo) were eluted with a linear gradient of from 15% to 35% methanol in 0.5 M ammonium acetate (pH 6.5) at a flow rate of 1 ml/min.,Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269600/),[ml] / [min],1,18038,DB02377,Guanine
,8269600,detection limit,The assay was linear over a 4-log concentration range with a detection limit of 0.1 microgram/ml.,Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269600/),[μg] / [ml],0.1,18039,DB02377,Guanine
,8269600,terminal half-life (t1/2),"At 20 mg/kg i.v., plasma O6-mG gave a biexponential profile with a terminal half-life (t1/2) of 24 min and a total clearance (CLT) of 23.7 ml min-1 kg-1.",Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269600/),min,24,18040,DB02377,Guanine
,8269600,total clearance (CLT),"At 20 mg/kg i.v., plasma O6-mG gave a biexponential profile with a terminal half-life (t1/2) of 24 min and a total clearance (CLT) of 23.7 ml min-1 kg-1.",Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269600/),[ml] / [kg·min],23.7,18041,DB02377,Guanine
,24528138,apparent oral clearance,"Final estimates in a standard 70 kg individual for apparent oral clearance, central volume of distribution, intercompartmental clearance and peripheral volume of distribution were 14.5 l h(-1) , 87.5 l, 4.80 l h(-1) and 42.6 l, respectively.",Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24528138/),[l] / [h],14.5,19077,DB02377,Guanine
,24528138,central volume of distribution,"Final estimates in a standard 70 kg individual for apparent oral clearance, central volume of distribution, intercompartmental clearance and peripheral volume of distribution were 14.5 l h(-1) , 87.5 l, 4.80 l h(-1) and 42.6 l, respectively.",Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24528138/),l,87.5,19078,DB02377,Guanine
,24528138,central volume of distribution,"Final estimates in a standard 70 kg individual for apparent oral clearance, central volume of distribution, intercompartmental clearance and peripheral volume of distribution were 14.5 l h(-1) , 87.5 l, 4.80 l h(-1) and 42.6 l, respectively.",Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24528138/),[l] / [h],4.80,19079,DB02377,Guanine
,24528138,intercompartmental clearance,"Final estimates in a standard 70 kg individual for apparent oral clearance, central volume of distribution, intercompartmental clearance and peripheral volume of distribution were 14.5 l h(-1) , 87.5 l, 4.80 l h(-1) and 42.6 l, respectively.",Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24528138/),l,87.5,19080,DB02377,Guanine
,24528138,intercompartmental clearance,"Final estimates in a standard 70 kg individual for apparent oral clearance, central volume of distribution, intercompartmental clearance and peripheral volume of distribution were 14.5 l h(-1) , 87.5 l, 4.80 l h(-1) and 42.6 l, respectively.",Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24528138/),[l] / [h],4.80,19081,DB02377,Guanine
,24528138,peripheral volume of distribution,"Final estimates in a standard 70 kg individual for apparent oral clearance, central volume of distribution, intercompartmental clearance and peripheral volume of distribution were 14.5 l h(-1) , 87.5 l, 4.80 l h(-1) and 42.6 l, respectively.",Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24528138/),l,42.6,19082,DB02377,Guanine
,24528138,terminal half-life,"The median terminal half-life for kidney, liver and lung transplant recipients was 9.4, 9.5 and 8.2 h, respectively.",Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24528138/),h,9.4,19083,DB02377,Guanine
,24528138,terminal half-life,"The median terminal half-life for kidney, liver and lung transplant recipients was 9.4, 9.5 and 8.2 h, respectively.",Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24528138/),h,9.5,19084,DB02377,Guanine
,24528138,terminal half-life,"The median terminal half-life for kidney, liver and lung transplant recipients was 9.4, 9.5 and 8.2 h, respectively.",Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24528138/),h,8.2,19085,DB02377,Guanine
,24528138,"AUC(0,∞)","Median exposure (i.e. AUC(0,∞) in subjects taking valganciclovir 900 mg or 450 mg once daily was 57.4 and 34.3 μg ml(-1) h, respectively.",Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24528138/),[h·μg] / [ml],57.4,19086,DB02377,Guanine
,24528138,"AUC(0,∞)","Median exposure (i.e. AUC(0,∞) in subjects taking valganciclovir 900 mg or 450 mg once daily was 57.4 and 34.3 μg ml(-1) h, respectively.",Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24528138/),[h·μg] / [ml],34.3,19087,DB02377,Guanine
,8878608,CL,"By using this model, typical values of the pharmacokinetic parameter CL and V were 0.428 +/- 0.079 liters/h and 1.773 +/- 0.320 liters, respectively.",Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878608/),[l] / [h],0.428,19558,DB02377,Guanine
,8878608,V,"By using this model, typical values of the pharmacokinetic parameter CL and V were 0.428 +/- 0.079 liters/h and 1.773 +/- 0.320 liters, respectively.",Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878608/),l,1.773,19559,DB02377,Guanine
,12658558,plasma bioavailability,"The plasma bioavailability for acyclovir, valacyclovir and val-valacyclovir were similar with area under curve values being 896.24 (+/-143.58), 776.54 (+/-197.52), 824.69 (+/-217.43) min x micromoles/L respectively.",Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658558/),[min·μmoles] / [l],896.24,19701,DB02377,Guanine
,12658558,area under curve,"The plasma bioavailability for acyclovir, valacyclovir and val-valacyclovir were similar with area under curve values being 896.24 (+/-143.58), 776.54 (+/-197.52), 824.69 (+/-217.43) min x micromoles/L respectively.",Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658558/),[min·μmoles] / [l],896.24,19702,DB02377,Guanine
,12658558,area under curve,"The plasma bioavailability for acyclovir, valacyclovir and val-valacyclovir were similar with area under curve values being 896.24 (+/-143.58), 776.54 (+/-197.52), 824.69 (+/-217.43) min x micromoles/L respectively.",Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658558/),[min·μmoles] / [l],776.54,19703,DB02377,Guanine
,12658558,area under curve,"The plasma bioavailability for acyclovir, valacyclovir and val-valacyclovir were similar with area under curve values being 896.24 (+/-143.58), 776.54 (+/-197.52), 824.69 (+/-217.43) min x micromoles/L respectively.",Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658558/),[min·μmoles] / [l],824.69,19704,DB02377,Guanine
,12658558,area under curve,"Anterior segment area under curve values were 53.70 (+/-35.58), 139.85 (+/-9.43) and 291.05 (+/-88.13) min x micromoles/L respectively while the mean residence time values were 46.47 (+/-24.94), 76.30 (+/-7.24) and 188.39 (+/-80.73) min respectively.",Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658558/),[min·μmoles] / [l],53.70,19705,DB02377,Guanine
,12658558,area under curve,"Anterior segment area under curve values were 53.70 (+/-35.58), 139.85 (+/-9.43) and 291.05 (+/-88.13) min x micromoles/L respectively while the mean residence time values were 46.47 (+/-24.94), 76.30 (+/-7.24) and 188.39 (+/-80.73) min respectively.",Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658558/),[min·μmoles] / [l],139.85,19706,DB02377,Guanine
,12658558,area under curve,"Anterior segment area under curve values were 53.70 (+/-35.58), 139.85 (+/-9.43) and 291.05 (+/-88.13) min x micromoles/L respectively while the mean residence time values were 46.47 (+/-24.94), 76.30 (+/-7.24) and 188.39 (+/-80.73) min respectively.",Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658558/),[min·μmoles] / [l],291.05,19707,DB02377,Guanine
,12658558,mean residence time,"Anterior segment area under curve values were 53.70 (+/-35.58), 139.85 (+/-9.43) and 291.05 (+/-88.13) min x micromoles/L respectively while the mean residence time values were 46.47 (+/-24.94), 76.30 (+/-7.24) and 188.39 (+/-80.73) min respectively.",Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658558/),min,46.47,19708,DB02377,Guanine
,12658558,mean residence time,"Anterior segment area under curve values were 53.70 (+/-35.58), 139.85 (+/-9.43) and 291.05 (+/-88.13) min x micromoles/L respectively while the mean residence time values were 46.47 (+/-24.94), 76.30 (+/-7.24) and 188.39 (+/-80.73) min respectively.",Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658558/),min,76.30,19709,DB02377,Guanine
,12658558,mean residence time,"Anterior segment area under curve values were 53.70 (+/-35.58), 139.85 (+/-9.43) and 291.05 (+/-88.13) min x micromoles/L respectively while the mean residence time values were 46.47 (+/-24.94), 76.30 (+/-7.24) and 188.39 (+/-80.73) min respectively.",Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658558/),min,188.39,19710,DB02377,Guanine
,9863965,Limits of quantitation,"Limits of quantitation and detection were 25 and 10 ng ml(-1), respectively.",Determination and pharmacokinetics of acyclovir after ingestion of suspension form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863965/),[ng] / [ml],25,20932,DB02377,Guanine
,9863965,Limits of quantitation,"Limits of quantitation and detection were 25 and 10 ng ml(-1), respectively.",Determination and pharmacokinetics of acyclovir after ingestion of suspension form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863965/),[ng] / [ml],10,20933,DB02377,Guanine
,9863965,detection,"Limits of quantitation and detection were 25 and 10 ng ml(-1), respectively.",Determination and pharmacokinetics of acyclovir after ingestion of suspension form. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863965/),[ng] / [ml],10,20934,DB02377,Guanine
,1846060,peak ganciclovir concentration,The patient's peak ganciclovir concentration was markedly elevated (20 micrograms/mL) compared with previously reported peak concentrations in patients with normal renal function.,Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1846060/),[μg] / [ml],20,21122,DB02377,Guanine
,1846060,elimination half-life (t1/2),"Similarly, the elimination half-life (t1/2) was increased (6.3 hours) in this patient compared with values reported in patients with normal renal function.",Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1846060/),h,6.3,21123,DB02377,Guanine
,1846060,volume of distribution,The volume of distribution (0.21 L/kg) and total body clearance prior to hemodialysis (35.5 mL/min) were diminished in this patient.,Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1846060/),[l] / [kg],0.21,21124,DB02377,Guanine
,1846060,total body clearance,The volume of distribution (0.21 L/kg) and total body clearance prior to hemodialysis (35.5 mL/min) were diminished in this patient.,Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1846060/),[ml] / [min],35.5,21125,DB02377,Guanine
,1846060,extraction coefficient,Hemodialysis reduced ganciclovir levels by approximately 62% with an extraction coefficient of 0.29 resulting in a dialyzer clearance of 48.3 mL/min.,Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1846060/),,0.29,21126,DB02377,Guanine
,1846060,clearance,Hemodialysis reduced ganciclovir levels by approximately 62% with an extraction coefficient of 0.29 resulting in a dialyzer clearance of 48.3 mL/min.,Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1846060/),[ml] / [min],48.3,21127,DB02377,Guanine
,25444844,SIWV,SIWV within the CAT model was varied between 52.5mL and 420mL.,Parameterization of small intestinal water volume using PBPK modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25444844/),ml,52.5,21571,DB02377,Guanine
,25444844,SIWV,SIWV within the CAT model was varied between 52.5mL and 420mL.,Parameterization of small intestinal water volume using PBPK modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25444844/),ml,420,21572,DB02377,Guanine
,25444844,SIWV,The derived SIWV (116mL) represents the optimal parameter value within the context of the developed CAT model.,Parameterization of small intestinal water volume using PBPK modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25444844/),ml,116,21573,DB02377,Guanine
,7297024,plasma half-life,The overall mean plasma half-life and total body clearance +/- SD of ACV were 2.1 +/- 0.5 hr and 297 +/- 53 ml/min/1.73 m2.,Disposition of intravenous radioactive acyclovir. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297024/),h,2.1,21755,DB02377,Guanine
,7297024,total body clearance,The overall mean plasma half-life and total body clearance +/- SD of ACV were 2.1 +/- 0.5 hr and 297 +/- 53 ml/min/1.73 m2.,Disposition of intravenous radioactive acyclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297024/),[ml] / [1.73·m2·min],297,21756,DB02377,Guanine
,7297024,Binding,Binding of ACV to plasma proteins was 15.4 +/- 4.4%.,Disposition of intravenous radioactive acyclovir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297024/),%,15.4,21757,DB02377,Guanine
,18638291,observed maximum serum ACV concentration (C(max)),"Following the administration of 5 g VCV, the mean observed maximum serum ACV concentration (C(max)) was 1.45 +/- 0.38 (SD) microg/mL, at 0.74 +/- 0.43 h.",Pharmacokinetics of valacyclovir in the adult horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638291/),[μg] / [ml],1.45,22199,DB02377,Guanine
,18638291,C(max),"At a dose of 15 g VCV, the mean C(max) was 5.26 +/- 2.82 microg/mL, at 1 +/- 0.27 h.",Pharmacokinetics of valacyclovir in the adult horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638291/),[μg] / [ml],5.26,22200,DB02377,Guanine
,18638291,bioavailability,"The mean bioavailability of ACV from oral VCV was 60 +/- 12% after 5 g of VCV and 48 +/- 12% after 15 g VCV, and did not differ significantly between dose rates (P > 0.05).",Pharmacokinetics of valacyclovir in the adult horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638291/),%,60,22201,DB02377,Guanine
,18638291,bioavailability,"The mean bioavailability of ACV from oral VCV was 60 +/- 12% after 5 g of VCV and 48 +/- 12% after 15 g VCV, and did not differ significantly between dose rates (P > 0.05).",Pharmacokinetics of valacyclovir in the adult horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638291/),%,48,22202,DB02377,Guanine
,15987831,area under concentration-time curve (AUC)(brain)/AUC(plasma) ratio,The mean area under concentration-time curve (AUC)(brain)/AUC(plasma) ratio of unbound pemetrexed was 0.078 +/- 0.038 in the i.v. bolus study.,Distribution of the novel antifolate pemetrexed to the brain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987831/),,0.078,22824,DB02377,Guanine
,15987831,steady-state brain-to-plasma unbound concentration ratio,The pemetrexed steady-state brain-to-plasma unbound concentration ratio after i.v. infusion was 0.106 +/- 0.054.,Distribution of the novel antifolate pemetrexed to the brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987831/),,0.106,22825,DB02377,Guanine
,26560486,MTD,The MTD of nintedanib plus pemetrexed was 200 mg bid.,Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26560486/),mg,200,23208,DB02377,Guanine
,26560486,MTD,"As in Caucasian patients, the MTD of nintedanib was 200 mg bid.",Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26560486/),mg,200,23209,DB02377,Guanine
,21726136,polydispersity index,Optimized formulation (NG8; Span60:Cholesterol 3:2 molar ratio) has shown a significantly high encapsulation of Ganciclovir (89±2.13%) with vesicle size of 144±3.47 nm (polydispersity index [PDI]=0.08).,Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726136/),,0.08,23241,DB02377,Guanine
>,21726136,effective drug concentration,The effective drug concentration (>0.69 µg/mL in plasma) was also maintained for at least 8 h on administration of the niosomal formulation.,Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726136/),[μg] / [ml],0.69,23242,DB02377,Guanine
,11743593,bioavailabilities,"The mean acyclovir bioavailabilities, estimated from urinary acyclovir excretion, were 26.7+/-17.8% and 44.9+/-17.9% for acyclovir and valacyclovir, respectively (P<0.007).",Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743593/),%,26.7,23386,DB02377,Guanine
,11743593,bioavailabilities,"The mean acyclovir bioavailabilities, estimated from urinary acyclovir excretion, were 26.7+/-17.8% and 44.9+/-17.9% for acyclovir and valacyclovir, respectively (P<0.007).",Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743593/),%,44.9,23387,DB02377,Guanine
,18089334,Maximum mean plasma concentrations (Cmax),"Maximum mean plasma concentrations (Cmax) were 6.73 microg/mL and 6.39 microg/mL for the valganciclovir tablet and oral solution, respectively, with identical mean AUC0-24 of 51.2 microg.h/mL.",Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089334/),[μg] / [ml],6.73,25059,DB02377,Guanine
,18089334,Maximum mean plasma concentrations (Cmax),"Maximum mean plasma concentrations (Cmax) were 6.73 microg/mL and 6.39 microg/mL for the valganciclovir tablet and oral solution, respectively, with identical mean AUC0-24 of 51.2 microg.h/mL.",Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089334/),[μg] / [ml],6.39,25060,DB02377,Guanine
,18089334,AUC0-24,"Maximum mean plasma concentrations (Cmax) were 6.73 microg/mL and 6.39 microg/mL for the valganciclovir tablet and oral solution, respectively, with identical mean AUC0-24 of 51.2 microg.h/mL.",Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089334/),[h·μg] / [ml],51.2,25061,DB02377,Guanine
,27580058,area under the curve,Estimated mean area under the curve during the 0-24 hours dosing interval for these patients was 68.1 μg·h/mL.,Pharmacokinetics and Safety of Valganciclovir in Pediatric Heart Transplant Recipients 4 Months of Age and Younger. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27580058/),[h·μg] / [ml],68.1,25742,DB02377,Guanine
,8655992,trough plasma concentration,"The mean trough plasma concentration was 0.6 +/- 0.3 mg/L (n = 24), and the mean peak concentration was 7.2 +/- 2.4 mg/L (n = 6).",Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655992/),[mg] / [l],0.6,26786,DB02377,Guanine
,8655992,peak concentration,"The mean trough plasma concentration was 0.6 +/- 0.3 mg/L (n = 24), and the mean peak concentration was 7.2 +/- 2.4 mg/L (n = 6).",Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655992/),[mg] / [l],7.2,26787,DB02377,Guanine
,19959884,maximum plasma concentrations,"Following an oral dose of famciclovir at 20 mg/kg, maximum plasma concentrations of penciclovir occurred between 0.75 and 1.5 hr (mean 0.94 + or - 0.38 hr) after dosing and were in the range 2.22 to 3.56 microg/ml (mean 2.87 + or - 0.61 microg/ml).",Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959884/),h,0.75 and 1.5,26790,DB02377,Guanine
,19959884,maximum plasma concentrations,"Following an oral dose of famciclovir at 20 mg/kg, maximum plasma concentrations of penciclovir occurred between 0.75 and 1.5 hr (mean 0.94 + or - 0.38 hr) after dosing and were in the range 2.22 to 3.56 microg/ml (mean 2.87 + or - 0.61 microg/ml).",Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959884/),h,0.94,26791,DB02377,Guanine
,19959884,maximum plasma concentrations,"Following an oral dose of famciclovir at 20 mg/kg, maximum plasma concentrations of penciclovir occurred between 0.75 and 1.5 hr (mean 0.94 + or - 0.38 hr) after dosing and were in the range 2.22 to 3.56 microg/ml (mean 2.87 + or - 0.61 microg/ml).",Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959884/),[μg] / [ml],2.87,26792,DB02377,Guanine
,19959884,half-life of the rapid elimination phase,The mean half-life of the rapid elimination phase was 1.73 + or - 0.34 hr whereas that of the slow elimination phase was 34.34 + or - 13.93 hr.,Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959884/),h,1.73,26793,DB02377,Guanine
,19959884,half-life of the rapid elimination phase,The mean half-life of the rapid elimination phase was 1.73 + or - 0.34 hr whereas that of the slow elimination phase was 34.34 + or - 13.93 hr.,Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19959884/),h,34.34,26794,DB02377,Guanine
,26403509,MTD,MTD of LY with pemetrexed/carboplatin was 40 mg.,"A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26403509/),mg,40,27239,DB02377,Guanine
,24305626,area under the time-concentration curve,An area under the time-concentration curve of 40-50 μg × h/mL is related to efficacy.,Optimal sparse sampling for estimating ganciclovir/valganciclovir AUC in solid organ transplant patients using NONMEN. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24305626/),[h·μg] / [ml],40-50,28276,DB02377,Guanine
,16352807,area under the concentration-time curve from drug administration to last observed concentration after 12 hours [AUC(0-12)],"Patients without I-GVHD had a higher exposure to GCV after V-GCV when compared with IV-GCV (area under the concentration-time curve from drug administration to last observed concentration after 12 hours [AUC(0-12)] 53.8 +/- 17.97 microg/mL . h [mean +/- SD] vs 39.5 +/- 13.91; P < .001; ratio of V-GCV/IV-GCV was 1.4; 90% confidence interval [CI], 1.2-1.5).",Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16352807/),[μg] / [h·ml],53.8,29763,DB02377,Guanine
,16352807,area under the concentration-time curve from drug administration to last observed concentration after 12 hours [AUC(0-12)],"Patients without I-GVHD had a higher exposure to GCV after V-GCV when compared with IV-GCV (area under the concentration-time curve from drug administration to last observed concentration after 12 hours [AUC(0-12)] 53.8 +/- 17.97 microg/mL . h [mean +/- SD] vs 39.5 +/- 13.91; P < .001; ratio of V-GCV/IV-GCV was 1.4; 90% confidence interval [CI], 1.2-1.5).",Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16352807/),,39.5,29764,DB02377,Guanine
,16352807,AUC(0-12),"This was also true in patients with I-GVHD grades I-II (AUC(0-12) 52.9 +/- 21.75 vs 33.1 +/- 12.97 mug/mL . h; P = .018; ratio 1.6; 90% CI, 1.3-2.0).",Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16352807/),[μg] / [h·ml],52.9,29765,DB02377,Guanine
,16352807,AUC(0-12),"This was also true in patients with I-GVHD grades I-II (AUC(0-12) 52.9 +/- 21.75 vs 33.1 +/- 12.97 mug/mL . h; P = .018; ratio 1.6; 90% CI, 1.3-2.0).",Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16352807/),[μg] / [h·ml],33.1,29766,DB02377,Guanine
,16352807,Absolute bioavailability,Absolute bioavailability of GCV after V-GCV was approximately 75% in individuals with or without I-GVHD grades I-II.,Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16352807/),%,75,29767,DB02377,Guanine
,17302367,maximum,"The mean maximum HBV DNA reduction was 3.05, 4.20, 3.67 and 3.68 log10 copies/ml for 30, 60, 120 and 240 mg per day, respectively.","A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17302367/),[copies·log10] / [ml],3.05,30005,DB02377,Guanine
,17302367,maximum,"The mean maximum HBV DNA reduction was 3.05, 4.20, 3.67 and 3.68 log10 copies/ml for 30, 60, 120 and 240 mg per day, respectively.","A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17302367/),[copies·log10] / [ml],4.20,30006,DB02377,Guanine
,17302367,maximum,"The mean maximum HBV DNA reduction was 3.05, 4.20, 3.67 and 3.68 log10 copies/ml for 30, 60, 120 and 240 mg per day, respectively.","A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17302367/),[copies·log10] / [ml],3.67,30007,DB02377,Guanine
,17302367,maximum,"The mean maximum HBV DNA reduction was 3.05, 4.20, 3.67 and 3.68 log10 copies/ml for 30, 60, 120 and 240 mg per day, respectively.","A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17302367/),[copies·log10] / [ml],3.68,30008,DB02377,Guanine
,9533527,maximum tolerated dose,"A maximum tolerated dose of 4.0 mg/m2/day was determined, with neutropenia as the predominant dose-limiting toxicity.","A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533527/),[mg] / [d·m2],4.0,30361,DB02377,Guanine
,9533527,total body clearance,"The drug was cleared with a day 1 total body clearance of 108.9 +/- 38.8 ml/min/m2, with plasma concentrations declining with a mean harmonic terminal half-life of 1.4 +/- 0.98 h.","A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533527/),[ml] / [m2·min],108.9,30362,DB02377,Guanine
,9533527,terminal half-life,"The drug was cleared with a day 1 total body clearance of 108.9 +/- 38.8 ml/min/m2, with plasma concentrations declining with a mean harmonic terminal half-life of 1.4 +/- 0.98 h.","A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533527/),h,1.4,30363,DB02377,Guanine
,26824942,time to reach target AUC,"The time to reach target AUC was significantly longer in group A than in group B (55.9 ± 8.2 versus 15.8 ± 2.3 days,P< 0.001).",Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26824942/),d,55.9,30717,DB02377,Guanine
,26824942,time to reach target AUC,"The time to reach target AUC was significantly longer in group A than in group B (55.9 ± 8.2 versus 15.8 ± 2.3 days,P< 0.001).",Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26824942/),d,15.8,30718,DB02377,Guanine
,26824942,time to viral clearance,A shorter time to viral clearance was observed in group B than in group A (12.5 versus 17.6 days;P= 0.125).,Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26824942/),d,12.5,30719,DB02377,Guanine
,26824942,time to viral clearance,A shorter time to viral clearance was observed in group B than in group A (12.5 versus 17.6 days;P= 0.125).,Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26824942/),d,17.6,30720,DB02377,Guanine
,30317534,Response rate,Response rate was 37.5% for cohort 1 and 30.4% for cohort 2.,Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30317534/),%,37.5,31239,DB02377,Guanine
,30317534,Response rate,Response rate was 37.5% for cohort 1 and 30.4% for cohort 2.,Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30317534/),%,30.4,31240,DB02377,Guanine
,16898525,bioavailability,"This drug has proved similar efficacy and good bioavailability (roughly 70%), however there is no registered liquid form which can be precisely and safety administered in small children.",[Evaluation of pharmacokinetics and safety of valganciclovir oral suspension treatment in pediatric kidney graft recipients--preliminary report]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898525/),%,70,31858,DB02377,Guanine
,16898525,CO,CO (mean = 0.74 microg/ml; max. 1.15; min. 0.38; SD +/- 0.25) was close to predefined values (0.4-1.0 microg/ml).,[Evaluation of pharmacokinetics and safety of valganciclovir oral suspension treatment in pediatric kidney graft recipients--preliminary report]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898525/),[μg] / [ml],0.74,31859,DB02377,Guanine
,16898525,CO,CO (mean = 0.74 microg/ml; max. 1.15; min. 0.38; SD +/- 0.25) was close to predefined values (0.4-1.0 microg/ml).,[Evaluation of pharmacokinetics and safety of valganciclovir oral suspension treatment in pediatric kidney graft recipients--preliminary report]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898525/),,1.15,31860,DB02377,Guanine
,16898525,Cmax,Concentration profile of GCV (Cmax 1.0-1.5 h post dose) was similar to profile observed in adult patient treated with VCG tablets.,[Evaluation of pharmacokinetics and safety of valganciclovir oral suspension treatment in pediatric kidney graft recipients--preliminary report]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898525/),h,1.0-1.5,31861,DB02377,Guanine
,19897764,clearance,"Final model estimates of clearance, volume of distribution, and fraction of acyclovir in oral wash supernatant are 49.9 L/h, 74.1 L, and 1.14%, respectively.",Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19897764/),[l] / [h],49.9,32675,DB02377,Guanine
,19897764,volume of distribution,"Final model estimates of clearance, volume of distribution, and fraction of acyclovir in oral wash supernatant are 49.9 L/h, 74.1 L, and 1.14%, respectively.",Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19897764/),l,74.1,32676,DB02377,Guanine
,19897764,volume of distribution,"Final model estimates of clearance, volume of distribution, and fraction of acyclovir in oral wash supernatant are 49.9 L/h, 74.1 L, and 1.14%, respectively.",Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19897764/),%,1.14,32677,DB02377,Guanine
,19897764,fraction,"Final model estimates of clearance, volume of distribution, and fraction of acyclovir in oral wash supernatant are 49.9 L/h, 74.1 L, and 1.14%, respectively.",Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19897764/),%,1.14,32678,DB02377,Guanine
,16759825,absolute bioavailability,"The absolute bioavailability of the prodrug valacyclovir, the l-valyl ester of acyclovir, after oral administration is approximately 54.5%.",Stability of valacyclovir: implications for its oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16759825/),%,54.5,33282,DB02377,Guanine
,2992899,oral bioavailability,Peak plasma concentrations occur 1.5 to 2.5 hours after administration and the oral bioavailability is 15 to 30 percent.,Evaluation of oral acyclovir therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2992899/),%,15 to 30,35132,DB02377,Guanine
,3986813,terminal half-life,Plasma clearance of Tiazofurin followed a biexponential pattern with a harmonic mean terminal half-life of 7.6 h.,"Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986813/),h,7.6,35435,DB02377,Guanine
,3986813,volume of distribution at steady state,"The mean volume of distribution at steady state was 30 liters/sq m, and the mean plasma clearance was 3 liters/h/sq m.","Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986813/),[l] / [m·sq],30,35436,DB02377,Guanine
,3986813,plasma clearance,"The mean volume of distribution at steady state was 30 liters/sq m, and the mean plasma clearance was 3 liters/h/sq m.","Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986813/),[l] / [h·m·sq],3,35437,DB02377,Guanine
,3986813,total cumulative urinary excretion,The total cumulative urinary excretion ranged from 15 to 49%.,"Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986813/),%,15 to 49,35438,DB02377,Guanine
,31507245,AUC0-∞,"The values of AUC0-∞ and MRT of coated ACV-SLNs were higher than free drug by about twofold, 233.36 ± 41.56 μg.h/mL and 1.81 ± 0.36 h, respectively.",Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31507245/),[h·μg] / [ml],233.36,35643,DB02377,Guanine
,31507245,MRT,"The values of AUC0-∞ and MRT of coated ACV-SLNs were higher than free drug by about twofold, 233.36 ± 41.56 μg.h/mL and 1.81 ± 0.36 h, respectively.",Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31507245/),h,1.81,35644,DB02377,Guanine
,31507245,AUC0-∞ brain/AUC0-∞ plasma ratio,"The AUC0-∞ brain/AUC0-∞ plasma ratio for coated ACV-SLNs and free ACV was 0.22 and 0.12, respectively.",Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31507245/),,0.22,35645,DB02377,Guanine
,31507245,AUC0-∞ brain/AUC0-∞ plasma ratio,"The AUC0-∞ brain/AUC0-∞ plasma ratio for coated ACV-SLNs and free ACV was 0.22 and 0.12, respectively.",Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31507245/),,0.12,35646,DB02377,Guanine
,9193870,AUC,"Doses (iv) of the compound showed high plasma levels, resulting in AUC values of 30-33 micrograms-hr/ml for mice and dogs after 20 and 7.5 mg/kg doses, respectively.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),[μgrams-hr] / [ml],30-33,35734,DB02377,Guanine
,9193870,Half-life,"Half-life values for mice and dogs were about 7 and 2 hr, respectively.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),h,7,35735,DB02377,Guanine
,9193870,Half-life,"Half-life values for mice and dogs were about 7 and 2 hr, respectively.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),h,2,35736,DB02377,Guanine
,9193870,plasma binding,"In vitro plasma binding measured 56% in mice, 46% in dogs, and 81% in humans.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),%,56,35737,DB02377,Guanine
,9193870,plasma binding,"In vitro plasma binding measured 56% in mice, 46% in dogs, and 81% in humans.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),%,46,35738,DB02377,Guanine
,9193870,plasma binding,"In vitro plasma binding measured 56% in mice, 46% in dogs, and 81% in humans.",Metabolism and disposition of the antifolate LY231514 in mice and dogs. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9193870/),%,81,35739,DB02377,Guanine
,14972713,flow rate,The probes were perfused with isotonic phosphate buffer saline (pH 7.4) at a flow rate of 2 microl/min.,Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),[μl] / [min],2,35813,DB02377,Guanine
,14972713,terminal elimination half-life,Vitreal terminal elimination half-life of GCV was found to be similar with all three doses and ranged from 325 to 401 min.,Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,325 to 401,35814,DB02377,Guanine
,14972713,elimination half-lives,"Vitreal elimination half-lives of GCV diacetate, dipropionate, and dibutyrate esters were found to be 112 +/- 37, 41.9 +/- 13.1, and 33.5 +/- 6.5 min, respectively.",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,112,35815,DB02377,Guanine
,14972713,elimination half-lives,"Vitreal elimination half-lives of GCV diacetate, dipropionate, and dibutyrate esters were found to be 112 +/- 37, 41.9 +/- 13.1, and 33.5 +/- 6.5 min, respectively.",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,41.9,35816,DB02377,Guanine
,14972713,elimination half-lives,"Vitreal elimination half-lives of GCV diacetate, dipropionate, and dibutyrate esters were found to be 112 +/- 37, 41.9 +/- 13.1, and 33.5 +/- 6.5 min, respectively.",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,33.5,35817,DB02377,Guanine
,14972713,Mean residence time (MRT),"Mean residence time (MRT) of regenerated GCV (356 +/- 16 min, 341 +/- 11 min and 324 +/- 19 min from GCV diacetate, dipropionate and dibutyrate, respectively) increased by 2-fold following prodrug administration as compared to direct GCV administration (185 +/- 28 min).",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,356,35818,DB02377,Guanine
,14972713,Mean residence time (MRT),"Mean residence time (MRT) of regenerated GCV (356 +/- 16 min, 341 +/- 11 min and 324 +/- 19 min from GCV diacetate, dipropionate and dibutyrate, respectively) increased by 2-fold following prodrug administration as compared to direct GCV administration (185 +/- 28 min).",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,341,35819,DB02377,Guanine
,14972713,Mean residence time (MRT),"Mean residence time (MRT) of regenerated GCV (356 +/- 16 min, 341 +/- 11 min and 324 +/- 19 min from GCV diacetate, dipropionate and dibutyrate, respectively) increased by 2-fold following prodrug administration as compared to direct GCV administration (185 +/- 28 min).",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,324,35820,DB02377,Guanine
,14972713,Mean residence time (MRT),"Mean residence time (MRT) of regenerated GCV (356 +/- 16 min, 341 +/- 11 min and 324 +/- 19 min from GCV diacetate, dipropionate and dibutyrate, respectively) increased by 2-fold following prodrug administration as compared to direct GCV administration (185 +/- 28 min).",Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14972713/),min,185,35821,DB02377,Guanine
,2820301,steady-state peak,"With a 20-mg/kg dose given every 6 h, mean steady-state peak and trough levels were 2.96 and 1.05 microM, respectively, and the area under the concentration-time curve from 0 to 24 h was 47 microM X h.",Human pharmacokinetics and tolerance of oral ganciclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2820301/),μM,2.96,36464,DB02377,Guanine
,2820301,trough levels,"With a 20-mg/kg dose given every 6 h, mean steady-state peak and trough levels were 2.96 and 1.05 microM, respectively, and the area under the concentration-time curve from 0 to 24 h was 47 microM X h.",Human pharmacokinetics and tolerance of oral ganciclovir. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2820301/),μM,1.05,36465,DB02377,Guanine
,2820301,area under the concentration-time curve from 0 to 24 h,"With a 20-mg/kg dose given every 6 h, mean steady-state peak and trough levels were 2.96 and 1.05 microM, respectively, and the area under the concentration-time curve from 0 to 24 h was 47 microM X h.",Human pharmacokinetics and tolerance of oral ganciclovir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2820301/),h·μM,47,36466,DB02377,Guanine
,2820301,absorption,"Calculated absorption was 3.0%, based on urinary excretion.",Human pharmacokinetics and tolerance of oral ganciclovir. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2820301/),%,3.0,36467,DB02377,Guanine
,10434231,bioavailability,"Valganciclovir was rapidly and extensively hydrolyzed to ganciclovir, resulting in significantly greater bioavailability compared to 1000 mg oral ganciclovir (60.9% vs. 5.6%, respectively).",Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434231/),%,60.9,36709,DB02377,Guanine
,10434231,bioavailability,"Valganciclovir was rapidly and extensively hydrolyzed to ganciclovir, resulting in significantly greater bioavailability compared to 1000 mg oral ganciclovir (60.9% vs. 5.6%, respectively).",Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434231/),%,5.6,36710,DB02377,Guanine
,10434231,peak serum concentrations,Higher peak serum concentrations were reached earlier following valganciclovir (ganciclovir [2.98 +/- 0.77 micrograms/mL at 1.0 +/- 0.3 h]) than following oral ganciclovir (0.47 +/- 0.17 microgram/mL and 2.2 +/- 1.0 h).,Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434231/),[μg] / [ml],2.98,36711,DB02377,Guanine
,10434231,peak serum concentrations,Higher peak serum concentrations were reached earlier following valganciclovir (ganciclovir [2.98 +/- 0.77 micrograms/mL at 1.0 +/- 0.3 h]) than following oral ganciclovir (0.47 +/- 0.17 microgram/mL and 2.2 +/- 1.0 h).,Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434231/),[μg] / [ml],0.47,36712,DB02377,Guanine
,10434231,peak serum concentrations,Higher peak serum concentrations were reached earlier following valganciclovir (ganciclovir [2.98 +/- 0.77 micrograms/mL at 1.0 +/- 0.3 h]) than following oral ganciclovir (0.47 +/- 0.17 microgram/mL and 2.2 +/- 1.0 h).,Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434231/),h,2.2,36713,DB02377,Guanine
,10434231,AUCs,Mean total ganciclovir AUCs following oral ganciclovir (1000 mg) and 360 mg valganciclovir (3.8 +/- 1.2 and 10.8 +/- 1.9 micrograms-h/mL) were less than that following a standard 5 mg/kg intravenous infusion of ganciclovir (25.1 +/- 3.8 micrograms-h/mL).,Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434231/),[μgrams-h] / [ml],3.8,36714,DB02377,Guanine
,10434231,AUCs,Mean total ganciclovir AUCs following oral ganciclovir (1000 mg) and 360 mg valganciclovir (3.8 +/- 1.2 and 10.8 +/- 1.9 micrograms-h/mL) were less than that following a standard 5 mg/kg intravenous infusion of ganciclovir (25.1 +/- 3.8 micrograms-h/mL).,Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434231/),[μgrams-h] / [ml],10.8,36715,DB02377,Guanine
,10434231,AUCs,Mean total ganciclovir AUCs following oral ganciclovir (1000 mg) and 360 mg valganciclovir (3.8 +/- 1.2 and 10.8 +/- 1.9 micrograms-h/mL) were less than that following a standard 5 mg/kg intravenous infusion of ganciclovir (25.1 +/- 3.8 micrograms-h/mL).,Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434231/),[μgrams-h] / [ml],25.1,36716,DB02377,Guanine
,23301502,terminal half-life,Intravenously administered ganciclovir disposition was best described by a three-compartment model with a prolonged terminal half-life of 72 ± 9 h.,Pharmacokinetics of ganciclovir and valganciclovir in the adult horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301502/),h,72,36780,DB02377,Guanine
,23301502,observed maximum serum ganciclovir concentration,"Following the oral administration of valganciclovir, the mean observed maximum serum ganciclovir concentration was 0.58 ± 0.37 μg/mL, and bioavailability of ganciclovir from oral valganciclovir was 41 ± 20%.",Pharmacokinetics of ganciclovir and valganciclovir in the adult horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301502/),[μg] / [ml],0.58,36781,DB02377,Guanine
,23301502,bioavailability,"Following the oral administration of valganciclovir, the mean observed maximum serum ganciclovir concentration was 0.58 ± 0.37 μg/mL, and bioavailability of ganciclovir from oral valganciclovir was 41 ± 20%.",Pharmacokinetics of ganciclovir and valganciclovir in the adult horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23301502/),%,41,36782,DB02377,Guanine
,9790357,Peak acyclovir plasma concentrations,"Peak acyclovir plasma concentrations (mean +/- standard deviation) were higher in valacyclovir recipients than in acyclovir recipients after the initial dose (3.14 +/- 0.7 microg/mL vs 0.74 +/- 0.6 microg/mL, P < .0001) and at steady state (3.03 +/- 1.0 microg/mL vs 0.94 +/- 0.7 microg/mL, P < .001).",Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9790357/),[μg] / [ml],3.14,37747,DB02377,Guanine
,9790357,Peak acyclovir plasma concentrations,"Peak acyclovir plasma concentrations (mean +/- standard deviation) were higher in valacyclovir recipients than in acyclovir recipients after the initial dose (3.14 +/- 0.7 microg/mL vs 0.74 +/- 0.6 microg/mL, P < .0001) and at steady state (3.03 +/- 1.0 microg/mL vs 0.94 +/- 0.7 microg/mL, P < .001).",Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9790357/),[μg] / [ml],0.74,37748,DB02377,Guanine
,9790357,Peak acyclovir plasma concentrations,"Peak acyclovir plasma concentrations (mean +/- standard deviation) were higher in valacyclovir recipients than in acyclovir recipients after the initial dose (3.14 +/- 0.7 microg/mL vs 0.74 +/- 0.6 microg/mL, P < .0001) and at steady state (3.03 +/- 1.0 microg/mL vs 0.94 +/- 0.7 microg/mL, P < .001).",Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9790357/),[μg] / [ml],3.03,37749,DB02377,Guanine
,9790357,Peak acyclovir plasma concentrations,"Peak acyclovir plasma concentrations (mean +/- standard deviation) were higher in valacyclovir recipients than in acyclovir recipients after the initial dose (3.14 +/- 0.7 microg/mL vs 0.74 +/- 0.6 microg/mL, P < .0001) and at steady state (3.03 +/- 1.0 microg/mL vs 0.94 +/- 0.7 microg/mL, P < .001).",Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9790357/),[μg] / [ml],0.94,37750,DB02377,Guanine
,9790357,area under the curve,"The daily area under the curve values were higher in valacyclovir recipients than acyclovir recipients after the initial dose (17.8 +/- 3.6 h x microg/mL vs 7.71 +/- 2.5 h x microg/mL, P < .001) and at steady state (19.65 +/- 6.4 h x microg/mL versus 11.0 +/- 4.5 h x microg/mL, P = .009).",Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9790357/),[h·μg] / [ml],17.8,37751,DB02377,Guanine
,9790357,area under the curve,"The daily area under the curve values were higher in valacyclovir recipients than acyclovir recipients after the initial dose (17.8 +/- 3.6 h x microg/mL vs 7.71 +/- 2.5 h x microg/mL, P < .001) and at steady state (19.65 +/- 6.4 h x microg/mL versus 11.0 +/- 4.5 h x microg/mL, P = .009).",Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9790357/),[h·μg] / [ml],7.71,37752,DB02377,Guanine
,9790357,area under the curve,"The daily area under the curve values were higher in valacyclovir recipients than acyclovir recipients after the initial dose (17.8 +/- 3.6 h x microg/mL vs 7.71 +/- 2.5 h x microg/mL, P < .001) and at steady state (19.65 +/- 6.4 h x microg/mL versus 11.0 +/- 4.5 h x microg/mL, P = .009).",Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9790357/),[h·μg] / [ml],19.65,37753,DB02377,Guanine
,9790357,area under the curve,"The daily area under the curve values were higher in valacyclovir recipients than acyclovir recipients after the initial dose (17.8 +/- 3.6 h x microg/mL vs 7.71 +/- 2.5 h x microg/mL, P < .001) and at steady state (19.65 +/- 6.4 h x microg/mL versus 11.0 +/- 4.5 h x microg/mL, P = .009).",Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9790357/),[h·μg] / [ml],11.0,37754,DB02377,Guanine
,9790357,steady state,"The daily area under the curve values were higher in valacyclovir recipients than acyclovir recipients after the initial dose (17.8 +/- 3.6 h x microg/mL vs 7.71 +/- 2.5 h x microg/mL, P < .001) and at steady state (19.65 +/- 6.4 h x microg/mL versus 11.0 +/- 4.5 h x microg/mL, P = .009).",Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9790357/),[h·μg] / [ml],19.65,37755,DB02377,Guanine
,9790357,steady state,"The daily area under the curve values were higher in valacyclovir recipients than acyclovir recipients after the initial dose (17.8 +/- 3.6 h x microg/mL vs 7.71 +/- 2.5 h x microg/mL, P < .001) and at steady state (19.65 +/- 6.4 h x microg/mL versus 11.0 +/- 4.5 h x microg/mL, P = .009).",Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9790357/),[h·μg] / [ml],11.0,37756,DB02377,Guanine
,9790357,plasma ratios,"Acyclovir was concentrated in the amniotic fluid; however, there was no evidence of preferential fetal drug accumulation (mean maternal/umbilical vein plasma ratios at delivery were 1.7 for valacyclovir and 1.3 for acyclovir).",Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9790357/),,1.7,37757,DB02377,Guanine
,9790357,plasma ratios,"Acyclovir was concentrated in the amniotic fluid; however, there was no evidence of preferential fetal drug accumulation (mean maternal/umbilical vein plasma ratios at delivery were 1.7 for valacyclovir and 1.3 for acyclovir).",Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9790357/),,1.3,37758,DB02377,Guanine
,18269776,time to progression,"Median time to progression was 5.3 months (95% CI, 3.1-8.9 months), and median time to treatment failure was 3.5 months (95% CI, 2.6-5.9 months).",Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18269776/),month,5.3,37883,DB02377,Guanine
,18269776,time to treatment failure,"Median time to progression was 5.3 months (95% CI, 3.1-8.9 months), and median time to treatment failure was 3.5 months (95% CI, 2.6-5.9 months).",Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18269776/),month,3.5,37884,DB02377,Guanine
,12479370,circulating plasma concentration (Cmax,"Low-circulating plasma concentration (Cmax = 87 microM; area under the curve = 1138 micromol x min/liters; after a bolus i.v. injection of 10 mg/kg) and rapid clearance of the drug (terminal half-life, t1/2 = 16 min) may contribute to the modest antitumor efficacy observed in vivo.",BCH-1868 [(-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-yl-methyl) tetrahydrofuran]: a cyclic nucleoside phosphonate with antitumor activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12479370/),μM,87,38555,DB02377,Guanine
,12479370,area under the curve,"Low-circulating plasma concentration (Cmax = 87 microM; area under the curve = 1138 micromol x min/liters; after a bolus i.v. injection of 10 mg/kg) and rapid clearance of the drug (terminal half-life, t1/2 = 16 min) may contribute to the modest antitumor efficacy observed in vivo.",BCH-1868 [(-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-yl-methyl) tetrahydrofuran]: a cyclic nucleoside phosphonate with antitumor activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12479370/),[min·μM] / [l],1138,38556,DB02377,Guanine
,12479370,"terminal half-life, t1/2","Low-circulating plasma concentration (Cmax = 87 microM; area under the curve = 1138 micromol x min/liters; after a bolus i.v. injection of 10 mg/kg) and rapid clearance of the drug (terminal half-life, t1/2 = 16 min) may contribute to the modest antitumor efficacy observed in vivo.",BCH-1868 [(-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-yl-methyl) tetrahydrofuran]: a cyclic nucleoside phosphonate with antitumor activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12479370/),min,16,38557,DB02377,Guanine
,12189361,bioavailability,"After oral administration of the prodrug valganciclovir, ganciclovir bioavailability was 60% and ganciclovir concentrations were higher (maximum concentration [C(max)], 8.5 microg/mL versus 5.8 microg/mL) and appeared later (time to maximum concentration [T(max)], 4.3 versus 2.0 hours) in patients with severe renal impairment compared with healthy subjects.",Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189361/),%,60,43346,DB02377,Guanine
,12189361,maximum concentration [C(max)],"After oral administration of the prodrug valganciclovir, ganciclovir bioavailability was 60% and ganciclovir concentrations were higher (maximum concentration [C(max)], 8.5 microg/mL versus 5.8 microg/mL) and appeared later (time to maximum concentration [T(max)], 4.3 versus 2.0 hours) in patients with severe renal impairment compared with healthy subjects.",Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189361/),[μg] / [ml],8.5,43347,DB02377,Guanine
,12189361,maximum concentration [C(max)],"After oral administration of the prodrug valganciclovir, ganciclovir bioavailability was 60% and ganciclovir concentrations were higher (maximum concentration [C(max)], 8.5 microg/mL versus 5.8 microg/mL) and appeared later (time to maximum concentration [T(max)], 4.3 versus 2.0 hours) in patients with severe renal impairment compared with healthy subjects.",Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189361/),[μg] / [ml],5.8,43348,DB02377,Guanine
,12189361,time to maximum concentration [T(max)],"After oral administration of the prodrug valganciclovir, ganciclovir bioavailability was 60% and ganciclovir concentrations were higher (maximum concentration [C(max)], 8.5 microg/mL versus 5.8 microg/mL) and appeared later (time to maximum concentration [T(max)], 4.3 versus 2.0 hours) in patients with severe renal impairment compared with healthy subjects.",Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189361/),h,4.3,43349,DB02377,Guanine
,12189361,time to maximum concentration [T(max)],"After oral administration of the prodrug valganciclovir, ganciclovir bioavailability was 60% and ganciclovir concentrations were higher (maximum concentration [C(max)], 8.5 microg/mL versus 5.8 microg/mL) and appeared later (time to maximum concentration [T(max)], 4.3 versus 2.0 hours) in patients with severe renal impairment compared with healthy subjects.",Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189361/),h,2.0,43350,DB02377,Guanine
,12189361,t(1/2),The elimination half-life (t(1/2)) of ganciclovir was longer in patients with renal failure (t(1/2) of 68.1 hours in patients with end-stage renal disease compared with 3.5 hours in healthy subjects).,Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189361/),h,68.1,43351,DB02377,Guanine
,12189361,t(1/2),The elimination half-life (t(1/2)) of ganciclovir was longer in patients with renal failure (t(1/2) of 68.1 hours in patients with end-stage renal disease compared with 3.5 hours in healthy subjects).,Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189361/),h,3.5,43352,DB02377,Guanine
,19509274,maximum inhibition,"However, maximum inhibition of thymidine incorporation into tumors was only 50%, which was insufficient to enhance pemetrexed antitumor activity in vivo.",Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19509274/),%,50,43494,DB02377,Guanine
,18028106,bioavailability (F),"However, the bioavailability (F) of acyclovir was 8.4% in group A versus 1.5% in group C.",Interaction between valproic acid and acyclovir after intravenous and oral administration in a rabbit model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18028106/),%,8.4,44441,DB02377,Guanine
,18028106,bioavailability (F),"However, the bioavailability (F) of acyclovir was 8.4% in group A versus 1.5% in group C.",Interaction between valproic acid and acyclovir after intravenous and oral administration in a rabbit model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18028106/),%,1.5,44442,DB02377,Guanine
,31425489,clearance (CL),"In the final model, the estimated clearance (CL) and volume of distribution (V1) were 2.3 L/h and 42 L, respectively, for a patient with the median CKD-EPI of the population (65 mL/min per 1.73 m).",Population Pharmacokinetics of Ganciclovir in Critically Ill Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425489/),[l] / [h],2.3,46055,DB02377,Guanine
,31425489,volume of distribution (V1),"In the final model, the estimated clearance (CL) and volume of distribution (V1) were 2.3 L/h and 42 L, respectively, for a patient with the median CKD-EPI of the population (65 mL/min per 1.73 m).",Population Pharmacokinetics of Ganciclovir in Critically Ill Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425489/),l,42,46056,DB02377,Guanine
>,31425489,trough level,MCS revealed that a substantial number of patients may not achieve the GCV PK/pharmacodynamic target trough level (>1.5 mg/L) when administering the label-recommended dose reductions for patients with CKD-EPI <50 mL/min.,Population Pharmacokinetics of Ganciclovir in Critically Ill Patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425489/),[mg] / [l],1.5,46057,DB02377,Guanine
exceeded,23054206,MTD,The MTD was exceeded at 100 mg/m(2)/d due to grade 3 anemia in 50 % of patients.,"A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23054206/),,100,46603,DB02377,Guanine
,23054206,t1/2,TRC102 exposure increased in proportion to dose with a mean t1/2 of 28 h.,"A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23054206/),h,28,46604,DB02377,Guanine
,15117573,ID(50)s,The aqueous humor ACV concentration maintained by LIPO-ACV during the plateau was in the upper range of the ID(50)s (0.01 to 0.7 microg/mL) reported for Herpes simplex type 1.,Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15117573/),[μg] / [ml],0.01 to 0.7,48284,DB02377,Guanine
,8690817,time to maximum concentration (tmax),The mean time to maximum concentration (tmax) was increased from 1.8 hours in the fasting state to 3.0 hours in the fed state.,Effect of food on the relative bioavailability of oral ganciclovir. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690817/),h,1.8,48524,DB02377,Guanine
,8690817,time to maximum concentration (tmax),The mean time to maximum concentration (tmax) was increased from 1.8 hours in the fasting state to 3.0 hours in the fed state.,Effect of food on the relative bioavailability of oral ganciclovir. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690817/),h,3.0,48525,DB02377,Guanine
,9145874,50% inhibitory concentration [IC50],"1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT).","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),μM,0.26,49026,DB02377,Guanine
,9145874,50% inhibitory concentration [IC50],"1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT).","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),μM,0.23,49027,DB02377,Guanine
,9145874,Ki,"The 5'-triphosphate of CBV was a potent, selective inhibitor of HIV-1 RT, with Ki values for DNA polymerases (alpha, beta, gamma, and epsilon which were 90-, 2,900-, 1,200-, and 1,900-fold greater, respectively, than for RT (Ki, 21 nM).","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),nM,21,49028,DB02377,Guanine
,9145874,IC50s,"1592U89 was relatively nontoxic to human bone marrow progenitors erythroid burst-forming unit and granulocyte-macrophage CFU (IC50s, 110 microM) and human leukemic and liver tumor cell lines.","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),μM,110,49029,DB02377,Guanine
,9145874,oral bioavailability,1592U89 had excellent oral bioavailability (105% in the rat) and penetrated the CNS (rat brain and monkey cerebrospinal fluid) as well as AZT.,"1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),%,105,49030,DB02377,Guanine
,1656863,oral bioavailability,"In mice, SQ 34,514 had an oral bioavailability of 80% based on urinary excretion.","Evaluation of SQ 34,514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1656863/),%,80,49321,DB02377,Guanine
,12183689,K(i),"VX-148 is a novel, uncompetitive IMPDH inhibitor with a K(i) value of 6 nM against IMPDH type II enzyme.","Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183689/),nM,6,49374,DB02377,Guanine
,12183689,IC(50),VX-148 is slightly more potent than mycophenolic acid and VX-497 in inhibiting the proliferation of mitogen-stimulated primary human lymphocytes (IC(50) value of ~80 nM).,"Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183689/),nM,80,49375,DB02377,Guanine
,12183689,ED(50),VX-148 is orally bioavailable in rats and mice; oral administration of VX-148 inhibits primary antibody response in mice in a dose-dependent manner with an ED(50) value of 38 mg/kg b.i.d.,"Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183689/),[mg] / [kg],38,49376,DB02377,Guanine
,32988829,trough concentrations,"Dosing simulations were used to obtain trough concentrations above a 50% inhibitory concentration for HSV or VZV (0.56 mg/liter and 1.125 mg/liter, respectively) and maximal peak concentrations below 25 mg/liter.",Population Pharmacokinetics of Intravenous and Oral Acyclovir and Oral Valacyclovir in Pediatric Population To Optimize Dosing Regimens. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988829/),[mg] / [l],0.56,50126,DB02377,Guanine
,32988829,trough concentrations,"Dosing simulations were used to obtain trough concentrations above a 50% inhibitory concentration for HSV or VZV (0.56 mg/liter and 1.125 mg/liter, respectively) and maximal peak concentrations below 25 mg/liter.",Population Pharmacokinetics of Intravenous and Oral Acyclovir and Oral Valacyclovir in Pediatric Population To Optimize Dosing Regimens. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988829/),[mg] / [l],1.125,50127,DB02377,Guanine
below,32988829,maximal peak concentrations,"Dosing simulations were used to obtain trough concentrations above a 50% inhibitory concentration for HSV or VZV (0.56 mg/liter and 1.125 mg/liter, respectively) and maximal peak concentrations below 25 mg/liter.",Population Pharmacokinetics of Intravenous and Oral Acyclovir and Oral Valacyclovir in Pediatric Population To Optimize Dosing Regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988829/),[mg] / [l],25,50128,DB02377,Guanine
,28383392,AUC0-24,"Median ganciclovir AUC0-24 was 21.0 mcg·h/mL (interquartile range, 17.1-39.8); 10 patients (77%) attained AUC0-24 <40 mcg·h/mL.",Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28383392/),[h·mcg] / [ml],21.0,50473,DB02377,Guanine
<,28383392,AUC0-24,"Median ganciclovir AUC0-24 was 21.0 mcg·h/mL (interquartile range, 17.1-39.8); 10 patients (77%) attained AUC0-24 <40 mcg·h/mL.",Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28383392/),[h·mcg] / [ml],40,50474,DB02377,Guanine
,19794230,oral bioavailability,Pharmacokinetic studies in mice established that the oral bioavailability of valcyclopropavir was 95%.,L-valine ester of cyclopropavir: a new antiviral prodrug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19794230/),%,95,50570,DB02377,Guanine
,8245883,peak plasma concentration (Cmax),"The 1,000 mg dose produced an acyclovir peak plasma concentration (Cmax) of 5-6 micrograms/ml, AUC6 of 19 hr.",Valaciclovir (BW256U87): the L-valyl ester of acyclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245883/),[μg] / [ml],5-6,51288,DB02377,Guanine
,8245883,AUC6,"The 1,000 mg dose produced an acyclovir peak plasma concentration (Cmax) of 5-6 micrograms/ml, AUC6 of 19 hr.",Valaciclovir (BW256U87): the L-valyl ester of acyclovir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245883/),h,19,51289,DB02377,Guanine
,8245883,time to maximum plasma concentration (Tmax),"micrograms/ml, time to maximum plasma concentration (Tmax) of 1-2 hr, and half-life (T1/2) of 2.8 hr.",Valaciclovir (BW256U87): the L-valyl ester of acyclovir. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245883/),h,1-2,51290,DB02377,Guanine
,8245883,half-life (T1/2),"micrograms/ml, time to maximum plasma concentration (Tmax) of 1-2 hr, and half-life (T1/2) of 2.8 hr.",Valaciclovir (BW256U87): the L-valyl ester of acyclovir. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245883/),h,2.8,51291,DB02377,Guanine
<,8245883,peak levels,"Plasma valaciclovir peak levels were < 0.3 micrograms/ml, and the prodrug was undetectable after 3 hr.",Valaciclovir (BW256U87): the L-valyl ester of acyclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245883/),[μg] / [ml],0.3,51292,DB02377,Guanine
,8245883,Cmax,"At the 2 g dose administered four times daily, steady-state acyclovir Cmax = 8.4 micrograms/ml, Tmax = 2.0 hr, AUC6 = 30.5 hr. micrograms/ml, and T1/2 = 3.3 hr.",Valaciclovir (BW256U87): the L-valyl ester of acyclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245883/),[μg] / [ml],8.4,51293,DB02377,Guanine
,8245883,Tmax,"At the 2 g dose administered four times daily, steady-state acyclovir Cmax = 8.4 micrograms/ml, Tmax = 2.0 hr, AUC6 = 30.5 hr. micrograms/ml, and T1/2 = 3.3 hr.",Valaciclovir (BW256U87): the L-valyl ester of acyclovir. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245883/),h,2.0,51294,DB02377,Guanine
,8245883,AUC6,"At the 2 g dose administered four times daily, steady-state acyclovir Cmax = 8.4 micrograms/ml, Tmax = 2.0 hr, AUC6 = 30.5 hr. micrograms/ml, and T1/2 = 3.3 hr.",Valaciclovir (BW256U87): the L-valyl ester of acyclovir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245883/),[h·μg] / [ml],30.5,51295,DB02377,Guanine
,8245883,T1/2,"At the 2 g dose administered four times daily, steady-state acyclovir Cmax = 8.4 micrograms/ml, Tmax = 2.0 hr, AUC6 = 30.5 hr. micrograms/ml, and T1/2 = 3.3 hr.",Valaciclovir (BW256U87): the L-valyl ester of acyclovir. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245883/),h,3.3,51296,DB02377,Guanine
,17683023,total analysis time,The total analysis time from injection to injection was 11 min.,Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17683023/),min,11,52986,DB02377,Guanine
> or =,17683023,recovery,"The lower and upper limits of quantitation were 0.056 and 56 ng/ml, respectively; recovery of SJG-136 from plasma was > or = 62% across the validated concentration range.",Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17683023/),%,62,52987,DB02377,Guanine
,24152053,AUC,"Data from 104 pediatric SOT recipients (kidney, liver, and heart) aged 0.3-16.9 yr and receiving v-GCV once a day were used for model development and validation with the Pmetrics package for R. Monte Carlo simulations were performed to compare the probability of a GCV AUC 40-60 mg*h/L with the different algorithms across a range of ages, weights, and GFRs.",New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152053/),[h·mg] / [l],40-60,54287,DB02377,Guanine
,24152053,k,"Simulations showed that our new algorithm, where v-GCV dose is: Weight [kg]*(0.07*GFR [mL/min]+k), where k = 5 for GFR ≤ 30 mL/min, k = 10 for GFR > 30 mL/min and weight > 30 kg and k = 15 for GFR > 30 mL/min and weight ≤ 30 kg, outperformed the other algorithms.",New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152053/),,10,54288,DB02377,Guanine
,24152053,k,"Simulations showed that our new algorithm, where v-GCV dose is: Weight [kg]*(0.07*GFR [mL/min]+k), where k = 5 for GFR ≤ 30 mL/min, k = 10 for GFR > 30 mL/min and weight > 30 kg and k = 15 for GFR > 30 mL/min and weight ≤ 30 kg, outperformed the other algorithms.",New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152053/),,15,54289,DB02377,Guanine
,1742847,plasma clearance,"The drug was cleared rapidly from plasma; at doses of 200-600 mg/m2, the mean plasma clearance was 61.64 +/- 9.97 l/h and the mean terminal-phase elimination half-life was 1.6 +/- 0.6 h.",Clinical pharmacokinetics of 3-deazaguanine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742847/),[l] / [h],61.64,55152,DB02377,Guanine
,1742847,terminal-phase elimination half-life,"The drug was cleared rapidly from plasma; at doses of 200-600 mg/m2, the mean plasma clearance was 61.64 +/- 9.97 l/h and the mean terminal-phase elimination half-life was 1.6 +/- 0.6 h.",Clinical pharmacokinetics of 3-deazaguanine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742847/),h,1.6,55153,DB02377,Guanine
,1742847,steady-state volume of distribution,The steady-state volume of distribution (98.9 +/- 29.1 l) and distribution coefficient (1.24 +/- 0.39 l/kg) indicated extensive tissue distribution for the drug.,Clinical pharmacokinetics of 3-deazaguanine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742847/),l,98.9,55154,DB02377,Guanine
,1742847,distribution coefficient,The steady-state volume of distribution (98.9 +/- 29.1 l) and distribution coefficient (1.24 +/- 0.39 l/kg) indicated extensive tissue distribution for the drug.,Clinical pharmacokinetics of 3-deazaguanine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742847/),[l] / [kg],1.24,55155,DB02377,Guanine
,7979285,time to maximum concentration,"The time to maximum concentration in serum and half-life of acyclovir after valaciclovir administration were approximately 2 and 3 h, respectively, which were similar to those reported after oral administration of acyclovir itself.","Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7979285/),h,2,56201,DB02377,Guanine
,7979285,half-life,"The time to maximum concentration in serum and half-life of acyclovir after valaciclovir administration were approximately 2 and 3 h, respectively, which were similar to those reported after oral administration of acyclovir itself.","Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7979285/),h,3,56202,DB02377,Guanine
,7979285,trough,"The mean trough and peak acyclovir concentrations and the daily area under the concentration-time curve acyclovir values at steady state were 2.5 and 8.4 micrograms/ml and 120 h micrograms/ml, respectively, after a dosage of 2,000 mg of valaciclovir four times daily.","Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7979285/),[μg] / [ml],2.5,56203,DB02377,Guanine
,7979285,peak acyclovir concentrations,"The mean trough and peak acyclovir concentrations and the daily area under the concentration-time curve acyclovir values at steady state were 2.5 and 8.4 micrograms/ml and 120 h micrograms/ml, respectively, after a dosage of 2,000 mg of valaciclovir four times daily.","Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7979285/),[μg] / [ml],2.5,56204,DB02377,Guanine
,7979285,area under the concentration-time curve,"The mean trough and peak acyclovir concentrations and the daily area under the concentration-time curve acyclovir values at steady state were 2.5 and 8.4 micrograms/ml and 120 h micrograms/ml, respectively, after a dosage of 2,000 mg of valaciclovir four times daily.","Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7979285/),[μg] / [ml],8.4,56205,DB02377,Guanine
,7979285,area under the concentration-time curve,"The mean trough and peak acyclovir concentrations and the daily area under the concentration-time curve acyclovir values at steady state were 2.5 and 8.4 micrograms/ml and 120 h micrograms/ml, respectively, after a dosage of 2,000 mg of valaciclovir four times daily.","Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7979285/),[h·μg] / [ml],120,56206,DB02377,Guanine
,3134696,alpha half-life,"These studies demonstrate a rapid, biphasic elimination pattern for the drug: alpha half-life of 8 minutes and beta, or terminal, half-life of 48 minutes.","New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134696/),min,8,56386,DB02377,Guanine
,3134696,terminal,"These studies demonstrate a rapid, biphasic elimination pattern for the drug: alpha half-life of 8 minutes and beta, or terminal, half-life of 48 minutes.","New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134696/),min,48,56387,DB02377,Guanine
,15297409,peak concentration,"The peak concentration of O(6)BG (mean +/- SD) was 11 +/- 4 microm, and the peak concentration of its active metabolite, 8-oxo-O(6)BG, was 35 +/- 10 microm.",Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15297409/),μm,11,57754,DB02377,Guanine
,15297409,peak concentration,"The peak concentration of O(6)BG (mean +/- SD) was 11 +/- 4 microm, and the peak concentration of its active metabolite, 8-oxo-O(6)BG, was 35 +/- 10 microm.",Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15297409/),μm,35,57755,DB02377,Guanine
,15297409,half-life,"O(6)BG was rapidly eliminated with a half-life of 85 +/- 140 min, area under the curve of 795 +/- 320 microm.",Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15297409/),min,85,57756,DB02377,Guanine
,15297409,area under the curve,"O(6)BG was rapidly eliminated with a half-life of 85 +/- 140 min, area under the curve of 795 +/- 320 microm.",Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15297409/),μm,795,57757,DB02377,Guanine
,15297409,clearance,min and clearance of 760 +/- 400 ml/min/m(2).,Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15297409/),[min·ml] / [m(2],760,57758,DB02377,Guanine
,15297409,area under the curve,"The area under the curve of 8-oxo-O(6)BG when extrapolated to infinity was 22,700 +/- 11,800 microm.",Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15297409/),μm,"22,700",57759,DB02377,Guanine
,15297409,clearance,"The clearance and terminal half-life of 8-oxo-O(6)BG were 30 +/- 15 ml/min/m(2) and 360 +/- 220 min, respectively.",Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15297409/),[min·ml] / [m(2],30,57760,DB02377,Guanine
,15297409,terminal half-life,"The clearance and terminal half-life of 8-oxo-O(6)BG were 30 +/- 15 ml/min/m(2) and 360 +/- 220 min, respectively.",Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15297409/),min,360,57761,DB02377,Guanine
,29597034,solubility,"EV-3-palmitate (named EV-P), exhibited the lowest solubility in phosphate buffered saline (pH 7.4, 1.1 μg/ml), with extended release profile compared with EV, EV-3-myristate, and EV-3-stearate, was selected as a candidate to formulate drug suspension.",Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29597034/),[μg] / [ml],1.1,58465,DB02377,Guanine
,29597034,maximum plasma concentration (Cmax,"After subcutaneous (SC) injection in beagle dogs (0.43 mg/kg as EV), the plasma concentrations of EV were markedly protracted with lowered maximum plasma concentration (Cmax, 4.7 ng/ml), extended time required to reach Cmax (Tmax, 9.0 days), and lengthened elimination half-life (T1/2, 129.3 h) compared with those after oral administration (0.0154 mg/kg, Cmax, 15.4 ng/ml; Tmax, 0.01 days; T1/2, 4.1 h).",Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29597034/),[ng] / [ml],4.7,58466,DB02377,Guanine
,29597034,time required to reach Cmax (Tmax,"After subcutaneous (SC) injection in beagle dogs (0.43 mg/kg as EV), the plasma concentrations of EV were markedly protracted with lowered maximum plasma concentration (Cmax, 4.7 ng/ml), extended time required to reach Cmax (Tmax, 9.0 days), and lengthened elimination half-life (T1/2, 129.3 h) compared with those after oral administration (0.0154 mg/kg, Cmax, 15.4 ng/ml; Tmax, 0.01 days; T1/2, 4.1 h).",Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29597034/),d,9.0,58467,DB02377,Guanine
,29597034,elimination half-life (T1/2,"After subcutaneous (SC) injection in beagle dogs (0.43 mg/kg as EV), the plasma concentrations of EV were markedly protracted with lowered maximum plasma concentration (Cmax, 4.7 ng/ml), extended time required to reach Cmax (Tmax, 9.0 days), and lengthened elimination half-life (T1/2, 129.3 h) compared with those after oral administration (0.0154 mg/kg, Cmax, 15.4 ng/ml; Tmax, 0.01 days; T1/2, 4.1 h).",Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29597034/),h,129.3,58468,DB02377,Guanine
,29597034,Cmax,"After subcutaneous (SC) injection in beagle dogs (0.43 mg/kg as EV), the plasma concentrations of EV were markedly protracted with lowered maximum plasma concentration (Cmax, 4.7 ng/ml), extended time required to reach Cmax (Tmax, 9.0 days), and lengthened elimination half-life (T1/2, 129.3 h) compared with those after oral administration (0.0154 mg/kg, Cmax, 15.4 ng/ml; Tmax, 0.01 days; T1/2, 4.1 h).",Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29597034/),[ng] / [ml],15.4,58469,DB02377,Guanine
,29597034,Tmax,"After subcutaneous (SC) injection in beagle dogs (0.43 mg/kg as EV), the plasma concentrations of EV were markedly protracted with lowered maximum plasma concentration (Cmax, 4.7 ng/ml), extended time required to reach Cmax (Tmax, 9.0 days), and lengthened elimination half-life (T1/2, 129.3 h) compared with those after oral administration (0.0154 mg/kg, Cmax, 15.4 ng/ml; Tmax, 0.01 days; T1/2, 4.1 h).",Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29597034/),d,0.01,58470,DB02377,Guanine
,29597034,T1/2,"After subcutaneous (SC) injection in beagle dogs (0.43 mg/kg as EV), the plasma concentrations of EV were markedly protracted with lowered maximum plasma concentration (Cmax, 4.7 ng/ml), extended time required to reach Cmax (Tmax, 9.0 days), and lengthened elimination half-life (T1/2, 129.3 h) compared with those after oral administration (0.0154 mg/kg, Cmax, 15.4 ng/ml; Tmax, 0.01 days; T1/2, 4.1 h).",Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29597034/),h,4.1,58471,DB02377,Guanine
,26333938,AUC0-∞,The AUC0-∞ and mean residence time of optimised formulation (7527.9 ng h/mL and 12.09 h) were significantly high than tablet dispersion (3841.13 ng h/mL and 7.97 h).,Development and optimisation of mucoadhesive nanoparticles of acyclovir using design of experiments approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333938/),[h·ng] / [ml],7527.9,59896,DB02377,Guanine
,26333938,AUC0-∞,The AUC0-∞ and mean residence time of optimised formulation (7527.9 ng h/mL and 12.09 h) were significantly high than tablet dispersion (3841.13 ng h/mL and 7.97 h).,Development and optimisation of mucoadhesive nanoparticles of acyclovir using design of experiments approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333938/),[h·ng] / [ml],3841.13,59897,DB02377,Guanine
,26333938,mean residence time,The AUC0-∞ and mean residence time of optimised formulation (7527.9 ng h/mL and 12.09 h) were significantly high than tablet dispersion (3841.13 ng h/mL and 7.97 h).,Development and optimisation of mucoadhesive nanoparticles of acyclovir using design of experiments approach. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333938/),h,12.09,59898,DB02377,Guanine
,26333938,mean residence time,The AUC0-∞ and mean residence time of optimised formulation (7527.9 ng h/mL and 12.09 h) were significantly high than tablet dispersion (3841.13 ng h/mL and 7.97 h).,Development and optimisation of mucoadhesive nanoparticles of acyclovir using design of experiments approach. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333938/),h,7.97,59899,DB02377,Guanine
,23136232,area under the concentration-time curve (AUC),"The combination of carboplatin at an area under the concentration-time curve (AUC) of 5, and 500 mg/m(2) pemetrexed, was determined to be the recommended dose for elderly patients with advanced nonsquamous NSCLC.",Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136232/),,5,59900,DB02377,Guanine
,23136232,overall response rate,The study had an overall response rate of 47.1%.,Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136232/),%,47.1,59901,DB02377,Guanine
,23136232,progression-free survival time,The median progression-free survival time was 142 days (95% confidence interval [CI] 68-216 days) and the median overall survival time was 461 days (95% CI 168-754 days).,Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136232/),d,142,59902,DB02377,Guanine
,23136232,overall survival time,The median progression-free survival time was 142 days (95% confidence interval [CI] 68-216 days) and the median overall survival time was 461 days (95% CI 168-754 days).,Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136232/),d,461,59903,DB02377,Guanine
,23136232,area under the curve (AUC),"This combination was a tolerable and effective regimen, and recommended dose (RD) was carboplatin [area under the curve (AUC) of 5]/pemetrexed (500 mg/m(2)) every 3 weeks, in chemotherapy-naïve, elderly (≥75 years old) patients with advanced nonsquamous NSCLC.",Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136232/),,5,59904,DB02377,Guanine
,16551692,AUC,"However, the decrease in the plasma ganciclovir concentration was slower in Group B (P = 0.09), and the AUC of all patients in both groups was distributed within a narrow range (25.6 +/- 4.77 microg x h/mL), when two patients with exceptionally high AUC values were excluded.",Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551692/),[h·μg] / [ml],25.6,59925,DB02377,Guanine
,9200543,detection limit,"It is both specific and sensitive with a detection limit of 30 ng/ml at a signal-to-noise ratio of 3:1, and is thus suitable for use in pharmacokinetic studies of acyclovir.",Simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma using fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200543/),[ng] / [ml],30,60944,DB02377,Guanine
,9200543,signal-to-noise ratio,"It is both specific and sensitive with a detection limit of 30 ng/ml at a signal-to-noise ratio of 3:1, and is thus suitable for use in pharmacokinetic studies of acyclovir.",Simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma using fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200543/),,3:1,60945,DB02377,Guanine
,9200543,absolute recovery,"The method had a mean absolute recovery of 96%, while the within-day and between-day coefficients of variation and percentages error were all less than 8%.",Simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma using fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200543/),%,96,60946,DB02377,Guanine
,27026342,particle size,The optimized TH-NP formulation exhibited particle size of 474.4±2.01 and an entrapment efficiency of 81.57%.,Improving oral bioavailability of acyclovir using nanoparticulates of thiolated xyloglucan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27026342/),,474.4,60983,DB02377,Guanine
,27026342,entrapment efficiency,The optimized TH-NP formulation exhibited particle size of 474.4±2.01 and an entrapment efficiency of 81.57%.,Improving oral bioavailability of acyclovir using nanoparticulates of thiolated xyloglucan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27026342/),%,81.57,60984,DB02377,Guanine
less,19358150,run times,"Characteristics of the assay include a low plasma volume (200 microL), perchloric acid protein precipitation, use of penciclovir as the internal standard, run times less than 8 min and a 50 ng/mL lower limit of quantification.","Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358150/),min,8,62965,DB02377,Guanine
,19358150,Acc,"Accuracy for all three drugs ranges from 89.5 to 106.4% for four quality controls (50, 100, 1000 and 10,000 ng/mL).","Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358150/),,89,62966,DB02377,Guanine
≥,32379860,trough concentrations,Ganciclovir trough concentrations ≥0.60 μg/mL have been suggested for CMV prophylaxis.,Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid-organ Transplant Recipients on Continuous Veno-venous Hemodialysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32379860/),[μg] / [ml],0.60,63144,DB02377,Guanine
≥,32379860,trough concentrations,This study was conducted to determine if valganciclovir 450 mg enterally every 24 hours achieves ganciclovir trough concentrations ≥0.60 μg/mL in patients on CVVHD.,Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid-organ Transplant Recipients on Continuous Veno-venous Hemodialysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32379860/),[μg] / [ml],0.60,63145,DB02377,Guanine
,32379860,trough concentrations,"Ganciclovir trough concentrations ranged from 0.31 to 3.16 μg/mL, and 80% of participants have trough concentrations ≥0.60 μg/mL.",Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid-organ Transplant Recipients on Continuous Veno-venous Hemodialysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32379860/),[μg] / [ml],0.31 to 3.16,63146,DB02377,Guanine
≥,32379860,trough concentrations,"Ganciclovir trough concentrations ranged from 0.31 to 3.16 μg/mL, and 80% of participants have trough concentrations ≥0.60 μg/mL.",Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid-organ Transplant Recipients on Continuous Veno-venous Hemodialysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32379860/),[μg] / [ml],0.60,63147,DB02377,Guanine
≥,32379860,trough concentrations,"Valganciclovir 450 mg enterally every 24 hours achieved ganciclovir trough concentrations ≥0.60 μg/mL in most patients on CVVHD, similar to those reported with intravenous ganciclovir for prophylaxis in this population.",Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid-organ Transplant Recipients on Continuous Veno-venous Hemodialysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32379860/),[μg] / [ml],0.60,63148,DB02377,Guanine
,2293208,distribution half-life,"Biexponential decay of ganciclovir plasma concentration-time and urinary excretion rate-time profiles was observed, with a mean distribution half-life of 15.8 min and an elimination half-life of 96 min.",A sensitive and specific liquid-chromatographic assay for determination of ganciclovir in plasma and urine and its application to pharmacokinetic studies in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293208/),min,15.8,64321,DB02377,Guanine
,2293208,elimination half-life,"Biexponential decay of ganciclovir plasma concentration-time and urinary excretion rate-time profiles was observed, with a mean distribution half-life of 15.8 min and an elimination half-life of 96 min.",A sensitive and specific liquid-chromatographic assay for determination of ganciclovir in plasma and urine and its application to pharmacokinetic studies in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293208/),min,96,64322,DB02377,Guanine
,2293208,renal clearance,"The mean renal clearance, 9.0 ml/min per kg, exceeds the glomerular filtration rate in the rabbit, indicating that ganciclovir is actively secreted in the renal tubule.",A sensitive and specific liquid-chromatographic assay for determination of ganciclovir in plasma and urine and its application to pharmacokinetic studies in the rabbit. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293208/),[ml] / [kg·min],9.0,64323,DB02377,Guanine
,26902907,percent drug entrapment efficiency,The percent drug entrapment efficiency varied between 56.12 ± 1.32 % to 87.32 ± 5.28 %.,Piperine containing floating microspheres: an approach for drug targeting to the upper gastrointestinal tract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902907/),%,56.12,64772,DB02377,Guanine
,26902907,percent drug entrapment efficiency,The percent drug entrapment efficiency varied between 56.12 ± 1.32 % to 87.32 ± 5.28 %.,Piperine containing floating microspheres: an approach for drug targeting to the upper gastrointestinal tract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902907/),%,87.32,64773,DB02377,Guanine
,26902907,AUC0-24,Nearly two times higher AUC0-24 value of acyclovir-loaded piperine containing microspheres (15614.13 ± 6953.13 ng h ml(-1)) was observed as compared to the drug solution (7552.33 ± 3219.09 ng h ml(-1)).,Piperine containing floating microspheres: an approach for drug targeting to the upper gastrointestinal tract. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902907/),[h·ng] / [ml],15614.13,64774,DB02377,Guanine
,26902907,AUC0-24,Nearly two times higher AUC0-24 value of acyclovir-loaded piperine containing microspheres (15614.13 ± 6953.13 ng h ml(-1)) was observed as compared to the drug solution (7552.33 ± 3219.09 ng h ml(-1)).,Piperine containing floating microspheres: an approach for drug targeting to the upper gastrointestinal tract. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902907/),[h·ng] / [ml],7552.33,64775,DB02377,Guanine
,18638532,C(max(T)) (maximum concentration),C(max(T)) (maximum concentration) of SACV was observed to be 39+/-22 microM in plasma which is 2 times better than VACV and 15 times better than ACV.,Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638532/),μM,39,65321,DB02377,Guanine
,18638532,C(last(T)),C(last(T)) (concentration at the last time point) of SACV was observed to be 0.18+/-0.06 microM in plasma which is two times better than VACV and three times better than ACV.,Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638532/),μM,0.18,65322,DB02377,Guanine
,18523891,release of,The release of drug was prolonged to 12 h (78.8 +/- 3.9) when incorporated into mucoadhesive microspheres.,Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18523891/),h,12,66989,DB02377,Guanine
,18523891,release of,The release of drug was prolonged to 12 h (78.8 +/- 3.9) when incorporated into mucoadhesive microspheres.,Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18523891/),h,78.8,66990,DB02377,Guanine
,18523891,retention,The results of mucoadhesion study showed better retention of thiolated chitosan microspheres (8.0 +/- 0.8 h) in duodenal and jejunum regions of intestine.,Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18523891/),h,8.0,66991,DB02377,Guanine
,18523891,AUC(0-24),"Thiolated chitosan microsphere showed superiority over the other formulations as observed with nearly 4.0-fold higher AUC(0-24) value (1,090 +/- 51 ng h/ml) in comparison to drug solution (281 +/- 28 ng h/ml).",Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18523891/),[h·ng] / [ml],"1,090",66992,DB02377,Guanine
,18523891,AUC(0-24),"Thiolated chitosan microsphere showed superiority over the other formulations as observed with nearly 4.0-fold higher AUC(0-24) value (1,090 +/- 51 ng h/ml) in comparison to drug solution (281 +/- 28 ng h/ml).",Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18523891/),[h·ng] / [ml],281,66993,DB02377,Guanine
,25260366,lead-in time,Prior supplementation with folic acid and vitamin B12 is required to reduce pemetrexed therapy toxicity; the recommended lead-in time is at least 7 days.,A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260366/),,7,67200,DB02377,Guanine
,25260366,response rate,The response rate to chemotherapy was 43%.,A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25260366/),%,43,67201,DB02377,Guanine
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.25,67452,DB02377,Guanine
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.27,67453,DB02377,Guanine
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.31,67454,DB02377,Guanine
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.26,67455,DB02377,Guanine
,11448930,IC(50),"The novel DP analogues inhibit thymidine (dThd) uptake into L1210 cells in vitro (NU3076 IC(50), 0.25 microM; NU3084 IC(50), 0.27 microM; NU3108 IC(50), 0.31 microM; NU3121 IC(50), 0.26 microM; and DP IC(50), 0.37 microM), but, unlike DP, their activity remains largely unaffected in the presence of 5 mg/ml AGP.",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,0.37,67456,DB02377,Guanine
,11448930,peak plasma concentrations,"i.p. administration of 10 mg/kg NU3108, NU3121, and DP produced peak plasma concentrations of 4.4, 2.1, and 6.7 microM, respectively, and levels were sustained above 1 microM for approximately 45 min (DP) and 120 min (NU3108 and NU3121).",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,4.4,67457,DB02377,Guanine
,11448930,peak plasma concentrations,"i.p. administration of 10 mg/kg NU3108, NU3121, and DP produced peak plasma concentrations of 4.4, 2.1, and 6.7 microM, respectively, and levels were sustained above 1 microM for approximately 45 min (DP) and 120 min (NU3108 and NU3121).",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,2.1,67458,DB02377,Guanine
,11448930,peak plasma concentrations,"i.p. administration of 10 mg/kg NU3108, NU3121, and DP produced peak plasma concentrations of 4.4, 2.1, and 6.7 microM, respectively, and levels were sustained above 1 microM for approximately 45 min (DP) and 120 min (NU3108 and NU3121).",In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448930/),μM,6.7,67459,DB02377,Guanine
,3717158,elimination half-life,"The elimination half-life (17.1 hours) was similar to that reported for end-stage renal disease (ESRD) patients, while the volume of the central compartment (29.6 L/1.73 m2), the steady state volume of distribution (68.1 L/1.73 m2), and the total body clearance (48.3 mL/min/1.73 m2) were greater.",Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717158/),h,17.1,69256,DB02377,Guanine
,3717158,volume of the central compartment,"The elimination half-life (17.1 hours) was similar to that reported for end-stage renal disease (ESRD) patients, while the volume of the central compartment (29.6 L/1.73 m2), the steady state volume of distribution (68.1 L/1.73 m2), and the total body clearance (48.3 mL/min/1.73 m2) were greater.",Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717158/),[l] / [1.73·m2],29.6,69257,DB02377,Guanine
,3717158,steady state volume of distribution,"The elimination half-life (17.1 hours) was similar to that reported for end-stage renal disease (ESRD) patients, while the volume of the central compartment (29.6 L/1.73 m2), the steady state volume of distribution (68.1 L/1.73 m2), and the total body clearance (48.3 mL/min/1.73 m2) were greater.",Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717158/),[l] / [1.73·m2],68.1,69258,DB02377,Guanine
,3717158,total body clearance,"The elimination half-life (17.1 hours) was similar to that reported for end-stage renal disease (ESRD) patients, while the volume of the central compartment (29.6 L/1.73 m2), the steady state volume of distribution (68.1 L/1.73 m2), and the total body clearance (48.3 mL/min/1.73 m2) were greater.",Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717158/),[ml] / [1.73·m2·min],48.3,69259,DB02377,Guanine
,3717158,clearance,"The mean CAPD clearance was only 4.4 mL/min, with less than 10% of an administered dose being recovered in the 24-hour dialysate.",Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3717158/),[ml] / [min],4.4,69260,DB02377,Guanine
,17419605,uptake rates,"In isolated rat hearts, neuronal uptake rates of [11C]1a-m ranged from 0.24 to 1.96 mL min-1 (g wet wt)-1, and six compounds had extremely long neuronal retention times (clearance T1/2 > 20 h) due to efficient vesicular storage.",Radiolabeled phenethylguanidines: novel imaging agents for cardiac sympathetic neurons and adrenergic tumors. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17419605/),[g·ml] / [min],0.24 to 1.96,69967,DB02377,Guanine
>,17419605,clearance T1/2,"In isolated rat hearts, neuronal uptake rates of [11C]1a-m ranged from 0.24 to 1.96 mL min-1 (g wet wt)-1, and six compounds had extremely long neuronal retention times (clearance T1/2 > 20 h) due to efficient vesicular storage.",Radiolabeled phenethylguanidines: novel imaging agents for cardiac sympathetic neurons and adrenergic tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17419605/),h,20,69968,DB02377,Guanine
,3356318,half-life,"BIOLF-143 was rapidly distributed in the body, the estimated half-life in blood plasma being 18-23 min.",The acute toxicity of BIOLF-143 in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356318/),min,18-23,70585,DB02377,Guanine
,3356318,recovery,"The recovery of the parent compound was 74.3 +/- 5.9% and 88.5 +/- 15.9% for male and female rats, respectively, with no metabolites or unidentifiable peaks being detected in HPLC chromatograms.",The acute toxicity of BIOLF-143 in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356318/),%,74.3,70586,DB02377,Guanine
,3356318,recovery,"The recovery of the parent compound was 74.3 +/- 5.9% and 88.5 +/- 15.9% for male and female rats, respectively, with no metabolites or unidentifiable peaks being detected in HPLC chromatograms.",The acute toxicity of BIOLF-143 in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356318/),%,88.5,70587,DB02377,Guanine
,11120958,elimination half-life,"The elimination half-life decreased sharply during the first month after birth, from 10 to 15 h to 2.5 h.",Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120958/),h,10,71024,DB02377,Guanine
,11120958,elimination half-life,"The elimination half-life decreased sharply during the first month after birth, from 10 to 15 h to 2.5 h.",Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120958/),h,2.5,71025,DB02377,Guanine
,11120958,Bioavailability,Bioavailability was 0.12.,Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120958/),,0.12,71026,DB02377,Guanine
,24348022,oral bioavailability,"Acyclovir has pharmacokinetic limitations, including poor oral bioavailability of 15%-30%, high variability, and short elimination half-life of 2.3 hours.",Development and characterization of gastroretentive sustained-release formulation by combination of swelling and mucoadhesive approach: a mechanistic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24348022/),%,15,71343,DB02377,Guanine
,24348022,elimination half-life,"Acyclovir has pharmacokinetic limitations, including poor oral bioavailability of 15%-30%, high variability, and short elimination half-life of 2.3 hours.",Development and characterization of gastroretentive sustained-release formulation by combination of swelling and mucoadhesive approach: a mechanistic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24348022/),h,2.3,71344,DB02377,Guanine
,24348022,Mean residence time,Mean residence time of the GR formulation was 7 hours versus 3.3 hours for the IR formulation.,Development and characterization of gastroretentive sustained-release formulation by combination of swelling and mucoadhesive approach: a mechanistic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24348022/),h,7,71345,DB02377,Guanine
,24348022,Mean residence time,Mean residence time of the GR formulation was 7 hours versus 3.3 hours for the IR formulation.,Development and characterization of gastroretentive sustained-release formulation by combination of swelling and mucoadhesive approach: a mechanistic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24348022/),h,3.3,71346,DB02377,Guanine
,24348022,relative bioavailability,The relative bioavailability of the GR formulation was 261% of the IR formulation.,Development and characterization of gastroretentive sustained-release formulation by combination of swelling and mucoadhesive approach: a mechanistic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24348022/),%,261,71347,DB02377,Guanine
,7779152,Cmax,"In the case of the 200 mg tablets, the mean Cmax-values were 454 ng/ml (pilot test formulation, T) and 525 ng/ml (reference formulation, R), whereas the mean Cmax-values after administration of the 400 mg tablets were 779 (T) and 800 (R) ng/ml for test and reference formulation, respectively.",Pharmacokinetics and bioavailability of different formulations of aciclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779152/),[ng] / [ml],454,71817,DB02377,Guanine
,7779152,Cmax,"In the case of the 200 mg tablets, the mean Cmax-values were 454 ng/ml (pilot test formulation, T) and 525 ng/ml (reference formulation, R), whereas the mean Cmax-values after administration of the 400 mg tablets were 779 (T) and 800 (R) ng/ml for test and reference formulation, respectively.",Pharmacokinetics and bioavailability of different formulations of aciclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779152/),[ng] / [ml],525,71818,DB02377,Guanine
,7779152,Cmax,"In the case of the 200 mg tablets, the mean Cmax-values were 454 ng/ml (pilot test formulation, T) and 525 ng/ml (reference formulation, R), whereas the mean Cmax-values after administration of the 400 mg tablets were 779 (T) and 800 (R) ng/ml for test and reference formulation, respectively.",Pharmacokinetics and bioavailability of different formulations of aciclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779152/),[ng] / [ml],779,71819,DB02377,Guanine
,7779152,Cmax,"In the case of the 200 mg tablets, the mean Cmax-values were 454 ng/ml (pilot test formulation, T) and 525 ng/ml (reference formulation, R), whereas the mean Cmax-values after administration of the 400 mg tablets were 779 (T) and 800 (R) ng/ml for test and reference formulation, respectively.",Pharmacokinetics and bioavailability of different formulations of aciclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779152/),[ng] / [ml],800,71820,DB02377,Guanine
,7779152,AUC,The mean AUC calculated to the time of the last measurement in each instance was in the order of 2290 (T) and 2275 (R) ng/ml x h (200 mg tablets) or 3726 (T) and 3855 (R) ng/ml x h (400 mg tablets).,Pharmacokinetics and bioavailability of different formulations of aciclovir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779152/),[ng] / [h·ml],2290,71821,DB02377,Guanine
,7779152,AUC,The mean AUC calculated to the time of the last measurement in each instance was in the order of 2290 (T) and 2275 (R) ng/ml x h (200 mg tablets) or 3726 (T) and 3855 (R) ng/ml x h (400 mg tablets).,Pharmacokinetics and bioavailability of different formulations of aciclovir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779152/),[ng] / [h·ml],2275,71822,DB02377,Guanine
,7779152,AUC,The mean AUC calculated to the time of the last measurement in each instance was in the order of 2290 (T) and 2275 (R) ng/ml x h (200 mg tablets) or 3726 (T) and 3855 (R) ng/ml x h (400 mg tablets).,Pharmacokinetics and bioavailability of different formulations of aciclovir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779152/),[ng] / [h·ml],3726,71823,DB02377,Guanine
,7779152,AUC,The mean AUC calculated to the time of the last measurement in each instance was in the order of 2290 (T) and 2275 (R) ng/ml x h (200 mg tablets) or 3726 (T) and 3855 (R) ng/ml x h (400 mg tablets).,Pharmacokinetics and bioavailability of different formulations of aciclovir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779152/),[ng] / [h·ml],3855,71824,DB02377,Guanine
,2243158,half-life,"The half-life in subjects receiving hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) is similarly prolonged (10.0 +/- 2.2 and 13.2 +/- 4.7 hours, respectively).",Intraperitoneal administration of acyclovir in patients receiving continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243158/),h,10.0,72562,DB02377,Guanine
,2243158,half-life,"The half-life in subjects receiving hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) is similarly prolonged (10.0 +/- 2.2 and 13.2 +/- 4.7 hours, respectively).",Intraperitoneal administration of acyclovir in patients receiving continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243158/),h,13.2,72563,DB02377,Guanine
,2243158,peritoneal clearance,"After intravenous dosage, peritoneal clearance was 3.4 +/- 0.2 mL/min.",Intraperitoneal administration of acyclovir in patients receiving continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243158/),[ml] / [min],3.4,72564,DB02377,Guanine
,2243158,bioavailability,Intraperitoneal dosing in subjects receiving CAPD resulted in a bioavailability of 61 +/- 10% and drug levels sufficient to inhibit herpes simplex virus (HSV) and varicella zoster virus (VZV).,Intraperitoneal administration of acyclovir in patients receiving continuous ambulatory peritoneal dialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243158/),%,61,72565,DB02377,Guanine
,8852725,Total turnaround time,Total turnaround time is 22 min; more than 3000 samples can be run on a single column without loss of peak quality.,Simple reversed-phase high-performance liquid chromatography quantitation of ganciclovir in human serum and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852725/),min,22,72830,DB02377,Guanine
,29935147,bioavailability,"Lastly, mass balance studies established that the bioavailability of acyclovir, after oral dosing of valacyclovir, was 77.5% in wildtype mice and 52.8% in huPepT1 mice, which corroborated values of 51.3% in clinical studies.",Evaluating the intestinal and oral absorption of the prodrug valacyclovir in wildtype and huPepT1 transgenic mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29935147/),%,77.5,73777,DB02377,Guanine
,29935147,bioavailability,"Lastly, mass balance studies established that the bioavailability of acyclovir, after oral dosing of valacyclovir, was 77.5% in wildtype mice and 52.8% in huPepT1 mice, which corroborated values of 51.3% in clinical studies.",Evaluating the intestinal and oral absorption of the prodrug valacyclovir in wildtype and huPepT1 transgenic mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29935147/),%,52.8,73778,DB02377,Guanine
,29935147,bioavailability,"Lastly, mass balance studies established that the bioavailability of acyclovir, after oral dosing of valacyclovir, was 77.5% in wildtype mice and 52.8% in huPepT1 mice, which corroborated values of 51.3% in clinical studies.",Evaluating the intestinal and oral absorption of the prodrug valacyclovir in wildtype and huPepT1 transgenic mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29935147/),%,51.3,73779,DB02377,Guanine
,6285713,peak acyclovir levels,"Mean peak acyclovir levels (microM +/- SD) at 5, 10, and 15 mg/kg per dose were 30.0 +/- 9.9, 61.2 +/- 18.3, and 86.1 +/- 23.5, with corresponding mean trough levels (microM +/- SD) of 5.3 +/- 3.4, 10.1 +/- 8.4, and 13.8 +/- 11.1, respectively.",Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285713/),μM,30.0,77147,DB02377,Guanine
,6285713,peak acyclovir levels,"Mean peak acyclovir levels (microM +/- SD) at 5, 10, and 15 mg/kg per dose were 30.0 +/- 9.9, 61.2 +/- 18.3, and 86.1 +/- 23.5, with corresponding mean trough levels (microM +/- SD) of 5.3 +/- 3.4, 10.1 +/- 8.4, and 13.8 +/- 11.1, respectively.",Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285713/),μM,61.2,77148,DB02377,Guanine
,6285713,peak acyclovir levels,"Mean peak acyclovir levels (microM +/- SD) at 5, 10, and 15 mg/kg per dose were 30.0 +/- 9.9, 61.2 +/- 18.3, and 86.1 +/- 23.5, with corresponding mean trough levels (microM +/- SD) of 5.3 +/- 3.4, 10.1 +/- 8.4, and 13.8 +/- 11.1, respectively.",Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285713/),μM,86.1,77149,DB02377,Guanine
,6285713,trough levels,"Mean peak acyclovir levels (microM +/- SD) at 5, 10, and 15 mg/kg per dose were 30.0 +/- 9.9, 61.2 +/- 18.3, and 86.1 +/- 23.5, with corresponding mean trough levels (microM +/- SD) of 5.3 +/- 3.4, 10.1 +/- 8.4, and 13.8 +/- 11.1, respectively.",Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285713/),μM,5.3,77150,DB02377,Guanine
,6285713,trough levels,"Mean peak acyclovir levels (microM +/- SD) at 5, 10, and 15 mg/kg per dose were 30.0 +/- 9.9, 61.2 +/- 18.3, and 86.1 +/- 23.5, with corresponding mean trough levels (microM +/- SD) of 5.3 +/- 3.4, 10.1 +/- 8.4, and 13.8 +/- 11.1, respectively.",Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285713/),μM,10.1,77151,DB02377,Guanine
,6285713,trough levels,"Mean peak acyclovir levels (microM +/- SD) at 5, 10, and 15 mg/kg per dose were 30.0 +/- 9.9, 61.2 +/- 18.3, and 86.1 +/- 23.5, with corresponding mean trough levels (microM +/- SD) of 5.3 +/- 3.4, 10.1 +/- 8.4, and 13.8 +/- 11.1, respectively.",Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285713/),μM,13.8,77152,DB02377,Guanine
,6285713,half-life (t 1/2 beta),The mean half-life (t 1/2 beta) of acyclovir was 3.78 +/- 1.21 hours.,Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285713/),h,3.78,77153,DB02377,Guanine
,6285713,overall,"The mean percent urinary recovery of acyclovir (+/- SD) at each dosage level was similar, with an overall mean recovery of 65 percent.",Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285713/),%,65,77154,DB02377,Guanine
,6285713,solubility,"The mean acyclovir concentration in urine did not exceed the solubility of acyclovir in bladder urine (1,300 micrograms/ml).",Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6285713/),[μg] / [ml],"1,300",77155,DB02377,Guanine
,24800919,relative bioavailability,"Based upon trough levels of the principal active metabolite,6-thioguanine nucleotides (6-TGN),a relative bioavailability of the liquid vs. capsules of 1.01 was found (90% CI 0.86 - 1.20), demonstrating bioequivalence.",A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients - results of a randomized clinical trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24800919/),,1.01,78755,DB02377,Guanine
,8811444,signal-to-noise ratio,Sample quantitation was reliable to 25 ng/ml with a signal-to-noise ratio of 8:1.,Determination of O6-benzylguanine in human plasma by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8811444/),,8:1,81917,DB02377,Guanine
,15014306,areas under the concentration curve,"The two oral dosages yielded areas under the concentration curve of 14.3 and 28.7 microg x h/ml, equivalent to 43% bioavailability of ganciclovir from valganciclovir, which exceeded the area under the concentration curve of 11.1 microg x h/ml yielded by ganciclovir 4.4 mg/kg iv.",Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014306/),[h·μg] / [ml],14.3,82404,DB02377,Guanine
,15014306,areas under the concentration curve,"The two oral dosages yielded areas under the concentration curve of 14.3 and 28.7 microg x h/ml, equivalent to 43% bioavailability of ganciclovir from valganciclovir, which exceeded the area under the concentration curve of 11.1 microg x h/ml yielded by ganciclovir 4.4 mg/kg iv.",Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014306/),[h·μg] / [ml],28.7,82405,DB02377,Guanine
,15014306,areas under the concentration curve,"The two oral dosages yielded areas under the concentration curve of 14.3 and 28.7 microg x h/ml, equivalent to 43% bioavailability of ganciclovir from valganciclovir, which exceeded the area under the concentration curve of 11.1 microg x h/ml yielded by ganciclovir 4.4 mg/kg iv.",Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014306/),%,43,82406,DB02377,Guanine
,15014306,bioavailability,"The two oral dosages yielded areas under the concentration curve of 14.3 and 28.7 microg x h/ml, equivalent to 43% bioavailability of ganciclovir from valganciclovir, which exceeded the area under the concentration curve of 11.1 microg x h/ml yielded by ganciclovir 4.4 mg/kg iv.",Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014306/),%,43,82407,DB02377,Guanine
,15014306,area under the concentration curve,"The two oral dosages yielded areas under the concentration curve of 14.3 and 28.7 microg x h/ml, equivalent to 43% bioavailability of ganciclovir from valganciclovir, which exceeded the area under the concentration curve of 11.1 microg x h/ml yielded by ganciclovir 4.4 mg/kg iv.",Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15014306/),[h·μg] / [ml],11.1,82408,DB02377,Guanine
,21400550,formation ratio,"While monitoring drug absorption into systematic circulation, the valaciclovir to acyclovir formation ratio was improved to 1:20 in healthy volunteers for the first time.",Controlled ex-vivo plasma hydrolysis of valaciclovir to acyclovir demonstration using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21400550/),,1:20,82824,DB02377,Guanine
,10991864,relative bioavailability,"h/ml) was found to be noninferior to that of oral GCV (20.15 microg. h/ml; 90% CI for relative bioavailability of 95 to 109%), and the exposure of 900 mg of VGC (42.69 microg.",Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991864/),%,95 to 109,82827,DB02377,Guanine
,10991864,relative bioavailability,"h/ml) was found to be noninferior to that of oral GCV (20.15 microg. h/ml; 90% CI for relative bioavailability of 95 to 109%), and the exposure of 900 mg of VGC (42.69 microg.",Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991864/),μg,42.69,82828,DB02377,Guanine
,15664366,flow rate,"Analysis was carried out on ODS column using methanol-phosphate buffer (0.05 M) containing sodium dodecyl sulfate (200 mg/L) and triethylamine (2 mL/L, v/v) as mobile phase (pH=2.3; 5:95, v/v) at flow rate of 2 ml/min.",Determination of acyclovir in human serum by high-performance liquid chromatography using liquid-liquid extraction and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664366/),[ml] / [min],2,83429,DB02377,Guanine
,22305377,Oral bioavailability,"Oral bioavailability of ganciclovir after administration of valganciclovir was 59%, and mean half-life was 3.73 ± 1.15 hours.",Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305377/),%,59,84120,DB02377,Guanine
,22305377,half-life,"Oral bioavailability of ganciclovir after administration of valganciclovir was 59%, and mean half-life was 3.73 ± 1.15 hours.",Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305377/),h,3.73,84121,DB02377,Guanine
,22305377,maximal concentration,"The maximal concentration after intravenous 5 mg/kg ganciclovir was significantly higher than after 450 mg valganciclovir (8.37 ± 3.03 mg/liter vs. 5.3 ± 2.09 mg/liter, respectively; p = 0.02) and similar to 900 mg valganciclovir (7.93 ± 3.97 mg/liter; p = 0.78).",Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305377/),[mg] / [l],8.37,84122,DB02377,Guanine
,22305377,maximal concentration,"The maximal concentration after intravenous 5 mg/kg ganciclovir was significantly higher than after 450 mg valganciclovir (8.37 ± 3.03 mg/liter vs. 5.3 ± 2.09 mg/liter, respectively; p = 0.02) and similar to 900 mg valganciclovir (7.93 ± 3.97 mg/liter; p = 0.78).",Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305377/),[mg] / [l],5.3,84123,DB02377,Guanine
,22305377,maximal concentration,"The maximal concentration after intravenous 5 mg/kg ganciclovir was significantly higher than after 450 mg valganciclovir (8.37 ± 3.03 mg/liter vs. 5.3 ± 2.09 mg/liter, respectively; p = 0.02) and similar to 900 mg valganciclovir (7.93 ± 3.97 mg/liter; p = 0.78).",Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305377/),[mg] / [l],7.93,84124,DB02377,Guanine
,22305377,area under the curve at 0-24 hours (AUC(0-24)),"A higher area under the curve at 0-24 hours (AUC(0-24)) was found with 900 mg valganciclovir compared with intravenous 5 mg/kg/day ganciclovir (47.8 ± 19.7 vs 32.9 ± 10.8 mg · hour/liter, respectively; p = 0.049).",Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305377/),[h·mg] / [l],47.8,84125,DB02377,Guanine
,22305377,area under the curve at 0-24 hours (AUC(0-24)),"A higher area under the curve at 0-24 hours (AUC(0-24)) was found with 900 mg valganciclovir compared with intravenous 5 mg/kg/day ganciclovir (47.8 ± 19.7 vs 32.9 ± 10.8 mg · hour/liter, respectively; p = 0.049).",Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305377/),[h·mg] / [l],32.9,84126,DB02377,Guanine
,22305377,AUC(0-24),The AUC(0-24) for 450 mg valganciclovir twice daily was 45.5 ± 22.9 mg · hour/liter.,Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305377/),[h·mg] / [l],45.5,84127,DB02377,Guanine
greater,9824783,steady-state average serum concentrations,"Mean steady-state average serum concentrations of ganciclovir were greater than 1.0 microgram/mL, which exceeds the median in vitro inhibitory concentration (IC50) of most CMV isolates (0.5-1.0 microgram/mL).","Steady-state relative bioavailability of three oral ganciclovir dosage regimens delivering 6,000 mg/day in patients with human immunodeficiency virus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824783/),[μg] / [ml],1.0,84810,DB02377,Guanine
,9824783,inhibitory concentration (IC50),"Mean steady-state average serum concentrations of ganciclovir were greater than 1.0 microgram/mL, which exceeds the median in vitro inhibitory concentration (IC50) of most CMV isolates (0.5-1.0 microgram/mL).","Steady-state relative bioavailability of three oral ganciclovir dosage regimens delivering 6,000 mg/day in patients with human immunodeficiency virus. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824783/),[μg] / [ml],0.5-1.0,84811,DB02377,Guanine
,26824940,Systemic clearance,"Systemic clearance was substantially higher in the obese than normal-weight patients (mean, 19.4 ± 5.3 versus 14.3 ± 5.4 liters/h; P = 0.047).","Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26824940/),[l] / [h],19.4,84981,DB02377,Guanine
,26824940,Systemic clearance,"Systemic clearance was substantially higher in the obese than normal-weight patients (mean, 19.4 ± 5.3 versus 14.3 ± 5.4 liters/h; P = 0.047).","Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26824940/),[l] / [h],14.3,84982,DB02377,Guanine
,26824940,Area under the concentration-time curve,"Area under the concentration-time curve was lower in the obese patients (15.2 ± 2.9 versus 24.0 ± 9.4 mg · h/liter; P = 0.011), as was maximum concentration (5.8 ± 0.9 versus 8.2 ± 1.3 mg/liter; P = 0.031).","Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26824940/),[h·mg] / [l],15.2,84983,DB02377,Guanine
,26824940,Area under the concentration-time curve,"Area under the concentration-time curve was lower in the obese patients (15.2 ± 2.9 versus 24.0 ± 9.4 mg · h/liter; P = 0.011), as was maximum concentration (5.8 ± 0.9 versus 8.2 ± 1.3 mg/liter; P = 0.031).","Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26824940/),[h·mg] / [l],24.0,84984,DB02377,Guanine
,26824940,maximum concentration,"Area under the concentration-time curve was lower in the obese patients (15.2 ± 2.9 versus 24.0 ± 9.4 mg · h/liter; P = 0.011), as was maximum concentration (5.8 ± 0.9 versus 8.2 ± 1.3 mg/liter; P = 0.031).","Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26824940/),[mg] / [l],5.8,84985,DB02377,Guanine
,26824940,maximum concentration,"Area under the concentration-time curve was lower in the obese patients (15.2 ± 2.9 versus 24.0 ± 9.4 mg · h/liter; P = 0.011), as was maximum concentration (5.8 ± 0.9 versus 8.2 ± 1.3 mg/liter; P = 0.031).","Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26824940/),[mg] / [l],8.2,84986,DB02377,Guanine
,7103460,renal clearance,"In the absence of probenecid, the renal clearance (248 +/- 80 ml/min per 1.73 m2) accounted for 83% of the total clearance (300 +/- 69 ml/min per 1.73 m2) and was almost threefold greater than the estimated creatinine clearance (90 +/- 48 ml/min per 1.73 m2).",Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103460/),[ml] / [1.73·m2·min],248,85514,DB02377,Guanine
,7103460,total clearance,"In the absence of probenecid, the renal clearance (248 +/- 80 ml/min per 1.73 m2) accounted for 83% of the total clearance (300 +/- 69 ml/min per 1.73 m2) and was almost threefold greater than the estimated creatinine clearance (90 +/- 48 ml/min per 1.73 m2).",Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103460/),[ml] / [1.73·m2·min],300,85515,DB02377,Guanine
,7103460,renal clearance,"After probenecid administration, there was a 32% decline in renal clearance (248 to 168 ml/min per 1.73 m2; P less than or equal to 0.05), a 40% increase in the area under the curve (91.3 to 127.6 nmol.h/ml; P less than 0.05), and an 18% increase in the terminal plasma half-life (2.3 to 2.7 h; P less than 0.01).",Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103460/),[ml] / [1.73·m2·min],248 to 168,85516,DB02377,Guanine
,7103460,area under the curve,"After probenecid administration, there was a 32% decline in renal clearance (248 to 168 ml/min per 1.73 m2; P less than or equal to 0.05), a 40% increase in the area under the curve (91.3 to 127.6 nmol.h/ml; P less than 0.05), and an 18% increase in the terminal plasma half-life (2.3 to 2.7 h; P less than 0.01).",Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103460/),[h·nM] / [ml],91.3 to 127.6,85517,DB02377,Guanine
,7103460,terminal plasma half-life,"After probenecid administration, there was a 32% decline in renal clearance (248 to 168 ml/min per 1.73 m2; P less than or equal to 0.05), a 40% increase in the area under the curve (91.3 to 127.6 nmol.h/ml; P less than 0.05), and an 18% increase in the terminal plasma half-life (2.3 to 2.7 h; P less than 0.01).",Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103460/),h,2.3 to 2.7,85518,DB02377,Guanine
,8319619,biological half-life,"The biological half-life of PhIP was 1 hr, with 90% of the dose being excreted via the urine.",Low-level biological dosimetry of heterocyclic amine carcinogens isolated from cooked food. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8319619/),h,1,86656,DB02377,Guanine
,12434403,oral bioavailability,The oral bioavailability of acyclovir is thereby affected and reaches only 15-30%.,Preliminary pharmacokinetic study of different preparations of acyclovir with beta-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12434403/),%,15-30,86782,DB02377,Guanine
,20160046,AUC(0-6),"Specifically, mean AUC(0-6) was 2.2 microg h/ml in infants aged 1 to <3 months, 3.2 microg h/ml in infants aged 3 to <6 months, and 8.8 microg h/ml in infants aged 6 to 12 months.",Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20160046/),[h·μg] / [ml],2.2,86914,DB02377,Guanine
,20160046,AUC(0-6),"Specifically, mean AUC(0-6) was 2.2 microg h/ml in infants aged 1 to <3 months, 3.2 microg h/ml in infants aged 3 to <6 months, and 8.8 microg h/ml in infants aged 6 to 12 months.",Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20160046/),[h·μg] / [ml],3.2,86915,DB02377,Guanine
,20160046,AUC(0-6),"Specifically, mean AUC(0-6) was 2.2 microg h/ml in infants aged 1 to <3 months, 3.2 microg h/ml in infants aged 3 to <6 months, and 8.8 microg h/ml in infants aged 6 to 12 months.",Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20160046/),[h·μg] / [ml],8.8,86916,DB02377,Guanine
,17238815,Elimination half-life,Elimination half-life of regenerated GCV from YVGCV administration was observed to be 157 min.,Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): in vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17238815/),min,157,87634,DB02377,Guanine
,21374647,flow-rate,"The method involved simple, one-step SPE procedure coupled with a C(18) , 75 × 4.mm, 3 µm column with a flow-rate of 0.5 mL/min, and acyclovir was used as the internal standard.",Determination of penciclovir in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21374647/),[ml] / [min],0.5,87996,DB02377,Guanine
,16777215,overall half-lives of elimination from the central compartment (T(1/2)),The overall half-lives of elimination from the central compartment (T(1/2))(K10) were 3.57+/-0.1h for IV and 2.38+/-0.11 h for IP.,In vivo disposition and stability of DNA frayed wires in mice. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16777215/),h,3.57,88721,DB02377,Guanine
,16777215,overall half-lives of elimination from the central compartment (T(1/2)),The overall half-lives of elimination from the central compartment (T(1/2))(K10) were 3.57+/-0.1h for IV and 2.38+/-0.11 h for IP.,In vivo disposition and stability of DNA frayed wires in mice. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16777215/),h,2.38,88722,DB02377,Guanine
,1650665,half-life,"After the first minute, ACV clearance from the discs appeared to be exponential with a half-life of 21 minutes.",Ocular acyclovir delivery by collagen discs: a mouse model to screen anti-viral agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1650665/),min,21,89170,DB02377,Guanine
,25609011,area under the plasma concentration-time curve (AUC0-12 h),"On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and 982.0 ng ∙ h/ml and 373 versus 208 and 235 ng/ml, respectively).",The Influence of Chitosan on the Oral Bioavailability of Acyclovir--a Comparative Bioavailability Study in Humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25609011/),[h·ng·∙] / [ml],1402,89802,DB02377,Guanine
,25609011,area under the plasma concentration-time curve (AUC0-12 h),"On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and 982.0 ng ∙ h/ml and 373 versus 208 and 235 ng/ml, respectively).",The Influence of Chitosan on the Oral Bioavailability of Acyclovir--a Comparative Bioavailability Study in Humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25609011/),[h·ng·∙] / [ml],1017,89803,DB02377,Guanine
,25609011,maximal plasma concentration (Cmax),"On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and 982.0 ng ∙ h/ml and 373 versus 208 and 235 ng/ml, respectively).",The Influence of Chitosan on the Oral Bioavailability of Acyclovir--a Comparative Bioavailability Study in Humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25609011/),[h·ng·∙] / [ml],982.0,89804,DB02377,Guanine
,25609011,maximal plasma concentration (Cmax),"On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and 982.0 ng ∙ h/ml and 373 versus 208 and 235 ng/ml, respectively).",The Influence of Chitosan on the Oral Bioavailability of Acyclovir--a Comparative Bioavailability Study in Humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25609011/),[ng] / [ml],373,89805,DB02377,Guanine
,25609011,maximal plasma concentration (Cmax),"On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and 982.0 ng ∙ h/ml and 373 versus 208 and 235 ng/ml, respectively).",The Influence of Chitosan on the Oral Bioavailability of Acyclovir--a Comparative Bioavailability Study in Humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25609011/),[ng] / [ml],208,89806,DB02377,Guanine
,25609011,maximal plasma concentration (Cmax),"On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and 982.0 ng ∙ h/ml and 373 versus 208 and 235 ng/ml, respectively).",The Influence of Chitosan on the Oral Bioavailability of Acyclovir--a Comparative Bioavailability Study in Humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25609011/),[ng] / [ml],235,89807,DB02377,Guanine
,25609011,Tmax,"In addition, Tmax increased significantly in presence of 1000 mg of chitosan from 1 to 2 h.",The Influence of Chitosan on the Oral Bioavailability of Acyclovir--a Comparative Bioavailability Study in Humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25609011/),h,1,89808,DB02377,Guanine
,25609011,Tmax,"In addition, Tmax increased significantly in presence of 1000 mg of chitosan from 1 to 2 h.",The Influence of Chitosan on the Oral Bioavailability of Acyclovir--a Comparative Bioavailability Study in Humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25609011/),h,2,89809,DB02377,Guanine
,24203082,extraction recovery,The extraction recovery averaged 93.9-96.7%.,A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203082/),%,93.9-96.7,89844,DB02377,Guanine
,24203082,area under the plasma concentration vs. time curves from time 0 to 24 h (AUC0-24),"The following pharmacokinetic parameters were obtained for rats and dogs, respectively: the area under the plasma concentration vs. time curves from time 0 to 24 h (AUC0-24) were 15.4 ± 4.5 and 23.4 ± 7.2 μg∙h/mL; the mean maximum plasma concentration (Cmax) were 2.4 ± 0.8 and 5.0 ± 0.9 μg/mL; the mean time to reach the maximum plasma concentrations (Tmax) were 1.7 ± 0.7 and 1.5 ± 0.4 h; and the mean elimination half-life (t1/2) were 5.3 ± 1.4 and 3.8 ± 1.3 h.",A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203082/),[μg∙h] / [ml],15.4,89845,DB02377,Guanine
,24203082,area under the plasma concentration vs. time curves from time 0 to 24 h (AUC0-24),"The following pharmacokinetic parameters were obtained for rats and dogs, respectively: the area under the plasma concentration vs. time curves from time 0 to 24 h (AUC0-24) were 15.4 ± 4.5 and 23.4 ± 7.2 μg∙h/mL; the mean maximum plasma concentration (Cmax) were 2.4 ± 0.8 and 5.0 ± 0.9 μg/mL; the mean time to reach the maximum plasma concentrations (Tmax) were 1.7 ± 0.7 and 1.5 ± 0.4 h; and the mean elimination half-life (t1/2) were 5.3 ± 1.4 and 3.8 ± 1.3 h.",A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203082/),[μg∙h] / [ml],23.4,89846,DB02377,Guanine
,24203082,maximum plasma concentration (Cmax),"The following pharmacokinetic parameters were obtained for rats and dogs, respectively: the area under the plasma concentration vs. time curves from time 0 to 24 h (AUC0-24) were 15.4 ± 4.5 and 23.4 ± 7.2 μg∙h/mL; the mean maximum plasma concentration (Cmax) were 2.4 ± 0.8 and 5.0 ± 0.9 μg/mL; the mean time to reach the maximum plasma concentrations (Tmax) were 1.7 ± 0.7 and 1.5 ± 0.4 h; and the mean elimination half-life (t1/2) were 5.3 ± 1.4 and 3.8 ± 1.3 h.",A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203082/),[μg] / [ml],2.4,89847,DB02377,Guanine
,24203082,maximum plasma concentration (Cmax),"The following pharmacokinetic parameters were obtained for rats and dogs, respectively: the area under the plasma concentration vs. time curves from time 0 to 24 h (AUC0-24) were 15.4 ± 4.5 and 23.4 ± 7.2 μg∙h/mL; the mean maximum plasma concentration (Cmax) were 2.4 ± 0.8 and 5.0 ± 0.9 μg/mL; the mean time to reach the maximum plasma concentrations (Tmax) were 1.7 ± 0.7 and 1.5 ± 0.4 h; and the mean elimination half-life (t1/2) were 5.3 ± 1.4 and 3.8 ± 1.3 h.",A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203082/),[μg] / [ml],5.0,89848,DB02377,Guanine
,24203082,time to reach the maximum plasma concentrations (Tmax),"The following pharmacokinetic parameters were obtained for rats and dogs, respectively: the area under the plasma concentration vs. time curves from time 0 to 24 h (AUC0-24) were 15.4 ± 4.5 and 23.4 ± 7.2 μg∙h/mL; the mean maximum plasma concentration (Cmax) were 2.4 ± 0.8 and 5.0 ± 0.9 μg/mL; the mean time to reach the maximum plasma concentrations (Tmax) were 1.7 ± 0.7 and 1.5 ± 0.4 h; and the mean elimination half-life (t1/2) were 5.3 ± 1.4 and 3.8 ± 1.3 h.",A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203082/),h,1.7,89849,DB02377,Guanine
,24203082,time to reach the maximum plasma concentrations (Tmax),"The following pharmacokinetic parameters were obtained for rats and dogs, respectively: the area under the plasma concentration vs. time curves from time 0 to 24 h (AUC0-24) were 15.4 ± 4.5 and 23.4 ± 7.2 μg∙h/mL; the mean maximum plasma concentration (Cmax) were 2.4 ± 0.8 and 5.0 ± 0.9 μg/mL; the mean time to reach the maximum plasma concentrations (Tmax) were 1.7 ± 0.7 and 1.5 ± 0.4 h; and the mean elimination half-life (t1/2) were 5.3 ± 1.4 and 3.8 ± 1.3 h.",A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203082/),h,1.5,89850,DB02377,Guanine
,24203082,elimination half-life (t1/2),"The following pharmacokinetic parameters were obtained for rats and dogs, respectively: the area under the plasma concentration vs. time curves from time 0 to 24 h (AUC0-24) were 15.4 ± 4.5 and 23.4 ± 7.2 μg∙h/mL; the mean maximum plasma concentration (Cmax) were 2.4 ± 0.8 and 5.0 ± 0.9 μg/mL; the mean time to reach the maximum plasma concentrations (Tmax) were 1.7 ± 0.7 and 1.5 ± 0.4 h; and the mean elimination half-life (t1/2) were 5.3 ± 1.4 and 3.8 ± 1.3 h.",A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203082/),h,5.3,89851,DB02377,Guanine
,24203082,elimination half-life (t1/2),"The following pharmacokinetic parameters were obtained for rats and dogs, respectively: the area under the plasma concentration vs. time curves from time 0 to 24 h (AUC0-24) were 15.4 ± 4.5 and 23.4 ± 7.2 μg∙h/mL; the mean maximum plasma concentration (Cmax) were 2.4 ± 0.8 and 5.0 ± 0.9 μg/mL; the mean time to reach the maximum plasma concentrations (Tmax) were 1.7 ± 0.7 and 1.5 ± 0.4 h; and the mean elimination half-life (t1/2) were 5.3 ± 1.4 and 3.8 ± 1.3 h.",A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24203082/),h,3.8,89852,DB02377,Guanine
,7553637,half-life,Elimination of O6BG from plasma was rapid; it had a half-life of 1.6 h and a clearance of 68 ml/min/m2.,Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7553637/),h,1.6,91367,DB02377,Guanine
,7553637,clearance,Elimination of O6BG from plasma was rapid; it had a half-life of 1.6 h and a clearance of 68 ml/min/m2.,Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7553637/),[ml] / [m2·min],68,91368,DB02377,Guanine
,7553637,half-life,The half-life (14 h) was 10-fold longer and the area under the curve (2420 microM/h) was 11-fold higher than that of O6BG (212 microM/h).,Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7553637/),h,14,91369,DB02377,Guanine
,7553637,area under the curve,The half-life (14 h) was 10-fold longer and the area under the curve (2420 microM/h) was 11-fold higher than that of O6BG (212 microM/h).,Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7553637/),[μM] / [h],2420,91370,DB02377,Guanine
,7553637,area under the curve,The half-life (14 h) was 10-fold longer and the area under the curve (2420 microM/h) was 11-fold higher than that of O6BG (212 microM/h).,Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7553637/),[μM] / [h],212,91371,DB02377,Guanine
,7553637,clearance rate,The clearance rate of O6-benzyl-8-oxoguanine was 6.4 ml/min/m2.,Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7553637/),[ml] / [m2·min],6.4,91372,DB02377,Guanine
,7553637,CSF:plasma ratio,"The CSF:plasma ratio was 4.3% for O6BG and 36% for O6-benzyl-8-oxoguanine, and the metabolite area under the curve was 90-fold higher than that of O6BG in CSF.",Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7553637/),%,4.3,91373,DB02377,Guanine
,7553637,CSF:plasma ratio,"The CSF:plasma ratio was 4.3% for O6BG and 36% for O6-benzyl-8-oxoguanine, and the metabolite area under the curve was 90-fold higher than that of O6BG in CSF.",Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7553637/),%,36,91374,DB02377,Guanine
,18956139,MTD,"MTD was 500/135 mg/m(2) (S1), 400/40 mg/m(2) (S2), and 500/120 mg/m(2) (S3).",Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956139/),mg,500,91617,DB02377,Guanine
,18956139,MTD,"MTD was 500/135 mg/m(2) (S1), 400/40 mg/m(2) (S2), and 500/120 mg/m(2) (S3).",Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956139/),mg,135,91618,DB02377,Guanine
,23240598,AUC,"Of the 28 ganciclovir AUC calculations performed, 11 (39%) were outside the therapeutic target range of 40-60 mcg h/L leading to a valganciclovir dose adjustment.",Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23240598/),[h·mcg] / [l],40-60,92133,DB02377,Guanine
,23240598,AUCs,Current manufacturer-recommended dosing based on BSA and CrCl was estimated to result in therapeutic AUCs in fewer patients than the simple weight-based formula used in our institution (4 vs. 13; p = 0.017).,Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23240598/),,4,92134,DB02377,Guanine
,23240598,AUCs,Current manufacturer-recommended dosing based on BSA and CrCl was estimated to result in therapeutic AUCs in fewer patients than the simple weight-based formula used in our institution (4 vs. 13; p = 0.017).,Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23240598/),,13,92135,DB02377,Guanine
,7738216,Tmax,Median Tmax for subjects with hepatic disease was significantly increased (by 0.75 hours) compared with subjects with normal liver function.,Pharmacokinetics of famciclovir in subjects with chronic hepatic disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738216/),h,0.75,92598,DB02377,Guanine
,19738014,clearance (CL),"The final pharmacokinetic parameters were as follows: ganciclovir clearance (CL) was 7.49.(CL(CR)/57) liter/h (57 was the mean population value of CL(CR)); the central and peripheral distribution volumes were 31.9 liters and 32.0 liters, respectively; intercompartmental clearance was 10.2 liter/h; the first-order absorption rate constant was 0.895 h(-1); bioavailability was 0.825; and lag time was 0.382 h.",Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738014/),[l] / [h],7.49.,92868,DB02377,Guanine
,19738014,central,"The final pharmacokinetic parameters were as follows: ganciclovir clearance (CL) was 7.49.(CL(CR)/57) liter/h (57 was the mean population value of CL(CR)); the central and peripheral distribution volumes were 31.9 liters and 32.0 liters, respectively; intercompartmental clearance was 10.2 liter/h; the first-order absorption rate constant was 0.895 h(-1); bioavailability was 0.825; and lag time was 0.382 h.",Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738014/),l,31.9,92869,DB02377,Guanine
,19738014,peripheral distribution volumes,"The final pharmacokinetic parameters were as follows: ganciclovir clearance (CL) was 7.49.(CL(CR)/57) liter/h (57 was the mean population value of CL(CR)); the central and peripheral distribution volumes were 31.9 liters and 32.0 liters, respectively; intercompartmental clearance was 10.2 liter/h; the first-order absorption rate constant was 0.895 h(-1); bioavailability was 0.825; and lag time was 0.382 h.",Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738014/),l,32.0,92870,DB02377,Guanine
,19738014,intercompartmental clearance,"The final pharmacokinetic parameters were as follows: ganciclovir clearance (CL) was 7.49.(CL(CR)/57) liter/h (57 was the mean population value of CL(CR)); the central and peripheral distribution volumes were 31.9 liters and 32.0 liters, respectively; intercompartmental clearance was 10.2 liter/h; the first-order absorption rate constant was 0.895 h(-1); bioavailability was 0.825; and lag time was 0.382 h.",Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738014/),[l] / [h],10.2,92871,DB02377,Guanine
,19738014,first-order absorption rate constant,"The final pharmacokinetic parameters were as follows: ganciclovir clearance (CL) was 7.49.(CL(CR)/57) liter/h (57 was the mean population value of CL(CR)); the central and peripheral distribution volumes were 31.9 liters and 32.0 liters, respectively; intercompartmental clearance was 10.2 liter/h; the first-order absorption rate constant was 0.895 h(-1); bioavailability was 0.825; and lag time was 0.382 h.",Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738014/),1/[h],0.895,92872,DB02377,Guanine
,19738014,bioavailability,"The final pharmacokinetic parameters were as follows: ganciclovir clearance (CL) was 7.49.(CL(CR)/57) liter/h (57 was the mean population value of CL(CR)); the central and peripheral distribution volumes were 31.9 liters and 32.0 liters, respectively; intercompartmental clearance was 10.2 liter/h; the first-order absorption rate constant was 0.895 h(-1); bioavailability was 0.825; and lag time was 0.382 h.",Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738014/),,0.825,92873,DB02377,Guanine
,19738014,lag time,"The final pharmacokinetic parameters were as follows: ganciclovir clearance (CL) was 7.49.(CL(CR)/57) liter/h (57 was the mean population value of CL(CR)); the central and peripheral distribution volumes were 31.9 liters and 32.0 liters, respectively; intercompartmental clearance was 10.2 liter/h; the first-order absorption rate constant was 0.895 h(-1); bioavailability was 0.825; and lag time was 0.382 h.",Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738014/),h,0.382,92874,DB02377,Guanine
,26003007,progression-free survival,"Five of 9 (56%) patients had a partial response and the median progression-free survival was 7 months (range, 1.5-15.1 months).","Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26003007/),month,7,95368,DB02377,Guanine
,26003007,progression-free survival,"Five of 9 (56%) patients had a partial response and the median progression-free survival was 7 months (range, 1.5-15.1 months).","Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26003007/),month,7,95369,DB02377,Guanine
,30885337,area under the concentration-time curve (AUC),The pharmacokinetic target was an area under the concentration-time curve (AUC) of 123-205 mg·h/L.,Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30885337/),[h·mg] / [l],123-205,96592,DB02377,Guanine
,30885337,systemic clearance,"Interestingly, a threefold increase in systemic clearance of pemetrexed was observed during hemodialysis (from 1.00 L/h to 3.01 L/h), which approximates the population clearance of pemetrexed.",Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30885337/),[l] / [h],1.00,96593,DB02377,Guanine
,30885337,systemic clearance,"Interestingly, a threefold increase in systemic clearance of pemetrexed was observed during hemodialysis (from 1.00 L/h to 3.01 L/h), which approximates the population clearance of pemetrexed.",Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30885337/),[l] / [h],3.01,96594,DB02377,Guanine
,19342996,concentration,The median TGN concentration in non-DS children above 2 years of age was 2.30 micromol/mmol Hb (range 0.57-25.3).,Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19342996/),[μM] / [hb·mM],2.30,97683,DB02377,Guanine
,2681370,inhibitory doses 50 (ID 50),"In as much as in vitro inhibitory doses 50 (ID 50) for HSV1, HSV2 and VZV ranged from 0.1 to 3 mumol/l, it is quite likely that levels noted above may be effective for in utero inhibition of viral replication.",[Acyclovir and pregnancy: current aspects]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681370/),[μM] / [l],0.1 to 3,98381,DB02377,Guanine
,20545521,absorption ratio,"The AV absorption ratio in different segments of rat's GI track for 3 hours was as following: stomach 9.46 +/- 0.62%, duodenum 20.22 +/- 1.50%, jejunum 15.7 +/- 1.33%, ileum 9.15 +/- 1.01%, and colon 4.59 +/- 0.48%.",Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545521/),%,9.46,98704,DB02377,Guanine
,20545521,absorption ratio,"The AV absorption ratio in different segments of rat's GI track for 3 hours was as following: stomach 9.46 +/- 0.62%, duodenum 20.22 +/- 1.50%, jejunum 15.7 +/- 1.33%, ileum 9.15 +/- 1.01%, and colon 4.59 +/- 0.48%.",Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545521/),%,20.22,98705,DB02377,Guanine
,20545521,absorption ratio,"The AV absorption ratio in different segments of rat's GI track for 3 hours was as following: stomach 9.46 +/- 0.62%, duodenum 20.22 +/- 1.50%, jejunum 15.7 +/- 1.33%, ileum 9.15 +/- 1.01%, and colon 4.59 +/- 0.48%.",Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545521/),%,15.7,98706,DB02377,Guanine
,20545521,absorption ratio,"The AV absorption ratio in different segments of rat's GI track for 3 hours was as following: stomach 9.46 +/- 0.62%, duodenum 20.22 +/- 1.50%, jejunum 15.7 +/- 1.33%, ileum 9.15 +/- 1.01%, and colon 4.59 +/- 0.48%.",Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545521/),%,9.15,98707,DB02377,Guanine
,20545521,absorption ratio,"The AV absorption ratio in different segments of rat's GI track for 3 hours was as following: stomach 9.46 +/- 0.62%, duodenum 20.22 +/- 1.50%, jejunum 15.7 +/- 1.33%, ileum 9.15 +/- 1.01%, and colon 4.59 +/- 0.48%.",Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545521/),%,4.59,98708,DB02377,Guanine
,20545521,t(max),The t(max) has increased from 2.33 hours (reference) to 5 hours (test).,Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545521/),h,2.33,98709,DB02377,Guanine
,20545521,t(max),The t(max) has increased from 2.33 hours (reference) to 5 hours (test).,Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545521/),h,5,98710,DB02377,Guanine
,20545521,relative bioavailability,"Meanwhile, the relative bioavailability of AV microspheres was 145%.",Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545521/),%,145,98711,DB02377,Guanine
,16140045,flow rate,"Separation was performed by a gradient elution with a mobile phase consisting of a mixture of acetonitrile and phosphate buffer 50mM containing 5mM of sodium octanesulfonate, pH 2.0, at a flow rate of 0.3 ml/min.",Development and validation of a new reversed-phase ion pairing liquid chromatographic method with fluorescence detection for penciclovir analysis in plasma and aqueous humor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16140045/),[ml] / [min],0.3,99470,DB02377,Guanine
,29546589,area under the drug concentration-time curve (AUC) target,A non-parametric pharmacokinetic analysis and Monte Carlo simulations to determine the probabilities of reaching an area under the drug concentration-time curve (AUC) target of 40-50 mg·h/L with various dosing regimens at different levels of renal function were conducted using the Pmetrics™ package for R.,Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29546589/),[h·mg] / [l],40-50,99541,DB02377,Guanine
,15940035,areas under the curve (AUCs),"Mean daily areas under the curve (AUCs) of ganciclovir from valganciclovir and oral ganciclovir were 46.3 +/- 15.2 and 28.0 +/- 10.9 microg.h/ml (mean +/- SD), respectively.",Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15940035/),[h·μg] / [ml],46.3,99832,DB02377,Guanine
,15940035,areas under the curve (AUCs),"Mean daily areas under the curve (AUCs) of ganciclovir from valganciclovir and oral ganciclovir were 46.3 +/- 15.2 and 28.0 +/- 10.9 microg.h/ml (mean +/- SD), respectively.",Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15940035/),[h·μg] / [ml],28.0,99833,DB02377,Guanine
,15940035,AUCs,"The development of viremia 1 month after ending prophylaxis was also reduced with higher ganciclovir AUC (median predicted incidence, 20% and 10% at AUCs of 33 and 50 microg h/ml, respectively).",Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15940035/),[h·μg] / [ml],33,99834,DB02377,Guanine
,15940035,AUCs,"The development of viremia 1 month after ending prophylaxis was also reduced with higher ganciclovir AUC (median predicted incidence, 20% and 10% at AUCs of 33 and 50 microg h/ml, respectively).",Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15940035/),[h·μg] / [ml],50,99835,DB02377,Guanine
,2541566,terminal half-life,"Pharmacokinetic properties of ganciclovir include biexponential decay with a terminal half-life of 2.5 hours, tissue uptake, cerebrospinal fluid penetration, and renal dependence for elimination.",Evaluation of ganciclovir for cytomegalovirus disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2541566/),h,2.5,101988,DB02377,Guanine
,2541566,response rate,"In uncontrolled trials, the response rate of CMV retinitis is approximately 80 percent.",Evaluation of ganciclovir for cytomegalovirus disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2541566/),%,80,101989,DB02377,Guanine
,2541566,overall response rate,The overall response rate for CMV pneumonitis has been approximately 50 percent.,Evaluation of ganciclovir for cytomegalovirus disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2541566/),%,50,101990,DB02377,Guanine
,23539240,Plasma clearance,Plasma clearance was 22.8±9.1 L/h and clearance from the aqueous humour was 8.2×10(-5) L/h.,Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23539240/),[l] / [h],22.8,102251,DB02377,Guanine
,23539240,clearance from the aqueous humour,Plasma clearance was 22.8±9.1 L/h and clearance from the aqueous humour was 8.2×10(-5) L/h.,Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23539240/),[l] / [h],8.2×10(-5),102252,DB02377,Guanine
,23539240,AUCs,"AUCs were 25.4±10.2 and 6.6±1.8 μg·h/mL in plasma and aqueous humour, respectively, yielding a penetration ratio of 0.28±0.06.",Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23539240/),[h·μg] / [ml],25.4,102253,DB02377,Guanine
,23539240,AUCs,"AUCs were 25.4±10.2 and 6.6±1.8 μg·h/mL in plasma and aqueous humour, respectively, yielding a penetration ratio of 0.28±0.06.",Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23539240/),[h·μg] / [ml],6.6,102254,DB02377,Guanine
,23539240,penetration ratio,"AUCs were 25.4±10.2 and 6.6±1.8 μg·h/mL in plasma and aqueous humour, respectively, yielding a penetration ratio of 0.28±0.06.",Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23539240/),,0.28,102255,DB02377,Guanine
,31065954,MTD,The MTD was defined as 15 mg/kg and used for cohort expansion.,"A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31065954/),[mg] / [kg],15,102565,DB02377,Guanine
,19650679,bioavailability,"Based on currently available literature, ganciclovir pharmacokinetics in adult solid organ transplant recipients receiving oral valganciclovir are characterized by bioavailability of 66 +/- 10% (mean +/- SD), a maximum plasma concentration of 3.1 +/- 0.8 mg/L after a dose of 450 mg and of 6.6 +/- 1.9 mg/L after a dose of 900 mg, a time to reach the maximum plasma concentration of 3.0 +/- 1.0 hours, area under the plasma concentration-time curve values of 29.1 +/- 5.3 mg.h/L and 51.9 +/- 18.3 mg.h/L (after 450 mg and 900 mg, respectively), apparent clearance of 12.4 +/- 3.8 L/h, an elimination half-life of 5.3 +/- 1.5 hours and an apparent terminal volume of distribution of 101 +/- 36 L.",Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650679/),%,66,103029,DB02377,Guanine
,19650679,maximum plasma concentration,"Based on currently available literature, ganciclovir pharmacokinetics in adult solid organ transplant recipients receiving oral valganciclovir are characterized by bioavailability of 66 +/- 10% (mean +/- SD), a maximum plasma concentration of 3.1 +/- 0.8 mg/L after a dose of 450 mg and of 6.6 +/- 1.9 mg/L after a dose of 900 mg, a time to reach the maximum plasma concentration of 3.0 +/- 1.0 hours, area under the plasma concentration-time curve values of 29.1 +/- 5.3 mg.h/L and 51.9 +/- 18.3 mg.h/L (after 450 mg and 900 mg, respectively), apparent clearance of 12.4 +/- 3.8 L/h, an elimination half-life of 5.3 +/- 1.5 hours and an apparent terminal volume of distribution of 101 +/- 36 L.",Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650679/),[mg] / [l],3.1,103030,DB02377,Guanine
,19650679,maximum plasma concentration,"Based on currently available literature, ganciclovir pharmacokinetics in adult solid organ transplant recipients receiving oral valganciclovir are characterized by bioavailability of 66 +/- 10% (mean +/- SD), a maximum plasma concentration of 3.1 +/- 0.8 mg/L after a dose of 450 mg and of 6.6 +/- 1.9 mg/L after a dose of 900 mg, a time to reach the maximum plasma concentration of 3.0 +/- 1.0 hours, area under the plasma concentration-time curve values of 29.1 +/- 5.3 mg.h/L and 51.9 +/- 18.3 mg.h/L (after 450 mg and 900 mg, respectively), apparent clearance of 12.4 +/- 3.8 L/h, an elimination half-life of 5.3 +/- 1.5 hours and an apparent terminal volume of distribution of 101 +/- 36 L.",Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650679/),[mg] / [l],6.6,103031,DB02377,Guanine
,19650679,time to reach the maximum plasma concentration,"Based on currently available literature, ganciclovir pharmacokinetics in adult solid organ transplant recipients receiving oral valganciclovir are characterized by bioavailability of 66 +/- 10% (mean +/- SD), a maximum plasma concentration of 3.1 +/- 0.8 mg/L after a dose of 450 mg and of 6.6 +/- 1.9 mg/L after a dose of 900 mg, a time to reach the maximum plasma concentration of 3.0 +/- 1.0 hours, area under the plasma concentration-time curve values of 29.1 +/- 5.3 mg.h/L and 51.9 +/- 18.3 mg.h/L (after 450 mg and 900 mg, respectively), apparent clearance of 12.4 +/- 3.8 L/h, an elimination half-life of 5.3 +/- 1.5 hours and an apparent terminal volume of distribution of 101 +/- 36 L.",Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650679/),h,3.0,103032,DB02377,Guanine
,19650679,area under the plasma concentration-time curve,"Based on currently available literature, ganciclovir pharmacokinetics in adult solid organ transplant recipients receiving oral valganciclovir are characterized by bioavailability of 66 +/- 10% (mean +/- SD), a maximum plasma concentration of 3.1 +/- 0.8 mg/L after a dose of 450 mg and of 6.6 +/- 1.9 mg/L after a dose of 900 mg, a time to reach the maximum plasma concentration of 3.0 +/- 1.0 hours, area under the plasma concentration-time curve values of 29.1 +/- 5.3 mg.h/L and 51.9 +/- 18.3 mg.h/L (after 450 mg and 900 mg, respectively), apparent clearance of 12.4 +/- 3.8 L/h, an elimination half-life of 5.3 +/- 1.5 hours and an apparent terminal volume of distribution of 101 +/- 36 L.",Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650679/),[h·mg] / [l],29.1,103033,DB02377,Guanine
,19650679,area under the plasma concentration-time curve,"Based on currently available literature, ganciclovir pharmacokinetics in adult solid organ transplant recipients receiving oral valganciclovir are characterized by bioavailability of 66 +/- 10% (mean +/- SD), a maximum plasma concentration of 3.1 +/- 0.8 mg/L after a dose of 450 mg and of 6.6 +/- 1.9 mg/L after a dose of 900 mg, a time to reach the maximum plasma concentration of 3.0 +/- 1.0 hours, area under the plasma concentration-time curve values of 29.1 +/- 5.3 mg.h/L and 51.9 +/- 18.3 mg.h/L (after 450 mg and 900 mg, respectively), apparent clearance of 12.4 +/- 3.8 L/h, an elimination half-life of 5.3 +/- 1.5 hours and an apparent terminal volume of distribution of 101 +/- 36 L.",Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650679/),[h·mg] / [l],51.9,103034,DB02377,Guanine
,19650679,apparent clearance,"Based on currently available literature, ganciclovir pharmacokinetics in adult solid organ transplant recipients receiving oral valganciclovir are characterized by bioavailability of 66 +/- 10% (mean +/- SD), a maximum plasma concentration of 3.1 +/- 0.8 mg/L after a dose of 450 mg and of 6.6 +/- 1.9 mg/L after a dose of 900 mg, a time to reach the maximum plasma concentration of 3.0 +/- 1.0 hours, area under the plasma concentration-time curve values of 29.1 +/- 5.3 mg.h/L and 51.9 +/- 18.3 mg.h/L (after 450 mg and 900 mg, respectively), apparent clearance of 12.4 +/- 3.8 L/h, an elimination half-life of 5.3 +/- 1.5 hours and an apparent terminal volume of distribution of 101 +/- 36 L.",Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650679/),[l] / [h],12.4,103035,DB02377,Guanine
,19650679,elimination half-life,"Based on currently available literature, ganciclovir pharmacokinetics in adult solid organ transplant recipients receiving oral valganciclovir are characterized by bioavailability of 66 +/- 10% (mean +/- SD), a maximum plasma concentration of 3.1 +/- 0.8 mg/L after a dose of 450 mg and of 6.6 +/- 1.9 mg/L after a dose of 900 mg, a time to reach the maximum plasma concentration of 3.0 +/- 1.0 hours, area under the plasma concentration-time curve values of 29.1 +/- 5.3 mg.h/L and 51.9 +/- 18.3 mg.h/L (after 450 mg and 900 mg, respectively), apparent clearance of 12.4 +/- 3.8 L/h, an elimination half-life of 5.3 +/- 1.5 hours and an apparent terminal volume of distribution of 101 +/- 36 L.",Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650679/),h,5.3,103036,DB02377,Guanine
,19650679,apparent terminal volume of distribution,"Based on currently available literature, ganciclovir pharmacokinetics in adult solid organ transplant recipients receiving oral valganciclovir are characterized by bioavailability of 66 +/- 10% (mean +/- SD), a maximum plasma concentration of 3.1 +/- 0.8 mg/L after a dose of 450 mg and of 6.6 +/- 1.9 mg/L after a dose of 900 mg, a time to reach the maximum plasma concentration of 3.0 +/- 1.0 hours, area under the plasma concentration-time curve values of 29.1 +/- 5.3 mg.h/L and 51.9 +/- 18.3 mg.h/L (after 450 mg and 900 mg, respectively), apparent clearance of 12.4 +/- 3.8 L/h, an elimination half-life of 5.3 +/- 1.5 hours and an apparent terminal volume of distribution of 101 +/- 36 L.",Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650679/),l,101,103037,DB02377,Guanine
,19650679,concentration producing 50% inhibition (IC(50)),The in vitro pharmacodynamics of ganciclovir reveal a mean concentration producing 50% inhibition (IC(50)) among CMV clinical strains of 0.7 mg/L (range 0.2-1.9 mg/L).,Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650679/),[mg] / [l],0.7,103038,DB02377,Guanine
,22556381,concentrations,"Median plasma aciclovir concentrations were 110.2 ng/mL (IQR, 85.9-233.5) 12-18 h after oral valaciclovir.",Safety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22556381/),[ng] / [ml],110.2,103543,DB02377,Guanine
,11422012,Cmax,"A wide interindividual variation in Cmax (median 313 pmol ml(-1), range 51-737) and AUC (median 586 pmol ml(-1) h, range 156-1306) was observed in the fasted state.",6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422012/),[pM] / [ml],313,103717,DB02377,Guanine
,11422012,AUC,"A wide interindividual variation in Cmax (median 313 pmol ml(-1), range 51-737) and AUC (median 586 pmol ml(-1) h, range 156-1306) was observed in the fasted state.",6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422012/),[h·pM] / [ml],586,103718,DB02377,Guanine
,11422012,Cmax,"Concomitant food administration resulted in a significant reduction in Cmax (median 71 vs 313 pmol ml(-1), P = 0.006, CI from 36 to 426), AUC (median 200 vs 586 pmol ml(-1) h, P = 0.006, 95% CI from 109 to 692), and time to reach Cmax (median 1.5 vs 3 h, P = 0.013, 95% CI from 0.74 to 2.73).",6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422012/),[pM] / [ml],71,103719,DB02377,Guanine
,11422012,Cmax,"Concomitant food administration resulted in a significant reduction in Cmax (median 71 vs 313 pmol ml(-1), P = 0.006, CI from 36 to 426), AUC (median 200 vs 586 pmol ml(-1) h, P = 0.006, 95% CI from 109 to 692), and time to reach Cmax (median 1.5 vs 3 h, P = 0.013, 95% CI from 0.74 to 2.73).",6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422012/),[pM] / [ml],313,103720,DB02377,Guanine
,11422012,AUC,"Concomitant food administration resulted in a significant reduction in Cmax (median 71 vs 313 pmol ml(-1), P = 0.006, CI from 36 to 426), AUC (median 200 vs 586 pmol ml(-1) h, P = 0.006, 95% CI from 109 to 692), and time to reach Cmax (median 1.5 vs 3 h, P = 0.013, 95% CI from 0.74 to 2.73).",6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422012/),[h·pM] / [ml],200,103721,DB02377,Guanine
,11422012,AUC,"Concomitant food administration resulted in a significant reduction in Cmax (median 71 vs 313 pmol ml(-1), P = 0.006, CI from 36 to 426), AUC (median 200 vs 586 pmol ml(-1) h, P = 0.006, 95% CI from 109 to 692), and time to reach Cmax (median 1.5 vs 3 h, P = 0.013, 95% CI from 0.74 to 2.73).",6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422012/),[h·pM] / [ml],586,103722,DB02377,Guanine
,11422012,time to reach Cmax,"Concomitant food administration resulted in a significant reduction in Cmax (median 71 vs 313 pmol ml(-1), P = 0.006, CI from 36 to 426), AUC (median 200 vs 586 pmol ml(-1) h, P = 0.006, 95% CI from 109 to 692), and time to reach Cmax (median 1.5 vs 3 h, P = 0.013, 95% CI from 0.74 to 2.73).",6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422012/),h,1.5,103723,DB02377,Guanine
,11422012,time to reach Cmax,"Concomitant food administration resulted in a significant reduction in Cmax (median 71 vs 313 pmol ml(-1), P = 0.006, CI from 36 to 426), AUC (median 200 vs 586 pmol ml(-1) h, P = 0.006, 95% CI from 109 to 692), and time to reach Cmax (median 1.5 vs 3 h, P = 0.013, 95% CI from 0.74 to 2.73).",6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422012/),h,3,103724,DB02377,Guanine
,2731174,terminal elimination half-life,"Two-compartment pharmacokinetic analysis revealed a terminal elimination half-life of 2.3 +/- 0.68 h, a total body clearance of 6.0 +/- 0.53 ml/min/kg, and a volume of distribution at steady state of 948 +/- 186 ml/kg.",Modulation of O6-alkylguanine-DNA alkyltransferase in rats following intravenous administration of O6-methylguanine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731174/),h,2.3,104080,DB02377,Guanine
,2731174,total body clearance,"Two-compartment pharmacokinetic analysis revealed a terminal elimination half-life of 2.3 +/- 0.68 h, a total body clearance of 6.0 +/- 0.53 ml/min/kg, and a volume of distribution at steady state of 948 +/- 186 ml/kg.",Modulation of O6-alkylguanine-DNA alkyltransferase in rats following intravenous administration of O6-methylguanine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731174/),[ml] / [kg·min],6.0,104081,DB02377,Guanine
,2731174,volume of distribution at steady state,"Two-compartment pharmacokinetic analysis revealed a terminal elimination half-life of 2.3 +/- 0.68 h, a total body clearance of 6.0 +/- 0.53 ml/min/kg, and a volume of distribution at steady state of 948 +/- 186 ml/kg.",Modulation of O6-alkylguanine-DNA alkyltransferase in rats following intravenous administration of O6-methylguanine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731174/),[ml] / [kg],948,104082,DB02377,Guanine
,2731174,steady state serum concentration,"A continuous infusion protocol, which achieved a steady state serum concentration of 10.3 +/- 1.5 micrograms O6-methylguanine/ml at 15 h, resulted in a similar degree of inactivation of tissue alkyltransferase to that observed following bolus drug infusion.",Modulation of O6-alkylguanine-DNA alkyltransferase in rats following intravenous administration of O6-methylguanine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731174/),μg,10.3,104083,DB02377,Guanine
,17050790,terminal half-life,Entecavir had a mean terminal half-life ranging from 128 to 149 hours and an effective half-life of approximately 24 hours.,"Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17050790/),h,128 to 149,104278,DB02377,Guanine
,17050790,effective half-life,Entecavir had a mean terminal half-life ranging from 128 to 149 hours and an effective half-life of approximately 24 hours.,"Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17050790/),h,24,104279,DB02377,Guanine
,17050790,urinary recovery,"Elimination was predominantly through renal excretion, with mean urinary recovery ranging from 62% to 73%.","Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17050790/),%,62,104280,DB02377,Guanine
,17050790,urinary recovery,"Elimination was predominantly through renal excretion, with mean urinary recovery ranging from 62% to 73%.","Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17050790/),%,73,104281,DB02377,Guanine
,8593015,absolute bioavailability,"The mean absolute bioavailability of acyclovir was 54.2%, a value three to five times that obtained previously with oral acyclovir.","Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593015/),%,54.2,106210,DB02377,Guanine
,8593015,maximum concentration,"The majority of plasma radioactivity was accounted for by acyclovir, with very low plasma valaciclovir concentrations (mean maximum concentration of drug in plasma = 0.19 microM), which were undetectable after 3 h postdose.","Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593015/),μM,0.19,106211,DB02377,Guanine
,7103443,concentrations,"The mean concentrations (+/- standard deviations) at the end of infusion as measured by radioimmunoassay were 4.52 +/0 0.31, 8.28 +/- 2.61, 14.6 +/- 2.30, and 22.7 +/- 10.4 microgram/ml, respectively.","Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103443/),μ,4.52,108421,DB02377,Guanine
,7103443,concentrations,"The mean concentrations (+/- standard deviations) at the end of infusion as measured by radioimmunoassay were 4.52 +/0 0.31, 8.28 +/- 2.61, 14.6 +/- 2.30, and 22.7 +/- 10.4 microgram/ml, respectively.","Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103443/),μ,8.28,108422,DB02377,Guanine
,7103443,concentrations,"The mean concentrations (+/- standard deviations) at the end of infusion as measured by radioimmunoassay were 4.52 +/0 0.31, 8.28 +/- 2.61, 14.6 +/- 2.30, and 22.7 +/- 10.4 microgram/ml, respectively.","Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103443/),μ,14.6,108423,DB02377,Guanine
,7103443,concentrations,"The mean concentrations (+/- standard deviations) at the end of infusion as measured by radioimmunoassay were 4.52 +/0 0.31, 8.28 +/- 2.61, 14.6 +/- 2.30, and 22.7 +/- 10.4 microgram/ml, respectively.","Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103443/),μ,22.7,108424,DB02377,Guanine
,7103443,terminal plasma half-life,"The mean terminal plasma half-life for each of the groups was 2.85, 2.80, 3.30, and 2.38 h, respectively.","Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103443/),h,2.85,108425,DB02377,Guanine
,7103443,terminal plasma half-life,"The mean terminal plasma half-life for each of the groups was 2.85, 2.80, 3.30, and 2.38 h, respectively.","Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103443/),h,2.80,108426,DB02377,Guanine
,7103443,terminal plasma half-life,"The mean terminal plasma half-life for each of the groups was 2.85, 2.80, 3.30, and 2.38 h, respectively.","Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103443/),h,3.30,108427,DB02377,Guanine
,7103443,terminal plasma half-life,"The mean terminal plasma half-life for each of the groups was 2.85, 2.80, 3.30, and 2.38 h, respectively.","Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7103443/),h,2.38,108428,DB02377,Guanine
,10999759,plasma clearances,"The plasma clearances of the four 8-substituted BG analogues were similar (0.04-0.06 l/h/kg), but half-lives ranged from <2 to >24 h.",Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999759/),[l] / [h·kg],0.04-0.06,108501,DB02377,Guanine
<,10999759,half-lives,"The plasma clearances of the four 8-substituted BG analogues were similar (0.04-0.06 l/h/kg), but half-lives ranged from <2 to >24 h.",Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999759/),h,2,108502,DB02377,Guanine
>,10999759,half-lives,"The plasma clearances of the four 8-substituted BG analogues were similar (0.04-0.06 l/h/kg), but half-lives ranged from <2 to >24 h.",Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999759/),h,24,108503,DB02377,Guanine
,1605599,half-life,"The half-life of acyclovir in blood was 2 h, while that of H2G was 28 min.","Pharmacokinetics and distribution over the blood brain barrier of two acyclic guanosine analogs in rats, studied by microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1605599/),h,2,108602,DB02377,Guanine
,1605599,half-life,"The half-life of acyclovir in blood was 2 h, while that of H2G was 28 min.","Pharmacokinetics and distribution over the blood brain barrier of two acyclic guanosine analogs in rats, studied by microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1605599/),min,28,108603,DB02377,Guanine
,7463350,terminal t1/2,"After i.v. injection, the acyclovir plasma concentration-time profile, determined by radioimmunoassay, exhibited a biexponential decay with a terminal t1/2 of 2.2 to 3.6 hr.",Pharmacokinetics and bioavailability of acyclovir in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463350/),h,2.2 to 3.6,110500,DB02377,Guanine
,7463350,Plasma clearance,Plasma clearance (3.48-5.83 ml/min/kg) approximated the normal glomerular filtration rate in dogs and the Vd beta (0.97-1.17 liters/kg) indicated distribution of the drug into tissues.,Pharmacokinetics and bioavailability of acyclovir in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463350/),[ml] / [kg·min],3.48-5.83,110501,DB02377,Guanine
,7463350,Vd beta,Plasma clearance (3.48-5.83 ml/min/kg) approximated the normal glomerular filtration rate in dogs and the Vd beta (0.97-1.17 liters/kg) indicated distribution of the drug into tissues.,Pharmacokinetics and bioavailability of acyclovir in the dog. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463350/),[l] / [kg],0.97-1.17,110502,DB02377,Guanine
,7463350,oral bioavailability,"Good oral bioavailability (91 and 80%) was observed after the administration of a capsule at the lower doses (5 and 20 mg/kg, respectively) but bioavailability declined (52%) at the 50 mg/kg dose, indicating the possibility that the gastrointestinal absorption of acyclovir is a saturable process.",Pharmacokinetics and bioavailability of acyclovir in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463350/),%,91,110503,DB02377,Guanine
,7463350,oral bioavailability,"Good oral bioavailability (91 and 80%) was observed after the administration of a capsule at the lower doses (5 and 20 mg/kg, respectively) but bioavailability declined (52%) at the 50 mg/kg dose, indicating the possibility that the gastrointestinal absorption of acyclovir is a saturable process.",Pharmacokinetics and bioavailability of acyclovir in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463350/),%,80,110504,DB02377,Guanine
,7463350,bioavailability,"Good oral bioavailability (91 and 80%) was observed after the administration of a capsule at the lower doses (5 and 20 mg/kg, respectively) but bioavailability declined (52%) at the 50 mg/kg dose, indicating the possibility that the gastrointestinal absorption of acyclovir is a saturable process.",Pharmacokinetics and bioavailability of acyclovir in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463350/),%,52,110505,DB02377,Guanine
>,17324644,m/z,Acquisition was performed in multiple reaction monitoring (MRM) mode by monitoring the transitions: m/z 254.00>152.09 for penciclovir and m/z 226.00>152.09 for IS.,Development and validation of a high-performance liquid chromatography-tandem mass spectrometry for the determination of penciclovir in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324644/),,254.,110752,DB02377,Guanine
>,17324644,m/z,Acquisition was performed in multiple reaction monitoring (MRM) mode by monitoring the transitions: m/z 254.00>152.09 for penciclovir and m/z 226.00>152.09 for IS.,Development and validation of a high-performance liquid chromatography-tandem mass spectrometry for the determination of penciclovir in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324644/),,152.09,110753,DB02377,Guanine
>,17324644,m/z,Acquisition was performed in multiple reaction monitoring (MRM) mode by monitoring the transitions: m/z 254.00>152.09 for penciclovir and m/z 226.00>152.09 for IS.,Development and validation of a high-performance liquid chromatography-tandem mass spectrometry for the determination of penciclovir in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324644/),,226.,110754,DB02377,Guanine
,17324644,total analysis time,"Results were linear over the studied range (0.05-10 microg/ml) with r(2)=0.9999, and the total analysis time for each run was 2 min.",Development and validation of a high-performance liquid chromatography-tandem mass spectrometry for the determination of penciclovir in human plasma: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324644/),min,2,110755,DB02377,Guanine
,2829714,maximum concentration in plasma (Cmax),"Among the 13 children who received the 600-mg/m2 dose, the maximum concentration in plasma (Cmax) was 0.99 +/- 0.38 microgram/ml (mean +/- standard deviation), the time to maximum concentration (Tmax) was 3.0 +/- 0.86 h, the area under the curve (AUC) was 5.56 +/- 2.17 micrograms.h/ml, and the elimination half-life (t1/2) was 2.59 +/- 0.78 h.",Pharmacokinetics of acyclovir suspension in infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829714/),[μg] / [ml],0.99,111398,DB02377,Guanine
,2829714,time to maximum concentration (Tmax),"Among the 13 children who received the 600-mg/m2 dose, the maximum concentration in plasma (Cmax) was 0.99 +/- 0.38 microgram/ml (mean +/- standard deviation), the time to maximum concentration (Tmax) was 3.0 +/- 0.86 h, the area under the curve (AUC) was 5.56 +/- 2.17 micrograms.h/ml, and the elimination half-life (t1/2) was 2.59 +/- 0.78 h.",Pharmacokinetics of acyclovir suspension in infants and children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829714/),h,3.0,111399,DB02377,Guanine
,2829714,area under the curve (AUC),"Among the 13 children who received the 600-mg/m2 dose, the maximum concentration in plasma (Cmax) was 0.99 +/- 0.38 microgram/ml (mean +/- standard deviation), the time to maximum concentration (Tmax) was 3.0 +/- 0.86 h, the area under the curve (AUC) was 5.56 +/- 2.17 micrograms.h/ml, and the elimination half-life (t1/2) was 2.59 +/- 0.78 h.",Pharmacokinetics of acyclovir suspension in infants and children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829714/),[h·μg] / [ml],5.56,111400,DB02377,Guanine
,2829714,elimination half-life (t1/2),"Among the 13 children who received the 600-mg/m2 dose, the maximum concentration in plasma (Cmax) was 0.99 +/- 0.38 microgram/ml (mean +/- standard deviation), the time to maximum concentration (Tmax) was 3.0 +/- 0.86 h, the area under the curve (AUC) was 5.56 +/- 2.17 micrograms.h/ml, and the elimination half-life (t1/2) was 2.59 +/- 0.78 h.",Pharmacokinetics of acyclovir suspension in infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829714/),h,2.59,111401,DB02377,Guanine
,2829714,Cmax,"The three infants less than 2 months of age who received the 300-mg/m2 dose had a Cmax of 1.88 +/- 1.11 micrograms/ml, a Tmax of 4.10 +/- 0.48 h, an AUC of 6.54 +/- 4.32 micrograms.h/ml, and a t1/2 of 3.26 +/- 0.33 h.",Pharmacokinetics of acyclovir suspension in infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829714/),[μg] / [ml],1.88,111402,DB02377,Guanine
,2829714,Tmax,"The three infants less than 2 months of age who received the 300-mg/m2 dose had a Cmax of 1.88 +/- 1.11 micrograms/ml, a Tmax of 4.10 +/- 0.48 h, an AUC of 6.54 +/- 4.32 micrograms.h/ml, and a t1/2 of 3.26 +/- 0.33 h.",Pharmacokinetics of acyclovir suspension in infants and children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829714/),h,4.10,111403,DB02377,Guanine
,2829714,AUC,"The three infants less than 2 months of age who received the 300-mg/m2 dose had a Cmax of 1.88 +/- 1.11 micrograms/ml, a Tmax of 4.10 +/- 0.48 h, an AUC of 6.54 +/- 4.32 micrograms.h/ml, and a t1/2 of 3.26 +/- 0.33 h.",Pharmacokinetics of acyclovir suspension in infants and children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829714/),[h·μg] / [ml],6.54,111404,DB02377,Guanine
,2829714,t1/2,"The three infants less than 2 months of age who received the 300-mg/m2 dose had a Cmax of 1.88 +/- 1.11 micrograms/ml, a Tmax of 4.10 +/- 0.48 h, an AUC of 6.54 +/- 4.32 micrograms.h/ml, and a t1/2 of 3.26 +/- 0.33 h.",Pharmacokinetics of acyclovir suspension in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2829714/),h,3.26,111405,DB02377,Guanine
,18561175,C(max),"Mean (+/-SD) C(max) values for acyclovir following oral valacyclovir were 18.8 +/- 7 microM with a total exposure of 4,106 +/- 1,519 microM min.",Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18561175/),μM,18.8,112016,DB02377,Guanine
,18561175,total exposure,"Mean (+/-SD) C(max) values for acyclovir following oral valacyclovir were 18.8 +/- 7 microM with a total exposure of 4,106 +/- 1,519 microM min.",Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18561175/),min·μM,"4,106",112017,DB02377,Guanine
,18561175,bioavailability,The mean bioavailability of acyclovir from valacyclovir was 64%.,Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18561175/),%,64,112018,DB02377,Guanine
,10972485,peak plasma concentration (Cmax),"The peak plasma concentration (Cmax), time to Cmax (tmax), and bioavailability (F) of oral BG were: 2.3 +/- 0.9 microg/ml, 2.3 +/- 0.6 h, and 65.5% respectively.",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),[μg] / [ml],2.3,113127,DB02377,Guanine
,10972485,time to Cmax (tmax),"The peak plasma concentration (Cmax), time to Cmax (tmax), and bioavailability (F) of oral BG were: 2.3 +/- 0.9 microg/ml, 2.3 +/- 0.6 h, and 65.5% respectively.",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),h,2.3,113128,DB02377,Guanine
,10972485,bioavailability (F),"The peak plasma concentration (Cmax), time to Cmax (tmax), and bioavailability (F) of oral BG were: 2.3 +/- 0.9 microg/ml, 2.3 +/- 0.6 h, and 65.5% respectively.",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),%,65.5,113129,DB02377,Guanine
,10972485,AUCs,The AUCs of BG and 8-oxo-BG were 13.1 +/- 4.6 microg x h/ml and 1.7 +/- 0.4 microg x h/ml after oral administration of BG.,Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),[h·μg] / [ml],13.1,113130,DB02377,Guanine
,10972485,AUCs,The AUCs of BG and 8-oxo-BG were 13.1 +/- 4.6 microg x h/ml and 1.7 +/- 0.4 microg x h/ml after oral administration of BG.,Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),[h·μg] / [ml],1.7,113131,DB02377,Guanine
,10972485,mean absorption time,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),h,2.0,113132,DB02377,Guanine
,10972485,mean absorption time,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),h,6.0,113133,DB02377,Guanine
,10972485,tmax,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),h,5,113134,DB02377,Guanine
,10972485,Cmax,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),[μg] / [ml],0.96,113135,DB02377,Guanine
,10972485,AUC0-inf ratio,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),,0.12,113136,DB02377,Guanine
,10972485,AUC0-inf ratio,"Coadministration with ketoconazole resulted in an increase in mean absorption time from 2.0 +/- 0.3 h to 6.0 +/- 0.9 h, a shift in tmax to 5 +/- 3.3 h, a decrease in Cmax to 0.96 +/- 0.8 microg/ml, and a decrease in AUC0-inf ratio of 8-oxo-BG:BG from about 0.12 to 0.04 (P < 0.05).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),,0.04,113137,DB02377,Guanine
,10972485,bioavailability,"The bioavailability of BG was not changed (65.5% vs 56.9%, P= 0.78).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),%,65.5,113138,DB02377,Guanine
,10972485,bioavailability,"The bioavailability of BG was not changed (65.5% vs 56.9%, P= 0.78).",Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972485/),%,56.9,113139,DB02377,Guanine
,29883728,Cmax,Acyclovir administered by semisolid SMEDDS reached twice higher Cmax (0.92 ± 0.21 μg/ml) and has significantly shorter Tmax (14 ± 10.84 min) compared to the suspension of acyclovir (Cmax 0.29 ± 0.09 μg/ml and Tmax 26.00 ± 5.48 min).,Semisolid self-microemulsifying drug delivery systems (SMEDDSs): Effects on pharmacokinetics of acyclovir in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883728/),[μg] / [ml],0.92,113395,DB02377,Guanine
,29883728,Tmax,Acyclovir administered by semisolid SMEDDS reached twice higher Cmax (0.92 ± 0.21 μg/ml) and has significantly shorter Tmax (14 ± 10.84 min) compared to the suspension of acyclovir (Cmax 0.29 ± 0.09 μg/ml and Tmax 26.00 ± 5.48 min).,Semisolid self-microemulsifying drug delivery systems (SMEDDSs): Effects on pharmacokinetics of acyclovir in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883728/),min,14,113396,DB02377,Guanine
,29883728,Cmax,Acyclovir administered by semisolid SMEDDS reached twice higher Cmax (0.92 ± 0.21 μg/ml) and has significantly shorter Tmax (14 ± 10.84 min) compared to the suspension of acyclovir (Cmax 0.29 ± 0.09 μg/ml and Tmax 26.00 ± 5.48 min).,Semisolid self-microemulsifying drug delivery systems (SMEDDSs): Effects on pharmacokinetics of acyclovir in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883728/),[μg] / [ml],0.29,113397,DB02377,Guanine
,29883728,Tmax,Acyclovir administered by semisolid SMEDDS reached twice higher Cmax (0.92 ± 0.21 μg/ml) and has significantly shorter Tmax (14 ± 10.84 min) compared to the suspension of acyclovir (Cmax 0.29 ± 0.09 μg/ml and Tmax 26.00 ± 5.48 min).,Semisolid self-microemulsifying drug delivery systems (SMEDDSs): Effects on pharmacokinetics of acyclovir in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883728/),min,26.00,113398,DB02377,Guanine
,31446981,objective response rate,"Amongst patients treated at the MTD, the objective response rate was 14%.",Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31446981/),%,14,114372,DB02377,Guanine
,31446981,MTD,"In patients with previously treated metastatic NSCLC, the MTD of luminespib in combination with pemetrexed was 55 mg/m2 per week.",Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31446981/),[mg] / [m2·week],55,114373,DB02377,Guanine
,11408358,peak plasma concentration (C(max)),"In rats, SK1899 was rapidly and extensively metabolized to penciclovir, which reached the peak plasma concentration (C(max)) of 39.5 microM at 0.5 h after 0.2-mmol/kg dosing.","Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408358/),μM,39.5,116686,DB02377,Guanine
,11408358,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) for penciclovir was 57.5 microM x h.,"Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408358/),h·μM,57.5,116687,DB02377,Guanine
,11408358,C(max),"The mean C(max) and AUC for penciclovir were 4.5 microM at 2.7 h and 28.2 microM x h, respectively.","Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408358/),μM,4.5,116688,DB02377,Guanine
,11408358,AUC,"The mean C(max) and AUC for penciclovir were 4.5 microM at 2.7 h and 28.2 microM x h, respectively.","Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408358/),h·μM,28.2,116689,DB02377,Guanine
,11408358,0- to 24-h,"The 0- to 24-h urinary recovery of penciclovir represented 36.1 and 36.3% of dose to rats and dogs, respectively.","Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408358/),%,36.1,116690,DB02377,Guanine
,11408358,0- to 24-h,"The 0- to 24-h urinary recovery of penciclovir represented 36.1 and 36.3% of dose to rats and dogs, respectively.","Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408358/),%,36.3,116691,DB02377,Guanine
,11408358,urinary recovery,"The 0- to 24-h urinary recovery of penciclovir represented 36.1 and 36.3% of dose to rats and dogs, respectively.","Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408358/),%,36.1,116692,DB02377,Guanine
,11408358,urinary recovery,"The 0- to 24-h urinary recovery of penciclovir represented 36.1 and 36.3% of dose to rats and dogs, respectively.","Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408358/),%,36.3,116693,DB02377,Guanine
,3348321,half-life,The elimination phase demonstrated a half-life of 2.8 hours in milk.,Acyclovir in human breast milk. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348321/),h,2.8,117230,DB02377,Guanine
,17309854,IC(50),"DRH-417 emerged from the EORTC-Drug Discovery Committee and NCI 60 cell line in vitro screening programs as a potent antiproliferative agent with differential sensitivity towards certain cancer types such as melanoma, breast and renal cell carcinoma (mean IC(50) = 3 nM).",Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17309854/),nM,3,118106,DB02377,Guanine
,17309854,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was established as 0.5 mg/kg given i.p.,Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17309854/),[mg] / [kg],0.5,118107,DB02377,Guanine
,17309854,plasma AUC,"At a dose of 0.5 mg kg(-1), the plasma AUC was 540 nM h (197.1 ng h ml(-1)) and the peak plasma concentration (171 nM [62.4 ng ml(-1)]) occurred at 30 min., reaching doses levels well above those needed for in vitro antiproliferative activity.",Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17309854/),h·nM,540,118108,DB02377,Guanine
,17309854,plasma AUC,"At a dose of 0.5 mg kg(-1), the plasma AUC was 540 nM h (197.1 ng h ml(-1)) and the peak plasma concentration (171 nM [62.4 ng ml(-1)]) occurred at 30 min., reaching doses levels well above those needed for in vitro antiproliferative activity.",Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17309854/),[h·ng] / [ml],197.1,118109,DB02377,Guanine
,17309854,peak plasma concentration,"At a dose of 0.5 mg kg(-1), the plasma AUC was 540 nM h (197.1 ng h ml(-1)) and the peak plasma concentration (171 nM [62.4 ng ml(-1)]) occurred at 30 min., reaching doses levels well above those needed for in vitro antiproliferative activity.",Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17309854/),nM,171,118110,DB02377,Guanine
,17309854,peak plasma concentration,"At a dose of 0.5 mg kg(-1), the plasma AUC was 540 nM h (197.1 ng h ml(-1)) and the peak plasma concentration (171 nM [62.4 ng ml(-1)]) occurred at 30 min., reaching doses levels well above those needed for in vitro antiproliferative activity.",Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17309854/),[ng] / [ml],62.4,118111,DB02377,Guanine
,27350064,progression-free survival,"The median progression-free survival was 2.3 months (range, 0-27.1).","Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27350064/),month,2.3,118513,DB02377,Guanine
,9808499,minimum steady-state concentration (Cmin),"The following GCV concentrations (mean +/-SD) were determined: with CrCl of > or =70 ml/min, the minimum steady-state concentration (Cmin) and maximum concentration (Cmax) were 0.78+/-0.46 microg/ml and 1.42+/-0.37 microg/ml, respectively, with a 24-hr area under the concentration time curve (AUC0-24) of 24.7+/-7.8 microg x hr/ml; with CrCl of 50-69 ml/min, the Cmin and Cmax were 1.93+/-0.48 and 2.57+/-0.39 microg/ml, respectively, with an AUC0-24 of 52.1+/-10.1 microg x hr/ml; with CrCl of 25-50 ml/min, the Cmin and Cmax were 0.41+/-0.27 and 1.17+/-0.32 microg/ml, respectively, with an AUC0-24 of 14.6+/-7.4 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[μg] / [ml],0.78,119642,DB02377,Guanine
,9808499,maximum concentration (Cmax),"The following GCV concentrations (mean +/-SD) were determined: with CrCl of > or =70 ml/min, the minimum steady-state concentration (Cmin) and maximum concentration (Cmax) were 0.78+/-0.46 microg/ml and 1.42+/-0.37 microg/ml, respectively, with a 24-hr area under the concentration time curve (AUC0-24) of 24.7+/-7.8 microg x hr/ml; with CrCl of 50-69 ml/min, the Cmin and Cmax were 1.93+/-0.48 and 2.57+/-0.39 microg/ml, respectively, with an AUC0-24 of 52.1+/-10.1 microg x hr/ml; with CrCl of 25-50 ml/min, the Cmin and Cmax were 0.41+/-0.27 and 1.17+/-0.32 microg/ml, respectively, with an AUC0-24 of 14.6+/-7.4 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[μg] / [ml],1.42,119643,DB02377,Guanine
,9808499,area under the concentration time curve (AUC0-24),"The following GCV concentrations (mean +/-SD) were determined: with CrCl of > or =70 ml/min, the minimum steady-state concentration (Cmin) and maximum concentration (Cmax) were 0.78+/-0.46 microg/ml and 1.42+/-0.37 microg/ml, respectively, with a 24-hr area under the concentration time curve (AUC0-24) of 24.7+/-7.8 microg x hr/ml; with CrCl of 50-69 ml/min, the Cmin and Cmax were 1.93+/-0.48 and 2.57+/-0.39 microg/ml, respectively, with an AUC0-24 of 52.1+/-10.1 microg x hr/ml; with CrCl of 25-50 ml/min, the Cmin and Cmax were 0.41+/-0.27 and 1.17+/-0.32 microg/ml, respectively, with an AUC0-24 of 14.6+/-7.4 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[h·μg] / [ml],24.7,119644,DB02377,Guanine
,9808499,Cmin,"The following GCV concentrations (mean +/-SD) were determined: with CrCl of > or =70 ml/min, the minimum steady-state concentration (Cmin) and maximum concentration (Cmax) were 0.78+/-0.46 microg/ml and 1.42+/-0.37 microg/ml, respectively, with a 24-hr area under the concentration time curve (AUC0-24) of 24.7+/-7.8 microg x hr/ml; with CrCl of 50-69 ml/min, the Cmin and Cmax were 1.93+/-0.48 and 2.57+/-0.39 microg/ml, respectively, with an AUC0-24 of 52.1+/-10.1 microg x hr/ml; with CrCl of 25-50 ml/min, the Cmin and Cmax were 0.41+/-0.27 and 1.17+/-0.32 microg/ml, respectively, with an AUC0-24 of 14.6+/-7.4 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[μg] / [ml],1.93,119645,DB02377,Guanine
,9808499,Cmax,"The following GCV concentrations (mean +/-SD) were determined: with CrCl of > or =70 ml/min, the minimum steady-state concentration (Cmin) and maximum concentration (Cmax) were 0.78+/-0.46 microg/ml and 1.42+/-0.37 microg/ml, respectively, with a 24-hr area under the concentration time curve (AUC0-24) of 24.7+/-7.8 microg x hr/ml; with CrCl of 50-69 ml/min, the Cmin and Cmax were 1.93+/-0.48 and 2.57+/-0.39 microg/ml, respectively, with an AUC0-24 of 52.1+/-10.1 microg x hr/ml; with CrCl of 25-50 ml/min, the Cmin and Cmax were 0.41+/-0.27 and 1.17+/-0.32 microg/ml, respectively, with an AUC0-24 of 14.6+/-7.4 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[μg] / [ml],2.57,119646,DB02377,Guanine
,9808499,AUC0-24,"The following GCV concentrations (mean +/-SD) were determined: with CrCl of > or =70 ml/min, the minimum steady-state concentration (Cmin) and maximum concentration (Cmax) were 0.78+/-0.46 microg/ml and 1.42+/-0.37 microg/ml, respectively, with a 24-hr area under the concentration time curve (AUC0-24) of 24.7+/-7.8 microg x hr/ml; with CrCl of 50-69 ml/min, the Cmin and Cmax were 1.93+/-0.48 and 2.57+/-0.39 microg/ml, respectively, with an AUC0-24 of 52.1+/-10.1 microg x hr/ml; with CrCl of 25-50 ml/min, the Cmin and Cmax were 0.41+/-0.27 and 1.17+/-0.32 microg/ml, respectively, with an AUC0-24 of 14.6+/-7.4 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[h·μg] / [ml],52.1,119647,DB02377,Guanine
,9808499,Cmin,"The following GCV concentrations (mean +/-SD) were determined: with CrCl of > or =70 ml/min, the minimum steady-state concentration (Cmin) and maximum concentration (Cmax) were 0.78+/-0.46 microg/ml and 1.42+/-0.37 microg/ml, respectively, with a 24-hr area under the concentration time curve (AUC0-24) of 24.7+/-7.8 microg x hr/ml; with CrCl of 50-69 ml/min, the Cmin and Cmax were 1.93+/-0.48 and 2.57+/-0.39 microg/ml, respectively, with an AUC0-24 of 52.1+/-10.1 microg x hr/ml; with CrCl of 25-50 ml/min, the Cmin and Cmax were 0.41+/-0.27 and 1.17+/-0.32 microg/ml, respectively, with an AUC0-24 of 14.6+/-7.4 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[μg] / [ml],0.41,119648,DB02377,Guanine
,9808499,Cmax,"The following GCV concentrations (mean +/-SD) were determined: with CrCl of > or =70 ml/min, the minimum steady-state concentration (Cmin) and maximum concentration (Cmax) were 0.78+/-0.46 microg/ml and 1.42+/-0.37 microg/ml, respectively, with a 24-hr area under the concentration time curve (AUC0-24) of 24.7+/-7.8 microg x hr/ml; with CrCl of 50-69 ml/min, the Cmin and Cmax were 1.93+/-0.48 and 2.57+/-0.39 microg/ml, respectively, with an AUC0-24 of 52.1+/-10.1 microg x hr/ml; with CrCl of 25-50 ml/min, the Cmin and Cmax were 0.41+/-0.27 and 1.17+/-0.32 microg/ml, respectively, with an AUC0-24 of 14.6+/-7.4 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[μg] / [ml],1.17,119649,DB02377,Guanine
,9808499,AUC0-24,"The following GCV concentrations (mean +/-SD) were determined: with CrCl of > or =70 ml/min, the minimum steady-state concentration (Cmin) and maximum concentration (Cmax) were 0.78+/-0.46 microg/ml and 1.42+/-0.37 microg/ml, respectively, with a 24-hr area under the concentration time curve (AUC0-24) of 24.7+/-7.8 microg x hr/ml; with CrCl of 50-69 ml/min, the Cmin and Cmax were 1.93+/-0.48 and 2.57+/-0.39 microg/ml, respectively, with an AUC0-24 of 52.1+/-10.1 microg x hr/ml; with CrCl of 25-50 ml/min, the Cmin and Cmax were 0.41+/-0.27 and 1.17+/-0.32 microg/ml, respectively, with an AUC0-24 of 14.6+/-7.4 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),,14.6,119650,DB02377,Guanine
,9808499,Cmin,"For one patient with a CrCl of 23.8 ml/min, the Cmin and Cmax were 0.32 and 0.7 microg/ml, respectively, with an AUC0-24 of 10.7 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[μg] / [ml],0.32,119651,DB02377,Guanine
,9808499,Cmax,"For one patient with a CrCl of 23.8 ml/min, the Cmin and Cmax were 0.32 and 0.7 microg/ml, respectively, with an AUC0-24 of 10.7 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[μg] / [ml],0.7,119652,DB02377,Guanine
,9808499,AUC0-24,"For one patient with a CrCl of 23.8 ml/min, the Cmin and Cmax were 0.32 and 0.7 microg/ml, respectively, with an AUC0-24 of 10.7 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[h·μg] / [ml],10.7,119653,DB02377,Guanine
,9808499,Cmin,"With CrCl of <10 ml/min, the mean Cmin and Cmax were 0.75+/-0.42 and 1.59+/-0.55 microg/ml, respectively, with a mean AUC0-24 of 64.6+/-18.8 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[μg] / [ml],0.75,119654,DB02377,Guanine
,9808499,Cmax,"With CrCl of <10 ml/min, the mean Cmin and Cmax were 0.75+/-0.42 and 1.59+/-0.55 microg/ml, respectively, with a mean AUC0-24 of 64.6+/-18.8 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[μg] / [ml],1.59,119655,DB02377,Guanine
,9808499,AUC0-24,"With CrCl of <10 ml/min, the mean Cmin and Cmax were 0.75+/-0.42 and 1.59+/-0.55 microg/ml, respectively, with a mean AUC0-24 of 64.6+/-18.8 microg x hr/ml.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[h·μg] / [ml],64.6,119656,DB02377,Guanine
,9808499,Absolute bioavailability,"Absolute bioavailability, for the nine patients so analyzed, was 7.2+/-2.4%.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),%,7.2,119657,DB02377,Guanine
,9808499,concentrations,"For those patients with end-stage renal failure, GCV concentrations fell during dialysis from a mean of 1.47+/-0.48 microg/ml before dialysis to 0.69+/-0.38 microg/ml after dialysis.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[μg] / [ml],1.47,119658,DB02377,Guanine
,9808499,concentrations,"For those patients with end-stage renal failure, GCV concentrations fell during dialysis from a mean of 1.47+/-0.48 microg/ml before dialysis to 0.69+/-0.38 microg/ml after dialysis.",Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808499/),[μg] / [ml],0.69,119659,DB02377,Guanine
,1682458,absolute bioavailabilities,"The absolute bioavailabilities for 1-, 2.5-, 3- and 8-week-old rats were 77.59, 51.52, 14.61 and 7.30%, respectively.",Effect of age on the gastrointestinal absorption of acyclovir in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682458/),%,77.59,120676,DB02377,Guanine
,1682458,absolute bioavailabilities,"The absolute bioavailabilities for 1-, 2.5-, 3- and 8-week-old rats were 77.59, 51.52, 14.61 and 7.30%, respectively.",Effect of age on the gastrointestinal absorption of acyclovir in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682458/),%,51.52,120677,DB02377,Guanine
,1682458,absolute bioavailabilities,"The absolute bioavailabilities for 1-, 2.5-, 3- and 8-week-old rats were 77.59, 51.52, 14.61 and 7.30%, respectively.",Effect of age on the gastrointestinal absorption of acyclovir in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682458/),%,14.61,120678,DB02377,Guanine
,1682458,absolute bioavailabilities,"The absolute bioavailabilities for 1-, 2.5-, 3- and 8-week-old rats were 77.59, 51.52, 14.61 and 7.30%, respectively.",Effect of age on the gastrointestinal absorption of acyclovir in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682458/),%,7.30,120679,DB02377,Guanine
,11563408,Tmax,"When ganciclovir was administered within 30 minutes following the breakfast, there was a mean increase of 110.6% +/- 79.0% and 114.1% +/- 81.7% in Cmax0-5 and AUC0-5, respectively, with a prolongation of mean Tmax from 1.8 to 2.7 hours.",Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563408/),h,1.8,120747,DB02377,Guanine
,11563408,Tmax,"When ganciclovir was administered within 30 minutes following the breakfast, there was a mean increase of 110.6% +/- 79.0% and 114.1% +/- 81.7% in Cmax0-5 and AUC0-5, respectively, with a prolongation of mean Tmax from 1.8 to 2.7 hours.",Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563408/),h,2.7,120748,DB02377,Guanine
,2854453,Elimination half-lives,"Elimination half-lives in plasma following intravenous administration to monkeys (100 mumol/kg of body weight) ranged from 1.8 to 2.2 h, and total body clearance was 9.0 +/- 0.4 ml/min per kg (mean +/- standard error).","Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2854453/),h,1.8 to 2.2,121678,DB02377,Guanine
,2854453,total body clearance,"Elimination half-lives in plasma following intravenous administration to monkeys (100 mumol/kg of body weight) ranged from 1.8 to 2.2 h, and total body clearance was 9.0 +/- 0.4 ml/min per kg (mean +/- standard error).","Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2854453/),[ml] / [kg·min],9.0,121679,DB02377,Guanine
,2854453,maximum concentration,"After oral administration, levels in plasma were low, with a maximum concentration of the drug of only 3.1 +/- 0.8 microM, a time to reach maximum concentration of drug of 2.7 +/- 0.4 h, and an oral bioavailability of 10.6 +/- 1.4%.","Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2854453/),μM,3.1,121680,DB02377,Guanine
,2854453,time to reach maximum concentration of drug,"After oral administration, levels in plasma were low, with a maximum concentration of the drug of only 3.1 +/- 0.8 microM, a time to reach maximum concentration of drug of 2.7 +/- 0.4 h, and an oral bioavailability of 10.6 +/- 1.4%.","Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2854453/),h,2.7,121681,DB02377,Guanine
,2854453,oral bioavailability,"After oral administration, levels in plasma were low, with a maximum concentration of the drug of only 3.1 +/- 0.8 microM, a time to reach maximum concentration of drug of 2.7 +/- 0.4 h, and an oral bioavailability of 10.6 +/- 1.4%.","Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2854453/),%,10.6,121682,DB02377,Guanine
,8380762,elimination half-life (t1/2),The mean elimination half-life (t1/2) for both dose groups was 2.4 hours.,Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8380762/),h,2.4,122878,DB02377,Guanine
,8380762,apparent volume of distribution (Vd),The mean apparent volume of distribution (Vd) was 669 +/- 70 ml/kg for the 4 mg/kg group and 749 +/- 59 ml/kg for the 6 mg/kg group.,Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8380762/),[ml] / [kg],669,122879,DB02377,Guanine
,8380762,apparent volume of distribution (Vd),The mean apparent volume of distribution (Vd) was 669 +/- 70 ml/kg for the 4 mg/kg group and 749 +/- 59 ml/kg for the 6 mg/kg group.,Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8380762/),[ml] / [kg],749,122880,DB02377,Guanine
,8380762,total body clearance (CL),"The mean total body clearance (CL) for the 4 mg/kg and 6 mg/kg groups was 189 +/- 28 ml/hr/kg and 213 +/- 21 ml/hr/kg, respectively.",Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8380762/),[ml] / [h·kg],189,122881,DB02377,Guanine
,8380762,total body clearance (CL),"The mean total body clearance (CL) for the 4 mg/kg and 6 mg/kg groups was 189 +/- 28 ml/hr/kg and 213 +/- 21 ml/hr/kg, respectively.",Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8380762/),[ml] / [h·kg],213,122882,DB02377,Guanine
,29748821,elimination half-life,"Amenamevir, after single intravenous administration to mice, had an elimination half-life of 2 h.","Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29748821/),h,2,123019,DB02377,Guanine
,29748821,Bioavailability,Bioavailability was 40% after single oral administration.,"Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29748821/),%,40,123020,DB02377,Guanine
,31465287,Particle size,Particle size was found to be of 131 ± 41.41 nm.,Effect of Acyclovir Solid Lipid Nanoparticles for the Treatment of Herpes Simplex Virus (HSV) Infection in an Animal Model of HSV-1 Infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31465287/),nm,131,123425,DB02377,Guanine
,31465287,AUC0-∞,"AUC0-∞ (119.43 ± 28.74 μg/ml h), AUMC0-∞ (14469 ± 4261.16 μg/ml h) and MRT (120.10 ± 9.21 h) were significantly higher for ACV SLN as compared to ACV AUC0-∞ (12.22 ± 2.47 μg/ml h), AUMC0-∞ (28.78 ± 30.16 μg/ml h) and MRT (2.07 ± 1.77 h), respectively (p<0.05).",Effect of Acyclovir Solid Lipid Nanoparticles for the Treatment of Herpes Simplex Virus (HSV) Infection in an Animal Model of HSV-1 Infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31465287/),[μg] / [h·ml],119.43,123426,DB02377,Guanine
,31465287,AUMC0-∞,"AUC0-∞ (119.43 ± 28.74 μg/ml h), AUMC0-∞ (14469 ± 4261.16 μg/ml h) and MRT (120.10 ± 9.21 h) were significantly higher for ACV SLN as compared to ACV AUC0-∞ (12.22 ± 2.47 μg/ml h), AUMC0-∞ (28.78 ± 30.16 μg/ml h) and MRT (2.07 ± 1.77 h), respectively (p<0.05).",Effect of Acyclovir Solid Lipid Nanoparticles for the Treatment of Herpes Simplex Virus (HSV) Infection in an Animal Model of HSV-1 Infection. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31465287/),[μg] / [h·ml],14469,123427,DB02377,Guanine
,31465287,MRT,"AUC0-∞ (119.43 ± 28.74 μg/ml h), AUMC0-∞ (14469 ± 4261.16 μg/ml h) and MRT (120.10 ± 9.21 h) were significantly higher for ACV SLN as compared to ACV AUC0-∞ (12.22 ± 2.47 μg/ml h), AUMC0-∞ (28.78 ± 30.16 μg/ml h) and MRT (2.07 ± 1.77 h), respectively (p<0.05).",Effect of Acyclovir Solid Lipid Nanoparticles for the Treatment of Herpes Simplex Virus (HSV) Infection in an Animal Model of HSV-1 Infection. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31465287/),h,120.10,123428,DB02377,Guanine
,31465287,AUC0-∞,"AUC0-∞ (119.43 ± 28.74 μg/ml h), AUMC0-∞ (14469 ± 4261.16 μg/ml h) and MRT (120.10 ± 9.21 h) were significantly higher for ACV SLN as compared to ACV AUC0-∞ (12.22 ± 2.47 μg/ml h), AUMC0-∞ (28.78 ± 30.16 μg/ml h) and MRT (2.07 ± 1.77 h), respectively (p<0.05).",Effect of Acyclovir Solid Lipid Nanoparticles for the Treatment of Herpes Simplex Virus (HSV) Infection in an Animal Model of HSV-1 Infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31465287/),[μg] / [h·ml],12.22,123429,DB02377,Guanine
,31465287,AUMC0-∞,"AUC0-∞ (119.43 ± 28.74 μg/ml h), AUMC0-∞ (14469 ± 4261.16 μg/ml h) and MRT (120.10 ± 9.21 h) were significantly higher for ACV SLN as compared to ACV AUC0-∞ (12.22 ± 2.47 μg/ml h), AUMC0-∞ (28.78 ± 30.16 μg/ml h) and MRT (2.07 ± 1.77 h), respectively (p<0.05).",Effect of Acyclovir Solid Lipid Nanoparticles for the Treatment of Herpes Simplex Virus (HSV) Infection in an Animal Model of HSV-1 Infection. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31465287/),[μg] / [h·ml],28.78,123430,DB02377,Guanine
,31465287,MRT,"AUC0-∞ (119.43 ± 28.74 μg/ml h), AUMC0-∞ (14469 ± 4261.16 μg/ml h) and MRT (120.10 ± 9.21 h) were significantly higher for ACV SLN as compared to ACV AUC0-∞ (12.22 ± 2.47 μg/ml h), AUMC0-∞ (28.78 ± 30.16 μg/ml h) and MRT (2.07 ± 1.77 h), respectively (p<0.05).",Effect of Acyclovir Solid Lipid Nanoparticles for the Treatment of Herpes Simplex Virus (HSV) Infection in an Animal Model of HSV-1 Infection. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31465287/),h,2.07,123431,DB02377,Guanine
,17255273,AUC,Regimen 1 was pemetrexed (200-600 mg/m(2)); regimen 2 was pemetrexed (500 mg/m(2)) with escalating carboplatin doses (AUC = 4-6).,"A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255273/),,4-6,123627,DB02377,Guanine
,17255273,AUC,"In regimen 2, one dose-limiting toxicity (grade 3 esophagitis) occurred (500 mg/m(2); AUC = 6); grade 3/4 leukopenia (4 of 12 patients) was the main hematologic toxicity.","A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255273/),,6,123628,DB02377,Guanine
,17255273,AUC,"When systemically active chemotherapy doses were reached, further dose escalation was discontinued, and a phase II dose-range was established (pemetrexed 500 mg/m(2) and carboplatin AUC = 5-6).","A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255273/),,5-6,123629,DB02377,Guanine
,17255273,AUC,"The combination of pemetrexed (500 mg/m(2)) and carboplatin (AUC = 5 or 6) with concurrent radiation is well tolerated, allows for the administration of systemically active chemotherapy doses, and shows signs of activity.","A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255273/),,5,123630,DB02377,Guanine
,17255273,AUC,"The combination of pemetrexed (500 mg/m(2)) and carboplatin (AUC = 5 or 6) with concurrent radiation is well tolerated, allows for the administration of systemically active chemotherapy doses, and shows signs of activity.","A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17255273/),,6,123631,DB02377,Guanine
,12883977,C(0),"After IV GCV administration, PK parameters were: C(0)=0.84+/-0.66 microg/ml; C(max)=11.77+/-2.82 microg/ml; AUC(0-12 h)=42.29+/-17.57 microg/ml per hour; Cl=0.13+/-0.05 l/h per kg.",Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883977/),[μg] / [ml],0.84,124514,DB02377,Guanine
,12883977,C(max),"After IV GCV administration, PK parameters were: C(0)=0.84+/-0.66 microg/ml; C(max)=11.77+/-2.82 microg/ml; AUC(0-12 h)=42.29+/-17.57 microg/ml per hour; Cl=0.13+/-0.05 l/h per kg.",Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883977/),[μg] / [ml],11.77,124515,DB02377,Guanine
,12883977,AUC(0-12 h),"After IV GCV administration, PK parameters were: C(0)=0.84+/-0.66 microg/ml; C(max)=11.77+/-2.82 microg/ml; AUC(0-12 h)=42.29+/-17.57 microg/ml per hour; Cl=0.13+/-0.05 l/h per kg.",Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883977/),[μg] / [h·ml],42.29,124516,DB02377,Guanine
,12883977,Cl,"After IV GCV administration, PK parameters were: C(0)=0.84+/-0.66 microg/ml; C(max)=11.77+/-2.82 microg/ml; AUC(0-12 h)=42.29+/-17.57 microg/ml per hour; Cl=0.13+/-0.05 l/h per kg.",Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883977/),[l] / [h·kg],0.13,124517,DB02377,Guanine
,12883977,C(0),"After p.o. GCV administration, PK parameters were: C(0)=1.08+/-0.68 microg/ml; C(max)=2.70+/-1.07 microg/ml; AUC(0-12 h)=18.97+/-9.36 microg/ml per hour; Cl/F=2.97+/-1.42 l/h per kg.",Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883977/),[μg] / [ml],1.08,124518,DB02377,Guanine
,12883977,C(max),"After p.o. GCV administration, PK parameters were: C(0)=1.08+/-0.68 microg/ml; C(max)=2.70+/-1.07 microg/ml; AUC(0-12 h)=18.97+/-9.36 microg/ml per hour; Cl/F=2.97+/-1.42 l/h per kg.",Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883977/),[μg] / [ml],2.70,124519,DB02377,Guanine
,12883977,AUC(0-12 h),"After p.o. GCV administration, PK parameters were: C(0)=1.08+/-0.68 microg/ml; C(max)=2.70+/-1.07 microg/ml; AUC(0-12 h)=18.97+/-9.36 microg/ml per hour; Cl/F=2.97+/-1.42 l/h per kg.",Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883977/),[μg] / [h·ml],18.97,124520,DB02377,Guanine
,12883977,Cl/F,"After p.o. GCV administration, PK parameters were: C(0)=1.08+/-0.68 microg/ml; C(max)=2.70+/-1.07 microg/ml; AUC(0-12 h)=18.97+/-9.36 microg/ml per hour; Cl/F=2.97+/-1.42 l/h per kg.",Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883977/),[l] / [h·kg],2.97,124521,DB02377,Guanine
,12883977,Bioavailability (F),Bioavailability (F) was 4.9+/-1.2%.,Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883977/),%,4.9,124522,DB02377,Guanine
,12883977,Pre,Pre-dose concentrations (C(0)) measured under p.o. GCV (n=51) were 1.29+/-0.80 microg/ml (8 C(0) values were below 0.5 microg/ml).,Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883977/),[μg] / [ml],1.29,124523,DB02377,Guanine
below,12883977,C(0),Pre-dose concentrations (C(0)) measured under p.o. GCV (n=51) were 1.29+/-0.80 microg/ml (8 C(0) values were below 0.5 microg/ml).,Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883977/),[μg] / [ml],0.5,124524,DB02377,Guanine
over,12883977,trough levels,"Because of the limited bioavailability, the recommended high doses of p.o. GCV (50 mg/kg per 12 h) were administered and were associated with trough levels over 0.5 microg/ml.",Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883977/),[μg] / [ml],0.5,124525,DB02377,Guanine
,28939476,Disease duration,"Disease duration was statistically significantly longer in patients with viral resistance compared to other HSK patients [35.5 ± 23.4 years (range, 6.8-68.4 years) versus 11.1 ± 12.3 years (range, 0.8-56.3 year) respectively; Mann-Whitney p = 0.01)].",Recurrent herpetic keratitis despite antiviral prophylaxis: A virological and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28939476/),years,35.5,124901,DB02377,Guanine
,28939476,Disease duration,"Disease duration was statistically significantly longer in patients with viral resistance compared to other HSK patients [35.5 ± 23.4 years (range, 6.8-68.4 years) versus 11.1 ± 12.3 years (range, 0.8-56.3 year) respectively; Mann-Whitney p = 0.01)].",Recurrent herpetic keratitis despite antiviral prophylaxis: A virological and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28939476/),years,11.1,124902,DB02377,Guanine
,1803995,half-lives,"Zidovudine concentrations in serum declined in a biphasic manner, with half-lives ranging from 1 to 2 h, and were independent of acyclovir administration or length of zidovudine therapy.",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),h,1 to 2,125522,DB02377,Guanine
,1803995,time of peak concentrations,"The median time of peak concentrations in serum following oral doses was 0.75 h (range, 0.25 to 3 h).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),h,0.75,125523,DB02377,Guanine
,1803995,oral Cmax,"Mean day 7 oral Cmax values were 0.20 +/- 0.12, 0.55 +/- 0.33, and 1.0 +/- 0.5 micrograms/ml for 17 patients receiving total daily doses of, respectively, 300, 600, and 1,500 mg of zidovudine alone, whereas Cmax values were, respectively, 0.27 +/- 0.18, 0.43 +/- 0.33, and 1.2 +/- 0.80 micrograms/ml for 15 comparably treated recipients of zidovudine plus acyclovir (P was not significant).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),[μg] / [ml],0.20,125524,DB02377,Guanine
,1803995,oral Cmax,"Mean day 7 oral Cmax values were 0.20 +/- 0.12, 0.55 +/- 0.33, and 1.0 +/- 0.5 micrograms/ml for 17 patients receiving total daily doses of, respectively, 300, 600, and 1,500 mg of zidovudine alone, whereas Cmax values were, respectively, 0.27 +/- 0.18, 0.43 +/- 0.33, and 1.2 +/- 0.80 micrograms/ml for 15 comparably treated recipients of zidovudine plus acyclovir (P was not significant).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),[μg] / [ml],0.55,125525,DB02377,Guanine
,1803995,oral Cmax,"Mean day 7 oral Cmax values were 0.20 +/- 0.12, 0.55 +/- 0.33, and 1.0 +/- 0.5 micrograms/ml for 17 patients receiving total daily doses of, respectively, 300, 600, and 1,500 mg of zidovudine alone, whereas Cmax values were, respectively, 0.27 +/- 0.18, 0.43 +/- 0.33, and 1.2 +/- 0.80 micrograms/ml for 15 comparably treated recipients of zidovudine plus acyclovir (P was not significant).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),[μg] / [ml],1.0,125526,DB02377,Guanine
,1803995,Cmax,"Mean day 7 oral Cmax values were 0.20 +/- 0.12, 0.55 +/- 0.33, and 1.0 +/- 0.5 micrograms/ml for 17 patients receiving total daily doses of, respectively, 300, 600, and 1,500 mg of zidovudine alone, whereas Cmax values were, respectively, 0.27 +/- 0.18, 0.43 +/- 0.33, and 1.2 +/- 0.80 micrograms/ml for 15 comparably treated recipients of zidovudine plus acyclovir (P was not significant).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),[μg] / [ml],0.27,125527,DB02377,Guanine
,1803995,Cmax,"Mean day 7 oral Cmax values were 0.20 +/- 0.12, 0.55 +/- 0.33, and 1.0 +/- 0.5 micrograms/ml for 17 patients receiving total daily doses of, respectively, 300, 600, and 1,500 mg of zidovudine alone, whereas Cmax values were, respectively, 0.27 +/- 0.18, 0.43 +/- 0.33, and 1.2 +/- 0.80 micrograms/ml for 15 comparably treated recipients of zidovudine plus acyclovir (P was not significant).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),[μg] / [ml],0.43,125528,DB02377,Guanine
,1803995,Cmax,"Mean day 7 oral Cmax values were 0.20 +/- 0.12, 0.55 +/- 0.33, and 1.0 +/- 0.5 micrograms/ml for 17 patients receiving total daily doses of, respectively, 300, 600, and 1,500 mg of zidovudine alone, whereas Cmax values were, respectively, 0.27 +/- 0.18, 0.43 +/- 0.33, and 1.2 +/- 0.80 micrograms/ml for 15 comparably treated recipients of zidovudine plus acyclovir (P was not significant).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),[μg] / [ml],1.2,125529,DB02377,Guanine
,1803995,bioavailability,The median bioavailability of oral zidovudine was 67% (42 to 120%) and did not vary with dosage.,Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),%,67,125530,DB02377,Guanine
,19566115,apparent systemic clearance (CL),"The mean population pharmacokinetic parameters were apparent systemic clearance (CL) 10.1L/h, apparent central volume of distribution 5.2 L, apparent peripheral volume of distribution 30.7 L, inter-tissue clearance 3.97 L/h, absorption rate constant 0.369 h-1 and lag-time 0.743 h.",Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566115/),[l] / [h],10.1,125756,DB02377,Guanine
,19566115,apparent central volume of distribution,"The mean population pharmacokinetic parameters were apparent systemic clearance (CL) 10.1L/h, apparent central volume of distribution 5.2 L, apparent peripheral volume of distribution 30.7 L, inter-tissue clearance 3.97 L/h, absorption rate constant 0.369 h-1 and lag-time 0.743 h.",Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566115/),l,5.2,125757,DB02377,Guanine
,19566115,apparent peripheral volume of distribution,"The mean population pharmacokinetic parameters were apparent systemic clearance (CL) 10.1L/h, apparent central volume of distribution 5.2 L, apparent peripheral volume of distribution 30.7 L, inter-tissue clearance 3.97 L/h, absorption rate constant 0.369 h-1 and lag-time 0.743 h.",Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566115/),l,30.7,125758,DB02377,Guanine
,19566115,inter-tissue clearance,"The mean population pharmacokinetic parameters were apparent systemic clearance (CL) 10.1L/h, apparent central volume of distribution 5.2 L, apparent peripheral volume of distribution 30.7 L, inter-tissue clearance 3.97 L/h, absorption rate constant 0.369 h-1 and lag-time 0.743 h.",Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566115/),[l] / [h],3.97,125759,DB02377,Guanine
,19566115,absorption rate constant,"The mean population pharmacokinetic parameters were apparent systemic clearance (CL) 10.1L/h, apparent central volume of distribution 5.2 L, apparent peripheral volume of distribution 30.7 L, inter-tissue clearance 3.97 L/h, absorption rate constant 0.369 h-1 and lag-time 0.743 h.",Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566115/),1/[h],0.369,125760,DB02377,Guanine
,19566115,lag-time,"The mean population pharmacokinetic parameters were apparent systemic clearance (CL) 10.1L/h, apparent central volume of distribution 5.2 L, apparent peripheral volume of distribution 30.7 L, inter-tissue clearance 3.97 L/h, absorption rate constant 0.369 h-1 and lag-time 0.743 h.",Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566115/),h,0.743,125761,DB02377,Guanine
,19566115,CL(CR),"The results of the simulation showed that for a typical patient (WT 28 kg and CL(CR) 89 mL/min), an area under the plasma concentration-time curve of 43 +/- 10.6 mg x h/mL will be achieved with valganciclovir 500 mg once daily.",Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566115/),[ml] / [min],89,125762,DB02377,Guanine
,19566115,area under the plasma concentration-time curve,"The results of the simulation showed that for a typical patient (WT 28 kg and CL(CR) 89 mL/min), an area under the plasma concentration-time curve of 43 +/- 10.6 mg x h/mL will be achieved with valganciclovir 500 mg once daily.",Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566115/),[h·mg] / [ml],43,125763,DB02377,Guanine
,11359026,elimination half-time,"The elimination half-time (15 h) was similar to that reported for end-stage renal disease patients, while the steady-state volume of distribution (85 l) and the area under the curve concentration (127 mg/l.h) were greater.",Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11359026/),h,15,125920,DB02377,Guanine
,11359026,steady-state volume of distribution,"The elimination half-time (15 h) was similar to that reported for end-stage renal disease patients, while the steady-state volume of distribution (85 l) and the area under the curve concentration (127 mg/l.h) were greater.",Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11359026/),l,85,125921,DB02377,Guanine
,11359026,area under the curve concentration,"The elimination half-time (15 h) was similar to that reported for end-stage renal disease patients, while the steady-state volume of distribution (85 l) and the area under the curve concentration (127 mg/l.h) were greater.",Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11359026/),[mg] / [h·l],127,125922,DB02377,Guanine
,11359026,dialysance,The mean CAPD dialysance was only 5.27 ml/min with less than 1% of an administered dose being recovered in the 24-hour dialysate.,Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11359026/),[ml] / [min],5.27,125923,DB02377,Guanine
,17145830,MTD,"The MTD of pemetrexed was 2,400 mg/m(2) (combined with cyclophosphamide, 600 mg/m(2)) with dose-limiting toxicities of grade 4 neutropenia with grade 4 infection and grade 3 diarrhea.",A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145830/),[mg] / [m],"2,400",126316,DB02377,Guanine
,8147583,EC50,A-73209 was two logs more potent than acyclovir against five thymidine kinase positive (TK+) strains of VZV in vitro (mean EC50 0.01 vs. 1.22 micrograms/ml).,"Efficacy of A-73209, a potent orally active agent against VZV and HSV infections. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147583/),[μg] / [ml],0.01,126684,DB02377,Guanine
,8147583,EC50,A-73209 was two logs more potent than acyclovir against five thymidine kinase positive (TK+) strains of VZV in vitro (mean EC50 0.01 vs. 1.22 micrograms/ml).,"Efficacy of A-73209, a potent orally active agent against VZV and HSV infections. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147583/),[μg] / [ml],1.22,126685,DB02377,Guanine
,8147583,EC50,The activity of A-73209 was one log more potent than acyclovir against TK+ HSV-1 strains in vitro (EC50 = 0.03 vs. 0.32 micrograms/ml).,"Efficacy of A-73209, a potent orally active agent against VZV and HSV infections. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147583/),[μg] / [ml],0.03,126686,DB02377,Guanine
,8147583,EC50,The activity of A-73209 was one log more potent than acyclovir against TK+ HSV-1 strains in vitro (EC50 = 0.03 vs. 0.32 micrograms/ml).,"Efficacy of A-73209, a potent orally active agent against VZV and HSV infections. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147583/),[μg] / [ml],0.32,126687,DB02377,Guanine
,8147583,EC50,A-73209 yielded a mean EC50 of 2.2 micrograms/ml compared to a mean EC50 of 0.37 micrograms/ml for acyclovir against a panel of TK+ HSV-2 strains in vitro.,"Efficacy of A-73209, a potent orally active agent against VZV and HSV infections. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147583/),[μg] / [ml],2.2,126688,DB02377,Guanine
,8147583,EC50,A-73209 yielded a mean EC50 of 2.2 micrograms/ml compared to a mean EC50 of 0.37 micrograms/ml for acyclovir against a panel of TK+ HSV-2 strains in vitro.,"Efficacy of A-73209, a potent orally active agent against VZV and HSV infections. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147583/),[μg] / [ml],0.37,126689,DB02377,Guanine
,9921974,peak ara-G concentration,"Plasma pharmacokinetic studies after an infusion of GW506U78 at a dose of 40 mg/kg showed GW506U78 concentrations of 60 microM, and a peak ara-G concentration of 260 microM in the plasma.",Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9921974/),μM,260,127366,DB02377,Guanine
,8787884,half-life,"The peak concentration of drug in plasma (Cmax) for acyclovir occurred at 1 to 2 h, and the half-life of acyclovir was 3 to 4 h in all three elderly groups.",Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787884/),h,3 to 4,127494,DB02377,Guanine
,8787884,Cmax,"The steady-state acyclovir Cmax (4.30 and 5.98 micrograms/ml) and daily AUC0-infinity (44 and 74 h.micrograms/ml) following dosing of valaciclovir (500 and 1,000 mg) three times a day were two to three times greater than those expected after high-dose oral acyclovir treatment (800 mg, five times daily).",Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787884/),[μg] / [ml],4.30,127495,DB02377,Guanine
,8787884,Cmax,"The steady-state acyclovir Cmax (4.30 and 5.98 micrograms/ml) and daily AUC0-infinity (44 and 74 h.micrograms/ml) following dosing of valaciclovir (500 and 1,000 mg) three times a day were two to three times greater than those expected after high-dose oral acyclovir treatment (800 mg, five times daily).",Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787884/),[μg] / [ml],5.98,127496,DB02377,Guanine
,8787884,AUC0-infinity,"The steady-state acyclovir Cmax (4.30 and 5.98 micrograms/ml) and daily AUC0-infinity (44 and 74 h.micrograms/ml) following dosing of valaciclovir (500 and 1,000 mg) three times a day were two to three times greater than those expected after high-dose oral acyclovir treatment (800 mg, five times daily).",Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787884/),[h·μg] / [ml],44,127497,DB02377,Guanine
,8787884,AUC0-infinity,"The steady-state acyclovir Cmax (4.30 and 5.98 micrograms/ml) and daily AUC0-infinity (44 and 74 h.micrograms/ml) following dosing of valaciclovir (500 and 1,000 mg) three times a day were two to three times greater than those expected after high-dose oral acyclovir treatment (800 mg, five times daily).",Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787884/),[h·μg] / [ml],74,127498,DB02377,Guanine
,22198827,AUC0-24 concentrations,"Median AUC0-24 concentrations obtained after intravenous and oral formulations were 22.9 µg•h/mL (range, 17-65.2) and 34.55 µg•h/mL (range, 20.8-84.2), respectively.",Pharmacokinetic profile of valganciclovir in pediatric transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198827/),[h·μg] / [ml],22.9,127539,DB02377,Guanine
,22198827,AUC0-24 concentrations,"Median AUC0-24 concentrations obtained after intravenous and oral formulations were 22.9 µg•h/mL (range, 17-65.2) and 34.55 µg•h/mL (range, 20.8-84.2), respectively.",Pharmacokinetic profile of valganciclovir in pediatric transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198827/),[h·μg] / [ml],34.55,127540,DB02377,Guanine
,22198827,AUC0-24 concentration,"After normalization on a 20 mg/kg/d valganciclovir dosage, the median AUC0-24 concentration was 37.6 µg•h/mL (range, 23.6-68).",Pharmacokinetic profile of valganciclovir in pediatric transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22198827/),[h·μg] / [ml],37.6,127541,DB02377,Guanine
,1662377,time of,Mean time of CMV occurrence from grafting was 49 days.,[Treatment of cytomegalovirus infections with ganciclovir in kidney transplant recipients. Clinical and pharmacokinetic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662377/),d,49,128153,DB02377,Guanine
,1662377,Maximal plasma concentration,"Maximal plasma concentration of DHPG (9.3 +/- 0.3 micrograms/ml, m +/- SEM) was reached at the end of the one hour infusion and decreased according to a biexponential model.",[Treatment of cytomegalovirus infections with ganciclovir in kidney transplant recipients. Clinical and pharmacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662377/),[μg] / [ml],9.3,128154,DB02377,Guanine
,1662377,half life of elimination,"The half life of elimination was 3.35 +/- 0.32 hours, the metabolic clearance 128 +/- 7 ml/min and the distribution volume about 50 percent body weight (0.48 +/- 0.02 l/kg).",[Treatment of cytomegalovirus infections with ganciclovir in kidney transplant recipients. Clinical and pharmacokinetic study]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662377/),h,3.35,128155,DB02377,Guanine
,1662377,metabolic clearance,"The half life of elimination was 3.35 +/- 0.32 hours, the metabolic clearance 128 +/- 7 ml/min and the distribution volume about 50 percent body weight (0.48 +/- 0.02 l/kg).",[Treatment of cytomegalovirus infections with ganciclovir in kidney transplant recipients. Clinical and pharmacokinetic study]. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662377/),[ml] / [min],128,128156,DB02377,Guanine
,1662377,distribution volume,"The half life of elimination was 3.35 +/- 0.32 hours, the metabolic clearance 128 +/- 7 ml/min and the distribution volume about 50 percent body weight (0.48 +/- 0.02 l/kg).",[Treatment of cytomegalovirus infections with ganciclovir in kidney transplant recipients. Clinical and pharmacokinetic study]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662377/),[l] / [kg],0.48,128157,DB02377,Guanine
,18391039,intercompartmental clearance,"The estimated population averages of intercompartmental clearance and the volumes of distribution in the central and peripheral compartments obtained with a 1-mg dose were 34.2 liters/h (interindividual variability, 30.2%), 115 liters (interindividual variability, 39.2%), and 1,830 liters (interindividual variability, 74%), respectively.",Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18391039/),[l] / [h],34.2,128307,DB02377,Guanine
,18391039,volumes of distribution in,"The estimated population averages of intercompartmental clearance and the volumes of distribution in the central and peripheral compartments obtained with a 1-mg dose were 34.2 liters/h (interindividual variability, 30.2%), 115 liters (interindividual variability, 39.2%), and 1,830 liters (interindividual variability, 74%), respectively.",Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18391039/),l,115,128308,DB02377,Guanine
,18391039,volumes of distribution in,"The estimated population averages of intercompartmental clearance and the volumes of distribution in the central and peripheral compartments obtained with a 1-mg dose were 34.2 liters/h (interindividual variability, 30.2%), 115 liters (interindividual variability, 39.2%), and 1,830 liters (interindividual variability, 74%), respectively.",Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18391039/),l,"1,830",128309,DB02377,Guanine
,18391039,steady-state area under the concentration-time curve,"The geometric mean (GM) of individual Bayesian estimates of the steady-state area under the concentration-time curve following 1-mg daily doses were 39.3 and 38.8 ng x h/ml in HIV- and HBV-coinfected and HBV-monoinfected patients, respectively.",Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18391039/),[h·ng] / [ml],39.3,128310,DB02377,Guanine
,18391039,steady-state area under the concentration-time curve,"The geometric mean (GM) of individual Bayesian estimates of the steady-state area under the concentration-time curve following 1-mg daily doses were 39.3 and 38.8 ng x h/ml in HIV- and HBV-coinfected and HBV-monoinfected patients, respectively.",Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18391039/),[h·ng] / [ml],38.8,128311,DB02377,Guanine
>,7734861,post-plasma concentrations,We describe nine infants who were treated with doses of oral acyclovir which were chosen to achieve 2-h post-plasma concentrations of > or = 2 micrograms/ml.,Dosing considerations for oral acyclovir following neonatal herpes disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7734861/),[μg] / [ml],2,128662,DB02377,Guanine
,7734861,ID30,The target plasma concentration was chosen in order to attain acyclovir cerebrospinal fluid distribution (< or = 50% plasma) for an estimated ID30 of Herpes simplex II strains of 0.1-0.5 microgram/ml.,Dosing considerations for oral acyclovir following neonatal herpes disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7734861/),[μg] / [ml],0.1-0.5,128663,DB02377,Guanine
,32212341,elimination half-life (t1/2 β ),"Following the administration of acyclovir alone, elimination half-life (t1/2 β ), area under the plasma concentration-time curve (AUC), total clearance (ClT ), and volume of distribution at steady-state (Vdss ) were 20.12 hr, 1,372 hr * µg/mL, 0.03 L hr-1 kg-1 , and 0.84 L/kg, respectively.",Effect of benzylpenicillin on intravenous pharmacokinetics of acyclovir in red-eared slider turtles (Trachemys scripta elegans). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32212341/),h,20.12,129749,DB02377,Guanine
,32212341,area under the plasma concentration-time curve (AUC),"Following the administration of acyclovir alone, elimination half-life (t1/2 β ), area under the plasma concentration-time curve (AUC), total clearance (ClT ), and volume of distribution at steady-state (Vdss ) were 20.12 hr, 1,372 hr * µg/mL, 0.03 L hr-1 kg-1 , and 0.84 L/kg, respectively.",Effect of benzylpenicillin on intravenous pharmacokinetics of acyclovir in red-eared slider turtles (Trachemys scripta elegans). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32212341/),[h·μg] / [ml],"1,372",129750,DB02377,Guanine
,32212341,area under the plasma concentration-time curve (AUC),"Following the administration of acyclovir alone, elimination half-life (t1/2 β ), area under the plasma concentration-time curve (AUC), total clearance (ClT ), and volume of distribution at steady-state (Vdss ) were 20.12 hr, 1,372 hr * µg/mL, 0.03 L hr-1 kg-1 , and 0.84 L/kg, respectively.",Effect of benzylpenicillin on intravenous pharmacokinetics of acyclovir in red-eared slider turtles (Trachemys scripta elegans). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32212341/),[l] / [h·kg],0.03,129751,DB02377,Guanine
,32212341,total clearance (ClT ),"Following the administration of acyclovir alone, elimination half-life (t1/2 β ), area under the plasma concentration-time curve (AUC), total clearance (ClT ), and volume of distribution at steady-state (Vdss ) were 20.12 hr, 1,372 hr * µg/mL, 0.03 L hr-1 kg-1 , and 0.84 L/kg, respectively.",Effect of benzylpenicillin on intravenous pharmacokinetics of acyclovir in red-eared slider turtles (Trachemys scripta elegans). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32212341/),[h·μg] / [ml],"1,372",129752,DB02377,Guanine
,32212341,total clearance (ClT ),"Following the administration of acyclovir alone, elimination half-life (t1/2 β ), area under the plasma concentration-time curve (AUC), total clearance (ClT ), and volume of distribution at steady-state (Vdss ) were 20.12 hr, 1,372 hr * µg/mL, 0.03 L hr-1 kg-1 , and 0.84 L/kg, respectively.",Effect of benzylpenicillin on intravenous pharmacokinetics of acyclovir in red-eared slider turtles (Trachemys scripta elegans). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32212341/),[l] / [h·kg],0.03,129753,DB02377,Guanine
,32212341,volume of distribution at steady-state (Vdss ),"Following the administration of acyclovir alone, elimination half-life (t1/2 β ), area under the plasma concentration-time curve (AUC), total clearance (ClT ), and volume of distribution at steady-state (Vdss ) were 20.12 hr, 1,372 hr * µg/mL, 0.03 L hr-1 kg-1 , and 0.84 L/kg, respectively.",Effect of benzylpenicillin on intravenous pharmacokinetics of acyclovir in red-eared slider turtles (Trachemys scripta elegans). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32212341/),[l] / [kg],0.84,129754,DB02377,Guanine
,10760756,overall response rate,"Among 39 patients eligible for efficacy analysis, 1 complete response and 5 partial responses were identified, for an overall response rate of 15.4% (95% confidence interval [CI], 4.1-26. 7%) for all patients.","Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10760756/),%,15.4,129883,DB02377,Guanine
,10760756,time to progression,"The median survival was 16.2 months (95% CI, 10.5-17.0%); 65% of patients were alive at 1 year, and the median time to progression was 4.4 months (range, 3.2-5.7 months).","Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10760756/),month,4.4,129884,DB02377,Guanine
,9829757,peak O6BG CSF concentration,"The peak O6BG CSF concentration was 412+/-86 microM, the t1/2 was 0.52+/-0.02 h, the clearance was 0.22+/-0.01 ml/min, and the area under the concentration-time curve was 319+/-15 microM x h in 4th ventricular CSF.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),μM,412,131145,DB02377,Guanine
,9829757,t1/2,"The peak O6BG CSF concentration was 412+/-86 microM, the t1/2 was 0.52+/-0.02 h, the clearance was 0.22+/-0.01 ml/min, and the area under the concentration-time curve was 319+/-15 microM x h in 4th ventricular CSF.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),h,0.52,131146,DB02377,Guanine
,9829757,clearance,"The peak O6BG CSF concentration was 412+/-86 microM, the t1/2 was 0.52+/-0.02 h, the clearance was 0.22+/-0.01 ml/min, and the area under the concentration-time curve was 319+/-15 microM x h in 4th ventricular CSF.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),[ml] / [min],0.22,131147,DB02377,Guanine
,9829757,area under the concentration-time curve,"The peak O6BG CSF concentration was 412+/-86 microM, the t1/2 was 0.52+/-0.02 h, the clearance was 0.22+/-0.01 ml/min, and the area under the concentration-time curve was 319+/-15 microM x h in 4th ventricular CSF.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),h·μM,319,131148,DB02377,Guanine
,9829757,peak CSF concentration,"The peak CSF concentration of 8-oxo-O6BG in CSF was 1.9+/-0.4 microM, the t1/2 was 0.76+/-0.03 h, and the area under the concentration-time curve was 5.0+/-1.1 microM x h.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),μM,1.9,131149,DB02377,Guanine
,9829757,t1/2,"The peak CSF concentration of 8-oxo-O6BG in CSF was 1.9+/-0.4 microM, the t1/2 was 0.76+/-0.03 h, and the area under the concentration-time curve was 5.0+/-1.1 microM x h.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),h,0.76,131150,DB02377,Guanine
,9829757,area under the concentration-time curve,"The peak CSF concentration of 8-oxo-O6BG in CSF was 1.9+/-0.4 microM, the t1/2 was 0.76+/-0.03 h, and the area under the concentration-time curve was 5.0+/-1.1 microM x h.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),h·μM,5.0,131151,DB02377,Guanine
,9829757,plasma peak concentration,"The plasma peak concentration of O6BG was 0.4 microM at 30 min, and the concentration was <0.1 microM by 3 h.",Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829757/),μM,0.4,131152,DB02377,Guanine
,18344549,apparent total body clearance,"Ganciclovir disposition was characterized by apparent total body clearance of 3.3 and 5.8 L/h, terminal half-life of 16.9 and 14.1 h, and apparent volume of distribution of 60.3 and 104.9 L in Patients 1 and 2, respectively.",Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18344549/),[l] / [h],3.3,131803,DB02377,Guanine
,18344549,apparent total body clearance,"Ganciclovir disposition was characterized by apparent total body clearance of 3.3 and 5.8 L/h, terminal half-life of 16.9 and 14.1 h, and apparent volume of distribution of 60.3 and 104.9 L in Patients 1 and 2, respectively.",Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18344549/),[l] / [h],5.8,131804,DB02377,Guanine
,18344549,terminal half-life,"Ganciclovir disposition was characterized by apparent total body clearance of 3.3 and 5.8 L/h, terminal half-life of 16.9 and 14.1 h, and apparent volume of distribution of 60.3 and 104.9 L in Patients 1 and 2, respectively.",Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18344549/),h,16.9,131805,DB02377,Guanine
,18344549,terminal half-life,"Ganciclovir disposition was characterized by apparent total body clearance of 3.3 and 5.8 L/h, terminal half-life of 16.9 and 14.1 h, and apparent volume of distribution of 60.3 and 104.9 L in Patients 1 and 2, respectively.",Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18344549/),h,14.1,131806,DB02377,Guanine
,18344549,apparent volume of distribution,"Ganciclovir disposition was characterized by apparent total body clearance of 3.3 and 5.8 L/h, terminal half-life of 16.9 and 14.1 h, and apparent volume of distribution of 60.3 and 104.9 L in Patients 1 and 2, respectively.",Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18344549/),l,60.3,131807,DB02377,Guanine
,18344549,apparent volume of distribution,"Ganciclovir disposition was characterized by apparent total body clearance of 3.3 and 5.8 L/h, terminal half-life of 16.9 and 14.1 h, and apparent volume of distribution of 60.3 and 104.9 L in Patients 1 and 2, respectively.",Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18344549/),l,104.9,131808,DB02377,Guanine
,18344549,sieving coefficient,"The observed sieving coefficient was 1.05 and 0.96, and the haemofiltration clearance was 3.3 and 3.1 L/h.",Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18344549/),,1.05,131809,DB02377,Guanine
,18344549,sieving coefficient,"The observed sieving coefficient was 1.05 and 0.96, and the haemofiltration clearance was 3.3 and 3.1 L/h.",Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18344549/),,0.96,131810,DB02377,Guanine
,18344549,clearance,"The observed sieving coefficient was 1.05 and 0.96, and the haemofiltration clearance was 3.3 and 3.1 L/h.",Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18344549/),[l] / [h],3.3,131811,DB02377,Guanine
,18344549,clearance,"The observed sieving coefficient was 1.05 and 0.96, and the haemofiltration clearance was 3.3 and 3.1 L/h.",Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18344549/),[l] / [h],3.1,131812,DB02377,Guanine
,7595747,half-life,"At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively.","Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595747/),h,2.02,132183,DB02377,Guanine
,7595747,maximum plasma concentration,"At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively.","Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595747/),[μg] / [ml],11.20,132184,DB02377,Guanine
,7595747,maximum plasma concentration,"At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively.","Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595747/),[ml] / [m2·min],52.3,132185,DB02377,Guanine
,7595747,clearance,"At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively.","Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595747/),[μg] / [ml],11.20,132186,DB02377,Guanine
,7595747,clearance,"At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively.","Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595747/),[ml] / [m2·min],52.3,132187,DB02377,Guanine
,7595747,apparent volume of distribution at steady-state,"At the 40-mg/m2/wk dose level, the mean harmonic half-life, maximum plasma concentration, clearance, and apparent volume of distribution at steady-state were 2.02 hours, 11.20 micrograms/mL, 52.3 mL/min/m2, and 6.64 L/m2, respectively.","Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595747/),[l] / [m2],6.64,132188,DB02377,Guanine
,9502557,stable plasma trough concentration,Mean stable plasma trough concentration was 0.91 +/- 0.68 microg/ml.,Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9502557/),[μg] / [ml],0.91,132346,DB02377,Guanine
,9502557,trough concentration,"The dosage rate, adjusted to a trough concentration of 1.0 microg/ml, correlated with the GFR.",Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9502557/),[μg] / [ml],1.0,132347,DB02377,Guanine
,19886325,half-life,Its half-life of 5 - 9 hours is increased to up to 132 hours in anuric patients.,Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19886325/),h,5 - 9,132995,DB02377,Guanine
up to,19886325,half-life,Its half-life of 5 - 9 hours is increased to up to 132 hours in anuric patients.,Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19886325/),h,132,132996,DB02377,Guanine
,19886325,plasma half-life,Its normal plasma half-life is 2 - 3 hours; dosage modifications are obligatory in renal insufficiency.,Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19886325/),h,2 - 3,132997,DB02377,Guanine
,32039681,zeta potential,The nanocomposites were found to have a particle size of 121.9 ± 1.85 nm and zeta potential -12.1 ± 0.63 mV.,"The Development of Pemetrexed Diacid-Loaded Gelatin-Cloisite 30B (MMT) Nanocomposite for Improved Oral Efficacy Against Cancer: Characterization, In-Vitro and Ex-Vivo Assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32039681/),mv,12.1,134402,DB02377,Guanine
,30643927,Cmax,"In the 450 and 900 mg groups, the Cmax for VGCV was 0.2 ± 0.10 and 0.4 ± 0.16 mg/L, respectively; the Cmax for GCV was 4.2 ± 1.1 and 8.6 ± 1.6 mg/L, respectively; and the AUC0-24 h for GCV was 28.4 ± 8.4 and 60.7 ± 17.5 mg·h/L, respectively.",Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30643927/),[mg] / [l],0.2,135084,DB02377,Guanine
,30643927,Cmax,"In the 450 and 900 mg groups, the Cmax for VGCV was 0.2 ± 0.10 and 0.4 ± 0.16 mg/L, respectively; the Cmax for GCV was 4.2 ± 1.1 and 8.6 ± 1.6 mg/L, respectively; and the AUC0-24 h for GCV was 28.4 ± 8.4 and 60.7 ± 17.5 mg·h/L, respectively.",Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30643927/),[mg] / [l],0.4,135085,DB02377,Guanine
,30643927,Cmax,"In the 450 and 900 mg groups, the Cmax for VGCV was 0.2 ± 0.10 and 0.4 ± 0.16 mg/L, respectively; the Cmax for GCV was 4.2 ± 1.1 and 8.6 ± 1.6 mg/L, respectively; and the AUC0-24 h for GCV was 28.4 ± 8.4 and 60.7 ± 17.5 mg·h/L, respectively.",Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30643927/),[mg] / [l],4.2,135086,DB02377,Guanine
,30643927,Cmax,"In the 450 and 900 mg groups, the Cmax for VGCV was 0.2 ± 0.10 and 0.4 ± 0.16 mg/L, respectively; the Cmax for GCV was 4.2 ± 1.1 and 8.6 ± 1.6 mg/L, respectively; and the AUC0-24 h for GCV was 28.4 ± 8.4 and 60.7 ± 17.5 mg·h/L, respectively.",Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30643927/),[mg] / [l],8.6,135087,DB02377,Guanine
,30643927,AUC0-24 h,"In the 450 and 900 mg groups, the Cmax for VGCV was 0.2 ± 0.10 and 0.4 ± 0.16 mg/L, respectively; the Cmax for GCV was 4.2 ± 1.1 and 8.6 ± 1.6 mg/L, respectively; and the AUC0-24 h for GCV was 28.4 ± 8.4 and 60.7 ± 17.5 mg·h/L, respectively.",Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30643927/),[h·mg] / [l],28.4,135088,DB02377,Guanine
,30643927,AUC0-24 h,"In the 450 and 900 mg groups, the Cmax for VGCV was 0.2 ± 0.10 and 0.4 ± 0.16 mg/L, respectively; the Cmax for GCV was 4.2 ± 1.1 and 8.6 ± 1.6 mg/L, respectively; and the AUC0-24 h for GCV was 28.4 ± 8.4 and 60.7 ± 17.5 mg·h/L, respectively.",Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30643927/),[h·mg] / [l],60.7,135089,DB02377,Guanine
,15244498,tmax,"Following coadministration of valaciclovir and MMF, aciclovir pharmacokinetic parameters were not significantly modified except for tmax (about 0.5 hour shorter with MMF).",Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244498/),h,0.5,138002,DB02377,Guanine
,21513847,oral clearance,The estimated population average of oral clearance in a typical patient with a reference ICrCL value of 100 mL/min was 26.4 L/h (interindividual variability: 19.4%).,Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21513847/),[l] / [h],100,140407,DB02377,Guanine
,21513847,oral clearance,The estimated population average of oral clearance in a typical patient with a reference ICrCL value of 100 mL/min was 26.4 L/h (interindividual variability: 19.4%).,Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21513847/),[l] / [h],26.4,140408,DB02377,Guanine
,21513847,ICrCL,The estimated population average of oral clearance in a typical patient with a reference ICrCL value of 100 mL/min was 26.4 L/h (interindividual variability: 19.4%).,Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21513847/),[l] / [h],100,140409,DB02377,Guanine
,21513847,ICrCL,The estimated population average of oral clearance in a typical patient with a reference ICrCL value of 100 mL/min was 26.4 L/h (interindividual variability: 19.4%).,Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21513847/),[l] / [h],26.4,140410,DB02377,Guanine
<,10701434,run times,"The method has a lower limit of quantification (LLOQ) adequate for sensitive pharmacokinetic studies ( < or = 0.05 microg/ml), has run times of < or = 15 min, and uses aliquot volumes adequate for pediatric studies (0.25 ml).","A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),min,15,140499,DB02377,Guanine
,10701434,lambda(ex),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,278,140500,DB02377,Guanine
,10701434,lambda(em),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,380,140501,DB02377,Guanine
<,10701434,% C.V.,All intra- and inter-assay % C.V. values were < 8%; all recoveries (accuracy) were within 7% of nominal values.,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),%,8,140502,DB02377,Guanine
,1315149,Plasma clearances,"Plasma clearances were 0.4, 1.1 and 2.2 ml/min per kg and were related to individual creatinine clearances (20, 45 and 60 ml/min per 1.73 m2); the corresponding elimination half-lives were 23.7, 9.9 and 3.9 h.",Pharmacokinetics of ganciclovir in renal transplant children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1315149/),[ml] / [kg·min],0.4,141408,DB02377,Guanine
,1315149,Plasma clearances,"Plasma clearances were 0.4, 1.1 and 2.2 ml/min per kg and were related to individual creatinine clearances (20, 45 and 60 ml/min per 1.73 m2); the corresponding elimination half-lives were 23.7, 9.9 and 3.9 h.",Pharmacokinetics of ganciclovir in renal transplant children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1315149/),[ml] / [kg·min],1.1,141409,DB02377,Guanine
,1315149,Plasma clearances,"Plasma clearances were 0.4, 1.1 and 2.2 ml/min per kg and were related to individual creatinine clearances (20, 45 and 60 ml/min per 1.73 m2); the corresponding elimination half-lives were 23.7, 9.9 and 3.9 h.",Pharmacokinetics of ganciclovir in renal transplant children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1315149/),[ml] / [kg·min],2.2,141410,DB02377,Guanine
,1315149,elimination half-lives,"Plasma clearances were 0.4, 1.1 and 2.2 ml/min per kg and were related to individual creatinine clearances (20, 45 and 60 ml/min per 1.73 m2); the corresponding elimination half-lives were 23.7, 9.9 and 3.9 h.",Pharmacokinetics of ganciclovir in renal transplant children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1315149/),h,23.7,141411,DB02377,Guanine
,1315149,elimination half-lives,"Plasma clearances were 0.4, 1.1 and 2.2 ml/min per kg and were related to individual creatinine clearances (20, 45 and 60 ml/min per 1.73 m2); the corresponding elimination half-lives were 23.7, 9.9 and 3.9 h.",Pharmacokinetics of ganciclovir in renal transplant children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1315149/),h,9.9,141412,DB02377,Guanine
,1315149,elimination half-lives,"Plasma clearances were 0.4, 1.1 and 2.2 ml/min per kg and were related to individual creatinine clearances (20, 45 and 60 ml/min per 1.73 m2); the corresponding elimination half-lives were 23.7, 9.9 and 3.9 h.",Pharmacokinetics of ganciclovir in renal transplant children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1315149/),h,3.9,141413,DB02377,Guanine
,22330926,peak concentration,"Geometric mean peak concentration and area under the concentration-time curve were 0.31 μg/ml and 1.59 h · μg/ml, respectively, 54% and 52% lower than values from non-Africans.","Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22330926/),[μg] / [ml],0.31,141638,DB02377,Guanine
,22330926,area under the concentration-time curve,"Geometric mean peak concentration and area under the concentration-time curve were 0.31 μg/ml and 1.59 h · μg/ml, respectively, 54% and 52% lower than values from non-Africans.","Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22330926/),[h·μg] / [ml],1.59,141639,DB02377,Guanine
,26379165,Ccrit,"Indicatively, for the treatment of varicella zoster virus, in ages 2-12 years, Ccrit and critical area under the curve in 24 hours at steady state were found to be 0.39 mg/L and 9.6 mg/L × h, respectively, using the acyclovir approved doses 20 mg/kg 4 times daily.",Extrapolation of Valacyclovir Posology to Children Based on Pharmacokinetic Modeling. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26379165/),[mg] / [l],0.39,141977,DB02377,Guanine
,26379165,critical area under the curve in 24 hours at steady state,"Indicatively, for the treatment of varicella zoster virus, in ages 2-12 years, Ccrit and critical area under the curve in 24 hours at steady state were found to be 0.39 mg/L and 9.6 mg/L × h, respectively, using the acyclovir approved doses 20 mg/kg 4 times daily.",Extrapolation of Valacyclovir Posology to Children Based on Pharmacokinetic Modeling. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26379165/),[mg] / [h·l],9.6,141978,DB02377,Guanine
,3680558,percent dose recovered,"The mean percent dose recovered in urine (24 hr) on days 2, 5, and 10 as carboxy-DCV (2%) and as carboxy-ACV (14%) along with recoveries of DCV (6%) and ACV (62%) gave a mean total of 84% cleared over a 24-hour period at steady state.","Metabolism of desciclovir, a prodrug of acyclovir, in humans after multiple oral dosing. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680558/),%,2,142321,DB02377,Guanine
,3680558,percent dose recovered,"The mean percent dose recovered in urine (24 hr) on days 2, 5, and 10 as carboxy-DCV (2%) and as carboxy-ACV (14%) along with recoveries of DCV (6%) and ACV (62%) gave a mean total of 84% cleared over a 24-hour period at steady state.","Metabolism of desciclovir, a prodrug of acyclovir, in humans after multiple oral dosing. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680558/),%,14,142322,DB02377,Guanine
,3680558,recoveries,"The mean percent dose recovered in urine (24 hr) on days 2, 5, and 10 as carboxy-DCV (2%) and as carboxy-ACV (14%) along with recoveries of DCV (6%) and ACV (62%) gave a mean total of 84% cleared over a 24-hour period at steady state.","Metabolism of desciclovir, a prodrug of acyclovir, in humans after multiple oral dosing. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680558/),%,6,142323,DB02377,Guanine
,3680558,recoveries,"The mean percent dose recovered in urine (24 hr) on days 2, 5, and 10 as carboxy-DCV (2%) and as carboxy-ACV (14%) along with recoveries of DCV (6%) and ACV (62%) gave a mean total of 84% cleared over a 24-hour period at steady state.","Metabolism of desciclovir, a prodrug of acyclovir, in humans after multiple oral dosing. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680558/),%,62,142324,DB02377,Guanine
,3680558,recoveries,"The mean percent dose recovered in urine (24 hr) on days 2, 5, and 10 as carboxy-DCV (2%) and as carboxy-ACV (14%) along with recoveries of DCV (6%) and ACV (62%) gave a mean total of 84% cleared over a 24-hour period at steady state.","Metabolism of desciclovir, a prodrug of acyclovir, in humans after multiple oral dosing. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680558/),,84,142325,DB02377,Guanine
greater,10694702,recovery,The analyte recovery was greater than 88%.,A rapid and sensitive method for the quantification of ganciclovir in plasma using liquid chromatography/selected reaction monitoring/mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10694702/),%,88,142646,DB02377,Guanine
,17026652,maximum acyclovir concentrations,"The mean maximum acyclovir concentrations in the plasma, skin and theoretical peripheral compartment were 3.16+/-0.86, 0.94+/-0.34 and 1.85+/-0.69 micromol/L, respectively, and were achieved after 1.6+/-0.4, 2.4+/-0.3 and 3.7+/-0.7 h.",Acyclovir concentrations in the skin of humans after a single oral dose assessed by in vivo cutaneous microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17026652/),[μM] / [l],3.16,143822,DB02377,Guanine
,17026652,maximum acyclovir concentrations,"The mean maximum acyclovir concentrations in the plasma, skin and theoretical peripheral compartment were 3.16+/-0.86, 0.94+/-0.34 and 1.85+/-0.69 micromol/L, respectively, and were achieved after 1.6+/-0.4, 2.4+/-0.3 and 3.7+/-0.7 h.",Acyclovir concentrations in the skin of humans after a single oral dose assessed by in vivo cutaneous microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17026652/),[μM] / [l],0.94,143823,DB02377,Guanine
,17026652,maximum acyclovir concentrations,"The mean maximum acyclovir concentrations in the plasma, skin and theoretical peripheral compartment were 3.16+/-0.86, 0.94+/-0.34 and 1.85+/-0.69 micromol/L, respectively, and were achieved after 1.6+/-0.4, 2.4+/-0.3 and 3.7+/-0.7 h.",Acyclovir concentrations in the skin of humans after a single oral dose assessed by in vivo cutaneous microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17026652/),[μM] / [l],1.85,143824,DB02377,Guanine
,9691165,bioavailabilities,"The bioavailabilities of acyclovir for neonatal control and CyA-treated rats after oral administration were significantly different at 15.6 and 22.0%, respectively, but those for the adult control and CyA-treated rats were the same at 15.6 and 14.0%, respectively.",Effect of cyclosporine A on the gastrointestinal absorption of acyclovir in neonatal and adult rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691165/),%,15.6,144775,DB02377,Guanine
,9691165,bioavailabilities,"The bioavailabilities of acyclovir for neonatal control and CyA-treated rats after oral administration were significantly different at 15.6 and 22.0%, respectively, but those for the adult control and CyA-treated rats were the same at 15.6 and 14.0%, respectively.",Effect of cyclosporine A on the gastrointestinal absorption of acyclovir in neonatal and adult rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691165/),%,22.0,144776,DB02377,Guanine
,9691165,bioavailabilities,"The bioavailabilities of acyclovir for neonatal control and CyA-treated rats after oral administration were significantly different at 15.6 and 22.0%, respectively, but those for the adult control and CyA-treated rats were the same at 15.6 and 14.0%, respectively.",Effect of cyclosporine A on the gastrointestinal absorption of acyclovir in neonatal and adult rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691165/),%,14.0,144777,DB02377,Guanine
,18279073,AUC12 (area under the concentration-time curve over a 12-h,"On the basis of a previous pharmacokinetic study of the use of intravenous ganciclovir in this population, a target AUC12 (area under the concentration-time curve over a 12-h period) of 27 mg x h/L was defined.",Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18279073/),[h·mg] / [l],27,146621,DB02377,Guanine
,18279073,AUC12,"The median dose of oral valganciclovir administered in the present trial was 16 mg/kg, which produced a geometric mean AUC12 of 27.4 mg x h/L.",Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18279073/),[h·mg] / [l],27.4,146622,DB02377,Guanine
,18279073,bioavailability,The bioavailability of valganciclovir was 41.1%.,Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18279073/),%,41.1,146623,DB02377,Guanine
,12353197,peak concentrations,"Mean (+/-SD) acyclovir peak concentrations from 250 mg and 500 mg valacyclovir were 4.11+/-1.41 and 5.19+/-1.96 microg/mL, respectively.",An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353197/),[μg] / [ml],4.11,146626,DB02377,Guanine
,12353197,peak concentrations,"Mean (+/-SD) acyclovir peak concentrations from 250 mg and 500 mg valacyclovir were 4.11+/-1.41 and 5.19+/-1.96 microg/mL, respectively.",An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353197/),[μg] / [ml],5.19,146627,DB02377,Guanine
,12353197,area-under-curve,Corresponding single dose area-under-curve values were 12.14+/-6.60 and 14.49+/-4.69h microg/mL.,An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353197/),[h·μg] / [ml],12.14,146628,DB02377,Guanine
,12353197,area-under-curve,Corresponding single dose area-under-curve values were 12.14+/-6.60 and 14.49+/-4.69h microg/mL.,An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353197/),[h·μg] / [ml],14.49,146629,DB02377,Guanine
,12353197,bioavailability,"By using historical data for intravenous acyclovir as reference, the overall estimate of acyclovir bioavailability from valacyclovir was 48%, 2- to 4-fold greater than for oral acyclovir.",An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353197/),%,48,146630,DB02377,Guanine
,10517221,chromatographic time,The chromatographic time is about 12 min.,Rapid determination of valaciclovir and acyclovir in human biological fluids by high-performance liquid chromatography using isocratic elution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517221/),min,12,147042,DB02377,Guanine
,2621178,peak,"In the CSF, the acyclovir concentration was relatively stable, with a mean of 0.83 microM, while the serum acyclovir concentration was variable with mean peak and trough concentrations of 4.08 and 2.47 microM, respectively.",Acyclovir concentrations in serum and cerebrospinal fluid at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621178/),μM,4.08,149505,DB02377,Guanine
,2621178,trough concentrations,"In the CSF, the acyclovir concentration was relatively stable, with a mean of 0.83 microM, while the serum acyclovir concentration was variable with mean peak and trough concentrations of 4.08 and 2.47 microM, respectively.",Acyclovir concentrations in serum and cerebrospinal fluid at steady state. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2621178/),μM,2.47,149506,DB02377,Guanine
,7561215,concentrations,The mean intravitreous foscarnet concentrations in patients receiving induction dosages were 189 +/- 177 microM (n = 5) versus 163 +/- 167 microM (n = 4; P > .20) for those receiving maintenance therapy.,Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7561215/),μM,189,149666,DB02377,Guanine
,7561215,concentrations,The mean intravitreous foscarnet concentrations in patients receiving induction dosages were 189 +/- 177 microM (n = 5) versus 163 +/- 167 microM (n = 4; P > .20) for those receiving maintenance therapy.,Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7561215/),μM,163,149667,DB02377,Guanine
,7561215,plasma concentration ratio,The foscarnet vitreous plasma concentration ratio averaged 1.43.,Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7561215/),,1.43,149668,DB02377,Guanine
,1979522,peak concentrations,"The obtained concentrations were effective against both herpesviruses and HIV: peak concentrations were 197 and 11 mumol/l in serum and CSF, respectively; the CSF:serum ratio of the areas under the curve was 82%.",A double-blind randomized placebo trial on very high doses of acyclovir in weakly symptomatic HIV-patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979522/),[μM] / [l],197,149746,DB02377,Guanine
,1979522,peak concentrations,"The obtained concentrations were effective against both herpesviruses and HIV: peak concentrations were 197 and 11 mumol/l in serum and CSF, respectively; the CSF:serum ratio of the areas under the curve was 82%.",A double-blind randomized placebo trial on very high doses of acyclovir in weakly symptomatic HIV-patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1979522/),[μM] / [l],11,149747,DB02377,Guanine
,16940981,MTD/RD,"The MTD/RD were determined to be 1,200/1,000 mg m(-2), respectively.",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,200",151074,DB02377,Guanine
,16940981,MTD/RD,"The MTD/RD were determined to be 1,200/1,000 mg m(-2), respectively.",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,000",151075,DB02377,Guanine
,16940981,MTD/RD,"The MTD/RD of pemetrexed were determined to be 1,200/1,000 mg m(-2), respectively, that is, a higher RD than without FA/VB(12) (500 mg m(-2)).",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,200",151076,DB02377,Guanine
,16940981,MTD/RD,"The MTD/RD of pemetrexed were determined to be 1,200/1,000 mg m(-2), respectively, that is, a higher RD than without FA/VB(12) (500 mg m(-2)).",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,000",151077,DB02377,Guanine
,19763643,C(trough),Pharmacokinetics showed GCV stable and effective plasma concentrations: mean C(trough) = 0.51 +/- 0.3 and C(2h) : 3.81 +/- 1.37 microg/ml.,Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19763643/),,0.51,151290,DB02377,Guanine
,19763643,C(2h),Pharmacokinetics showed GCV stable and effective plasma concentrations: mean C(trough) = 0.51 +/- 0.3 and C(2h) : 3.81 +/- 1.37 microg/ml.,Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19763643/),[μg] / [ml],3.81,151291,DB02377,Guanine
,7571721,excretion,"Drug-related material was well absorbed following oral administration of 14C-famciclovir to the male rat at doses up to 4000 mg/kg and to the male dog at doses up to 250 mg/kg, as judged by the early onset of the peak blood or plasma concentrations of radioactivity (usually < or = 1.5h) and the rapid extensive excretion of radioactivity in the urine (57-76 and 86-89% of dose in rat and dog respectively).",Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571721/),%,57-76,152719,DB02377,Guanine
,7571721,excretion,"Drug-related material was well absorbed following oral administration of 14C-famciclovir to the male rat at doses up to 4000 mg/kg and to the male dog at doses up to 250 mg/kg, as judged by the early onset of the peak blood or plasma concentrations of radioactivity (usually < or = 1.5h) and the rapid extensive excretion of radioactivity in the urine (57-76 and 86-89% of dose in rat and dog respectively).",Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571721/),%,86-89,152720,DB02377,Guanine
,7571721,peak concentrations,"In rat, following dosing at 40 mg/kg, famciclovir was rapidly and extensively metabolized to the active antiviral compound penciclovir, which reached peak concentrations in the plasma (mean 3.5 micrograms/ml) at 0.5 h.",Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571721/),[μg] / [ml],3.5,152721,DB02377,Guanine
,7571721,Cmax,Cmax values for BRL 42359 (mean 2.2 micrograms/ml) were also achieved at 0.5 h.,Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571721/),[μg] / [ml],2.2,152722,DB02377,Guanine
,7571721,Cmax,"In dog, following dosing at 25 mg/kg, Cmax values for penciclovir (mean 4.4 micrograms/ml) occurred at 3 h and were lower than the Cmax values for BRL 42359 (mean 10.0 micrograms/ml) which were achieved at 1h.",Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571721/),[μg] / [ml],4.4,152723,DB02377,Guanine
,7571721,Cmax,"In dog, following dosing at 25 mg/kg, Cmax values for penciclovir (mean 4.4 micrograms/ml) occurred at 3 h and were lower than the Cmax values for BRL 42359 (mean 10.0 micrograms/ml) which were achieved at 1h.",Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571721/),[μg] / [ml],10.0,152724,DB02377,Guanine
,7571721,recoveries,Corresponding recoveries of the two metabolites in the dog were 34 and 50% of dose.,Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571721/),%,34,152725,DB02377,Guanine
,7571721,recoveries,Corresponding recoveries of the two metabolites in the dog were 34 and 50% of dose.,Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571721/),%,50,152726,DB02377,Guanine
,17392728,clearance (,"The typical value of clearance (l/h), distribution volume (l), and bioavailability of ganciclovir were 0.146 x body weight (WT)(1.68), 1.15 x WT, and 53.6%, respectively.",Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17392728/),,0.146,152865,DB02377,Guanine
,17392728,distribution volume (l),"The typical value of clearance (l/h), distribution volume (l), and bioavailability of ganciclovir were 0.146 x body weight (WT)(1.68), 1.15 x WT, and 53.6%, respectively.",Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17392728/),%,1.15,152866,DB02377,Guanine
,17392728,bioavailability,"The typical value of clearance (l/h), distribution volume (l), and bioavailability of ganciclovir were 0.146 x body weight (WT)(1.68), 1.15 x WT, and 53.6%, respectively.",Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17392728/),%,53.6,152867,DB02377,Guanine
,27260855,fetal-to-maternal blood ratio,"In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5.",Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27260855/),,0.5,152907,DB02377,Guanine
,12401354,limits of detection,"The limits of detection for ganciclovir and acyclovir quantitation were 10 ng/ml and 50 ng/ml (signal/noise >3), respectively.",Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401354/),[ng] / [ml],10,153904,DB02377,Guanine
,12401354,limits of detection,"The limits of detection for ganciclovir and acyclovir quantitation were 10 ng/ml and 50 ng/ml (signal/noise >3), respectively.",Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401354/),[ng] / [ml],50,153905,DB02377,Guanine
>,12401354,signal/noise,"The limits of detection for ganciclovir and acyclovir quantitation were 10 ng/ml and 50 ng/ml (signal/noise >3), respectively.",Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401354/),,3,153906,DB02377,Guanine
,12401354,areas under the curves,"The areas under the curves of ganciclovir up to 12 h postdosing (AUC(0-->12)) at the inlet and outlet of the dialyzer were 12.54 microg h/ml and 7.16 microg h/ml, respectively.",Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401354/),[h·μg] / [ml],12.54,153907,DB02377,Guanine
,12401354,areas under the curves,"The areas under the curves of ganciclovir up to 12 h postdosing (AUC(0-->12)) at the inlet and outlet of the dialyzer were 12.54 microg h/ml and 7.16 microg h/ml, respectively.",Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401354/),[h·μg] / [ml],7.16,153908,DB02377,Guanine
,12401354,ultrafiltrate,The ultrafiltrate of ganciclovir was 16.6 mg.,Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401354/),mg,16.6,153909,DB02377,Guanine
,12401354,terminal elimination half-life (T(1/2)),The terminal elimination half-life (T(1/2)) of ganciclovir during CHDF was 3.6 h.,Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401354/),h,3.6,153910,DB02377,Guanine
,32926418,CL/F,"The CL/F, V2 /F, Q/F, V3 /F, Ka , and lag time of GCV were 15.8 ± 0.71 L/h, 10.9 ± 2.38 L, 3.98 ± 0.40 L/h, 167 ± 44.0 L, 0.23 ± 0.0078 1/h, and 0.93 ± 0.017 hours, respectively.",Population Pharmacokinetics and Bayesian Estimation of the Area Under the Concentration-Time Curve for Ganciclovir in Adult Chinese Renal Allograft Recipients After Valganciclovir Administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32926418/),[l] / [h],15.8,154110,DB02377,Guanine
,32926418,lag time,"The CL/F, V2 /F, Q/F, V3 /F, Ka , and lag time of GCV were 15.8 ± 0.71 L/h, 10.9 ± 2.38 L, 3.98 ± 0.40 L/h, 167 ± 44.0 L, 0.23 ± 0.0078 1/h, and 0.93 ± 0.017 hours, respectively.",Population Pharmacokinetics and Bayesian Estimation of the Area Under the Concentration-Time Curve for Ganciclovir in Adult Chinese Renal Allograft Recipients After Valganciclovir Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32926418/),h,0.93,154111,DB02377,Guanine
,12953345,t1/2 alpha,"O6-Benzylguanine is eliminated rapidly from the plasma compartment in humans (t1/2 alpha and t1/2 beta are 2 +/- 2 min and 26 +/- 15 min [mean +/- SD, n = 7], respectively), and its plasma clearance (513 +/- 148 mL/min/m2) is not dose dependent.","Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953345/),min,2,156147,DB02377,Guanine
,12953345,t1/2 beta,"O6-Benzylguanine is eliminated rapidly from the plasma compartment in humans (t1/2 alpha and t1/2 beta are 2 +/- 2 min and 26 +/- 15 min [mean +/- SD, n = 7], respectively), and its plasma clearance (513 +/- 148 mL/min/m2) is not dose dependent.","Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953345/),min,26,156148,DB02377,Guanine
,12953345,plasma clearance,"O6-Benzylguanine is eliminated rapidly from the plasma compartment in humans (t1/2 alpha and t1/2 beta are 2 +/- 2 min and 26 +/- 15 min [mean +/- SD, n = 7], respectively), and its plasma clearance (513 +/- 148 mL/min/m2) is not dose dependent.","Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953345/),[ml] / [m2·min],513,156149,DB02377,Guanine
,7585846,peak serum concentrations,"Mean peak serum concentrations were 8.27, 1.02, and 1.18 micrograms/mL for the i.v. and oral regimens, respectively.",Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7585846/),[μg] / [ml],8.27,156263,DB02377,Guanine
,7585846,peak serum concentrations,"Mean peak serum concentrations were 8.27, 1.02, and 1.18 micrograms/mL for the i.v. and oral regimens, respectively.",Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7585846/),[μg] / [ml],1.02,156264,DB02377,Guanine
,7585846,peak serum concentrations,"Mean peak serum concentrations were 8.27, 1.02, and 1.18 micrograms/mL for the i.v. and oral regimens, respectively.",Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7585846/),[μg] / [ml],1.18,156265,DB02377,Guanine
,7585846,area under the curve (AUC),"Twenty-four-hour area under the curve (AUC) for the oral regimens--500 mg every 3 hours and 1,000 mg TID--were 15.9 and 15.4 micrograms.h/mL, respectively, as compared with a total AUC of 22.1 micrograms.h/mL for the single i.v. dose.",Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7585846/),[h·μg] / [ml],15.9,156266,DB02377,Guanine
,7585846,area under the curve (AUC),"Twenty-four-hour area under the curve (AUC) for the oral regimens--500 mg every 3 hours and 1,000 mg TID--were 15.9 and 15.4 micrograms.h/mL, respectively, as compared with a total AUC of 22.1 micrograms.h/mL for the single i.v. dose.",Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7585846/),[h·μg] / [ml],15.4,156267,DB02377,Guanine
,7585846,total AUC,"Twenty-four-hour area under the curve (AUC) for the oral regimens--500 mg every 3 hours and 1,000 mg TID--were 15.9 and 15.4 micrograms.h/mL, respectively, as compared with a total AUC of 22.1 micrograms.h/mL for the single i.v. dose.",Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7585846/),[h·μg] / [ml],22.1,156268,DB02377,Guanine
,7585846,absolute bioavailabilities,"The absolute bioavailabilities for the two oral regimens were 8.84% and 8.53%, respectively.",Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7585846/),%,8.84,156269,DB02377,Guanine
,7585846,absolute bioavailabilities,"The absolute bioavailabilities for the two oral regimens were 8.84% and 8.53%, respectively.",Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7585846/),%,8.53,156270,DB02377,Guanine
,7585846,peak-to-trough concentration ratio (Cmax:Cmin),"The peak-to-trough concentration ratio (Cmax:Cmin) was greater for the 1,000-mg TID regimen than for the regimen of 500 mg every 3 hours (5.35 vs 3.81 [P < 0.01]).",Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7585846/),,5.35,156271,DB02377,Guanine
,7585846,peak-to-trough concentration ratio (Cmax:Cmin),"The peak-to-trough concentration ratio (Cmax:Cmin) was greater for the 1,000-mg TID regimen than for the regimen of 500 mg every 3 hours (5.35 vs 3.81 [P < 0.01]).",Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7585846/),,3.81,156272,DB02377,Guanine
>,12271452,recovery,"All samples are prepared by acetonitrile protein precipitation, which yields high recovery (>84% for acyclovir).",Hydrophilic interaction liquid chromatography/electrospray mass spectrometry determination of acyclovir in pregnant rat plasma and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12271452/),%,84,156618,DB02377,Guanine
,18974607,t(1/2),ACV t(1/2) was significantly affected by ALDH2 genotype and prolonged in the order of ALDH2*1/*1 (18.1 hr)<ALDH2*1/*2 (21.9 hr)<ALDH2*2/*2 (26.7 hr).,Influence of ALDH2 genetic polymorphisms on aciclovir pharmacokinetics following oral administration of valaciclovir in Japanese end-stage renal disease patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18974607/),h,18.1,157069,DB02377,Guanine
,18974607,t(1/2),ACV t(1/2) was significantly affected by ALDH2 genotype and prolonged in the order of ALDH2*1/*1 (18.1 hr)<ALDH2*1/*2 (21.9 hr)<ALDH2*2/*2 (26.7 hr).,Influence of ALDH2 genetic polymorphisms on aciclovir pharmacokinetics following oral administration of valaciclovir in Japanese end-stage renal disease patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18974607/),h,21.9,157070,DB02377,Guanine
,18974607,t(1/2),ACV t(1/2) was significantly affected by ALDH2 genotype and prolonged in the order of ALDH2*1/*1 (18.1 hr)<ALDH2*1/*2 (21.9 hr)<ALDH2*2/*2 (26.7 hr).,Influence of ALDH2 genetic polymorphisms on aciclovir pharmacokinetics following oral administration of valaciclovir in Japanese end-stage renal disease patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18974607/),h,26.7,157071,DB02377,Guanine
,20422949,maximum plasma concentrations (C(max)),The pharmacokinetic parameters of test and reference formulations were estimated as follows: the maximum plasma concentrations (C(max)) were 2.04 +/- 0.43 microg/mL and 2.01 +/- 0.50 microg/mL; the median T(max) were 1.1 +/- 0.3 h and 1.0 +/- 0.3 h; plasma elimination half-lives (t1/2) were 2.94 +/- 0.42 h and 2.85 +/- 0.28 h.,Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422949/),[μg] / [ml],2.04,157153,DB02377,Guanine
,20422949,maximum plasma concentrations (C(max)),The pharmacokinetic parameters of test and reference formulations were estimated as follows: the maximum plasma concentrations (C(max)) were 2.04 +/- 0.43 microg/mL and 2.01 +/- 0.50 microg/mL; the median T(max) were 1.1 +/- 0.3 h and 1.0 +/- 0.3 h; plasma elimination half-lives (t1/2) were 2.94 +/- 0.42 h and 2.85 +/- 0.28 h.,Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422949/),[μg] / [ml],2.01,157154,DB02377,Guanine
,20422949,T(max),The pharmacokinetic parameters of test and reference formulations were estimated as follows: the maximum plasma concentrations (C(max)) were 2.04 +/- 0.43 microg/mL and 2.01 +/- 0.50 microg/mL; the median T(max) were 1.1 +/- 0.3 h and 1.0 +/- 0.3 h; plasma elimination half-lives (t1/2) were 2.94 +/- 0.42 h and 2.85 +/- 0.28 h.,Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422949/),h,1.1,157155,DB02377,Guanine
,20422949,T(max),The pharmacokinetic parameters of test and reference formulations were estimated as follows: the maximum plasma concentrations (C(max)) were 2.04 +/- 0.43 microg/mL and 2.01 +/- 0.50 microg/mL; the median T(max) were 1.1 +/- 0.3 h and 1.0 +/- 0.3 h; plasma elimination half-lives (t1/2) were 2.94 +/- 0.42 h and 2.85 +/- 0.28 h.,Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422949/),h,1.0,157156,DB02377,Guanine
,20422949,plasma elimination half-lives (t1/2),The pharmacokinetic parameters of test and reference formulations were estimated as follows: the maximum plasma concentrations (C(max)) were 2.04 +/- 0.43 microg/mL and 2.01 +/- 0.50 microg/mL; the median T(max) were 1.1 +/- 0.3 h and 1.0 +/- 0.3 h; plasma elimination half-lives (t1/2) were 2.94 +/- 0.42 h and 2.85 +/- 0.28 h.,Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422949/),h,2.94,157157,DB02377,Guanine
,20422949,plasma elimination half-lives (t1/2),The pharmacokinetic parameters of test and reference formulations were estimated as follows: the maximum plasma concentrations (C(max)) were 2.04 +/- 0.43 microg/mL and 2.01 +/- 0.50 microg/mL; the median T(max) were 1.1 +/- 0.3 h and 1.0 +/- 0.3 h; plasma elimination half-lives (t1/2) were 2.94 +/- 0.42 h and 2.85 +/- 0.28 h.,Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422949/),h,2.85,157158,DB02377,Guanine
,20422949,AUC(0-15),AUC(0-15) were 6.70 +/- 1.26 microg x h/ mL and 6.96 +/- 1.25 microg x h/mL.,Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422949/),[h·μg] / [ml],6.70,157159,DB02377,Guanine
,20422949,AUC(0-15),AUC(0-15) were 6.70 +/- 1.26 microg x h/ mL and 6.96 +/- 1.25 microg x h/mL.,Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422949/),[h·μg] / [ml],6.96,157160,DB02377,Guanine
,20422949,Areas under the plasma concentration-time curve (AUC(0-infinity)),Areas under the plasma concentration-time curve (AUC(0-infinity)) were 6.90 +/- 1.30 microg x h/mL and 7.15 +/- 1.31 microg x h/mL.,Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422949/),[h·μg] / [ml],6.90,157161,DB02377,Guanine
,20422949,Areas under the plasma concentration-time curve (AUC(0-infinity)),Areas under the plasma concentration-time curve (AUC(0-infinity)) were 6.90 +/- 1.30 microg x h/mL and 7.15 +/- 1.31 microg x h/mL.,Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20422949/),[h·μg] / [ml],7.15,157162,DB02377,Guanine
,28371303,AUC0-inf,"Mean AUC0-inf for the generic and innovator formulations was 218.2 ± 19.18 and 223.6 ± 34.24 μg·h/mL, respectively, and mean Cmax was 119 ± 13.44 and 113 ± 7.26 μg/mL, respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),[h·μg] / [ml],218.2,157838,DB02377,Guanine
,28371303,AUC0-inf,"Mean AUC0-inf for the generic and innovator formulations was 218.2 ± 19.18 and 223.6 ± 34.24 μg·h/mL, respectively, and mean Cmax was 119 ± 13.44 and 113 ± 7.26 μg/mL, respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),[h·μg] / [ml],223.6,157839,DB02377,Guanine
,28371303,Cmax,"Mean AUC0-inf for the generic and innovator formulations was 218.2 ± 19.18 and 223.6 ± 34.24 μg·h/mL, respectively, and mean Cmax was 119 ± 13.44 and 113 ± 7.26 μg/mL, respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),[μg] / [ml],119,157840,DB02377,Guanine
,28371303,Cmax,"Mean AUC0-inf for the generic and innovator formulations was 218.2 ± 19.18 and 223.6 ± 34.24 μg·h/mL, respectively, and mean Cmax was 119 ± 13.44 and 113 ± 7.26 μg/mL, respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),[μg] / [ml],113,157841,DB02377,Guanine
,28371303,Volume of distribution,"Volume of distribution of pemetrexed was 17.5 and 27.6 L, clearance was 4.2 versus 4.72 L/h, and half-life was 4.3 and 4.83 h in the 2 arms respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),l,17.5,157842,DB02377,Guanine
,28371303,Volume of distribution,"Volume of distribution of pemetrexed was 17.5 and 27.6 L, clearance was 4.2 versus 4.72 L/h, and half-life was 4.3 and 4.83 h in the 2 arms respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),l,27.6,157843,DB02377,Guanine
,28371303,clearance,"Volume of distribution of pemetrexed was 17.5 and 27.6 L, clearance was 4.2 versus 4.72 L/h, and half-life was 4.3 and 4.83 h in the 2 arms respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),[l] / [h],4.2,157844,DB02377,Guanine
,28371303,clearance,"Volume of distribution of pemetrexed was 17.5 and 27.6 L, clearance was 4.2 versus 4.72 L/h, and half-life was 4.3 and 4.83 h in the 2 arms respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),[l] / [h],4.72,157845,DB02377,Guanine
,28371303,half-life,"Volume of distribution of pemetrexed was 17.5 and 27.6 L, clearance was 4.2 versus 4.72 L/h, and half-life was 4.3 and 4.83 h in the 2 arms respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),h,4.3,157846,DB02377,Guanine
,28371303,half-life,"Volume of distribution of pemetrexed was 17.5 and 27.6 L, clearance was 4.2 versus 4.72 L/h, and half-life was 4.3 and 4.83 h in the 2 arms respectively.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),h,4.83,157847,DB02377,Guanine
,28371303,objective response,"Both formulations showed comparable response rates (objective response of 45% versus 50% in the Pemgem and Alimta arms, respectively) and similar safety profiles.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),,45,157848,DB02377,Guanine
,28371303,objective response,"Both formulations showed comparable response rates (objective response of 45% versus 50% in the Pemgem and Alimta arms, respectively) and similar safety profiles.",A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371303/),,50,157849,DB02377,Guanine
,18540483,AUC(o-t),"The main pharmacokinetic parameters obtained were: AUC(o-t) 6.50 +/- 1.47 and 7.13 +/- 1.44 microg x h/ml, AUC(0-infinity) 6.77 +/- 1.48 and 7.41 +/- 1.49 microg x h/ml, C(max) 2.27 +/- 0.57 and 2.27 +/- 0.62 microg/ml, t(1/2) 2.96 +/- 0.41 and 2.88 +/- 0.33 h, t(max) 0.8 +/- 0.3 and 1.0 +/- 0.5 h for test and reference formulations, respectively.",A simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma and application to a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540483/),[h·μg] / [ml],6.50,159271,DB02377,Guanine
,18540483,AUC(o-t),"The main pharmacokinetic parameters obtained were: AUC(o-t) 6.50 +/- 1.47 and 7.13 +/- 1.44 microg x h/ml, AUC(0-infinity) 6.77 +/- 1.48 and 7.41 +/- 1.49 microg x h/ml, C(max) 2.27 +/- 0.57 and 2.27 +/- 0.62 microg/ml, t(1/2) 2.96 +/- 0.41 and 2.88 +/- 0.33 h, t(max) 0.8 +/- 0.3 and 1.0 +/- 0.5 h for test and reference formulations, respectively.",A simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma and application to a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540483/),[h·μg] / [ml],7.13,159272,DB02377,Guanine
,18540483,AUC(0-infinity),"The main pharmacokinetic parameters obtained were: AUC(o-t) 6.50 +/- 1.47 and 7.13 +/- 1.44 microg x h/ml, AUC(0-infinity) 6.77 +/- 1.48 and 7.41 +/- 1.49 microg x h/ml, C(max) 2.27 +/- 0.57 and 2.27 +/- 0.62 microg/ml, t(1/2) 2.96 +/- 0.41 and 2.88 +/- 0.33 h, t(max) 0.8 +/- 0.3 and 1.0 +/- 0.5 h for test and reference formulations, respectively.",A simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma and application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540483/),[h·μg] / [ml],6.77,159273,DB02377,Guanine
,18540483,AUC(0-infinity),"The main pharmacokinetic parameters obtained were: AUC(o-t) 6.50 +/- 1.47 and 7.13 +/- 1.44 microg x h/ml, AUC(0-infinity) 6.77 +/- 1.48 and 7.41 +/- 1.49 microg x h/ml, C(max) 2.27 +/- 0.57 and 2.27 +/- 0.62 microg/ml, t(1/2) 2.96 +/- 0.41 and 2.88 +/- 0.33 h, t(max) 0.8 +/- 0.3 and 1.0 +/- 0.5 h for test and reference formulations, respectively.",A simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma and application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540483/),[h·μg] / [ml],7.41,159274,DB02377,Guanine
,18540483,C(max),"The main pharmacokinetic parameters obtained were: AUC(o-t) 6.50 +/- 1.47 and 7.13 +/- 1.44 microg x h/ml, AUC(0-infinity) 6.77 +/- 1.48 and 7.41 +/- 1.49 microg x h/ml, C(max) 2.27 +/- 0.57 and 2.27 +/- 0.62 microg/ml, t(1/2) 2.96 +/- 0.41 and 2.88 +/- 0.33 h, t(max) 0.8 +/- 0.3 and 1.0 +/- 0.5 h for test and reference formulations, respectively.",A simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540483/),[μg] / [ml],2.27,159275,DB02377,Guanine
,18540483,C(max),"The main pharmacokinetic parameters obtained were: AUC(o-t) 6.50 +/- 1.47 and 7.13 +/- 1.44 microg x h/ml, AUC(0-infinity) 6.77 +/- 1.48 and 7.41 +/- 1.49 microg x h/ml, C(max) 2.27 +/- 0.57 and 2.27 +/- 0.62 microg/ml, t(1/2) 2.96 +/- 0.41 and 2.88 +/- 0.33 h, t(max) 0.8 +/- 0.3 and 1.0 +/- 0.5 h for test and reference formulations, respectively.",A simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540483/),[μg] / [ml],2.27,159276,DB02377,Guanine
,18540483,t(1/2),"The main pharmacokinetic parameters obtained were: AUC(o-t) 6.50 +/- 1.47 and 7.13 +/- 1.44 microg x h/ml, AUC(0-infinity) 6.77 +/- 1.48 and 7.41 +/- 1.49 microg x h/ml, C(max) 2.27 +/- 0.57 and 2.27 +/- 0.62 microg/ml, t(1/2) 2.96 +/- 0.41 and 2.88 +/- 0.33 h, t(max) 0.8 +/- 0.3 and 1.0 +/- 0.5 h for test and reference formulations, respectively.",A simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma and application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540483/),h,2.96,159277,DB02377,Guanine
,18540483,t(1/2),"The main pharmacokinetic parameters obtained were: AUC(o-t) 6.50 +/- 1.47 and 7.13 +/- 1.44 microg x h/ml, AUC(0-infinity) 6.77 +/- 1.48 and 7.41 +/- 1.49 microg x h/ml, C(max) 2.27 +/- 0.57 and 2.27 +/- 0.62 microg/ml, t(1/2) 2.96 +/- 0.41 and 2.88 +/- 0.33 h, t(max) 0.8 +/- 0.3 and 1.0 +/- 0.5 h for test and reference formulations, respectively.",A simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma and application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540483/),h,2.88,159278,DB02377,Guanine
,18540483,t(max),"The main pharmacokinetic parameters obtained were: AUC(o-t) 6.50 +/- 1.47 and 7.13 +/- 1.44 microg x h/ml, AUC(0-infinity) 6.77 +/- 1.48 and 7.41 +/- 1.49 microg x h/ml, C(max) 2.27 +/- 0.57 and 2.27 +/- 0.62 microg/ml, t(1/2) 2.96 +/- 0.41 and 2.88 +/- 0.33 h, t(max) 0.8 +/- 0.3 and 1.0 +/- 0.5 h for test and reference formulations, respectively.",A simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma and application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540483/),h,0.8,159279,DB02377,Guanine
,18540483,t(max),"The main pharmacokinetic parameters obtained were: AUC(o-t) 6.50 +/- 1.47 and 7.13 +/- 1.44 microg x h/ml, AUC(0-infinity) 6.77 +/- 1.48 and 7.41 +/- 1.49 microg x h/ml, C(max) 2.27 +/- 0.57 and 2.27 +/- 0.62 microg/ml, t(1/2) 2.96 +/- 0.41 and 2.88 +/- 0.33 h, t(max) 0.8 +/- 0.3 and 1.0 +/- 0.5 h for test and reference formulations, respectively.",A simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma and application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18540483/),h,1.0,159280,DB02377,Guanine
,8893152,Peak plasma levels,Peak plasma levels of 8.95 +/- 3.95 microM were achieved at 4.1 +/- 1.85 h with the T1/2 calculated to be 14.52 +/- 3 h.,Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893152/),μM,8.95,159899,DB02377,Guanine
,8893152,T1/2,Peak plasma levels of 8.95 +/- 3.95 microM were achieved at 4.1 +/- 1.85 h with the T1/2 calculated to be 14.52 +/- 3 h.,Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893152/),h,14.52,159900,DB02377,Guanine
,8893152,serum,"The mean predicted serum acyclovir levels at steady state after 1,600-, 800- and 600-mg daily doses were 13.76, 6.88 and 5.16 microM, respectively.",Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893152/),μ,13.76,159901,DB02377,Guanine
,8893152,serum,"The mean predicted serum acyclovir levels at steady state after 1,600-, 800- and 600-mg daily doses were 13.76, 6.88 and 5.16 microM, respectively.",Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893152/),μ,6.88,159902,DB02377,Guanine
,8893152,serum,"The mean predicted serum acyclovir levels at steady state after 1,600-, 800- and 600-mg daily doses were 13.76, 6.88 and 5.16 microM, respectively.",Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893152/),μ,5.16,159903,DB02377,Guanine
,8893152,levels at steady state,"The mean predicted serum acyclovir levels at steady state after 1,600-, 800- and 600-mg daily doses were 13.76, 6.88 and 5.16 microM, respectively.",Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893152/),μ,13.76,159904,DB02377,Guanine
,8893152,levels at steady state,"The mean predicted serum acyclovir levels at steady state after 1,600-, 800- and 600-mg daily doses were 13.76, 6.88 and 5.16 microM, respectively.",Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893152/),μ,6.88,159905,DB02377,Guanine
,8893152,levels at steady state,"The mean predicted serum acyclovir levels at steady state after 1,600-, 800- and 600-mg daily doses were 13.76, 6.88 and 5.16 microM, respectively.",Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8893152/),μ,5.16,159906,DB02377,Guanine
,16618945,complete response rate,"The complete response rate improved from 35% after fludarabine induction to 79.4% after alemtuzumab consolidation, including 19 patients (56%) who achieved MRD negativity.",Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618945/),%,35,163691,DB02377,Guanine
,16618945,complete response rate,"The complete response rate improved from 35% after fludarabine induction to 79.4% after alemtuzumab consolidation, including 19 patients (56%) who achieved MRD negativity.",Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16618945/),%,79.4,163692,DB02377,Guanine
,10395379,tumor volumes,"Average tumor volumes were 19 +/- 15, 7 +/- 9, and <1 mm3 for the control, free GCV, and lip-GCV groups, respectively.",Liposomal encapsulation of ganciclovir enhances the efficacy of herpes simplex virus type 1 thymidine kinase suicide gene therapy against hepatic tumors in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10395379/),mm3,19,165488,DB02377,Guanine
,10395379,tumor volumes,"Average tumor volumes were 19 +/- 15, 7 +/- 9, and <1 mm3 for the control, free GCV, and lip-GCV groups, respectively.",Liposomal encapsulation of ganciclovir enhances the efficacy of herpes simplex virus type 1 thymidine kinase suicide gene therapy against hepatic tumors in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10395379/),mm3,7,165489,DB02377,Guanine
,10395379,tumor volumes,"Average tumor volumes were 19 +/- 15, 7 +/- 9, and <1 mm3 for the control, free GCV, and lip-GCV groups, respectively.",Liposomal encapsulation of ganciclovir enhances the efficacy of herpes simplex virus type 1 thymidine kinase suicide gene therapy against hepatic tumors in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10395379/),mm3,<,165490,DB02377,Guanine
,10395379,tumor volumes,"Average tumor volumes were 19 +/- 15, 7 +/- 9, and <1 mm3 for the control, free GCV, and lip-GCV groups, respectively.",Liposomal encapsulation of ganciclovir enhances the efficacy of herpes simplex virus type 1 thymidine kinase suicide gene therapy against hepatic tumors in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10395379/),mm3,1,165491,DB02377,Guanine
,18444933,AUC(0-24),IV GCV and oral VGCV 900 mg daily achieved similar values for AUC(0-24) (median 60.63 vs. 62.86 microg/h/mL).,Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18444933/),[μg] / [h·ml],60.63,166018,DB02377,Guanine
,18444933,AUC(0-24),IV GCV and oral VGCV 900 mg daily achieved similar values for AUC(0-24) (median 60.63 vs. 62.86 microg/h/mL).,Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18444933/),[μg] / [h·ml],62.86,166019,DB02377,Guanine
,18444933,AUC(0-24),Oral VGCV 450 mg achieved comparable AUC(0-24) values as oral GCV 1000 mg Q8 H (median AUC(0-24) 35.9 vs. 29.04 microg/h/mL).,Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18444933/),[μg] / [h·ml],35.9,166020,DB02377,Guanine
,18444933,AUC(0-24),Oral VGCV 450 mg achieved comparable AUC(0-24) values as oral GCV 1000 mg Q8 H (median AUC(0-24) 35.9 vs. 29.04 microg/h/mL).,Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18444933/),[μg] / [h·ml],29.04,166021,DB02377,Guanine
,18823074,unbound concentration,The limit of quantification for the unbound concentration was set at 5 ng mL(-1) and at 2 ng mL(-1) for body fluids.,Determination of acyclovir in horse plasma and body fluids by high-performance liquid chromatography combined with fluorescence detection and heated electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823074/),[ng] / [ml],5,167361,DB02377,Guanine
,18823074,unbound concentration,The limit of quantification for the unbound concentration was set at 5 ng mL(-1) and at 2 ng mL(-1) for body fluids.,Determination of acyclovir in horse plasma and body fluids by high-performance liquid chromatography combined with fluorescence detection and heated electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823074/),[ng] / [ml],2,167362,DB02377,Guanine
,7247383,slow disposition half-life values (t1/2beta),"After doses of 0.5 and 1.0 mg/kg, the slow disposition half-life values (t1/2beta) ranged from 2.2 to 3.1 h for the 1-h infusions and from 1.8 to 3.7 h for the 6-h infusions.",Single-dose pharmacokinetics of acyclovir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7247383/),h,2.2 to 3.1,169908,DB02377,Guanine
,7247383,slow disposition half-life values (t1/2beta),"After doses of 0.5 and 1.0 mg/kg, the slow disposition half-life values (t1/2beta) ranged from 2.2 to 3.1 h for the 1-h infusions and from 1.8 to 3.7 h for the 6-h infusions.",Single-dose pharmacokinetics of acyclovir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7247383/),h,1.8 to 3.7,169909,DB02377,Guanine
,7247383,peak plasma concentrations,"Mean peak plasma concentrations obtained at 0.5 and 1.0 mg/kg administered over 1 h were 3.03 and 5.99 microM, respectively.",Single-dose pharmacokinetics of acyclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7247383/),μM,3.03,169910,DB02377,Guanine
,7247383,peak plasma concentrations,"Mean peak plasma concentrations obtained at 0.5 and 1.0 mg/kg administered over 1 h were 3.03 and 5.99 microM, respectively.",Single-dose pharmacokinetics of acyclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7247383/),μM,5.99,169911,DB02377,Guanine
,7247383,peak levels,Mean peak levels for the 6-h infusions were 1.07 microM at 0.5 mg/kg and 2.58 microM at 1.0 mg/kg.,Single-dose pharmacokinetics of acyclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7247383/),μM,1.07,169912,DB02377,Guanine
,7247383,peak levels,Mean peak levels for the 6-h infusions were 1.07 microM at 0.5 mg/kg and 2.58 microM at 1.0 mg/kg.,Single-dose pharmacokinetics of acyclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7247383/),μM,2.58,169913,DB02377,Guanine
,9165564,oral plasma clearance,Mean (+/-SD) oral plasma clearance for mycophenolic acid alone and with ganciclovir was 3.11 +/- 0.72 and 3.19 +/- 0.72 ml/min/kg (p = 0.64).,Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165564/),[ml] / [kg·min],3.11,171525,DB02377,Guanine
,9165564,oral plasma clearance,Mean (+/-SD) oral plasma clearance for mycophenolic acid alone and with ganciclovir was 3.11 +/- 0.72 and 3.19 +/- 0.72 ml/min/kg (p = 0.64).,Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165564/),[ml] / [kg·min],3.19,171526,DB02377,Guanine
,9165564,serum clearance,Mean genciclovir serum clearance was 1.80 +/- 0.58 ml/min/kg for ganciclovir and 1.70 +/- 0.55 ml/min/kg for ganciclovir plus mycophenolate mofetil (p = 0.11; 10 patients).,Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165564/),[ml] / [kg·min],1.80,171527,DB02377,Guanine
,9165564,serum clearance,Mean genciclovir serum clearance was 1.80 +/- 0.58 ml/min/kg for ganciclovir and 1.70 +/- 0.55 ml/min/kg for ganciclovir plus mycophenolate mofetil (p = 0.11; 10 patients).,Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165564/),[ml] / [kg·min],1.70,171528,DB02377,Guanine
,9165564,Renal clearance,"Renal clearance of ganciclovir was decreased when the drugs were administered in combination, 1.43 +/- 0.54 (ganciclovir) and 1.26 +/- 0.44 (both drugs) ml/min/kg (p = 0.02; 10 patients).",Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165564/),[ml] / [kg·min],1.43,171529,DB02377,Guanine
,9165564,Renal clearance,"Renal clearance of ganciclovir was decreased when the drugs were administered in combination, 1.43 +/- 0.54 (ganciclovir) and 1.26 +/- 0.44 (both drugs) ml/min/kg (p = 0.02; 10 patients).",Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165564/),[ml] / [kg·min],1.26,171530,DB02377,Guanine
,17442992,MTD,"The MTD was 1,910 mg/m2.",Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442992/),[mg] / [m2],"1,910",172410,DB02377,Guanine
,17442992,plasma clearance,"Mean plasma clearance, half-life, and steady-state volume of distribution values were 2.3 L/h/m2, 2.5 hours, and 5.4 L/m2, respectively.",Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442992/),[l] / [h·m2],2.3,172411,DB02377,Guanine
,17442992,half-life,"Mean plasma clearance, half-life, and steady-state volume of distribution values were 2.3 L/h/m2, 2.5 hours, and 5.4 L/m2, respectively.",Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442992/),h,2.5,172412,DB02377,Guanine
,17442992,steady-state volume of distribution,"Mean plasma clearance, half-life, and steady-state volume of distribution values were 2.3 L/h/m2, 2.5 hours, and 5.4 L/m2, respectively.",Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442992/),[l] / [m2],5.4,172413,DB02377,Guanine
,28717975,entrapment efficiency,An entrapment efficiency of 85% was achieved as ACV has enhanced affinity for the hydrophobic inner core of the complex.,Development of a Novel Polymeric Nanocomposite Complex for Drugs with Low Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28717975/),%,85,175034,DB02377,Guanine
,27550172,trough level,"Subsequently, the trough level and the estimated 12-h area under the concentration-time curve (AUC0-12) were decreased from 3.5 mg/L to 0.3 mg/L and 53.9 mg · h/L to 19.2 mg · h/L, respectively, resulting in an exacerbation of viremia and clinical condition.",Therapeutic drug monitoring of ganciclovir for postnatal cytomegalovirus infection in an extremely low birth weight infant: a case report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550172/),[mg] / [l],12,175950,DB02377,Guanine
,27550172,trough level,"Subsequently, the trough level and the estimated 12-h area under the concentration-time curve (AUC0-12) were decreased from 3.5 mg/L to 0.3 mg/L and 53.9 mg · h/L to 19.2 mg · h/L, respectively, resulting in an exacerbation of viremia and clinical condition.",Therapeutic drug monitoring of ganciclovir for postnatal cytomegalovirus infection in an extremely low birth weight infant: a case report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550172/),[mg] / [l],3.5,175951,DB02377,Guanine
,27550172,area under the concentration-time curve (AUC0-12),"Subsequently, the trough level and the estimated 12-h area under the concentration-time curve (AUC0-12) were decreased from 3.5 mg/L to 0.3 mg/L and 53.9 mg · h/L to 19.2 mg · h/L, respectively, resulting in an exacerbation of viremia and clinical condition.",Therapeutic drug monitoring of ganciclovir for postnatal cytomegalovirus infection in an extremely low birth weight infant: a case report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550172/),[mg] / [l],12,175952,DB02377,Guanine
,27550172,area under the concentration-time curve (AUC0-12),"Subsequently, the trough level and the estimated 12-h area under the concentration-time curve (AUC0-12) were decreased from 3.5 mg/L to 0.3 mg/L and 53.9 mg · h/L to 19.2 mg · h/L, respectively, resulting in an exacerbation of viremia and clinical condition.",Therapeutic drug monitoring of ganciclovir for postnatal cytomegalovirus infection in an extremely low birth weight infant: a case report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550172/),[h·mg] / [l],53.9,175953,DB02377,Guanine
,27550172,area under the concentration-time curve (AUC0-12),"Subsequently, the trough level and the estimated 12-h area under the concentration-time curve (AUC0-12) were decreased from 3.5 mg/L to 0.3 mg/L and 53.9 mg · h/L to 19.2 mg · h/L, respectively, resulting in an exacerbation of viremia and clinical condition.",Therapeutic drug monitoring of ganciclovir for postnatal cytomegalovirus infection in an extremely low birth weight infant: a case report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550172/),[h·mg] / [l],19.2,175954,DB02377,Guanine
,27550172,peak level,"Adjustment of dosing interval from 24 h to 12 h led to a peak level of 4.2 mg/L, trough level of 1.1 mg/L, and AUC0-12 of 31.8 mg · h/L, resulting in a marked suppression of viral load.",Therapeutic drug monitoring of ganciclovir for postnatal cytomegalovirus infection in an extremely low birth weight infant: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550172/),[mg] / [l],4.2,175955,DB02377,Guanine
,27550172,trough level,"Adjustment of dosing interval from 24 h to 12 h led to a peak level of 4.2 mg/L, trough level of 1.1 mg/L, and AUC0-12 of 31.8 mg · h/L, resulting in a marked suppression of viral load.",Therapeutic drug monitoring of ganciclovir for postnatal cytomegalovirus infection in an extremely low birth weight infant: a case report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550172/),[mg] / [l],1.1,175956,DB02377,Guanine
,27550172,AUC0-12,"Adjustment of dosing interval from 24 h to 12 h led to a peak level of 4.2 mg/L, trough level of 1.1 mg/L, and AUC0-12 of 31.8 mg · h/L, resulting in a marked suppression of viral load.",Therapeutic drug monitoring of ganciclovir for postnatal cytomegalovirus infection in an extremely low birth weight infant: a case report. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550172/),[h·mg] / [l],31.8,175957,DB02377,Guanine
,29228826,AUC,In vivo ocular pharmacokinetics study showed that area under drug-time curve (AUC) and half-life of PBLA-PEG-PBLA in situ hydrogel was higher (AUC was 61.80 μg·mL-1·h (p < .01) and t1/2 was 10.29 h in aqueous humor; AUC was 1008.66 μg·mL-1·h (p < .01) and t1/2 was 13.26 h (p < .01) in vitreous) than GCV injection with extended therapeutic activity.,"Synthesis, physicochemical properties and ocular pharmacokinetics of thermosensitive in situ hydrogels for ganciclovir in cytomegalovirus retinitis treatment. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29228826/),[h·μg] / [ml],61.80,178231,DB02377,Guanine
,29228826,t1/2,In vivo ocular pharmacokinetics study showed that area under drug-time curve (AUC) and half-life of PBLA-PEG-PBLA in situ hydrogel was higher (AUC was 61.80 μg·mL-1·h (p < .01) and t1/2 was 10.29 h in aqueous humor; AUC was 1008.66 μg·mL-1·h (p < .01) and t1/2 was 13.26 h (p < .01) in vitreous) than GCV injection with extended therapeutic activity.,"Synthesis, physicochemical properties and ocular pharmacokinetics of thermosensitive in situ hydrogels for ganciclovir in cytomegalovirus retinitis treatment. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29228826/),h,10.29,178232,DB02377,Guanine
,29228826,AUC,In vivo ocular pharmacokinetics study showed that area under drug-time curve (AUC) and half-life of PBLA-PEG-PBLA in situ hydrogel was higher (AUC was 61.80 μg·mL-1·h (p < .01) and t1/2 was 10.29 h in aqueous humor; AUC was 1008.66 μg·mL-1·h (p < .01) and t1/2 was 13.26 h (p < .01) in vitreous) than GCV injection with extended therapeutic activity.,"Synthesis, physicochemical properties and ocular pharmacokinetics of thermosensitive in situ hydrogels for ganciclovir in cytomegalovirus retinitis treatment. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29228826/),[h·μg] / [ml],1008.66,178233,DB02377,Guanine
,29228826,t1/2,In vivo ocular pharmacokinetics study showed that area under drug-time curve (AUC) and half-life of PBLA-PEG-PBLA in situ hydrogel was higher (AUC was 61.80 μg·mL-1·h (p < .01) and t1/2 was 10.29 h in aqueous humor; AUC was 1008.66 μg·mL-1·h (p < .01) and t1/2 was 13.26 h (p < .01) in vitreous) than GCV injection with extended therapeutic activity.,"Synthesis, physicochemical properties and ocular pharmacokinetics of thermosensitive in situ hydrogels for ganciclovir in cytomegalovirus retinitis treatment. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29228826/),h,13.26,178234,DB02377,Guanine
,2840229,peak,"Mean peak and trough concentrations on days 5, 6 or 7 were 25 and 18 mumol/L, respectively.",Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840229/),[μM] / [l],25,178558,DB02377,Guanine
,2840229,trough concentrations,"Mean peak and trough concentrations on days 5, 6 or 7 were 25 and 18 mumol/L, respectively.",Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840229/),[μM] / [l],18,178559,DB02377,Guanine
,1433488,elimination half-life,"After i.v. injection at a dose of 20 mg/kg of acyclovir, elimination half-life was estimated at 0.65 h, volume of distribution at steady state was 627.65 ml/kg, and clearance was 11.22 ml/kg/min.","Acyclovir (Zovirax) pharmacokinetics in Quaker parakeets, Myiopsitta monachus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433488/),h,0.65,179006,DB02377,Guanine
,1433488,volume of distribution at steady state,"After i.v. injection at a dose of 20 mg/kg of acyclovir, elimination half-life was estimated at 0.65 h, volume of distribution at steady state was 627.65 ml/kg, and clearance was 11.22 ml/kg/min.","Acyclovir (Zovirax) pharmacokinetics in Quaker parakeets, Myiopsitta monachus. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433488/),[ml] / [kg],627.65,179007,DB02377,Guanine
,1433488,clearance,"After i.v. injection at a dose of 20 mg/kg of acyclovir, elimination half-life was estimated at 0.65 h, volume of distribution at steady state was 627.65 ml/kg, and clearance was 11.22 ml/kg/min.","Acyclovir (Zovirax) pharmacokinetics in Quaker parakeets, Myiopsitta monachus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433488/),[ml] / [kg·min],11.22,179008,DB02377,Guanine
,1433488,elimination half-life,The estimated pharmacokinetic values after i.m. injection at a dose of 40 mg/kg of acyclovir were an elimination half-life of 0.71 h and a bioavailability of 90.1%.,"Acyclovir (Zovirax) pharmacokinetics in Quaker parakeets, Myiopsitta monachus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433488/),h,0.71,179009,DB02377,Guanine
,1433488,bioavailability,The estimated pharmacokinetic values after i.m. injection at a dose of 40 mg/kg of acyclovir were an elimination half-life of 0.71 h and a bioavailability of 90.1%.,"Acyclovir (Zovirax) pharmacokinetics in Quaker parakeets, Myiopsitta monachus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433488/),%,90.1,179010,DB02377,Guanine
,11015151,intestinal permeability,"Mean intestinal permeability increased as HIV disease progressed (0. 05, 0.1, and 0.2 for groups A, B, and C, respectively).",Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11015151/),,0. 05,179409,DB02377,Guanine
,11015151,intestinal permeability,"Mean intestinal permeability increased as HIV disease progressed (0. 05, 0.1, and 0.2 for groups A, B, and C, respectively).",Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11015151/),,0.1,179410,DB02377,Guanine
,11015151,intestinal permeability,"Mean intestinal permeability increased as HIV disease progressed (0. 05, 0.1, and 0.2 for groups A, B, and C, respectively).",Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11015151/),,0.2,179411,DB02377,Guanine
,11015151,weight-adjusted maximum concentration (Cmax),"Average weight-adjusted maximum concentration (Cmax) in group C was twofold more than that in group A and B patients (12.5 versus 6 and 6.4 ng/ml/kg), and average area under the curve (AUC0-infinity) was threefold greater in group C patients (193 versus 59 and 65 ng. hour/ml/kg in groups A and B, respectively).",Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11015151/),[ng] / [kg·ml],12.5,179412,DB02377,Guanine
,11015151,weight-adjusted maximum concentration (Cmax),"Average weight-adjusted maximum concentration (Cmax) in group C was twofold more than that in group A and B patients (12.5 versus 6 and 6.4 ng/ml/kg), and average area under the curve (AUC0-infinity) was threefold greater in group C patients (193 versus 59 and 65 ng. hour/ml/kg in groups A and B, respectively).",Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11015151/),[ng] / [kg·ml],6,179413,DB02377,Guanine
,11015151,weight-adjusted maximum concentration (Cmax),"Average weight-adjusted maximum concentration (Cmax) in group C was twofold more than that in group A and B patients (12.5 versus 6 and 6.4 ng/ml/kg), and average area under the curve (AUC0-infinity) was threefold greater in group C patients (193 versus 59 and 65 ng. hour/ml/kg in groups A and B, respectively).",Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11015151/),[ng] / [kg·ml],6.4,179414,DB02377,Guanine
,11015151,area under the curve (AUC0-infinity),"Average weight-adjusted maximum concentration (Cmax) in group C was twofold more than that in group A and B patients (12.5 versus 6 and 6.4 ng/ml/kg), and average area under the curve (AUC0-infinity) was threefold greater in group C patients (193 versus 59 and 65 ng. hour/ml/kg in groups A and B, respectively).",Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11015151/),[h·ng] / [kg·ml],193,179415,DB02377,Guanine
,11015151,area under the curve (AUC0-infinity),"Average weight-adjusted maximum concentration (Cmax) in group C was twofold more than that in group A and B patients (12.5 versus 6 and 6.4 ng/ml/kg), and average area under the curve (AUC0-infinity) was threefold greater in group C patients (193 versus 59 and 65 ng. hour/ml/kg in groups A and B, respectively).",Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11015151/),[h·ng] / [kg·ml],59,179416,DB02377,Guanine
,11015151,area under the curve (AUC0-infinity),"Average weight-adjusted maximum concentration (Cmax) in group C was twofold more than that in group A and B patients (12.5 versus 6 and 6.4 ng/ml/kg), and average area under the curve (AUC0-infinity) was threefold greater in group C patients (193 versus 59 and 65 ng. hour/ml/kg in groups A and B, respectively).",Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11015151/),[h·ng] / [kg·ml],65,179417,DB02377,Guanine
,11015151,oral clearance,"Mean oral clearance was threefold lower in group C (96 versus 258 and 212 L/hour in groups A and B, respectively).",Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11015151/),[l] / [h],96,179418,DB02377,Guanine
,11015151,oral clearance,"Mean oral clearance was threefold lower in group C (96 versus 258 and 212 L/hour in groups A and B, respectively).",Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11015151/),[l] / [h],258,179419,DB02377,Guanine
,11015151,oral clearance,"Mean oral clearance was threefold lower in group C (96 versus 258 and 212 L/hour in groups A and B, respectively).",Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11015151/),[l] / [h],212,179420,DB02377,Guanine
,18081360,maximum plasma concentration (C(max)),"The mean values of maximum plasma concentration (C(max)), time to C(max) (t(max)), area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)) and from time 0 to infinity (AUC(infinity)), and plasma half-life following administration of the test product were 999.6 microg/L, 2.08 h, 4911.2 microg/L . h, 5417.7 microg/L . h and 3.08 h, respectively, and for the reference product 775.8 microg/L, 2.58 h, 3862.1 microg/L . h, 4295.4 microg/L . h and 3.14 h, respectively.",Lack of bioequivalence between two aciclovir tablets in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081360/),[μg] / [l],999.6,179565,DB02377,Guanine
,18081360,time to C(max) (t(max)),"The mean values of maximum plasma concentration (C(max)), time to C(max) (t(max)), area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)) and from time 0 to infinity (AUC(infinity)), and plasma half-life following administration of the test product were 999.6 microg/L, 2.08 h, 4911.2 microg/L . h, 5417.7 microg/L . h and 3.08 h, respectively, and for the reference product 775.8 microg/L, 2.58 h, 3862.1 microg/L . h, 4295.4 microg/L . h and 3.14 h, respectively.",Lack of bioequivalence between two aciclovir tablets in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081360/),h,2.08,179566,DB02377,Guanine
,18081360,time to C(max) (t(max)),"The mean values of maximum plasma concentration (C(max)), time to C(max) (t(max)), area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)) and from time 0 to infinity (AUC(infinity)), and plasma half-life following administration of the test product were 999.6 microg/L, 2.08 h, 4911.2 microg/L . h, 5417.7 microg/L . h and 3.08 h, respectively, and for the reference product 775.8 microg/L, 2.58 h, 3862.1 microg/L . h, 4295.4 microg/L . h and 3.14 h, respectively.",Lack of bioequivalence between two aciclovir tablets in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081360/),[μg] / [h·l],4911.2,179567,DB02377,Guanine
,18081360,time to C(max) (t(max)),"The mean values of maximum plasma concentration (C(max)), time to C(max) (t(max)), area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)) and from time 0 to infinity (AUC(infinity)), and plasma half-life following administration of the test product were 999.6 microg/L, 2.08 h, 4911.2 microg/L . h, 5417.7 microg/L . h and 3.08 h, respectively, and for the reference product 775.8 microg/L, 2.58 h, 3862.1 microg/L . h, 4295.4 microg/L . h and 3.14 h, respectively.",Lack of bioequivalence between two aciclovir tablets in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081360/),[μg] / [h·l],5417.7,179568,DB02377,Guanine
,18081360,area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)),"The mean values of maximum plasma concentration (C(max)), time to C(max) (t(max)), area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)) and from time 0 to infinity (AUC(infinity)), and plasma half-life following administration of the test product were 999.6 microg/L, 2.08 h, 4911.2 microg/L . h, 5417.7 microg/L . h and 3.08 h, respectively, and for the reference product 775.8 microg/L, 2.58 h, 3862.1 microg/L . h, 4295.4 microg/L . h and 3.14 h, respectively.",Lack of bioequivalence between two aciclovir tablets in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081360/),h,2.08,179569,DB02377,Guanine
,18081360,area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)),"The mean values of maximum plasma concentration (C(max)), time to C(max) (t(max)), area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)) and from time 0 to infinity (AUC(infinity)), and plasma half-life following administration of the test product were 999.6 microg/L, 2.08 h, 4911.2 microg/L . h, 5417.7 microg/L . h and 3.08 h, respectively, and for the reference product 775.8 microg/L, 2.58 h, 3862.1 microg/L . h, 4295.4 microg/L . h and 3.14 h, respectively.",Lack of bioequivalence between two aciclovir tablets in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081360/),[μg] / [h·l],4911.2,179570,DB02377,Guanine
,18081360,area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)),"The mean values of maximum plasma concentration (C(max)), time to C(max) (t(max)), area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)) and from time 0 to infinity (AUC(infinity)), and plasma half-life following administration of the test product were 999.6 microg/L, 2.08 h, 4911.2 microg/L . h, 5417.7 microg/L . h and 3.08 h, respectively, and for the reference product 775.8 microg/L, 2.58 h, 3862.1 microg/L . h, 4295.4 microg/L . h and 3.14 h, respectively.",Lack of bioequivalence between two aciclovir tablets in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081360/),[μg] / [h·l],5417.7,179571,DB02377,Guanine
,18081360,from time 0 to infinity (AUC(infinity)),"The mean values of maximum plasma concentration (C(max)), time to C(max) (t(max)), area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)) and from time 0 to infinity (AUC(infinity)), and plasma half-life following administration of the test product were 999.6 microg/L, 2.08 h, 4911.2 microg/L . h, 5417.7 microg/L . h and 3.08 h, respectively, and for the reference product 775.8 microg/L, 2.58 h, 3862.1 microg/L . h, 4295.4 microg/L . h and 3.14 h, respectively.",Lack of bioequivalence between two aciclovir tablets in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081360/),h,2.08,179572,DB02377,Guanine
,18081360,from time 0 to infinity (AUC(infinity)),"The mean values of maximum plasma concentration (C(max)), time to C(max) (t(max)), area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)) and from time 0 to infinity (AUC(infinity)), and plasma half-life following administration of the test product were 999.6 microg/L, 2.08 h, 4911.2 microg/L . h, 5417.7 microg/L . h and 3.08 h, respectively, and for the reference product 775.8 microg/L, 2.58 h, 3862.1 microg/L . h, 4295.4 microg/L . h and 3.14 h, respectively.",Lack of bioequivalence between two aciclovir tablets in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081360/),[μg] / [h·l],4911.2,179573,DB02377,Guanine
,18081360,from time 0 to infinity (AUC(infinity)),"The mean values of maximum plasma concentration (C(max)), time to C(max) (t(max)), area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)) and from time 0 to infinity (AUC(infinity)), and plasma half-life following administration of the test product were 999.6 microg/L, 2.08 h, 4911.2 microg/L . h, 5417.7 microg/L . h and 3.08 h, respectively, and for the reference product 775.8 microg/L, 2.58 h, 3862.1 microg/L . h, 4295.4 microg/L . h and 3.14 h, respectively.",Lack of bioequivalence between two aciclovir tablets in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081360/),[μg] / [h·l],5417.7,179574,DB02377,Guanine
,18081360,plasma half-life,"The mean values of maximum plasma concentration (C(max)), time to C(max) (t(max)), area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)) and from time 0 to infinity (AUC(infinity)), and plasma half-life following administration of the test product were 999.6 microg/L, 2.08 h, 4911.2 microg/L . h, 5417.7 microg/L . h and 3.08 h, respectively, and for the reference product 775.8 microg/L, 2.58 h, 3862.1 microg/L . h, 4295.4 microg/L . h and 3.14 h, respectively.",Lack of bioequivalence between two aciclovir tablets in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081360/),h,3.08,179575,DB02377,Guanine
,18081360,plasma half-life,"The mean values of maximum plasma concentration (C(max)), time to C(max) (t(max)), area under the plasma concentration-time curve from time 0 to 12 hours (AUC(12)) and from time 0 to infinity (AUC(infinity)), and plasma half-life following administration of the test product were 999.6 microg/L, 2.08 h, 4911.2 microg/L . h, 5417.7 microg/L . h and 3.08 h, respectively, and for the reference product 775.8 microg/L, 2.58 h, 3862.1 microg/L . h, 4295.4 microg/L . h and 3.14 h, respectively.",Lack of bioequivalence between two aciclovir tablets in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081360/),h,3.14,179576,DB02377,Guanine
,12021536,apparent total clearance,High inter-patient variations were observed with acyclovir apparent total clearance 7.238 +/- 4 l/h and half-life (T1/2) 22.27 +/- 16.82 h.,Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021536/),[l] / [h],7.238,179891,DB02377,Guanine
,12021536,half-life (T1/2),High inter-patient variations were observed with acyclovir apparent total clearance 7.238 +/- 4 l/h and half-life (T1/2) 22.27 +/- 16.82 h.,Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021536/),h,22.27,179892,DB02377,Guanine
,23108697,relative dose intensity,"Cumulative myelosuppression was problematic: the median relative dose intensity (% actual/intended) across all cycles was 61 % for sunitinib, 78 % for pemetrexed, and 74 % for cisplatin.","Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108697/),,61,180535,DB02377,Guanine
,23108697,relative dose intensity,"Cumulative myelosuppression was problematic: the median relative dose intensity (% actual/intended) across all cycles was 61 % for sunitinib, 78 % for pemetrexed, and 74 % for cisplatin.","Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108697/),,78,180536,DB02377,Guanine
,2307315,plasma half-life,"The nucleoside was rapidly distributed in the body, with the dose-dependent, estimated plasma half-life being 21-44 min.","Disposition and elimination of BIOLF-143, an antiviral agent, in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2307315/),min,21-44,180567,DB02377,Guanine
,10761169,terminal half-life,"The calculated terminal half-life was 3.5 +/- 1.0 h, and the absolute bioavailability of the oral formulation was approximately 51%.","Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761169/),h,3.5,180583,DB02377,Guanine
,10761169,absolute bioavailability,"The calculated terminal half-life was 3.5 +/- 1.0 h, and the absolute bioavailability of the oral formulation was approximately 51%.","Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761169/),%,51,180584,DB02377,Guanine
,10761169,terminal half-life,"The calculated terminal half-life of inosine and 2'-deoxyguanosine was 15.3 +/- 1.8 h and 1.3 +/- 0.1 h, respectively.","Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761169/),h,15.3,180585,DB02377,Guanine
,10761169,terminal half-life,"The calculated terminal half-life of inosine and 2'-deoxyguanosine was 15.3 +/- 1.8 h and 1.3 +/- 0.1 h, respectively.","Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761169/),h,1.3,180586,DB02377,Guanine
,24934863,elimination half-life (t ½ elimination),The plasma PEM pharmacokinetics calculated showed an elimination half-life (t ½ elimination) of 3.2 h and distribution half-life (t ½-distribution) of 6 min.,Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),h,3.2,180591,DB02377,Guanine
,24934863,distribution half-life (t ½-distribution),The plasma PEM pharmacokinetics calculated showed an elimination half-life (t ½ elimination) of 3.2 h and distribution half-life (t ½-distribution) of 6 min.,Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),min,6,180592,DB02377,Guanine
,24934863,Clearance (CL),"Clearance (CL) was 5.1 L/h, central volume of distribution (V(central)) 23.2 L and peripheral volume distribution (V(peripheral)) 10.6 L, and the area under the curve was 186 μg h/mL.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),[l] / [h],5.1,180593,DB02377,Guanine
,24934863,central volume of distribution (V(central)),"Clearance (CL) was 5.1 L/h, central volume of distribution (V(central)) 23.2 L and peripheral volume distribution (V(peripheral)) 10.6 L, and the area under the curve was 186 μg h/mL.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),l,23.2,180594,DB02377,Guanine
,24934863,peripheral volume distribution (V(peripheral)),"Clearance (CL) was 5.1 L/h, central volume of distribution (V(central)) 23.2 L and peripheral volume distribution (V(peripheral)) 10.6 L, and the area under the curve was 186 μg h/mL.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),l,10.6,180595,DB02377,Guanine
,24934863,area under the curve,"Clearance (CL) was 5.1 L/h, central volume of distribution (V(central)) 23.2 L and peripheral volume distribution (V(peripheral)) 10.6 L, and the area under the curve was 186 μg h/mL.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),[h·μg] / [ml],186,180596,DB02377,Guanine
,24934863,elimination half-life,"Using non-compartment methods, an elimination half-life of 3.1 h and an apparent CL of 3.2 L/h were measured, whereas an apparent steady-state volume became 14.2 L.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),h,3.1,180597,DB02377,Guanine
,24934863,apparent CL,"Using non-compartment methods, an elimination half-life of 3.1 h and an apparent CL of 3.2 L/h were measured, whereas an apparent steady-state volume became 14.2 L.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),[l] / [h],3.2,180598,DB02377,Guanine
,24934863,apparent steady-state volume,"Using non-compartment methods, an elimination half-life of 3.1 h and an apparent CL of 3.2 L/h were measured, whereas an apparent steady-state volume became 14.2 L.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),l,14.2,180599,DB02377,Guanine
,24934863,elimination half-life,"The pleura concentrations were only half of simultaneous plasma concentrations, and elimination half-life was 3.15 h.",Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934863/),h,3.15,180600,DB02377,Guanine
,16737936,AUC0-infinity,"The ganciclovir exposure after 900 mg of valganciclovir noninferior to that of intravenous ganciclovir (AUC0-infinity, 52.1 and 53.8 microg.h/mL, respectively; 95% confidence interval of the ratio of least square means of AUC0-infinity, 82.48%-118.02%).",Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16737936/),[h·μg] / [ml],52.1,181045,DB02377,Guanine
,16737936,AUC0-infinity,"The ganciclovir exposure after 900 mg of valganciclovir noninferior to that of intravenous ganciclovir (AUC0-infinity, 52.1 and 53.8 microg.h/mL, respectively; 95% confidence interval of the ratio of least square means of AUC0-infinity, 82.48%-118.02%).",Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16737936/),[h·μg] / [ml],53.8,181046,DB02377,Guanine
,12177114,area under the plasma concentration-time curve (AUC),"Doses ranged from pemetrexed 400 mg/m(2) (as a 10-minute intravenous infusion), followed by carboplatin area under the plasma concentration-time curve (AUC) 4 mg/mL.min (as a 30-minute intravenous infusion) to pemetrexed 500 mg/m(2), carboplatin AUC 6 mg/mL.min.",Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),[mg] / [min·ml],4,181201,DB02377,Guanine
,12177114,AUC,"Doses ranged from pemetrexed 400 mg/m(2) (as a 10-minute intravenous infusion), followed by carboplatin area under the plasma concentration-time curve (AUC) 4 mg/mL.min (as a 30-minute intravenous infusion) to pemetrexed 500 mg/m(2), carboplatin AUC 6 mg/mL.min.",Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),[mg] / [min·ml],6,181202,DB02377,Guanine
,12177114,response rate,Eight partial responses (in 25 assessable patients) were observed for a response rate of 32%.,Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),%,32,181203,DB02377,Guanine
,12177114,time to progression,"Median time to progression was 305 days, and median survival time was 451 days.",Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),d,305,181204,DB02377,Guanine
,12177114,survival time,"Median time to progression was 305 days, and median survival time was 451 days.",Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),d,451,181205,DB02377,Guanine
,12177114,AUC,The MTD was pemetrexed 500 mg/m(2) and carboplatin AUC 6 mg/mL.min.,Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),[mg] / [min·ml],6,181206,DB02377,Guanine
,12177114,AUC,The recommended phase II dose of the combination is pemetrexed 500 mg/m(2) and carboplatin AUC 5 mg/mL.min.,Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177114/),[mg] / [min·ml],5,181207,DB02377,Guanine
,27351137,Si,"The formulation containing drug loaded polyvinyl pyrrolidone-Eudragit RSPO hybrid polymeric nanoparticles (Size ∼99±3nm, Zeta ∼+26.1±1.5mV) in 15% Pluronic F-127 gel exhibited improved permeability through vaginal membrane (KP=2.20±0.19×10(-6)cm/s).",Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27351137/),m,26.1,181310,DB02377,Guanine
,27351137,Zeta ∼,"The formulation containing drug loaded polyvinyl pyrrolidone-Eudragit RSPO hybrid polymeric nanoparticles (Size ∼99±3nm, Zeta ∼+26.1±1.5mV) in 15% Pluronic F-127 gel exhibited improved permeability through vaginal membrane (KP=2.20±0.19×10(-6)cm/s).",Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27351137/),m,26.1,181311,DB02377,Guanine
,27351137,KP,"The formulation containing drug loaded polyvinyl pyrrolidone-Eudragit RSPO hybrid polymeric nanoparticles (Size ∼99±3nm, Zeta ∼+26.1±1.5mV) in 15% Pluronic F-127 gel exhibited improved permeability through vaginal membrane (KP=2.20±0.19×10(-6)cm/s).",Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27351137/),[cm] / [s],2.20,181312,DB02377,Guanine
,27351137,mean residence time,Significant improvement in mean residence time of the drug (12.52±1.12h) was observed with a two-fold increase in the relative bioavailability (AUC0-24h=14.92±2.44μgh/mL) compared to that of the pure drug (7.18±1.79μgh/mL).,Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27351137/),h,12.52,181313,DB02377,Guanine
,27351137,relative bioavailability (AUC0-24h,Significant improvement in mean residence time of the drug (12.52±1.12h) was observed with a two-fold increase in the relative bioavailability (AUC0-24h=14.92±2.44μgh/mL) compared to that of the pure drug (7.18±1.79μgh/mL).,Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27351137/),[μgh] / [ml],14.92,181314,DB02377,Guanine
,27351137,relative bioavailability (AUC0-24h,Significant improvement in mean residence time of the drug (12.52±1.12h) was observed with a two-fold increase in the relative bioavailability (AUC0-24h=14.92±2.44μgh/mL) compared to that of the pure drug (7.18±1.79μgh/mL).,Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27351137/),[μgh] / [ml],7.18,181315,DB02377,Guanine
,17025257,solubility,"Acyclovir, a poorly soluble drug, displayed high solubility in a microemulsion formulation using Labrafac (10%), Labrasol (32%), Plurol Oleique (8%), and water (50%).",Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17025257/),%,10,182085,DB02377,Guanine
,17025257,solubility,"Acyclovir, a poorly soluble drug, displayed high solubility in a microemulsion formulation using Labrafac (10%), Labrasol (32%), Plurol Oleique (8%), and water (50%).",Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17025257/),%,32,182086,DB02377,Guanine
,17025257,solubility,"Acyclovir, a poorly soluble drug, displayed high solubility in a microemulsion formulation using Labrafac (10%), Labrasol (32%), Plurol Oleique (8%), and water (50%).",Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17025257/),%,8,182087,DB02377,Guanine
,17025257,solubility,"Acyclovir, a poorly soluble drug, displayed high solubility in a microemulsion formulation using Labrafac (10%), Labrasol (32%), Plurol Oleique (8%), and water (50%).",Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17025257/),%,50,182088,DB02377,Guanine
,23264448,K(m),"In wild-type mice, jejunal uptake of valacyclovir was best described by both saturable (K(m) = 10.2 mM) and nonsaturable components where the saturable pathway accounted for 82% of total transport.",Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264448/),mM,10.2,184163,DB02377,Guanine
,23264448,P(eff),"Valacyclovir P(eff) was 2.4 × 10(-4) cm/s in duodenum, 1.7 × 10(-4) cm/s in jejunum, 2.1 × 10(-4) cm/s in ileum, and 0.27 × 10(-4) cm/s in colon.",Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264448/),[cm] / [s],2.4 × 10(-4),184164,DB02377,Guanine
,23264448,P(eff),"Valacyclovir P(eff) was 2.4 × 10(-4) cm/s in duodenum, 1.7 × 10(-4) cm/s in jejunum, 2.1 × 10(-4) cm/s in ileum, and 0.27 × 10(-4) cm/s in colon.",Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264448/),[cm] / [s],1.7 × 10(-4),184165,DB02377,Guanine
,23264448,P(eff),"Valacyclovir P(eff) was 2.4 × 10(-4) cm/s in duodenum, 1.7 × 10(-4) cm/s in jejunum, 2.1 × 10(-4) cm/s in ileum, and 0.27 × 10(-4) cm/s in colon.",Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264448/),[cm] / [s],2.1 × 10(-4),184166,DB02377,Guanine
,23264448,P(eff),"Valacyclovir P(eff) was 2.4 × 10(-4) cm/s in duodenum, 1.7 × 10(-4) cm/s in jejunum, 2.1 × 10(-4) cm/s in ileum, and 0.27 × 10(-4) cm/s in colon.",Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264448/),[cm] / [s],0.27 × 10(-4),184167,DB02377,Guanine
,17975982,maximum concentration (C(max)),"Following a single dose of famciclovir, the dose-normalized (15 mg/kg) maximum concentration (C(max)) of penciclovir (350 +/- 180 ng/mL) occurred at 4.6 +/- 1.8 hours and mean +/- SD apparent elimination half-life was 3.1 +/- 0.9 hours.",Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975982/),[ng] / [ml],350,185210,DB02377,Guanine
,17975982,apparent elimination half-life,"Following a single dose of famciclovir, the dose-normalized (15 mg/kg) maximum concentration (C(max)) of penciclovir (350 +/- 180 ng/mL) occurred at 4.6 +/- 1.8 hours and mean +/- SD apparent elimination half-life was 3.1 +/- 0.9 hours.",Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975982/),h,3.1,185211,DB02377,Guanine
,17975982,C(max),"Dose-normalized penciclovir C(max)following administration of famciclovir every 12 or 8 hours (290 +/- 150 ng/mL or 780 +/- 250 ng/mL, respectively) was notably less than the in vitro concentration (3,500 ng/mL) required for activity against feline herpesvirus-1.",Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975982/),[ng] / [ml],290,185212,DB02377,Guanine
,17975982,C(max),"Dose-normalized penciclovir C(max)following administration of famciclovir every 12 or 8 hours (290 +/- 150 ng/mL or 780 +/- 250 ng/mL, respectively) was notably less than the in vitro concentration (3,500 ng/mL) required for activity against feline herpesvirus-1.",Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975982/),[ng] / [ml],780,185213,DB02377,Guanine
,17975982,C(max),"Dose-normalized penciclovir C(max)following administration of famciclovir every 12 or 8 hours (290 +/- 150 ng/mL or 780 +/- 250 ng/mL, respectively) was notably less than the in vitro concentration (3,500 ng/mL) required for activity against feline herpesvirus-1.",Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975982/),ng,"3,500",185214,DB02377,Guanine
,11032594,elimination half-life,"O(6)-BG rapidly disappeared from plasma (elimination half-life = 0. 54 +/- 0.14 hours) and was converted to a longer-lived metabolite, 8-oxo-O(6)-BG (elimination half-life = 5.6 +/- 2.7 hours) and further to 8-oxoguanine.",Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11032594/),h,0. 54,185470,DB02377,Guanine
,11032594,elimination half-life,"O(6)-BG rapidly disappeared from plasma (elimination half-life = 0. 54 +/- 0.14 hours) and was converted to a longer-lived metabolite, 8-oxo-O(6)-BG (elimination half-life = 5.6 +/- 2.7 hours) and further to 8-oxoguanine.",Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11032594/),h,5.6,185471,DB02377,Guanine
,8689950,Half-life,"Half-life, clearance, and volume of distribution were respectively, 1.6 hr, 160 ml/hr/kg, and 405 ml/kg for O6-benzylguanine, and 1.2 hr, 312 ml/hr/kg, and 507 ml/kg for O6-benzyl-8-oxoguanine.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),h,1.6,185521,DB02377,Guanine
,8689950,clearance,"Half-life, clearance, and volume of distribution were respectively, 1.6 hr, 160 ml/hr/kg, and 405 ml/kg for O6-benzylguanine, and 1.2 hr, 312 ml/hr/kg, and 507 ml/kg for O6-benzyl-8-oxoguanine.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[ml] / [h·kg],160,185522,DB02377,Guanine
,8689950,clearance,"Half-life, clearance, and volume of distribution were respectively, 1.6 hr, 160 ml/hr/kg, and 405 ml/kg for O6-benzylguanine, and 1.2 hr, 312 ml/hr/kg, and 507 ml/kg for O6-benzyl-8-oxoguanine.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),h,1.2,185523,DB02377,Guanine
,8689950,clearance,"Half-life, clearance, and volume of distribution were respectively, 1.6 hr, 160 ml/hr/kg, and 405 ml/kg for O6-benzylguanine, and 1.2 hr, 312 ml/hr/kg, and 507 ml/kg for O6-benzyl-8-oxoguanine.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[ml] / [h·kg],312,185524,DB02377,Guanine
,8689950,volume of distribution,"Half-life, clearance, and volume of distribution were respectively, 1.6 hr, 160 ml/hr/kg, and 405 ml/kg for O6-benzylguanine, and 1.2 hr, 312 ml/hr/kg, and 507 ml/kg for O6-benzyl-8-oxoguanine.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[ml] / [kg],405,185525,DB02377,Guanine
,8689950,volume of distribution,"Half-life, clearance, and volume of distribution were respectively, 1.6 hr, 160 ml/hr/kg, and 405 ml/kg for O6-benzylguanine, and 1.2 hr, 312 ml/hr/kg, and 507 ml/kg for O6-benzyl-8-oxoguanine.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[ml] / [kg],507,185526,DB02377,Guanine
,8689950,Renal,"Renal excretion accounted for 8 and 62% of the administered O6-benzylguanine and O6-benzyl-8-oxoguanine, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),,8,185527,DB02377,Guanine
,8689950,Renal,"Renal excretion accounted for 8 and 62% of the administered O6-benzylguanine and O6-benzyl-8-oxoguanine, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),,62,185528,DB02377,Guanine
,8689950,KM,"Kinetic constants, KM and Vmax were estimated as 19.6 microM and 0.02 nmol/min/mg protein and 13.4 microM and 0.96 nmol/min/mg protein, for uninduced and induced rat liver microsomes, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),μM,19.6,185529,DB02377,Guanine
,8689950,KM,"Kinetic constants, KM and Vmax were estimated as 19.6 microM and 0.02 nmol/min/mg protein and 13.4 microM and 0.96 nmol/min/mg protein, for uninduced and induced rat liver microsomes, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[nM] / [mg·min],0.02,185530,DB02377,Guanine
,8689950,KM,"Kinetic constants, KM and Vmax were estimated as 19.6 microM and 0.02 nmol/min/mg protein and 13.4 microM and 0.96 nmol/min/mg protein, for uninduced and induced rat liver microsomes, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),μM,13.4,185531,DB02377,Guanine
,8689950,Vmax,"Kinetic constants, KM and Vmax were estimated as 19.6 microM and 0.02 nmol/min/mg protein and 13.4 microM and 0.96 nmol/min/mg protein, for uninduced and induced rat liver microsomes, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[nM] / [mg·min],0.02,185532,DB02377,Guanine
,8689950,Vmax,"Kinetic constants, KM and Vmax were estimated as 19.6 microM and 0.02 nmol/min/mg protein and 13.4 microM and 0.96 nmol/min/mg protein, for uninduced and induced rat liver microsomes, respectively.",Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689950/),[nM] / [mg·min],0.96,185533,DB02377,Guanine
,26046929,Tmax,Drug concentration in the viable epidermis continued to increase even after termination of therapy (Tmax=4 h) and then declined rapidly.,Quantification of uptake and clearance of acyclovir in skin layers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26046929/),h,4,185708,DB02377,Guanine
,26046929,availability,The availability of acyclovir in the target was comparatively low (approximately 0.4% of the applied dose) although an order of magnitude higher percentage was determined in the stratum corneum.,Quantification of uptake and clearance of acyclovir in skin layers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26046929/),%,0.4,185709,DB02377,Guanine
,8125715,terminal elimination half-life,The ocular pharmacokinetics of foscarnet determined by noncompartmental analysis showed a 34-hour terminal elimination half-life and an apparent volume of distribution of 1.9 ml.,"Toxicologic and pharmacokinetic analysis of intravitreal injections of foscarnet, either alone or in combination with ganciclovir. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8125715/),h,34,186698,DB02377,Guanine
,8125715,apparent volume of distribution,The ocular pharmacokinetics of foscarnet determined by noncompartmental analysis showed a 34-hour terminal elimination half-life and an apparent volume of distribution of 1.9 ml.,"Toxicologic and pharmacokinetic analysis of intravitreal injections of foscarnet, either alone or in combination with ganciclovir. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8125715/),ml,1.9,186699,DB02377,Guanine
,1336464,volume of distribution,"Penciclovir was distributed into tissues with an overall mean volume of distribution of approximately 1.5 l.kg-1, i.e. approximately double that of body water.","The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336464/),[l] / [kg],1.5,187697,DB02377,Guanine
,1336464,total plasma clearance,"It was rapidly eliminated, with a mean total plasma clearance of 39.3 l.h-1, and a mean terminal-phase half-life of 2.0 h.","The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336464/),[l] / [h],39.3,187698,DB02377,Guanine
,1336464,terminal-phase half-life,"It was rapidly eliminated, with a mean total plasma clearance of 39.3 l.h-1, and a mean terminal-phase half-life of 2.0 h.","The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336464/),h,2.0,187699,DB02377,Guanine
,1336464,renal clearance,"Mean renal clearance of BRL 39,123 was 28.1 l.h-1, which exceeds normal glomerular filtration rate and approaches renal plasma flow.","The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336464/),[l] / [h],28.1,187700,DB02377,Guanine
,29507070,area under the concentration-time curve from 0 to 24 h (AUC0-24),A target area under the concentration-time curve from 0 to 24 h (AUC0-24) of 40 to 50 μg · h/ml is recommended.,Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29507070/),[h·μg] / [ml],40 to 50,188038,DB02377,Guanine
,29507070,AUC0-24,"The adjusted doses were increased by 28.6% to 60.0% in these five patients, and all adapted AUC0-24 values achieved the target (range, 48.6 to 66.1 μg · h/ml).",Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29507070/),[h·μg] / [ml],48.6 to 66.1,188039,DB02377,Guanine
,11301564,steady-state average serum concentrations,"Mean steady-state average serum concentrations of ganciclovir were 0.54, 0.79, and 0.99 microgram/mL, respectively, with the 3, 4, and 6 g/day oral regimens.",Absolute bioavailability and dose proportionality of oral ganciclovir after ascending multiple doses in human immunodeficiency virus (HIV)-positive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301564/),[μg] / [ml],0.54,188503,DB02377,Guanine
,11301564,steady-state average serum concentrations,"Mean steady-state average serum concentrations of ganciclovir were 0.54, 0.79, and 0.99 microgram/mL, respectively, with the 3, 4, and 6 g/day oral regimens.",Absolute bioavailability and dose proportionality of oral ganciclovir after ascending multiple doses in human immunodeficiency virus (HIV)-positive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301564/),[μg] / [ml],0.79,188504,DB02377,Guanine
,11301564,steady-state average serum concentrations,"Mean steady-state average serum concentrations of ganciclovir were 0.54, 0.79, and 0.99 microgram/mL, respectively, with the 3, 4, and 6 g/day oral regimens.",Absolute bioavailability and dose proportionality of oral ganciclovir after ascending multiple doses in human immunodeficiency virus (HIV)-positive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301564/),[μg] / [ml],0.99,188505,DB02377,Guanine
,7038177,half-lives,"The drug half-lives were 3.91, 3.83, and 3.40 hours, respectively.",Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7038177/),h,3.91,188547,DB02377,Guanine
,7038177,half-lives,"The drug half-lives were 3.91, 3.83, and 3.40 hours, respectively.",Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7038177/),h,3.83,188548,DB02377,Guanine
,7038177,half-lives,"The drug half-lives were 3.91, 3.83, and 3.40 hours, respectively.",Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7038177/),h,3.40,188549,DB02377,Guanine
,18806697,activity,The activity of inosine 5'-monophosphate dehydrogenase (IMPDH) at time 0 ranged from 1.2 to 7.2 pmol per 10 cells/min.,Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806697/),pM,1.2 to 7.2,189351,DB02377,Guanine
,18806697,EC50 (concentration required for 50% inhibition),IMPDH was strongly inhibited by MPA; MPA EC50 (concentration required for 50% inhibition) of 2.3 mg/L was determined by a pooled data analysis.,Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806697/),[mg] / [l],2.3,189352,DB02377,Guanine
,18806697,AUC0-12h,"IMPDH activity AUC0-12h approached maximum reduction at MPA AUC0-12h 22 mg x h/L (corresponding to the 500 mg dose), whereas plasma concentrations exceeding approximately 6 mg/L did not further increase the IMPDH inhibition.",Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806697/),[h·mg] / [l],22,189353,DB02377,Guanine
,30373792,effective concentration,"We tested novel synthetic ozonides with longer half-lives against HCMV in vitro and mouse cytomegalovirus (MCMV) in vivo Screening of the activities of four ozonides against a pp28-luciferase-expressing HCMV Towne recombinant identified OZ418 to have the best selectivity; its effective concentration inhibiting viral growth by 50% (EC50) was 9.8 ± 0.2 µM, and cytotoxicity in noninfected human fibroblasts (the concentration inhibiting cell growth by 50% [CC50]) was 128.1 ± 8.0 µM.",Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30373792/),μM,9.8,190650,DB02377,Guanine
,30373792,EC50,"We tested novel synthetic ozonides with longer half-lives against HCMV in vitro and mouse cytomegalovirus (MCMV) in vivo Screening of the activities of four ozonides against a pp28-luciferase-expressing HCMV Towne recombinant identified OZ418 to have the best selectivity; its effective concentration inhibiting viral growth by 50% (EC50) was 9.8 ± 0.2 µM, and cytotoxicity in noninfected human fibroblasts (the concentration inhibiting cell growth by 50% [CC50]) was 128.1 ± 8.0 µM.",Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30373792/),μM,9.8,190651,DB02377,Guanine
,19414579,50% inhibitory concentration,"Simulations (n = 1,000) were conducted to explore the ability of the current doses to maintain acyclovir concentrations above the recommended 50% inhibitory concentration for HSV or VZV (0.56 mg/liter or 1.125 mg/liter, respectively) for more than 12 h.",Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414579/),[mg] / [l],0.56,190858,DB02377,Guanine
,19414579,50% inhibitory concentration,"Simulations (n = 1,000) were conducted to explore the ability of the current doses to maintain acyclovir concentrations above the recommended 50% inhibitory concentration for HSV or VZV (0.56 mg/liter or 1.125 mg/liter, respectively) for more than 12 h.",Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414579/),[mg] / [l],1.125,190859,DB02377,Guanine
,19414579,clearance (CL),"The population mean estimates for clearance (CL), volume of distribution (V), absorption rate (k(a)), and bioavailability (F) were 3.55 liters/h, 7.36 liters, 0.63 h(-1), and 0.60, respectively.",Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414579/),[l] / [h],3.55,190860,DB02377,Guanine
,19414579,volume of distribution (V),"The population mean estimates for clearance (CL), volume of distribution (V), absorption rate (k(a)), and bioavailability (F) were 3.55 liters/h, 7.36 liters, 0.63 h(-1), and 0.60, respectively.",Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414579/),l,7.36,190861,DB02377,Guanine
,19414579,volume of distribution (V),"The population mean estimates for clearance (CL), volume of distribution (V), absorption rate (k(a)), and bioavailability (F) were 3.55 liters/h, 7.36 liters, 0.63 h(-1), and 0.60, respectively.",Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414579/),1/[h],0.63,190862,DB02377,Guanine
,19414579,absorption rate (k(a)),"The population mean estimates for clearance (CL), volume of distribution (V), absorption rate (k(a)), and bioavailability (F) were 3.55 liters/h, 7.36 liters, 0.63 h(-1), and 0.60, respectively.",Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414579/),l,7.36,190863,DB02377,Guanine
,19414579,absorption rate (k(a)),"The population mean estimates for clearance (CL), volume of distribution (V), absorption rate (k(a)), and bioavailability (F) were 3.55 liters/h, 7.36 liters, 0.63 h(-1), and 0.60, respectively.",Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414579/),1/[h],0.63,190864,DB02377,Guanine
,19414579,bioavailability (F),"The population mean estimates for clearance (CL), volume of distribution (V), absorption rate (k(a)), and bioavailability (F) were 3.55 liters/h, 7.36 liters, 0.63 h(-1), and 0.60, respectively.",Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414579/),,0.60,190865,DB02377,Guanine
,19414579,CL(CR),"Simulations revealed that with the use of the current doses, maximal efficacy can be achieved in over 45% of patients weighing 25 to 50 kg and with CL(CR) levels of 2.0 to 4.0 liters/h/m(2), but only in a much smaller proportion of patients, with low weights (10 kg) and high CL(CR)s (5.5 liters/h/m(2)), suggesting that higher doses are required for this subgroup.",Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414579/),[h·l] / [m(2],2.0 to 4.0,190866,DB02377,Guanine
,19414579,CL(CR)s,"Simulations revealed that with the use of the current doses, maximal efficacy can be achieved in over 45% of patients weighing 25 to 50 kg and with CL(CR) levels of 2.0 to 4.0 liters/h/m(2), but only in a much smaller proportion of patients, with low weights (10 kg) and high CL(CR)s (5.5 liters/h/m(2)), suggesting that higher doses are required for this subgroup.",Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414579/),[h·l] / [m(2],5.5,190867,DB02377,Guanine
,3707815,areas under the plasma concentration-time curves (AUCs),"Mean areas under the plasma concentration-time curves (AUCs) +/- s.d. for tablet (T), intraduodenal infusion (I) and sipping (S) were, respectively: T = 14.7 +/- 5.1; I = 24.6 +/- 5.1; S = 28.4 +/- 9.5 (n = 6) mumol l-1 h.",Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),[h·μM] / [l],14.7,191206,DB02377,Guanine
,3707815,areas under the plasma concentration-time curves (AUCs),"Mean areas under the plasma concentration-time curves (AUCs) +/- s.d. for tablet (T), intraduodenal infusion (I) and sipping (S) were, respectively: T = 14.7 +/- 5.1; I = 24.6 +/- 5.1; S = 28.4 +/- 9.5 (n = 6) mumol l-1 h.",Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),[h·μM] / [l],24.6,191207,DB02377,Guanine
,3707815,areas under the plasma concentration-time curves (AUCs),"Mean areas under the plasma concentration-time curves (AUCs) +/- s.d. for tablet (T), intraduodenal infusion (I) and sipping (S) were, respectively: T = 14.7 +/- 5.1; I = 24.6 +/- 5.1; S = 28.4 +/- 9.5 (n = 6) mumol l-1 h.",Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),[h·μM] / [l],28.4,191208,DB02377,Guanine
,3707815,apparent maximum plasma concentrations (Cmax),Mean apparent maximum plasma concentrations (Cmax) +/- s.d. were T = 3.8 +/- 1.5; I = 4.8 +/- 0.9; S = 5.1 +/- 1.5 mumol l-1.,Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),[μM] / [l],3.8,191209,DB02377,Guanine
,3707815,apparent maximum plasma concentrations (Cmax),Mean apparent maximum plasma concentrations (Cmax) +/- s.d. were T = 3.8 +/- 1.5; I = 4.8 +/- 0.9; S = 5.1 +/- 1.5 mumol l-1.,Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),[μM] / [l],4.8,191210,DB02377,Guanine
,3707815,T,Mean apparent maximum plasma concentrations (Cmax) +/- s.d. were T = 3.8 +/- 1.5; I = 4.8 +/- 0.9; S = 5.1 +/- 1.5 mumol l-1.,Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),[μM] / [l],3.8,191211,DB02377,Guanine
,3707815,I,Mean apparent maximum plasma concentrations (Cmax) +/- s.d. were T = 3.8 +/- 1.5; I = 4.8 +/- 0.9; S = 5.1 +/- 1.5 mumol l-1.,Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),[μM] / [l],4.8,191212,DB02377,Guanine
,3707815,S,Mean apparent maximum plasma concentrations (Cmax) +/- s.d. were T = 3.8 +/- 1.5; I = 4.8 +/- 0.9; S = 5.1 +/- 1.5 mumol l-1.,Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),[μM] / [l],5.1,191213,DB02377,Guanine
,3707815,apparent plasma disappearance half-lives (t1/2),"Mean apparent plasma disappearance half-lives (t1/2) +/- s.d. were respectively T = 2.3 +/- 0.4; I = 2.7 +/- 0.5; S = 3.0 +/- 0.2 h, I being significantly greater than T (2P less than 0.05), as was S greater than T (2P less than 0.01).",Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),h,2.3,191214,DB02377,Guanine
,3707815,apparent plasma disappearance half-lives (t1/2),"Mean apparent plasma disappearance half-lives (t1/2) +/- s.d. were respectively T = 2.3 +/- 0.4; I = 2.7 +/- 0.5; S = 3.0 +/- 0.2 h, I being significantly greater than T (2P less than 0.05), as was S greater than T (2P less than 0.01).",Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),h,2.7,191215,DB02377,Guanine
,3707815,apparent plasma disappearance half-lives (t1/2),"Mean apparent plasma disappearance half-lives (t1/2) +/- s.d. were respectively T = 2.3 +/- 0.4; I = 2.7 +/- 0.5; S = 3.0 +/- 0.2 h, I being significantly greater than T (2P less than 0.05), as was S greater than T (2P less than 0.01).",Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),h,3.0,191216,DB02377,Guanine
,3707815,T,"Mean apparent plasma disappearance half-lives (t1/2) +/- s.d. were respectively T = 2.3 +/- 0.4; I = 2.7 +/- 0.5; S = 3.0 +/- 0.2 h, I being significantly greater than T (2P less than 0.05), as was S greater than T (2P less than 0.01).",Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),h,2.3,191217,DB02377,Guanine
,3707815,I,"Mean apparent plasma disappearance half-lives (t1/2) +/- s.d. were respectively T = 2.3 +/- 0.4; I = 2.7 +/- 0.5; S = 3.0 +/- 0.2 h, I being significantly greater than T (2P less than 0.05), as was S greater than T (2P less than 0.01).",Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),h,2.7,191218,DB02377,Guanine
,3707815,S,"Mean apparent plasma disappearance half-lives (t1/2) +/- s.d. were respectively T = 2.3 +/- 0.4; I = 2.7 +/- 0.5; S = 3.0 +/- 0.2 h, I being significantly greater than T (2P less than 0.05), as was S greater than T (2P less than 0.01).",Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707815/),h,3.0,191219,DB02377,Guanine
,33373493,area under the concentration-time curve (AUC0-24h ),Optimal dosing was determined based on the achievement of the surrogate efficacy target: GCV 24 h area under the concentration-time curve (AUC0-24h ) of 40-60 mg.h.L-1 .,Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33373493/),[h·mg] / [l],40-60,194320,DB02377,Guanine
,18181527,percentage entrapment,The percentage entrapment was approximately 11% of acyclovir used in the hydration process.,Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18181527/),%,11,196702,DB02377,Guanine
,18181527,most probable size,"The vesicles have an average size of 0.95 microm, a most probable size of 0.8 microm, and a size range of 0.4 to 2.2 microm.",Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18181527/),,0.8,196703,DB02377,Guanine
,18181527,relative bioavailability,The average relative bioavailability of the drug from the niosomal dispersion in relation to the free solution was 2.55 indicating more than 2-fold increase in drug bioavailability.,Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18181527/),,2.55,196704,DB02377,Guanine
,19307355,clearance/G,"Systemic clearance was markedly influenced by the glomerular filtration rate (GFR), patient gender, and graft type (clearance/GFR = 1.7 in kidney, 0.9 in heart, and 1.2 in lung and liver recipients) with interpatient and interoccasion variabilities of 26 and 12%, respectively.",Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19307355/),,1.7,197093,DB02377,Guanine
,19307355,clearance/G,"Systemic clearance was markedly influenced by the glomerular filtration rate (GFR), patient gender, and graft type (clearance/GFR = 1.7 in kidney, 0.9 in heart, and 1.2 in lung and liver recipients) with interpatient and interoccasion variabilities of 26 and 12%, respectively.",Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19307355/),,0.9,197094,DB02377,Guanine
,19307355,clearance/G,"Systemic clearance was markedly influenced by the glomerular filtration rate (GFR), patient gender, and graft type (clearance/GFR = 1.7 in kidney, 0.9 in heart, and 1.2 in lung and liver recipients) with interpatient and interoccasion variabilities of 26 and 12%, respectively.",Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19307355/),,1.2,197095,DB02377,Guanine
,19307355,central,Body weight and sex influenced central volume of distribution (V(1) = 0.34 liter/kg in males and 0.27 liter/kg in females [20% interpatient variability]).,Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19307355/),[l] / [kg],0.34,197096,DB02377,Guanine
,7777108,Peak plasma levels,"Peak plasma levels were achieved at 3 h (12.54 +/- 1.76 microM, range 8.5-17.5 microM) with the half-life calculated to be 20.2 +/- 4.6 h.",Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7777108/),μM,12.54,197203,DB02377,Guanine
,7777108,half-life,"Peak plasma levels were achieved at 3 h (12.54 +/- 1.76 microM, range 8.5-17.5 microM) with the half-life calculated to be 20.2 +/- 4.6 h.",Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7777108/),h,20.2,197204,DB02377,Guanine
,7777108,plasma level,Mean plasma level of 6.29 +/- 0.94 microM were within the quoted range to inhibit herpes zoster virus (4-8 microM) at 18 h.,Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7777108/),,6,197205,DB02377,Guanine
,7048913,peak,"Although peak and trough acyclovir concentrations rose from 8.5 to 15.8 microM and from 1.7 to 4.1 microM, respectively, these rises are fully attributable to the decreases in GFR seen in both drug- and placebo-treated groups.",Acyclovir concentrations and tolerance during repetitive administration for 18 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7048913/),μM,8.5 to 15.8,198876,DB02377,Guanine
,7048913,trough a,"Although peak and trough acyclovir concentrations rose from 8.5 to 15.8 microM and from 1.7 to 4.1 microM, respectively, these rises are fully attributable to the decreases in GFR seen in both drug- and placebo-treated groups.",Acyclovir concentrations and tolerance during repetitive administration for 18 days. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7048913/),μM,8.5 to 15.8,198877,DB02377,Guanine
,7048913,trough a,"Although peak and trough acyclovir concentrations rose from 8.5 to 15.8 microM and from 1.7 to 4.1 microM, respectively, these rises are fully attributable to the decreases in GFR seen in both drug- and placebo-treated groups.",Acyclovir concentrations and tolerance during repetitive administration for 18 days. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7048913/),μM,1.7 to 4.1,198878,DB02377,Guanine
,3017630,distribution t1/2,Biexponential decay with a mean distribution t1/2 of 0.23 hours and terminal t1/2 of 2.53 hours was observed.,Human pharmacokinetics of the antiviral drug DHPG. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3017630/),h,0.23,199851,DB02377,Guanine
,3017630,terminal t1/2,Biexponential decay with a mean distribution t1/2 of 0.23 hours and terminal t1/2 of 2.53 hours was observed.,Human pharmacokinetics of the antiviral drug DHPG. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3017630/),h,2.53,199852,DB02377,Guanine
,3017630,volume of the central compartment,Mean volume of the central compartment was 15.26 L/1.73 m2 and the volume of distribution at steady state was 32.8 L/1.73 m2.,Human pharmacokinetics of the antiviral drug DHPG. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3017630/),[l] / [1.73·m2],15.26,199853,DB02377,Guanine
,3017630,volume of distribution at steady state,Mean volume of the central compartment was 15.26 L/1.73 m2 and the volume of distribution at steady state was 32.8 L/1.73 m2.,Human pharmacokinetics of the antiviral drug DHPG. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3017630/),[l] / [1.73·m2],32.8,199854,DB02377,Guanine
,3017630,Peak,"Peak (model predicted) and trough plasma concentrations were 4.75 to 6.20 micrograms/ml and less than 0.25 to 0.63 microgram/ml, respectively, in patients receiving 2.5 mg/kg.",Human pharmacokinetics of the antiviral drug DHPG. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3017630/),[μg] / [ml],4.75 to 6.20,199855,DB02377,Guanine
less,3017630,trough plasma concentrations,"Peak (model predicted) and trough plasma concentrations were 4.75 to 6.20 micrograms/ml and less than 0.25 to 0.63 microgram/ml, respectively, in patients receiving 2.5 mg/kg.",Human pharmacokinetics of the antiviral drug DHPG. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3017630/),[μg] / [ml],0.25 to 0.63,199856,DB02377,Guanine
,1847004,first dose peak,"The mean +/- SD plasma levels for the 200 and 400 mg groups, respectively, were: first dose peak, 1.7 +/- 0.6 and 2.3 +/- 1.0 mumol/L; steady-state trough, 0.7 +/- 0.3 and 0.8 +/- 0.6 mumol/L; steady-state peak, 1.9 +/- 1.0 and 3.3 +/- 1.0 mumol/L.",Pharmacokinetics of acyclovir in the term human pregnancy and neonate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1847004/),[μM] / [l],1.7,200552,DB02377,Guanine
,1847004,first dose peak,"The mean +/- SD plasma levels for the 200 and 400 mg groups, respectively, were: first dose peak, 1.7 +/- 0.6 and 2.3 +/- 1.0 mumol/L; steady-state trough, 0.7 +/- 0.3 and 0.8 +/- 0.6 mumol/L; steady-state peak, 1.9 +/- 1.0 and 3.3 +/- 1.0 mumol/L.",Pharmacokinetics of acyclovir in the term human pregnancy and neonate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1847004/),[μM] / [l],2.3,200553,DB02377,Guanine
,1847004,steady-state trough,"The mean +/- SD plasma levels for the 200 and 400 mg groups, respectively, were: first dose peak, 1.7 +/- 0.6 and 2.3 +/- 1.0 mumol/L; steady-state trough, 0.7 +/- 0.3 and 0.8 +/- 0.6 mumol/L; steady-state peak, 1.9 +/- 1.0 and 3.3 +/- 1.0 mumol/L.",Pharmacokinetics of acyclovir in the term human pregnancy and neonate. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1847004/),[μM] / [l],0.7,200554,DB02377,Guanine
,1847004,steady-state trough,"The mean +/- SD plasma levels for the 200 and 400 mg groups, respectively, were: first dose peak, 1.7 +/- 0.6 and 2.3 +/- 1.0 mumol/L; steady-state trough, 0.7 +/- 0.3 and 0.8 +/- 0.6 mumol/L; steady-state peak, 1.9 +/- 1.0 and 3.3 +/- 1.0 mumol/L.",Pharmacokinetics of acyclovir in the term human pregnancy and neonate. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1847004/),[μM] / [l],0.8,200555,DB02377,Guanine
,1847004,steady-state peak,"The mean +/- SD plasma levels for the 200 and 400 mg groups, respectively, were: first dose peak, 1.7 +/- 0.6 and 2.3 +/- 1.0 mumol/L; steady-state trough, 0.7 +/- 0.3 and 0.8 +/- 0.6 mumol/L; steady-state peak, 1.9 +/- 1.0 and 3.3 +/- 1.0 mumol/L.",Pharmacokinetics of acyclovir in the term human pregnancy and neonate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1847004/),[μM] / [l],1.9,200556,DB02377,Guanine
,1847004,steady-state peak,"The mean +/- SD plasma levels for the 200 and 400 mg groups, respectively, were: first dose peak, 1.7 +/- 0.6 and 2.3 +/- 1.0 mumol/L; steady-state trough, 0.7 +/- 0.3 and 0.8 +/- 0.6 mumol/L; steady-state peak, 1.9 +/- 1.0 and 3.3 +/- 1.0 mumol/L.",Pharmacokinetics of acyclovir in the term human pregnancy and neonate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1847004/),[μM] / [l],3.3,200557,DB02377,Guanine
,1847004,maternal/infant,"Acyclovir was concentrated in the amniotic fluid; however, there was no accumulation in the fetus (mean maternal/infant plasma ratio at delivery was 1.3).",Pharmacokinetics of acyclovir in the term human pregnancy and neonate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1847004/),,1.3,200558,DB02377,Guanine
,1847004,plasma ratio,"Acyclovir was concentrated in the amniotic fluid; however, there was no accumulation in the fetus (mean maternal/infant plasma ratio at delivery was 1.3).",Pharmacokinetics of acyclovir in the term human pregnancy and neonate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1847004/),,1.3,200559,DB02377,Guanine
>,8674155,t1/2,"HPLC analysis showed that ET-729 was stable in organic solvents, mobile phase and acidic buffer (t1/2 > 100 h).","Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674155/),h,100,200868,DB02377,Guanine
<,8674155,t1/2,Stability was diminished under neutral and basic conditions (t1/2 < 14 h).,"Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674155/),h,14,200869,DB02377,Guanine
,8674155,50% growth inhibitory concentrations (IC50),"Following a 48-h incubation with L1210 cells in growth medium in the absence and presence of 2.5% murine plasma, the 50% growth inhibitory concentrations (IC50) of ET-729 were 37 and 72 pM, respectively.","Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674155/),pM,37,200870,DB02377,Guanine
,8674155,50% growth inhibitory concentrations (IC50),"Following a 48-h incubation with L1210 cells in growth medium in the absence and presence of 2.5% murine plasma, the 50% growth inhibitory concentrations (IC50) of ET-729 were 37 and 72 pM, respectively.","Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674155/),pM,72,200871,DB02377,Guanine
,8674155,elimination half-life,"The mean values of the elimination half-life and plasma clearance were 28 min and 39.7 ml/min per kg, respectively.","Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674155/),min,28,200872,DB02377,Guanine
,8674155,plasma clearance,"The mean values of the elimination half-life and plasma clearance were 28 min and 39.7 ml/min per kg, respectively.","Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674155/),[ml] / [kg·min],39.7,200873,DB02377,Guanine
,8674155,Intraperitoneal bioavailability,Intraperitoneal bioavailability varied over a wide range (20-91%).,"Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674155/),%,20-91,200874,DB02377,Guanine
less,8674155,total 48-h urinary recovery,"Antiproliferative activity was detected in every urine sample following intravenous and intraperitoneal administration, but the total 48-h urinary recovery was less than 0.1%.","Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674155/),%,0.1,200875,DB02377,Guanine
,6355048,T1/2 beta,"For patients with normal renal function (creatinine clearance (Clcr) greater than 80 ml/min/1.73m2) mean T1/2 beta and Cltot were 2.5 h and 327 ml/min/1.73 m2, respectively.",Pharmacokinetics of acyclovir after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6355048/),h,2.5,201206,DB02377,Guanine
,6355048,Cltot,"For patients with normal renal function (creatinine clearance (Clcr) greater than 80 ml/min/1.73m2) mean T1/2 beta and Cltot were 2.5 h and 327 ml/min/1.73 m2, respectively.",Pharmacokinetics of acyclovir after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6355048/),[ml] / [1.73·m2·min],327,201207,DB02377,Guanine
,6355048,bioavailability,"After oral administration, the bioavailability of acyclovir was approximately 20%.(ABSTRACT TRUNCATED AT 250 WORDS)",Pharmacokinetics of acyclovir after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6355048/),%,20,201208,DB02377,Guanine
,12019194,flow rate,The probes were perfused with isotonic phosphate buffer saline (pH 7.4) at a flow rate of 2 microl/min.,Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019194/),[μl] / [min],2,201249,DB02377,Guanine
,12019194,terminal elimination half-life (t(1/2)beta),The vitreal terminal elimination half-life (t(1/2)beta) of GCV was found to be 426 +/- 109 min.,Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019194/),min,426,201250,DB02377,Guanine
,12019194,elimination half-lives (t(1/2k10)),"The vitreal elimination half-lives (t(1/2k10)) of GCV, acetate, propionate, butyrate, and valerate esters of GCV were 170 +/- 37, 117 +/- 50, 122 +/- 13, 55 +/- 26, and 107 +/- 14 min, respectively.",Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019194/),min,170,201251,DB02377,Guanine
,12019194,elimination half-lives (t(1/2k10)),"The vitreal elimination half-lives (t(1/2k10)) of GCV, acetate, propionate, butyrate, and valerate esters of GCV were 170 +/- 37, 117 +/- 50, 122 +/- 13, 55 +/- 26, and 107 +/- 14 min, respectively.",Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019194/),min,117,201252,DB02377,Guanine
,12019194,elimination half-lives (t(1/2k10)),"The vitreal elimination half-lives (t(1/2k10)) of GCV, acetate, propionate, butyrate, and valerate esters of GCV were 170 +/- 37, 117 +/- 50, 122 +/- 13, 55 +/- 26, and 107 +/- 14 min, respectively.",Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019194/),min,122,201253,DB02377,Guanine
,12019194,elimination half-lives (t(1/2k10)),"The vitreal elimination half-lives (t(1/2k10)) of GCV, acetate, propionate, butyrate, and valerate esters of GCV were 170 +/- 37, 117 +/- 50, 122 +/- 13, 55 +/- 26, and 107 +/- 14 min, respectively.",Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019194/),min,55,201254,DB02377,Guanine
,12019194,elimination half-lives (t(1/2k10)),"The vitreal elimination half-lives (t(1/2k10)) of GCV, acetate, propionate, butyrate, and valerate esters of GCV were 170 +/- 37, 117 +/- 50, 122 +/- 13, 55 +/- 26, and 107 +/- 14 min, respectively.",Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019194/),min,107,201255,DB02377,Guanine
,7102704,plasma half-life,The overall mean acyclovir plasma half-life and total body clearance +/- SD were 2.1 +/- 0.5 hours and 297 +/- 53 ml/min/1.73 m2.,Metabolic fate of radioactive acyclovir in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102704/),h,2.1,203836,DB02377,Guanine
,7102704,total body clearance,The overall mean acyclovir plasma half-life and total body clearance +/- SD were 2.1 +/- 0.5 hours and 297 +/- 53 ml/min/1.73 m2.,Metabolic fate of radioactive acyclovir in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102704/),[ml] / [1.73·m2·min],297,203837,DB02377,Guanine
,7102704,Binding,Binding of acyclovir to plasma proteins was 15.4 +/- 4.4 percent.,Metabolic fate of radioactive acyclovir in humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102704/),%,15.4,203838,DB02377,Guanine
,11389118,AUC0-8,"The mean (s.d.) values for aciclovir after oral valaciclovir and iv aciclovir were: AUC0-8 76.3 (29.7) and 64.2 (20.0) microM x h; peak plasma concentration (Cmax) 26.6 (10.5) and 34.0 (11.9) microM; time to maximal plasma concentration (tmax) 2.01 (0.65) and 0.95 (0.19); and plasma elimination half-life (t1/2) 2.83 (0.91) and 2.44 (0.62) h, respectively.",Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389118/),h·μM,76.3,204076,DB02377,Guanine
,11389118,AUC0-8,"The mean (s.d.) values for aciclovir after oral valaciclovir and iv aciclovir were: AUC0-8 76.3 (29.7) and 64.2 (20.0) microM x h; peak plasma concentration (Cmax) 26.6 (10.5) and 34.0 (11.9) microM; time to maximal plasma concentration (tmax) 2.01 (0.65) and 0.95 (0.19); and plasma elimination half-life (t1/2) 2.83 (0.91) and 2.44 (0.62) h, respectively.",Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389118/),h·μM,64.2,204077,DB02377,Guanine
,11389118,peak plasma concentration (Cmax),"The mean (s.d.) values for aciclovir after oral valaciclovir and iv aciclovir were: AUC0-8 76.3 (29.7) and 64.2 (20.0) microM x h; peak plasma concentration (Cmax) 26.6 (10.5) and 34.0 (11.9) microM; time to maximal plasma concentration (tmax) 2.01 (0.65) and 0.95 (0.19); and plasma elimination half-life (t1/2) 2.83 (0.91) and 2.44 (0.62) h, respectively.",Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389118/),μM,26.6,204078,DB02377,Guanine
,11389118,peak plasma concentration (Cmax),"The mean (s.d.) values for aciclovir after oral valaciclovir and iv aciclovir were: AUC0-8 76.3 (29.7) and 64.2 (20.0) microM x h; peak plasma concentration (Cmax) 26.6 (10.5) and 34.0 (11.9) microM; time to maximal plasma concentration (tmax) 2.01 (0.65) and 0.95 (0.19); and plasma elimination half-life (t1/2) 2.83 (0.91) and 2.44 (0.62) h, respectively.",Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389118/),μM,34.0,204079,DB02377,Guanine
,11389118,time to maximal plasma concentration (tmax),"The mean (s.d.) values for aciclovir after oral valaciclovir and iv aciclovir were: AUC0-8 76.3 (29.7) and 64.2 (20.0) microM x h; peak plasma concentration (Cmax) 26.6 (10.5) and 34.0 (11.9) microM; time to maximal plasma concentration (tmax) 2.01 (0.65) and 0.95 (0.19); and plasma elimination half-life (t1/2) 2.83 (0.91) and 2.44 (0.62) h, respectively.",Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389118/),,2.01,204080,DB02377,Guanine
,11389118,time to maximal plasma concentration (tmax),"The mean (s.d.) values for aciclovir after oral valaciclovir and iv aciclovir were: AUC0-8 76.3 (29.7) and 64.2 (20.0) microM x h; peak plasma concentration (Cmax) 26.6 (10.5) and 34.0 (11.9) microM; time to maximal plasma concentration (tmax) 2.01 (0.65) and 0.95 (0.19); and plasma elimination half-life (t1/2) 2.83 (0.91) and 2.44 (0.62) h, respectively.",Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389118/),h,0.95,204081,DB02377,Guanine
,11389118,plasma elimination half-life (t1/2),"The mean (s.d.) values for aciclovir after oral valaciclovir and iv aciclovir were: AUC0-8 76.3 (29.7) and 64.2 (20.0) microM x h; peak plasma concentration (Cmax) 26.6 (10.5) and 34.0 (11.9) microM; time to maximal plasma concentration (tmax) 2.01 (0.65) and 0.95 (0.19); and plasma elimination half-life (t1/2) 2.83 (0.91) and 2.44 (0.62) h, respectively.",Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389118/),h,2.83,204082,DB02377,Guanine
,11389118,plasma elimination half-life (t1/2),"The mean (s.d.) values for aciclovir after oral valaciclovir and iv aciclovir were: AUC0-8 76.3 (29.7) and 64.2 (20.0) microM x h; peak plasma concentration (Cmax) 26.6 (10.5) and 34.0 (11.9) microM; time to maximal plasma concentration (tmax) 2.01 (0.65) and 0.95 (0.19); and plasma elimination half-life (t1/2) 2.83 (0.91) and 2.44 (0.62) h, respectively.",Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389118/),h,2.44,204083,DB02377,Guanine
,11389118,absolute bioavailability,The mean absolute bioavailability of aciclovir from oral valaciclovir was 60 +/- 21%.,Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389118/),%,60,204084,DB02377,Guanine
,11920787,bioavailability,The bioavailability of acyclovir after oral administration of valacyclovir was 45% (median value; 95% CI: 37-55%).,Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920787/),%,45,204919,DB02377,Guanine
,7492090,half-life,The pharmacokinetics of compound 2242 in 10 rabbits injected intravitreally with 30 microM showed an intravitreal half-life of 8 h.,"Evaluation of retinal toxicity and efficacy of the anticytomegalovirus compound 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7492090/),h,8,205626,DB02377,Guanine
,24215288,relative bioavailability,"In vivo pharmacokinetic data signify increased rate and extent of acyclovir absorption (relative bioavailability ∼160%; p < 0.0001) from inclusion complex, compared to physical mixture.",Enhanced oral bioavailability of acyclovir by inclusion complex using hydroxypropyl-β-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24215288/),%,∼160,206731,DB02377,Guanine
,2298719,half-time of elimination,The results with or without PE were not significantly different: half-time of elimination 3 vs.,Acyclovir pharmacokinetics in plasmapheresis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298719/),,3,208003,DB02377,Guanine
,2298719,volume of distribution,"2.3 h, volume of distribution 1.8 vs.",Acyclovir pharmacokinetics in plasmapheresis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298719/),,1.8,208004,DB02377,Guanine
,2298719,total clearance,"1.14 liter/kg, and total clearance 404 vs. 314 ml/min.",Acyclovir pharmacokinetics in plasmapheresis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298719/),[ml] / [min],404,208005,DB02377,Guanine
,2298719,total clearance,"1.14 liter/kg, and total clearance 404 vs. 314 ml/min.",Acyclovir pharmacokinetics in plasmapheresis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298719/),[ml] / [min],314,208006,DB02377,Guanine
,2298719,clearance,"The clearance and the fraction of elimination due to PE were 5.27 ml/min and 2.5%, respectively.",Acyclovir pharmacokinetics in plasmapheresis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298719/),[ml] / [min],5.27,208007,DB02377,Guanine
,2298719,fraction of elimination,"The clearance and the fraction of elimination due to PE were 5.27 ml/min and 2.5%, respectively.",Acyclovir pharmacokinetics in plasmapheresis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298719/),%,2.5,208008,DB02377,Guanine
,19247087,C(max),The C(max) was significantly lower after intrapleural versus intravenous administration of 10 mg/kg pemetrexed (14.36 microg/ml versus 29.83 microg/ml; p = 0.008) or 100 mg/kg pemetrexed (70.64 microg/ml versus 218.64 microg/ml; p = 0.001).,Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19247087/),[μg] / [ml],14.36,208888,DB02377,Guanine
,19247087,C(max),The C(max) was significantly lower after intrapleural versus intravenous administration of 10 mg/kg pemetrexed (14.36 microg/ml versus 29.83 microg/ml; p = 0.008) or 100 mg/kg pemetrexed (70.64 microg/ml versus 218.64 microg/ml; p = 0.001).,Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19247087/),[μg] / [ml],29.83,208889,DB02377,Guanine
,19247087,C(max),The C(max) was significantly lower after intrapleural versus intravenous administration of 10 mg/kg pemetrexed (14.36 microg/ml versus 29.83 microg/ml; p = 0.008) or 100 mg/kg pemetrexed (70.64 microg/ml versus 218.64 microg/ml; p = 0.001).,Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19247087/),[μg] / [ml],70.64,208890,DB02377,Guanine
,19247087,C(max),The C(max) was significantly lower after intrapleural versus intravenous administration of 10 mg/kg pemetrexed (14.36 microg/ml versus 29.83 microg/ml; p = 0.008) or 100 mg/kg pemetrexed (70.64 microg/ml versus 218.64 microg/ml; p = 0.001).,Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19247087/),[μg] / [ml],218.64,208891,DB02377,Guanine
,31561135,AUC1,"Patients with severe chemotherapy-related AEs (n = 55) had significantly higher AUC1 values than patients without them (n = 51) (226 ± 53 vs 190 ± 31, p < 0.001).",Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31561135/),,226,209616,DB02377,Guanine
,31561135,AUC1,"Patients with severe chemotherapy-related AEs (n = 55) had significantly higher AUC1 values than patients without them (n = 51) (226 ± 53 vs 190 ± 31, p < 0.001).",Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31561135/),,190,209617,DB02377,Guanine
,15871635,area under the plasma concentration-time curve,"Exposure to ganciclovir from valganciclovir averaged 1.65-fold greater than that from oral ganciclovir (95% CI 1.58, 1.81); respective daily area under the plasma concentration-time curve values were 46.3 +/- 15.2 microg .","Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871635/),μg,46.3,210176,DB02377,Guanine
,15871635,Expo,"Exposure to ganciclovir from valganciclovir was similar among liver, heart and kidney transplant recipients (46.0 +/- 16.1, 40.2 +/- 11.8 and 48.2 +/- 14.6 microg . h/ mL, respectively).","Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871635/),[h·μg] / [ml],46.0,210177,DB02377,Guanine
,15871635,Expo,"Exposure to ganciclovir from valganciclovir was similar among liver, heart and kidney transplant recipients (46.0 +/- 16.1, 40.2 +/- 11.8 and 48.2 +/- 14.6 microg . h/ mL, respectively).","Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871635/),[h·μg] / [ml],40.2,210178,DB02377,Guanine
,15871635,Expo,"Exposure to ganciclovir from valganciclovir was similar among liver, heart and kidney transplant recipients (46.0 +/- 16.1, 40.2 +/- 11.8 and 48.2 +/- 14.6 microg . h/ mL, respectively).","Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871635/),[h·μg] / [ml],48.2,210179,DB02377,Guanine
,11078617,area under the curve (AUC),When MTA was delivered at 10 mg/kg the area under the curve (AUC) of the peritoneal fluid was significantly higher with intraperitoneal administration (10 778 microg/mlxmin) compared to intravenous administration (454 microg/mlxmin) (P<0.0001).,Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11078617/),[μg] / [min·ml],10 778,212451,DB02377,Guanine
,11078617,area under the curve (AUC),When MTA was delivered at 10 mg/kg the area under the curve (AUC) of the peritoneal fluid was significantly higher with intraperitoneal administration (10 778 microg/mlxmin) compared to intravenous administration (454 microg/mlxmin) (P<0.0001).,Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11078617/),[μg] / [min·ml],454,212452,DB02377,Guanine
,11078617,AUC ratio (AUC peritoneal fluid/AUC plasma),The AUC ratio (AUC peritoneal fluid/AUC plasma) was 40.8 for intraperitoneal delivery as opposed to 0.014 for intravenous delivery (P=0.0063).,Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11078617/),,40.8,212453,DB02377,Guanine
,11078617,AUC ratio (AUC peritoneal fluid/AUC plasma),The AUC ratio (AUC peritoneal fluid/AUC plasma) was 40.8 for intraperitoneal delivery as opposed to 0.014 for intravenous delivery (P=0.0063).,Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11078617/),,0.014,212454,DB02377,Guanine
,11078617,AUC ratio,The AUC ratio for intraperitoneal MTA at 100 mg/kg was 19.2.,Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11078617/),,19.2,212455,DB02377,Guanine
,11078617,half-life,The half-life of MTA in the peritoneal fluid after intraperitoneal infusion was approximately 2 hours.,Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11078617/),h,2,212456,DB02377,Guanine
,8149891,urinary excretion,"The mean urinary excretion of radioactivity following oral and intravenous administration of [8-14C]valaciclovir (25 mg/kg) was 65% and 95% of the dose, respectively.",Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149891/),%,65,213263,DB02377,Guanine
,8149891,urinary excretion,"The mean urinary excretion of radioactivity following oral and intravenous administration of [8-14C]valaciclovir (25 mg/kg) was 65% and 95% of the dose, respectively.",Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149891/),%,95,213264,DB02377,Guanine
,8149891,half-life,"The half-life of acyclovir derived from valaciclovir was approximately 1 hr, whereas that of valaciclovir was approximately 7 min.",Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149891/),h,1,213265,DB02377,Guanine
,8149891,half-life,"The half-life of acyclovir derived from valaciclovir was approximately 1 hr, whereas that of valaciclovir was approximately 7 min.",Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149891/),min,7,213266,DB02377,Guanine
,11707060,elimination half-life (t1/2beta),"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1.5 to 4,214390,DB02377,Guanine
,11707060,biological half-lives,"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,12 to 36,214391,DB02377,Guanine
,11707060,t1/2beta,"Rapid acetylation in the intestinal wall and liver (t1/2beta 0.5 to 2 hours) and transport probably by P-glycoprotein affect mucosal concentrations of mesalazine, which apparently determine clinical response.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,0.5 to 2,214392,DB02377,Guanine
,11707060,oral bioavailability,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),%,90,214393,DB02377,Guanine
,11707060,t1/2beta,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,6 to 10,214394,DB02377,Guanine
,11707060,total clearance,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],4,214395,DB02377,Guanine
,11707060,t1/2beta,"Ciprofloxacin is largely excreted unchanged both renally (about 45% of dose) and extrarenally (25%), with a relatively short t1/2beta (3.5 to 7 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,3.5 to 7,214396,DB02377,Guanine
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1 to 2,214397,DB02377,Guanine
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,3 to 13,214398,DB02377,Guanine
up to,11707060,t1/2beta,"Almost complete bioavailability has been observed after intramuscular and subcutaneous administration of methotrexate, which is predominantly (85%) excreted as unchanged drug with a t1/2beta of up to 50 hours.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,50,214399,DB02377,Guanine
,11707060,t1/2beta,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214400,DB02377,Guanine
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214401,DB02377,Guanine
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],0.46,214402,DB02377,Guanine
,11707060,t1/2beta,Infliximab is predominantly distributed to the vascular compartment and eliminated with a t1/2beta between 10 and 14 days.,Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,10 and 14,214403,DB02377,Guanine
,22738064,maximum plasma concentration (C(max)),"Mean ± SD maximum plasma concentration (C(max)) of penciclovir following oral administration of 40 and 90 mg of famciclovir/kg was 1.34 ± 0.33 μg/mL and 1.28 ± 0.42 μg/mL and occurred at 2.8 ± 1.8 hours and 3.0 ± 1.1 hours, respectively; penciclovir elimination half-life was 4.2 ± 0.6 hours and 4.8 ± 1.4 hours, respectively; and penciclovir bioavailability was 12.5 ± 3.0% and 7.0 ± 1.8%, respectively.",Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738064/),[μg] / [ml],1.34,214887,DB02377,Guanine
,22738064,maximum plasma concentration (C(max)),"Mean ± SD maximum plasma concentration (C(max)) of penciclovir following oral administration of 40 and 90 mg of famciclovir/kg was 1.34 ± 0.33 μg/mL and 1.28 ± 0.42 μg/mL and occurred at 2.8 ± 1.8 hours and 3.0 ± 1.1 hours, respectively; penciclovir elimination half-life was 4.2 ± 0.6 hours and 4.8 ± 1.4 hours, respectively; and penciclovir bioavailability was 12.5 ± 3.0% and 7.0 ± 1.8%, respectively.",Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738064/),[μg] / [ml],1.28,214888,DB02377,Guanine
,22738064,elimination half-life,"Mean ± SD maximum plasma concentration (C(max)) of penciclovir following oral administration of 40 and 90 mg of famciclovir/kg was 1.34 ± 0.33 μg/mL and 1.28 ± 0.42 μg/mL and occurred at 2.8 ± 1.8 hours and 3.0 ± 1.1 hours, respectively; penciclovir elimination half-life was 4.2 ± 0.6 hours and 4.8 ± 1.4 hours, respectively; and penciclovir bioavailability was 12.5 ± 3.0% and 7.0 ± 1.8%, respectively.",Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738064/),h,4.2,214889,DB02377,Guanine
,22738064,elimination half-life,"Mean ± SD maximum plasma concentration (C(max)) of penciclovir following oral administration of 40 and 90 mg of famciclovir/kg was 1.34 ± 0.33 μg/mL and 1.28 ± 0.42 μg/mL and occurred at 2.8 ± 1.8 hours and 3.0 ± 1.1 hours, respectively; penciclovir elimination half-life was 4.2 ± 0.6 hours and 4.8 ± 1.4 hours, respectively; and penciclovir bioavailability was 12.5 ± 3.0% and 7.0 ± 1.8%, respectively.",Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738064/),h,4.8,214890,DB02377,Guanine
,22738064,bioavailability,"Mean ± SD maximum plasma concentration (C(max)) of penciclovir following oral administration of 40 and 90 mg of famciclovir/kg was 1.34 ± 0.33 μg/mL and 1.28 ± 0.42 μg/mL and occurred at 2.8 ± 1.8 hours and 3.0 ± 1.1 hours, respectively; penciclovir elimination half-life was 4.2 ± 0.6 hours and 4.8 ± 1.4 hours, respectively; and penciclovir bioavailability was 12.5 ± 3.0% and 7.0 ± 1.8%, respectively.",Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738064/),%,12.5,214891,DB02377,Guanine
,22738064,bioavailability,"Mean ± SD maximum plasma concentration (C(max)) of penciclovir following oral administration of 40 and 90 mg of famciclovir/kg was 1.34 ± 0.33 μg/mL and 1.28 ± 0.42 μg/mL and occurred at 2.8 ± 1.8 hours and 3.0 ± 1.1 hours, respectively; penciclovir elimination half-life was 4.2 ± 0.6 hours and 4.8 ± 1.4 hours, respectively; and penciclovir bioavailability was 12.5 ± 3.0% and 7.0 ± 1.8%, respectively.",Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738064/),%,7.0,214892,DB02377,Guanine
,22738064,clearance,"Following IV infusion of penciclovir (10 mg/kg), mean ± SD penciclovir clearance, volume of distribution, and elimination half-life were 4.3 ± 0.8 mL/min/kg, 0.6 ± 0.1 L/kg, and 1.9 ± 0.4 hours, respectively.",Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738064/),[ml] / [kg·min],4.3,214893,DB02377,Guanine
,22738064,volume of distribution,"Following IV infusion of penciclovir (10 mg/kg), mean ± SD penciclovir clearance, volume of distribution, and elimination half-life were 4.3 ± 0.8 mL/min/kg, 0.6 ± 0.1 L/kg, and 1.9 ± 0.4 hours, respectively.",Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738064/),[l] / [kg],0.6,214894,DB02377,Guanine
,22738064,elimination half-life,"Following IV infusion of penciclovir (10 mg/kg), mean ± SD penciclovir clearance, volume of distribution, and elimination half-life were 4.3 ± 0.8 mL/min/kg, 0.6 ± 0.1 L/kg, and 1.9 ± 0.4 hours, respectively.",Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738064/),h,1.9,214895,DB02377,Guanine
,11810093,peak breast milk concentration,The peak serum acyclovir concentration occurred 3 hours before the peak breast milk concentration (2.7 microg/mL at 1 hour vs 4.2 microg/mL at 4 hours).,Acyclovir concentrations in human breast milk after valaciclovir administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11810093/),[μg] / [ml],2.7,214918,DB02377,Guanine
,11810093,peak breast milk concentration,The peak serum acyclovir concentration occurred 3 hours before the peak breast milk concentration (2.7 microg/mL at 1 hour vs 4.2 microg/mL at 4 hours).,Acyclovir concentrations in human breast milk after valaciclovir administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11810093/),[μg] / [ml],4.2,214919,DB02377,Guanine
,11810093,elimination half-life,The serum acyclovir elimination half-life was 2.3 hours.,Acyclovir concentrations in human breast milk after valaciclovir administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11810093/),h,2.3,214920,DB02377,Guanine
,11810093,concentration at steady state,The median infant urine acyclovir concentration at steady state was 0.74 microg/mL.,Acyclovir concentrations in human breast milk after valaciclovir administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11810093/),[μg] / [ml],0.74,214921,DB02377,Guanine
,30081070,T85%,The plasma concentration-time profiles of valacyclovir and its metabolite acyclovir were not sensitive to dissolution rate faster than T85% = 120 min.,A physiologically based pharmacokinetic model for valacyclovir established based on absolute expression quantity of hPEPT1 and its application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30081070/),min,120,215773,DB02377,Guanine
,22492020,maximum tolerated dose,The maximum tolerated dose was defined as 150 mg/m(2).,"Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22492020/),[mg] / [m],150,216549,DB02377,Guanine
,21323897,AUC,The median AUC per mg 6-TG was 1068 (p.o.) and 7184 (i.v.) pmol·h (8 × 10(8) RBC)(-1) .,Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323897/),(·h·pM,1068,217132,DB02377,Guanine
,21323897,AUC,The median AUC per mg 6-TG was 1068 (p.o.) and 7184 (i.v.) pmol·h (8 × 10(8) RBC)(-1) .,Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323897/),(·h·pM,7184,217133,DB02377,Guanine
,25349125,areas under the concentration curve,"The areas under the concentration curve of unbound GCV in blood, brain extracellular fluid (ECF), and tumor ECF were 6157, 1658, and 4834 μM⋅min, respectively.",Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349125/),min·μM,6157,217339,DB02377,Guanine
,25349125,areas under the concentration curve,"The areas under the concentration curve of unbound GCV in blood, brain extracellular fluid (ECF), and tumor ECF were 6157, 1658, and 4834 μM⋅min, respectively.",Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349125/),min·μM,1658,217340,DB02377,Guanine
,25349125,areas under the concentration curve,"The areas under the concentration curve of unbound GCV in blood, brain extracellular fluid (ECF), and tumor ECF were 6157, 1658, and 4834 μM⋅min, respectively.",Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349125/),min·μM,4834,217341,DB02377,Guanine
,25349125,apparent maximum unbound concentrations,"The apparent maximum unbound concentrations achieved within 60 minutes were 46.9, 11.8, and 25.8 μM in blood, brain, and tumor, respectively.",Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349125/),μM,46.9,217342,DB02377,Guanine
,25349125,apparent maximum unbound concentrations,"The apparent maximum unbound concentrations achieved within 60 minutes were 46.9, 11.8, and 25.8 μM in blood, brain, and tumor, respectively.",Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349125/),μM,11.8,217343,DB02377,Guanine
,25349125,apparent maximum unbound concentrations,"The apparent maximum unbound concentrations achieved within 60 minutes were 46.9, 11.8, and 25.8 μM in blood, brain, and tumor, respectively.",Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349125/),μM,25.8,217344,DB02377,Guanine
,25349125,unbound,"The unbound GCV concentrations in brain and tumor after in situ rat brain perfusion were 0.41 and 1.39 nmol/g, respectively.",Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349125/),nm,0.41,217345,DB02377,Guanine
,25349125,unbound,"The unbound GCV concentrations in brain and tumor after in situ rat brain perfusion were 0.41 and 1.39 nmol/g, respectively.",Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349125/),nm,1.39,217346,DB02377,Guanine
,25349125,concentrations,"The unbound GCV concentrations in brain and tumor after in situ rat brain perfusion were 0.41 and 1.39 nmol/g, respectively.",Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349125/),nm,0.41,217347,DB02377,Guanine
,25349125,concentrations,"The unbound GCV concentrations in brain and tumor after in situ rat brain perfusion were 0.41 and 1.39 nmol/g, respectively.",Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349125/),nm,1.39,217348,DB02377,Guanine
,25349125,uptake,"However, GCV uptake into BT4C cells at 100 μM was only 2.1 pmol/mg of protein, and no active transporter-mediated disposition of GCV could be detected in vitro.",Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349125/),[pM] / [mg],2.1,217349,DB02377,Guanine
,15505067,area under concentration-time curve (AUC),"Microfluidized particles of HDP-P-GCV showed an increased drug release rate compared with the large-particle drug formulation, with area under concentration-time curve (AUC) of 219.8 +/- 114.1 (n=3) versus 108.3 +/- 47.2 (n=3) for unmodified HDP-P-GCV during the 12-week period after a 2.8-micromole intravitreal injection.",Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505067/),,219.8,218100,DB02377,Guanine
,15505067,area under concentration-time curve (AUC),"Microfluidized particles of HDP-P-GCV showed an increased drug release rate compared with the large-particle drug formulation, with area under concentration-time curve (AUC) of 219.8 +/- 114.1 (n=3) versus 108.3 +/- 47.2 (n=3) for unmodified HDP-P-GCV during the 12-week period after a 2.8-micromole intravitreal injection.",Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505067/),,108.3,218101,DB02377,Guanine
,15505067,IC50,The concentration at week 8 (0.002 microM) remained above the IC50 for cytomegalovirus (0.0003 microM).,Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505067/),μM,0.0003,218102,DB02377,Guanine
,16855840,distribution half-life,Pemetrexed disappearance from plasma was best described by a two compartment model with a mean distribution half-life of 13.8 +/- 3.2 min and an elimination half-life of 70.0 +/- 16.0 min.,Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855840/),min,13.8,219681,DB02377,Guanine
,16855840,elimination half-life,Pemetrexed disappearance from plasma was best described by a two compartment model with a mean distribution half-life of 13.8 +/- 3.2 min and an elimination half-life of 70.0 +/- 16.0 min.,Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855840/),min,70.0,219682,DB02377,Guanine
,16855840,volume of distribution of,"The volume of distribution of and the clearance from the central compartment were 0.066 +/- 0.017 l/kg and 3.6 +/- 0.6 ml/min/kg, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855840/),[l] / [kg],0.066,219683,DB02377,Guanine
,16855840,clearance from the central compartment,"The volume of distribution of and the clearance from the central compartment were 0.066 +/- 0.017 l/kg and 3.6 +/- 0.6 ml/min/kg, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855840/),[ml] / [kg·min],3.6,219684,DB02377,Guanine
,16855840,Peak CSF concentrations,Peak CSF concentrations occurred 40-71 min after the start of the infusion with an average of 0.26 +/- 0.15 microM.,Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855840/),μM,0.26,219685,DB02377,Guanine
,19853420,C(max),"The mean C(max) of F2, F5, and Zovirax were 0.61+/-0.06, 0.73+/-0.07 and 0.92+/-0.21 microg/ml respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [ml],0.61,219981,DB02377,Guanine
,19853420,C(max),"The mean C(max) of F2, F5, and Zovirax were 0.61+/-0.06, 0.73+/-0.07 and 0.92+/-0.21 microg/ml respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [ml],0.73,219982,DB02377,Guanine
,19853420,C(max),"The mean C(max) of F2, F5, and Zovirax were 0.61+/-0.06, 0.73+/-0.07 and 0.92+/-0.21 microg/ml respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [ml],0.92,219983,DB02377,Guanine
,19853420,AUC(0-12),"Furthermore, the AUC(0-12) of F2 and F5 was significantly higher than that of Zovirax((R)) with values of 4.37+/-0.88, 5.14+/-0.87 and 3.21+/-0.53 microg/ml h respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [h·ml],4.37,219984,DB02377,Guanine
,19853420,AUC(0-12),"Furthermore, the AUC(0-12) of F2 and F5 was significantly higher than that of Zovirax((R)) with values of 4.37+/-0.88, 5.14+/-0.87 and 3.21+/-0.53 microg/ml h respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [h·ml],5.14,219985,DB02377,Guanine
,19853420,AUC(0-12),"Furthermore, the AUC(0-12) of F2 and F5 was significantly higher than that of Zovirax((R)) with values of 4.37+/-0.88, 5.14+/-0.87 and 3.21+/-0.53 microg/ml h respectively.",Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),[μg] / [h·ml],3.21,219986,DB02377,Guanine
,19853420,relative bioavailability,The higher AUC(0-12) for both F2 and F5 reflected high relative bioavailability of 136.2% and 159.9% respectively compared to commercial ACV tablets.,Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),%,136.2,219987,DB02377,Guanine
,19853420,relative bioavailability,The higher AUC(0-12) for both F2 and F5 reflected high relative bioavailability of 136.2% and 159.9% respectively compared to commercial ACV tablets.,Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853420/),%,159.9,219988,DB02377,Guanine
,30169593,elimination half-life,"All patients discontinuing thiopurines displayed first-order elimination kinetics of 6-TGN, with a median elimination half-life of 6.8 days [interquartile range 5.9-8.4].",Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169593/),d,6.8,221293,DB02377,Guanine
less,30169593,elimination half-life,"Upon 6MP/azathioprine discontinuation, a 6-TGN elimination half-life of less than 10 days is expected in most patients.",Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169593/),d,10,221294,DB02377,Guanine
,1914362,bioavailability,"When ddI was given to fasting patients as an oral solution with antacid, the bioavailability was 41% +/- 7% (mean +/- SEM).","Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,41,222567,DB02377,Guanine
,1914362,bioavailability,"However, when given as buffered tablets, the bioavailability was considerably less (25% +/- 5%).","Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,25,222568,DB02377,Guanine
,1914362,bioavailability,The bioavailability increased slightly when the tablets were given with supplemental antacid (36% +/- 6%).,"Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,36,222569,DB02377,Guanine
,1914362,bioavailability,"Two enteric-coated preparations had reasonable bioavailability (36% +/- 5% and 26% +/- 5%), but the peak plasma level was much lower and occurred at a much later time than with the oral solution.","Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,36,222570,DB02377,Guanine
,1914362,bioavailability,"Two enteric-coated preparations had reasonable bioavailability (36% +/- 5% and 26% +/- 5%), but the peak plasma level was much lower and occurred at a much later time than with the oral solution.","Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,26,222571,DB02377,Guanine
,1914362,bioavailability,"When ddI was given as a premeasured powder containing sucrose and buffer to be reconstituted by the patient (the ""sachet"" preparation), the bioavailability was 29% +/- 6%.","Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,29,222572,DB02377,Guanine
,1914362,bioavailability,"However, the bioavailability of the sachet was only 17% +/- 4% when administered with food.","Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. The effects of different oral formulations and the presence of other medications. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914362/),%,17,222573,DB02377,Guanine
,24989332,MTD,The MTD of SS1P was established as 45 mcg/kg.,"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989332/),[mcg] / [kg],45,222694,DB02377,Guanine
,17081425,peak concentrations,"The peak concentrations of GCV in aqueous humors for GCV-ISG group and the GCV-ED group were 4.79 microg/ml and 0.96 microg/ml, respectively.",[Ocular pharmacokinetics and bioavailability of 0.2% ganciclovir in-situ gelling eye drops]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17081425/),[μg] / [ml],4.79,222818,DB02377,Guanine
,17081425,peak concentrations,"The peak concentrations of GCV in aqueous humors for GCV-ISG group and the GCV-ED group were 4.79 microg/ml and 0.96 microg/ml, respectively.",[Ocular pharmacokinetics and bioavailability of 0.2% ganciclovir in-situ gelling eye drops]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17081425/),[μg] / [ml],0.96,222819,DB02377,Guanine
,17081425,half-lives,"The half-lives of GCV in aqueous humors and corneas for GCV-ISG group were 59 minutes and 223 minutes, and for GCV-ED group were 43 minutes and 87 minutes, respectively.",[Ocular pharmacokinetics and bioavailability of 0.2% ganciclovir in-situ gelling eye drops]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17081425/),min,59,222820,DB02377,Guanine
,17081425,half-lives,"The half-lives of GCV in aqueous humors and corneas for GCV-ISG group were 59 minutes and 223 minutes, and for GCV-ED group were 43 minutes and 87 minutes, respectively.",[Ocular pharmacokinetics and bioavailability of 0.2% ganciclovir in-situ gelling eye drops]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17081425/),min,223,222821,DB02377,Guanine
,17081425,half-lives,"The half-lives of GCV in aqueous humors and corneas for GCV-ISG group were 59 minutes and 223 minutes, and for GCV-ED group were 43 minutes and 87 minutes, respectively.",[Ocular pharmacokinetics and bioavailability of 0.2% ganciclovir in-situ gelling eye drops]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17081425/),min,43,222822,DB02377,Guanine
,17081425,half-lives,"The half-lives of GCV in aqueous humors and corneas for GCV-ISG group were 59 minutes and 223 minutes, and for GCV-ED group were 43 minutes and 87 minutes, respectively.",[Ocular pharmacokinetics and bioavailability of 0.2% ganciclovir in-situ gelling eye drops]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17081425/),min,87,222823,DB02377,Guanine
,6549167,plasma elimination half life,A515U was rapidly cleared with a short plasma elimination half life of approximately 0.5 h.,"Tolerance and pharmacokinetics of A515U, an acyclovir analogue, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6549167/),h,0.5,222970,DB02377,Guanine
,7102701,peak levels,Peak plasma acyclovir levels are found 1.5 to 1.75 hours after oral administration; peak levels range from 1.4 to 4.0 microM with a mean of 2.5 microM.,Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102701/),μM,1.4 to 4.0,223152,DB02377,Guanine
,7102701,peak levels,Peak plasma acyclovir levels are found 1.5 to 1.75 hours after oral administration; peak levels range from 1.4 to 4.0 microM with a mean of 2.5 microM.,Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102701/),μM,2.5,223153,DB02377,Guanine
,7102701,peak levels,Simultaneous plasma and vaginal secretion acyclovir levels are poorly correlated; peak levels in vaginal secretions range from 0.5 to 3.6 microM.,Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102701/),μM,0.5 to 3.6,223154,DB02377,Guanine
,22658814,MTD,"Therefore, the MTD for BI 2536 in combination with pemetrexed was 300 mg.",A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22658814/),mg,300,223182,DB02377,Guanine
,17680662,apparent permeability coefficient (Papp),"We found that the apparent permeability coefficient (Papp) of GAN in absence of absorption enhancers (control) were 0.261 +/- 0.072 x 10(-6) and 0.486 +/- 0.063 x 10(-6) cm/s in Caco-2 and MDCK cell monolayers, respectively, whereas in the presence of DMbetaCD, CH, SLS, and their combinations, Papp of GAN increased by 5- to 25-fold and 7- to 33-fold as compared to control in Caco-2 and MDCK cell monolayers, respectively.",Modulation of ganciclovir intestinal absorption in presence of absorption enhancers. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17680662/),[cm] / [s],0.261,223502,DB02377,Guanine
,17680662,apparent permeability coefficient (Papp),"We found that the apparent permeability coefficient (Papp) of GAN in absence of absorption enhancers (control) were 0.261 +/- 0.072 x 10(-6) and 0.486 +/- 0.063 x 10(-6) cm/s in Caco-2 and MDCK cell monolayers, respectively, whereas in the presence of DMbetaCD, CH, SLS, and their combinations, Papp of GAN increased by 5- to 25-fold and 7- to 33-fold as compared to control in Caco-2 and MDCK cell monolayers, respectively.",Modulation of ganciclovir intestinal absorption in presence of absorption enhancers. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17680662/),[cm] / [s],0.486,223503,DB02377,Guanine
,12501905,t 1/2,The t 1/2 for the test (4.5 +/- 2.4 h) and Zoviraxl (3.9 +/- 2.6 h) were comparable.,Bioequivalence study of generic acyclovir compared with the brand name acyclovir. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501905/),h,4.5,224399,DB02377,Guanine
,12501905,t 1/2,The t 1/2 for the test (4.5 +/- 2.4 h) and Zoviraxl (3.9 +/- 2.6 h) were comparable.,Bioequivalence study of generic acyclovir compared with the brand name acyclovir. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501905/),h,3.9,224400,DB02377,Guanine
,12501905,Tmax,The analysis of variance was carried out and the median Tmax (1.50 h) for the test was not statistically difference from Zovirax.,Bioequivalence study of generic acyclovir compared with the brand name acyclovir. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501905/),h,1.50,224401,DB02377,Guanine
,1484085,determination limit,The determination limit is 6-10 ng/ml human plasma.,"New, high-sensitivity high-performance liquid chromatographic method for the determination of acyclovir in human plasma, using fluorometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484085/),[ng] / [ml],6-10,224785,DB02377,Guanine
,1484085,absolute recovery rate,The absolute recovery rate is between 102 and 113%.,"New, high-sensitivity high-performance liquid chromatographic method for the determination of acyclovir in human plasma, using fluorometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484085/),%,102 and 113,224786,DB02377,Guanine
,3026186,elimination half-life,The elimination half-life of ganciclovir from the vitreous was estimated to be 13.3 hours.,Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3026186/),h,13.3,225523,DB02377,Guanine
,22495424,area under the curve (AUC),A posterior dosage adaptation was required in children to achieve the daily target area under the curve (AUC) of 40-50 μg·h·mL(-1).,Individualization of valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495424/),[h·μg] / [ml],40-50,226397,DB02377,Guanine
,21515246,extraction recoveries,The extraction recoveries were around 85% for both the analytes.,Determination of valganciclovir and ganciclovir in human plasma by liquid chromatography tandem mass spectrometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21515246/),%,85,228888,DB02377,Guanine
,8149890,AUC,"Dose-independent kinetics were observed for acyclovir derived from orally administered [8-14C]valaciclovir at the 10 and 25 mg/kg dose levels, with both AUC (24 and 60 microM.hr, respectively) and Cmax (8 and 23 microM, respectively) increasing nearly in proportion to the dose.",Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149890/),h·μM,24,229282,DB02377,Guanine
,8149890,AUC,"Dose-independent kinetics were observed for acyclovir derived from orally administered [8-14C]valaciclovir at the 10 and 25 mg/kg dose levels, with both AUC (24 and 60 microM.hr, respectively) and Cmax (8 and 23 microM, respectively) increasing nearly in proportion to the dose.",Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149890/),h·μM,60,229283,DB02377,Guanine
,8149890,Cmax,"Dose-independent kinetics were observed for acyclovir derived from orally administered [8-14C]valaciclovir at the 10 and 25 mg/kg dose levels, with both AUC (24 and 60 microM.hr, respectively) and Cmax (8 and 23 microM, respectively) increasing nearly in proportion to the dose.",Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149890/),μM,8,229284,DB02377,Guanine
,8149890,Cmax,"Dose-independent kinetics were observed for acyclovir derived from orally administered [8-14C]valaciclovir at the 10 and 25 mg/kg dose levels, with both AUC (24 and 60 microM.hr, respectively) and Cmax (8 and 23 microM, respectively) increasing nearly in proportion to the dose.",Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149890/),μM,23,229285,DB02377,Guanine
,8149890,apparent half-life,"The elimination of acyclovir after oral administration was monophasic, with an apparent half-life of 1.3-1.5 hr.",Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149890/),h,1.3-1.5,229286,DB02377,Guanine
,8149890,apparent elimination half-lives,"Similar to acyclovir, both 8-hydroxyacyclovir and CMMG demonstrated dose-independent kinetics with apparent elimination half-lives of 1-1.6 hr.",Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149890/),h,1-1.6,229287,DB02377,Guanine
,8149890,elimination half-life,"Intravenously administered [8-14C]valaciclovir (10 mg/kg) was rapidly converted to acyclovir, with the elimination half-life of acyclovir (0.9 hr) being 1.5-fold that of the prodrug (0.6 hr).",Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149890/),h,0.9,229288,DB02377,Guanine
,8149890,elimination half-life,"Intravenously administered [8-14C]valaciclovir (10 mg/kg) was rapidly converted to acyclovir, with the elimination half-life of acyclovir (0.9 hr) being 1.5-fold that of the prodrug (0.6 hr).",Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149890/),h,0.6,229289,DB02377,Guanine
,8149890,oral bioavailability,"The oral bioavailability of acyclovir derived from valaciclovir in cynomolgus monkey was 67 +/- 13%, representing a significant improvement over the limited bioavailability after acyclovir administration to primates.",Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149890/),%,67,229290,DB02377,Guanine
,19646083,EC(50),"This dosage regimen resulted in plasma concentrations that were higher than the EC(50)-value of 1.7 microg/mL, i.e. EC(50) of an isolate highly susceptible to acyclovir, for 80% of the treatment period; and higher than the EC(50)-value of 3.0 microg/mL, i.e. EC(50) of an isolate less susceptible to acyclovir, for 60% of the treatment period.",Multiple oral dosing of valacyclovir in horses and ponies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646083/),[μg] / [ml],1.7,229469,DB02377,Guanine
,19646083,EC(50),"This dosage regimen resulted in plasma concentrations that were higher than the EC(50)-value of 1.7 microg/mL, i.e. EC(50) of an isolate highly susceptible to acyclovir, for 80% of the treatment period; and higher than the EC(50)-value of 3.0 microg/mL, i.e. EC(50) of an isolate less susceptible to acyclovir, for 60% of the treatment period.",Multiple oral dosing of valacyclovir in horses and ponies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646083/),[μg] / [ml],3.0,229470,DB02377,Guanine
,19646083,Concentration,"Concentration in nasal mucus samples and CSF was 0.36-1.17 microg/mL and 0.11-0.23 microg/mL, respectively.",Multiple oral dosing of valacyclovir in horses and ponies. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646083/),[μg] / [ml],0.36-1.17,229471,DB02377,Guanine
,19646083,Concentration,"Concentration in nasal mucus samples and CSF was 0.36-1.17 microg/mL and 0.11-0.23 microg/mL, respectively.",Multiple oral dosing of valacyclovir in horses and ponies. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19646083/),[μg] / [ml],0.11-0.23,229472,DB02377,Guanine
,11695713,bioavailability,"The bioavailability of sustained release tablets relative to conventional tablets following single and multiple dosing was 105.9 +/- 12.0% and 95.2 +/- 8.4%, respectively.",Pharmacokinetics and bioavailability of sustained release and conventional formulation of acyclovir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695713/),%,105.9,230082,DB02377,Guanine
,11695713,bioavailability,"The bioavailability of sustained release tablets relative to conventional tablets following single and multiple dosing was 105.9 +/- 12.0% and 95.2 +/- 8.4%, respectively.",Pharmacokinetics and bioavailability of sustained release and conventional formulation of acyclovir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695713/),%,95.2,230083,DB02377,Guanine
,8773936,half lives,"The vitreous elimination of ganciclovir (GCV) and acyclovir (ACV) was extremely rapid, having vitreous half lives of 2.62 and 2.98 hours, respectively, and a transretinal mechanism of clearance was established for these compounds.",Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773936/),h,2.62,232018,DB02377,Guanine
,8773936,half lives,"The vitreous elimination of ganciclovir (GCV) and acyclovir (ACV) was extremely rapid, having vitreous half lives of 2.62 and 2.98 hours, respectively, and a transretinal mechanism of clearance was established for these compounds.",Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773936/),h,2.98,232019,DB02377,Guanine
,8773936,t 1/2,The rate of elimination of GCV and ACV from the vitreous of the pigmented rabbit was much slower than the elimination from the albino rabbit (t 1/2 = 5.59 vs. 2.62 for GCV and 8.63 vs. 2.98 for ACV).,Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773936/),,5.59,232020,DB02377,Guanine
,8773936,t 1/2,The rate of elimination of GCV and ACV from the vitreous of the pigmented rabbit was much slower than the elimination from the albino rabbit (t 1/2 = 5.59 vs. 2.62 for GCV and 8.63 vs. 2.98 for ACV).,Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773936/),,2.62,232021,DB02377,Guanine
,8773936,t 1/2,The rate of elimination of GCV and ACV from the vitreous of the pigmented rabbit was much slower than the elimination from the albino rabbit (t 1/2 = 5.59 vs. 2.62 for GCV and 8.63 vs. 2.98 for ACV).,Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773936/),,8.63,232022,DB02377,Guanine
,8773936,t 1/2,The rate of elimination of GCV and ACV from the vitreous of the pigmented rabbit was much slower than the elimination from the albino rabbit (t 1/2 = 5.59 vs. 2.62 for GCV and 8.63 vs. 2.98 for ACV).,Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773936/),,2.98,232023,DB02377,Guanine
,23354655,time to progression,Median time to progression and survival was 2.7 and 7.3 months; PFS six was 22 %.,Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354655/),month,2.7,232543,DB02377,Guanine
,23354655,survival,Median time to progression and survival was 2.7 and 7.3 months; PFS six was 22 %.,Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354655/),month,2.7,232544,DB02377,Guanine
,23354655,survival,Median time to progression and survival was 2.7 and 7.3 months; PFS six was 22 %.,Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354655/),month,7.3,232545,DB02377,Guanine
,8844800,t1/2,"We have found that tissue clearance rates for [2-(14)C]-PhIP are rapid (t1/2 = 1 h) at low dose (41 ng/kg), with most of the radiocarbon distributed to the liver and G.I. tract.",Assessment of the DNA adduction and pharmacokinetics of PhIP and MeIOx in rodents at doses approximating human exposure using the technique of accelerator mass spectrometry (AMS) and 32P-postlabeling. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8844800/),h,1,234832,DB02377,Guanine
,8364481,bioavailabilities,"Rectal administration of a triglyceride (Vosco S-55 and Vosco S-55 + methylcellulose) suppository gave relatively high plasma concentrations and bioavailabilities (95.3 and 83.4%, respectively) compared with Witepsol and macrogol suppositories.",Rectal absorption of acyclovir in rats and improvement of absorption by triglyceride base. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364481/),%,95.3,235602,DB02377,Guanine
,8364481,bioavailabilities,"Rectal administration of a triglyceride (Vosco S-55 and Vosco S-55 + methylcellulose) suppository gave relatively high plasma concentrations and bioavailabilities (95.3 and 83.4%, respectively) compared with Witepsol and macrogol suppositories.",Rectal absorption of acyclovir in rats and improvement of absorption by triglyceride base. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364481/),%,83.4,235603,DB02377,Guanine
,24145543,peak,"Mean peak and trough prefilter ganciclovir concentrations were 11.8 ± 3.5 mg/liter and 2.4 ± 0.7 mg/liter, respectively.",Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24145543/),[mg] / [l],11.8,236561,DB02377,Guanine
,24145543,trough prefilter,"Mean peak and trough prefilter ganciclovir concentrations were 11.8 ± 3.5 mg/liter and 2.4 ± 0.7 mg/liter, respectively.",Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24145543/),[mg] / [l],11.8,236562,DB02377,Guanine
,24145543,concentrations,"Mean peak and trough prefilter ganciclovir concentrations were 11.8 ± 3.5 mg/liter and 2.4 ± 0.7 mg/liter, respectively.",Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24145543/),[mg] / [l],2.4,236563,DB02377,Guanine
,24145543,elimination half-life,"The pharmacokinetic parameters elimination half-life (24.2 ± 7.6 h), volume of distribution (81.2 ± 38.3 liters), sieving coefficient (0.76 ± 0.1), total clearance (2.7 ± 1.2 liters/h), and clearance of CVVHDF (1.5 ± 0.2 liters/h) were determined.",Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24145543/),h,24.2,236564,DB02377,Guanine
,24145543,volume of distribution,"The pharmacokinetic parameters elimination half-life (24.2 ± 7.6 h), volume of distribution (81.2 ± 38.3 liters), sieving coefficient (0.76 ± 0.1), total clearance (2.7 ± 1.2 liters/h), and clearance of CVVHDF (1.5 ± 0.2 liters/h) were determined.",Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24145543/),l,81.2,236565,DB02377,Guanine
,24145543,sieving coefficient,"The pharmacokinetic parameters elimination half-life (24.2 ± 7.6 h), volume of distribution (81.2 ± 38.3 liters), sieving coefficient (0.76 ± 0.1), total clearance (2.7 ± 1.2 liters/h), and clearance of CVVHDF (1.5 ± 0.2 liters/h) were determined.",Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24145543/),,0.76,236566,DB02377,Guanine
,24145543,total clearance,"The pharmacokinetic parameters elimination half-life (24.2 ± 7.6 h), volume of distribution (81.2 ± 38.3 liters), sieving coefficient (0.76 ± 0.1), total clearance (2.7 ± 1.2 liters/h), and clearance of CVVHDF (1.5 ± 0.2 liters/h) were determined.",Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24145543/),[l] / [h],2.7,236567,DB02377,Guanine
,24145543,clearance,"The pharmacokinetic parameters elimination half-life (24.2 ± 7.6 h), volume of distribution (81.2 ± 38.3 liters), sieving coefficient (0.76 ± 0.1), total clearance (2.7 ± 1.2 liters/h), and clearance of CVVHDF (1.5 ± 0.2 liters/h) were determined.",Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24145543/),[l] / [h],1.5,236568,DB02377,Guanine
,24145543,area under the curve (AUC),"Based on population pharmacokinetic simulations with respect to a target area under the curve (AUC) of 50 mg · h/liter and a trough level of 2 mg/liter, a ganciclovir dose of 2.5 mg/kg once daily seems to be adequate for anuric critically ill patients during CVVHDF.",Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24145543/),[h·mg] / [l],50,236569,DB02377,Guanine
,24145543,trough level,"Based on population pharmacokinetic simulations with respect to a target area under the curve (AUC) of 50 mg · h/liter and a trough level of 2 mg/liter, a ganciclovir dose of 2.5 mg/kg once daily seems to be adequate for anuric critically ill patients during CVVHDF.",Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24145543/),[mg] / [l],2,236570,DB02377,Guanine
,9421114,Peak plasma concentrations,"Peak plasma concentrations were 9.3 mg/l for the patient receiving 5 mg/kg daily, 29.6 mg/l and 20.7 mg/l for the two patients with 10 mg/kg every 48 hours.",Pharmacokinetics of acyclovir in patients undergoing continuous venovenous hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421114/),[mg] / [l],9.3,236791,DB02377,Guanine
,9421114,Peak plasma concentrations,"Peak plasma concentrations were 9.3 mg/l for the patient receiving 5 mg/kg daily, 29.6 mg/l and 20.7 mg/l for the two patients with 10 mg/kg every 48 hours.",Pharmacokinetics of acyclovir in patients undergoing continuous venovenous hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421114/),[mg] / [l],29.6,236792,DB02377,Guanine
,9421114,Peak plasma concentrations,"Peak plasma concentrations were 9.3 mg/l for the patient receiving 5 mg/kg daily, 29.6 mg/l and 20.7 mg/l for the two patients with 10 mg/kg every 48 hours.",Pharmacokinetics of acyclovir in patients undergoing continuous venovenous hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421114/),[mg] / [l],20.7,236793,DB02377,Guanine
,9421114,elimination half-life,The elimination half-life ranged from 8.8 to 11.2 hours and was approximately half those found in patients with renal impairment.,Pharmacokinetics of acyclovir in patients undergoing continuous venovenous hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421114/),h,8.8 to 11.2,236794,DB02377,Guanine
,9421114,clearance by ultrafiltration,The clearance by ultrafiltration was from 17.4 to 22.3 ml/minute and reached nearly 35% of the total clearance.,Pharmacokinetics of acyclovir in patients undergoing continuous venovenous hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421114/),[ml] / [min],17.4 to 22.3,236795,DB02377,Guanine
,9421114,si,The sieving coefficient ranged from 0.92 to 0.98 with an average rate of removal over the dosing interval ranging from 6.7 to 13.0 mg/hour.,Pharmacokinetics of acyclovir in patients undergoing continuous venovenous hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421114/),,0.92 to 0.98,236796,DB02377,Guanine
,9421114,rate of removal,The sieving coefficient ranged from 0.92 to 0.98 with an average rate of removal over the dosing interval ranging from 6.7 to 13.0 mg/hour.,Pharmacokinetics of acyclovir in patients undergoing continuous venovenous hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421114/),[mg] / [h],6.7 to 13.0,236797,DB02377,Guanine
,19232011,K(m),"Uptake of [3H] biotin into ARPE-19 was linear over 7 min, and found to be saturable with K(m) of 138.25 muM and Vmax of 38.85 pmol/min/mg protein.",Vitreal pharmacokinetics of biotinylated ganciclovir: role of sodium-dependent multivitamin transporter expressed on retina. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19232011/),muM,138.25,236860,DB02377,Guanine
,19232011,Vmax,"Uptake of [3H] biotin into ARPE-19 was linear over 7 min, and found to be saturable with K(m) of 138.25 muM and Vmax of 38.85 pmol/min/mg protein.",Vitreal pharmacokinetics of biotinylated ganciclovir: role of sodium-dependent multivitamin transporter expressed on retina. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19232011/),[pM] / [mg·min],38.85,236861,DB02377,Guanine
,12460785,MTD,"The MTD was reached at 14 and 16 mg/m(2) in heavily (HP) and minimally pretreated/non-pretreated (MP) patients, respectively, with thrombocytopenia as the DLT.","Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12460785/),[mg] / [m(2],14,237177,DB02377,Guanine
,12460785,MTD,"The MTD was reached at 14 and 16 mg/m(2) in heavily (HP) and minimally pretreated/non-pretreated (MP) patients, respectively, with thrombocytopenia as the DLT.","Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12460785/),[mg] / [m(2],16,237178,DB02377,Guanine
,23963796,AUC,Pemetrexed (400-500 mg/m(2) IV) and carboplatin (AUC = 5 mg·min/ml IV) were administered q3w.,Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23963796/),[mg·min] / [ml],5,237840,DB02377,Guanine
,23963796,AUC,The MTD on Schedule 2/1 was sunitinib 37.5 mg/day with pemetrexed 500 mg/m(2) and carboplatin AUC = 5 mg·min/ml; MTD on the CDD schedule was not established.,Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23963796/),[mg·min] / [ml],5,237841,DB02377,Guanine
,23963796,MTD,"With this combination, in patients with advanced solid malignancies, sunitinib MTD on Schedule 2/1 was 37.5 mg/day.",Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23963796/),[mg] / [d],37.5,237842,DB02377,Guanine
,16715778,T1/2,"The main pharmacokinetics parameters of the acyclovir sustained-release tablet were as follows: T1/2, Tmax and Cmax were 4.10 +/- 0.20 h, 4.05 +/- 0.54 h and 6.90 +/- 0.68 [microg x ml(-1), respectively.",Pharmacokinetics and bioavailability of acyclovir sustained-release tablets in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715778/),h,4.10,238688,DB02377,Guanine
,16715778,Tmax,"The main pharmacokinetics parameters of the acyclovir sustained-release tablet were as follows: T1/2, Tmax and Cmax were 4.10 +/- 0.20 h, 4.05 +/- 0.54 h and 6.90 +/- 0.68 [microg x ml(-1), respectively.",Pharmacokinetics and bioavailability of acyclovir sustained-release tablets in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715778/),h,4.05,238689,DB02377,Guanine
,16715778,Cmax,"The main pharmacokinetics parameters of the acyclovir sustained-release tablet were as follows: T1/2, Tmax and Cmax were 4.10 +/- 0.20 h, 4.05 +/- 0.54 h and 6.90 +/- 0.68 [microg x ml(-1), respectively.",Pharmacokinetics and bioavailability of acyclovir sustained-release tablets in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715778/),[μg] / [ml],6.90,238690,DB02377,Guanine
,16715778,MRT,MRT was 9.02 +/- 0.44 h.,Pharmacokinetics and bioavailability of acyclovir sustained-release tablets in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715778/),h,9.02,238691,DB02377,Guanine
,16715778,relative bioavailability,"Using acyclovir standard tablet as control, relative bioavailability of the acyclovir sustained-release tablet was 152.2 +/- 49.90%.",Pharmacokinetics and bioavailability of acyclovir sustained-release tablets in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715778/),%,152.2,238692,DB02377,Guanine
,15226381,area under plasma-concentration time curves,"The area under plasma-concentration time curves expressed as minutes microgram milliliter(-1) for total concentration of VACV (208.4 +/- 41.2), and the dipeptide prodrugs Gly-Val-ACV (GVACV) (416.1 +/- 140.9), Val-Val-ACV (VVACV) (147.7 +/- 89.3), and Val-Tyr-ACV (VYACV) (180.7 +/- 81.2) were significantly higher than that of ACV (21.2 +/- 5.2) upon intestinal absorption.",Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15226381/),[min·μg] / [milliliter],208.4,239449,DB02377,Guanine
,15226381,area under plasma-concentration time curves,"The area under plasma-concentration time curves expressed as minutes microgram milliliter(-1) for total concentration of VACV (208.4 +/- 41.2), and the dipeptide prodrugs Gly-Val-ACV (GVACV) (416.1 +/- 140.9), Val-Val-ACV (VVACV) (147.7 +/- 89.3), and Val-Tyr-ACV (VYACV) (180.7 +/- 81.2) were significantly higher than that of ACV (21.2 +/- 5.2) upon intestinal absorption.",Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15226381/),[min·μg] / [milliliter],416.1,239450,DB02377,Guanine
,15226381,area under plasma-concentration time curves,"The area under plasma-concentration time curves expressed as minutes microgram milliliter(-1) for total concentration of VACV (208.4 +/- 41.2), and the dipeptide prodrugs Gly-Val-ACV (GVACV) (416.1 +/- 140.9), Val-Val-ACV (VVACV) (147.7 +/- 89.3), and Val-Tyr-ACV (VYACV) (180.7 +/- 81.2) were significantly higher than that of ACV (21.2 +/- 5.2) upon intestinal absorption.",Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15226381/),[min·μg] / [milliliter],147.7,239451,DB02377,Guanine
,15226381,area under plasma-concentration time curves,"The area under plasma-concentration time curves expressed as minutes microgram milliliter(-1) for total concentration of VACV (208.4 +/- 41.2), and the dipeptide prodrugs Gly-Val-ACV (GVACV) (416.1 +/- 140.9), Val-Val-ACV (VVACV) (147.7 +/- 89.3), and Val-Tyr-ACV (VYACV) (180.7 +/- 81.2) were significantly higher than that of ACV (21.2 +/- 5.2) upon intestinal absorption.",Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15226381/),[min·μg] / [milliliter],180.7,239452,DB02377,Guanine
,15226381,area under plasma-concentration time curves,"The area under plasma-concentration time curves expressed as minutes microgram milliliter(-1) for total concentration of VACV (208.4 +/- 41.2), and the dipeptide prodrugs Gly-Val-ACV (GVACV) (416.1 +/- 140.9), Val-Val-ACV (VVACV) (147.7 +/- 89.3), and Val-Tyr-ACV (VYACV) (180.7 +/- 81.2) were significantly higher than that of ACV (21.2 +/- 5.2) upon intestinal absorption.",Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15226381/),[min·μg] / [milliliter],21.2,239453,DB02377,Guanine
,11170022,zeta potential,"The presence of PEG also resulted in a change in zeta potential, from -25.9 mV for uncoated nanospheres to -12.2 mV for PEG-coated PECA nanospheres.",Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11170022/),mv,-,240524,DB02377,Guanine
,11170022,zeta potential,"The presence of PEG also resulted in a change in zeta potential, from -25.9 mV for uncoated nanospheres to -12.2 mV for PEG-coated PECA nanospheres.",Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11170022/),mv,25.9,240525,DB02377,Guanine
,11170022,zeta potential,"The presence of PEG also resulted in a change in zeta potential, from -25.9 mV for uncoated nanospheres to -12.2 mV for PEG-coated PECA nanospheres.",Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11170022/),m,12.2,240526,DB02377,Guanine
,7102700,half-life,The drug's half-life showed little variation with a mean of 3.16 +/- 0.20 hours.,Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102700/),h,3.16,241265,DB02377,Guanine
,7102700,recovery,The kidney was the principal route of drug clearance with a mean recovery of 60 +/- 12 percent.,Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102700/),%,60,241266,DB02377,Guanine
,7957527,peak concentration,"A biexponential decrease in plasma ganciclovir was observed, with a peak concentration of 3.7 mg.l-1 followed by a steady state value of 2.6 mg.l-1 for almost 40 h.",Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957527/),[mg] / [l],3.7,241785,DB02377,Guanine
,7957527,steady state value,"A biexponential decrease in plasma ganciclovir was observed, with a peak concentration of 3.7 mg.l-1 followed by a steady state value of 2.6 mg.l-1 for almost 40 h.",Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957527/),[mg] / [l],2.6,241786,DB02377,Guanine
,7957527,total plasma clearance,"The total plasma clearance was 0.05 ml.min-1.kg-1, the volume of distribution at steady state was 0.6 l.kg-1, the elimination half life was 132 h, the area under curve was 372 micrograms.h.ml-1, the mean residence time was 190 h, and the percentage of ganciclovir cleared from plasma after a 5 h haemodialysis session was 52.1%.",Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957527/),[ml] / [kg·min],0.05,241787,DB02377,Guanine
,7957527,volume of distribution at steady state,"The total plasma clearance was 0.05 ml.min-1.kg-1, the volume of distribution at steady state was 0.6 l.kg-1, the elimination half life was 132 h, the area under curve was 372 micrograms.h.ml-1, the mean residence time was 190 h, and the percentage of ganciclovir cleared from plasma after a 5 h haemodialysis session was 52.1%.",Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957527/),[l] / [kg],0.6,241788,DB02377,Guanine
,7957527,elimination half life,"The total plasma clearance was 0.05 ml.min-1.kg-1, the volume of distribution at steady state was 0.6 l.kg-1, the elimination half life was 132 h, the area under curve was 372 micrograms.h.ml-1, the mean residence time was 190 h, and the percentage of ganciclovir cleared from plasma after a 5 h haemodialysis session was 52.1%.",Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957527/),h,132,241789,DB02377,Guanine
,7957527,area under curve,"The total plasma clearance was 0.05 ml.min-1.kg-1, the volume of distribution at steady state was 0.6 l.kg-1, the elimination half life was 132 h, the area under curve was 372 micrograms.h.ml-1, the mean residence time was 190 h, and the percentage of ganciclovir cleared from plasma after a 5 h haemodialysis session was 52.1%.",Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957527/),[h·μg] / [ml],372,241790,DB02377,Guanine
,7957527,mean residence time,"The total plasma clearance was 0.05 ml.min-1.kg-1, the volume of distribution at steady state was 0.6 l.kg-1, the elimination half life was 132 h, the area under curve was 372 micrograms.h.ml-1, the mean residence time was 190 h, and the percentage of ganciclovir cleared from plasma after a 5 h haemodialysis session was 52.1%.",Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957527/),h,190,241791,DB02377,Guanine
,31091273,time corresponding to 80% dissolution (T80),"In the dissolution test, the sustained-release characteristic of the GR system was identified with a time corresponding to 80% dissolution (T80) of 2.52 h.",Development of a gastroretentive delivery system for acyclovir by 3D printing technology and its in vivo pharmacokinetic evaluation in Beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31091273/),h,2.52,242648,DB02377,Guanine
,19465102,AUC(0-t),"The AUC(0-t) and mean residence time (MRT) of ACV-ad-ms (6055.9 ng h/mL and 7.2 h) were significantly higher than that of ACV suspension (2335.6 ng h/mL and 3.7 h) (P<0.05), which indicated that the bioavailability of acyclovir was greatly improved due to the prolonged retention of ACV-ad-ms in gastrointestinal tract.",Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19465102/),[h·ng] / [ml],6055.9,243033,DB02377,Guanine
,19465102,AUC(0-t),"The AUC(0-t) and mean residence time (MRT) of ACV-ad-ms (6055.9 ng h/mL and 7.2 h) were significantly higher than that of ACV suspension (2335.6 ng h/mL and 3.7 h) (P<0.05), which indicated that the bioavailability of acyclovir was greatly improved due to the prolonged retention of ACV-ad-ms in gastrointestinal tract.",Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19465102/),[h·ng] / [ml],2335.6,243034,DB02377,Guanine
,19465102,mean residence time (MRT),"The AUC(0-t) and mean residence time (MRT) of ACV-ad-ms (6055.9 ng h/mL and 7.2 h) were significantly higher than that of ACV suspension (2335.6 ng h/mL and 3.7 h) (P<0.05), which indicated that the bioavailability of acyclovir was greatly improved due to the prolonged retention of ACV-ad-ms in gastrointestinal tract.",Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19465102/),h,7.2,243035,DB02377,Guanine
,19465102,mean residence time (MRT),"The AUC(0-t) and mean residence time (MRT) of ACV-ad-ms (6055.9 ng h/mL and 7.2 h) were significantly higher than that of ACV suspension (2335.6 ng h/mL and 3.7 h) (P<0.05), which indicated that the bioavailability of acyclovir was greatly improved due to the prolonged retention of ACV-ad-ms in gastrointestinal tract.",Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19465102/),h,3.7,243036,DB02377,Guanine
,20236726,area under the concentration-time curve (AUC),Patients received escalated doses of carboplatin area under the concentration-time curve (AUC) of 5 (cohort 1) or 6 (cohort 2) and pemetrexed 500 mg/m(2) every 3 weeks for six cycles.,Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20236726/),,5,243095,DB02377,Guanine
,20236726,area under the concentration-time curve (AUC),Patients received escalated doses of carboplatin area under the concentration-time curve (AUC) of 5 (cohort 1) or 6 (cohort 2) and pemetrexed 500 mg/m(2) every 3 weeks for six cycles.,Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20236726/),,6,243096,DB02377,Guanine
,20236726,overall response rate,"No complete responses and 12 partial responses were observed, giving an overall response rate of 60.0% [95% confidence interval (CI), 36.1-80.9%].",Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20236726/),%,60.0,243097,DB02377,Guanine
,20236726,progression-free survival time,Median progression-free survival time for all patients was 7.6 months (95% CI: 4.8-8.0 months).,Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20236726/),month,7.6,243098,DB02377,Guanine
,8996645,area under the curve from 0 to infinity of theophylline (AUC0-infinity),"The area under the curve from 0 to infinity of theophylline (AUC0-infinity) after coadministration of aciclovir was increased from 189.9 +/- 18.2 to 274.9 +/- 34.3 micrograms.h/ml (p < 0.01), and total body clearance was decreased from 28.4 +/- 2.9 to 19.8 +/- 2.5 ml/h/kg (p < 0.01).",Inhibition of theophylline metabolism by aciclovir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996645/),[h·μg] / [ml],189.9,244120,DB02377,Guanine
,8996645,area under the curve from 0 to infinity of theophylline (AUC0-infinity),"The area under the curve from 0 to infinity of theophylline (AUC0-infinity) after coadministration of aciclovir was increased from 189.9 +/- 18.2 to 274.9 +/- 34.3 micrograms.h/ml (p < 0.01), and total body clearance was decreased from 28.4 +/- 2.9 to 19.8 +/- 2.5 ml/h/kg (p < 0.01).",Inhibition of theophylline metabolism by aciclovir. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996645/),[h·μg] / [ml],274.9,244121,DB02377,Guanine
,8996645,total body clearance,"The area under the curve from 0 to infinity of theophylline (AUC0-infinity) after coadministration of aciclovir was increased from 189.9 +/- 18.2 to 274.9 +/- 34.3 micrograms.h/ml (p < 0.01), and total body clearance was decreased from 28.4 +/- 2.9 to 19.8 +/- 2.5 ml/h/kg (p < 0.01).",Inhibition of theophylline metabolism by aciclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996645/),[ml] / [h·kg],28.4,244122,DB02377,Guanine
,8996645,total body clearance,"The area under the curve from 0 to infinity of theophylline (AUC0-infinity) after coadministration of aciclovir was increased from 189.9 +/- 18.2 to 274.9 +/- 34.3 micrograms.h/ml (p < 0.01), and total body clearance was decreased from 28.4 +/- 2.9 to 19.8 +/- 2.5 ml/h/kg (p < 0.01).",Inhibition of theophylline metabolism by aciclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996645/),[ml] / [h·kg],19.8,244123,DB02377,Guanine
,3275502,apparent half-life,"Repair of O6-HEdG was very rapid in liver (apparent half-life, 12 h), and somewhat slower in kidney and lung (approximate half-life, 40 h and 48 h respectively).",Formation and persistence of O6-(2-hydroxyethyl)-2' -deoxyguanosine in DNA of various rat tissues following a single dose of N-nitroso-N-(2-hydroxyethyl)urea. An immuno-slot-blot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3275502/),h,12,244565,DB02377,Guanine
,3275502,half-life,"Repair of O6-HEdG was very rapid in liver (apparent half-life, 12 h), and somewhat slower in kidney and lung (approximate half-life, 40 h and 48 h respectively).",Formation and persistence of O6-(2-hydroxyethyl)-2' -deoxyguanosine in DNA of various rat tissues following a single dose of N-nitroso-N-(2-hydroxyethyl)urea. An immuno-slot-blot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3275502/),h,40,244566,DB02377,Guanine
,3275502,half-life,"Repair of O6-HEdG was very rapid in liver (apparent half-life, 12 h), and somewhat slower in kidney and lung (approximate half-life, 40 h and 48 h respectively).",Formation and persistence of O6-(2-hydroxyethyl)-2' -deoxyguanosine in DNA of various rat tissues following a single dose of N-nitroso-N-(2-hydroxyethyl)urea. An immuno-slot-blot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3275502/),h,48,244567,DB02377,Guanine
,20725726,ED(50),O(4)BF and the metabolite inactivated purified AGT with ED(50) of 0.04 mcM.,Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20725726/),mcM,0.04,244804,DB02377,Guanine
,20725726,clearance,The median clearance of O(4)BF was 8 ml/min/kg and half-life was 1.1 h.,Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20725726/),[ml] / [kg·min],8,244805,DB02377,Guanine
,20725726,half-life,The median clearance of O(4)BF was 8 ml/min/kg and half-life was 1.1 h.,Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20725726/),h,1.1,244806,DB02377,Guanine
>,20725726,half-life,The metabolite had a substantially longer half-life (>20 h) and greater AUC than O(4)BF.,Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20725726/),h,20,244807,DB02377,Guanine
less,20725726,C(max),"At the 50 mg/kg dose level, the C(max) in CSF for O(4)BF was less than 0.09 mcM and for the metabolite the C(max) ranged from 0.02 to 0.04 mcM (O(4)BF equivalents).",Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20725726/),mcM,0.09,244808,DB02377,Guanine
,20725726,C(max),"At the 50 mg/kg dose level, the C(max) in CSF for O(4)BF was less than 0.09 mcM and for the metabolite the C(max) ranged from 0.02 to 0.04 mcM (O(4)BF equivalents).",Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20725726/),mcM,0.02 to 0.04,244809,DB02377,Guanine
,6655561,peak plasma ACV concentrations,"Mean peak plasma ACV concentrations achieved in the dog were 57, 156 and 285 microM after A134U doses of 20, 50 and 120 mg/kg, respectively, and increased in near proportion to the dose.","Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6655561/),μM,57,245184,DB02377,Guanine
,6655561,peak plasma ACV concentrations,"Mean peak plasma ACV concentrations achieved in the dog were 57, 156 and 285 microM after A134U doses of 20, 50 and 120 mg/kg, respectively, and increased in near proportion to the dose.","Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6655561/),μM,156,245185,DB02377,Guanine
,6655561,peak plasma ACV concentrations,"Mean peak plasma ACV concentrations achieved in the dog were 57, 156 and 285 microM after A134U doses of 20, 50 and 120 mg/kg, respectively, and increased in near proportion to the dose.","Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6655561/),μM,285,245186,DB02377,Guanine
,6655561,peak plasma ACV concentrations,"In the rat, peak plasma ACV concentrations were 3.1 and 10.7 microM, respectively, after 20- and 50-mg/kg doses of A134U.","Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6655561/),μM,3.1,245187,DB02377,Guanine
,6655561,peak plasma ACV concentrations,"In the rat, peak plasma ACV concentrations were 3.1 and 10.7 microM, respectively, after 20- and 50-mg/kg doses of A134U.","Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6655561/),μM,10.7,245188,DB02377,Guanine
,11505404,response rates,Phase II trials showed single-agent response rates of 16% and 23% in untreated patients with nonsmall cell lung carcinoma (NSCLC).,"Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505404/),%,16,245732,DB02377,Guanine
,11505404,response rates,Phase II trials showed single-agent response rates of 16% and 23% in untreated patients with nonsmall cell lung carcinoma (NSCLC).,"Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505404/),%,23,245733,DB02377,Guanine
,11505404,survival rate,"The median survival rate was 8.9 months (range, 1-15+ months).","Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505404/),month,8.9,245734,DB02377,Guanine
,7712668,plasma clearance (CL),"For regimen A, the plasma clearance (CL) of foscarnet did not change in the presence of ganciclovir, averaging 0.12 +/- 0.08 and 0.11 +/- 0.02 L/hr/kg on study days 2 and 14, respectively (p = 0.34).",Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712668/),[l] / [h·kg],0.12,246390,DB02377,Guanine
,7712668,plasma clearance (CL),"For regimen A, the plasma clearance (CL) of foscarnet did not change in the presence of ganciclovir, averaging 0.12 +/- 0.08 and 0.11 +/- 0.02 L/hr/kg on study days 2 and 14, respectively (p = 0.34).",Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712668/),[l] / [h·kg],0.11,246391,DB02377,Guanine
,7712668,CL,"CL and MRT of foscarnet did not change for regimen B, although a slight increase in VSS was observed before (0.38 +/- 0.05 L/kg) and after (0.46 +/- 0.07 L/kg) alternating therapy (p = 0.03).",Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712668/),l,0.38,246392,DB02377,Guanine
,7712668,MRT,"CL and MRT of foscarnet did not change for regimen B, although a slight increase in VSS was observed before (0.38 +/- 0.05 L/kg) and after (0.46 +/- 0.07 L/kg) alternating therapy (p = 0.03).",Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712668/),l,0.38,246393,DB02377,Guanine
,7712668,VSS,"CL and MRT of foscarnet did not change for regimen B, although a slight increase in VSS was observed before (0.38 +/- 0.05 L/kg) and after (0.46 +/- 0.07 L/kg) alternating therapy (p = 0.03).",Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712668/),l,0.38,246394,DB02377,Guanine
,7712668,VSS,"CL and MRT of foscarnet did not change for regimen B, although a slight increase in VSS was observed before (0.38 +/- 0.05 L/kg) and after (0.46 +/- 0.07 L/kg) alternating therapy (p = 0.03).",Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712668/),l,0.46,246395,DB02377,Guanine
,7712668,CL,"Ganciclovir CL did not change for either regimen, with mean values of 0.21 +/- 0.10 and 0.25 +/- 0.10 L/hr/kg (regimen A, p = 0.17) and 0.32 +/- 0.10 and 0.34 +/- 0.11 L/hr/kg (regimen B, p = 0.24).",Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712668/),[l] / [h·kg],0.21,246396,DB02377,Guanine
,7712668,CL,"Ganciclovir CL did not change for either regimen, with mean values of 0.21 +/- 0.10 and 0.25 +/- 0.10 L/hr/kg (regimen A, p = 0.17) and 0.32 +/- 0.10 and 0.34 +/- 0.11 L/hr/kg (regimen B, p = 0.24).",Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712668/),[l] / [h·kg],0.25,246397,DB02377,Guanine
,7712668,CL,"Ganciclovir CL did not change for either regimen, with mean values of 0.21 +/- 0.10 and 0.25 +/- 0.10 L/hr/kg (regimen A, p = 0.17) and 0.32 +/- 0.10 and 0.34 +/- 0.11 L/hr/kg (regimen B, p = 0.24).",Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712668/),[l] / [h·kg],0.32,246398,DB02377,Guanine
,7712668,CL,"Ganciclovir CL did not change for either regimen, with mean values of 0.21 +/- 0.10 and 0.25 +/- 0.10 L/hr/kg (regimen A, p = 0.17) and 0.32 +/- 0.10 and 0.34 +/- 0.11 L/hr/kg (regimen B, p = 0.24).",Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712668/),[l] / [h·kg],0.34,246399,DB02377,Guanine
,15554220,rate constant,Acyclovir will be slowly released from the obtained conjugate in pH 7.4 phosphate buffer solution (PBS) at 37 degrees C with a rate constant of 0.0035 hr(-1).,Studies on acyclovir-dextran conjugate: synthesis and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15554220/),1/[hr],0.0035,246427,DB02377,Guanine
,12403050,oral uptake,The oral uptake (11+/-2%) and the urinary recovery (106+/-5%) were determined.,Validation of microdialysis sampling for oral availability studies by means of a new ganciclovir prodrug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403050/),%,11,246558,DB02377,Guanine
,12403050,urinary recovery,The oral uptake (11+/-2%) and the urinary recovery (106+/-5%) were determined.,Validation of microdialysis sampling for oral availability studies by means of a new ganciclovir prodrug. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403050/),%,106,246559,DB02377,Guanine
,12403050,oral bioavailability,The oral bioavailability of the prodrug was 40+/-7% estimated from microdialysis sampling data and 48+/-4% estimated from urine sampling data.,Validation of microdialysis sampling for oral availability studies by means of a new ganciclovir prodrug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403050/),%,40,246560,DB02377,Guanine
,12403050,oral bioavailability,The oral bioavailability of the prodrug was 40+/-7% estimated from microdialysis sampling data and 48+/-4% estimated from urine sampling data.,Validation of microdialysis sampling for oral availability studies by means of a new ganciclovir prodrug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403050/),%,48,246561,DB02377,Guanine
,18460034,AUC(0-infinity),"AUC(0-infinity) for the 2677TA genotype was 17.45 +/- 2.40 microg x h/ml, which was much higher compared with the 2677GG, GA and TT genotypes of 10.44 +/- 1.00, 11.84 +/- 2.83, 11.34 +/- 2.32 microg x h/ml, respectively (P < 0.05).",MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18460034/),[h·μg] / [ml],17.45,247219,DB02377,Guanine
,18460034,AUC(0-infinity),"AUC(0-infinity) for the 2677TA genotype was 17.45 +/- 2.40 microg x h/ml, which was much higher compared with the 2677GG, GA and TT genotypes of 10.44 +/- 1.00, 11.84 +/- 2.83, 11.34 +/- 2.32 microg x h/ml, respectively (P < 0.05).",MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18460034/),[h·μg] / [ml],10.44,247220,DB02377,Guanine
,18460034,AUC(0-infinity),"AUC(0-infinity) for the 2677TA genotype was 17.45 +/- 2.40 microg x h/ml, which was much higher compared with the 2677GG, GA and TT genotypes of 10.44 +/- 1.00, 11.84 +/- 2.83, 11.34 +/- 2.32 microg x h/ml, respectively (P < 0.05).",MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18460034/),[h·μg] / [ml],11.84,247221,DB02377,Guanine
,18460034,AUC(0-infinity),"AUC(0-infinity) for the 2677TA genotype was 17.45 +/- 2.40 microg x h/ml, which was much higher compared with the 2677GG, GA and TT genotypes of 10.44 +/- 1.00, 11.84 +/- 2.83, 11.34 +/- 2.32 microg x h/ml, respectively (P < 0.05).",MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18460034/),[h·μg] / [ml],11.34,247222,DB02377,Guanine
>,28100102,recovery rates,"2. Protein precipitation by perchloric acid was used to separate crotonoside from the biological samples, and the recovery rates for crotonoside and the internal standard (luteoloside) were >80%.",Pharmacokinetics and tissue distribution of crotonoside. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28100102/),%,80,247307,DB02377,Guanine
,31740393,Km,"Kinetic constants for crizotinib uptake by OCT2 were Km 1.16 ± 0.26 µM, Vmax 12.05 ± 0.53 µmol/min mg-1 protein and Ki 9.711 nM.",Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31740393/),μM,1.16,248526,DB02377,Guanine
,31740393,Vmax,"Kinetic constants for crizotinib uptake by OCT2 were Km 1.16 ± 0.26 µM, Vmax 12.05 ± 0.53 µmol/min mg-1 protein and Ki 9.711 nM.",Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31740393/),[μM] / [mg·min],12.05,248527,DB02377,Guanine
,31740393,Ki,"Kinetic constants for crizotinib uptake by OCT2 were Km 1.16 ± 0.26 µM, Vmax 12.05 ± 0.53 µmol/min mg-1 protein and Ki 9.711 nM.",Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31740393/),nM,9.711,248528,DB02377,Guanine
,9885300,area under the plasma concentration-time-curve (AUC0-24h),"The mean area under the plasma concentration-time-curve (AUC0-24h), in the presence of the extracorporal magnet was 2802.7 ngh/ml.",Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885300/),[ngh] / [ml],2802.7,249072,DB02377,Guanine
,9885300,AUC0-24h,Without the extracorporal magnet a mean AUC0-24h of 1598.8 ngh/ml was achieved.,Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885300/),[ngh] / [ml],1598.8,249073,DB02377,Guanine
,18006772,MTDs,"Whereas the estimated MTDs of temozolomide for Str1 and Str2 were 562 and 407 mg/m(2), respectively, the doses recommended for phase II investigations are 472 and 355 mg/m(2), respectively.",Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18006772/),[mg] / [m(2],562,249373,DB02377,Guanine
,18006772,MTDs,"Whereas the estimated MTDs of temozolomide for Str1 and Str2 were 562 and 407 mg/m(2), respectively, the doses recommended for phase II investigations are 472 and 355 mg/m(2), respectively.",Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18006772/),[mg] / [m(2],407,249374,DB02377,Guanine
,18006772,MTDs,"Whereas the estimated MTDs of temozolomide for Str1 and Str2 were 562 and 407 mg/m(2), respectively, the doses recommended for phase II investigations are 472 and 355 mg/m(2), respectively.",Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18006772/),[mg] / [m],472,249375,DB02377,Guanine
,18006772,MTDs,"Whereas the estimated MTDs of temozolomide for Str1 and Str2 were 562 and 407 mg/m(2), respectively, the doses recommended for phase II investigations are 472 and 355 mg/m(2), respectively.",Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18006772/),[mg] / [m],355,249376,DB02377,Guanine
,11288106,half-life,"L-phenylalanyl ester is highly susceptible to plasma esterases, with an in vitro half-life 1.33 min.","Chemical stability, enzymatic hydrolysis, and nasal uptake of amino acid ester prodrugs of acyclovir. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11288106/),min,1.33,250959,DB02377,Guanine
,33150655,steady-state trough concentrations,"Using high-performance liquid chromatography, we measured 156 steady-state trough concentrations of 6-TGN within the range 0.09 to 1.16 mg/L (ie 133-1733 pmol per 8 × 108 RBC).",Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33150655/),[mg] / [l],0.09 to 1.16,251320,DB02377,Guanine
,33150655,steady-state trough concentrations,"Using high-performance liquid chromatography, we measured 156 steady-state trough concentrations of 6-TGN within the range 0.09 to 1.16 mg/L (ie 133-1733 pmol per 8 × 108 RBC).",Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33150655/),pM,133-1733,251321,DB02377,Guanine
,3624115,peak,"Steady-state was reached by the third day, with little change in mean peak or trough plasma levels between day one (25 and 3 microM) and day five (29 and 4 microM).",Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624115/),μM,25,252339,DB02377,Guanine
,3624115,trough plasma levels,"Steady-state was reached by the third day, with little change in mean peak or trough plasma levels between day one (25 and 3 microM) and day five (29 and 4 microM).",Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624115/),μM,3,252340,DB02377,Guanine
,3624115,trough plasma levels,"Steady-state was reached by the third day, with little change in mean peak or trough plasma levels between day one (25 and 3 microM) and day five (29 and 4 microM).",Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624115/),μM,29,252341,DB02377,Guanine
,3624115,trough plasma levels,"Steady-state was reached by the third day, with little change in mean peak or trough plasma levels between day one (25 and 3 microM) and day five (29 and 4 microM).",Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624115/),μM,4,252342,DB02377,Guanine
,3624115,total plasma clearance,"Mean total plasma clearance was 46 ml/h/kg, of which 12% was due to peritoneal dialysis.",Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624115/),[ml] / [h·kg],46,252343,DB02377,Guanine
,3624115,bioavailability,"The model parameters predicted efficient transfer of acyclovir from the peritoneum to plasma, such that hypothetical peritoneal dosing might give 91% bioavailability.",Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624115/),%,91,252344,DB02377,Guanine
,34052705,progression free survival (PFS),"Median progression free survival (PFS) was 4.5 months (95% CI 2.6 months-NA), with a 6-month and 12-month PFS rate of 38.5% (95% CI 19.3%-76.5%) and 25.6% (95% CI 8.9%-73.6%), respectively.","A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34052705/),month,4.5,252389,DB02377,Guanine
,18763162,Entrapment efficiency,"Entrapment efficiency showed that multilamellar and unilamellar liposomes were 43.2% +/- 0.83 and 21% +/- 1.01, respectively.",Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18763162/),%,43.2,252934,DB02377,Guanine
,18763162,Entrapment efficiency,"Entrapment efficiency showed that multilamellar and unilamellar liposomes were 43.2% +/- 0.83 and 21% +/- 1.01, respectively.",Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18763162/),%,21,252935,DB02377,Guanine
,18763162,bioavailability,The bioavailability of acyclovir from nasal mucoadhesive gel was 60.72% compared with intravenous route.,Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18763162/),%,60.72,252936,DB02377,Guanine
,17846132,peak concentration,The peak concentration of i.v. acyclovir was approximately 10 mug/ml for both the total and the unbound plasma concentrations.,Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17846132/),[μg] / [ml],10,253456,DB02377,Guanine
,17846132,half-life of elimination,The mean half-life of elimination was between 5.05 h (total concentration) and 11.9 h (unbound concentration).,Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17846132/),h,5.05,253457,DB02377,Guanine
,17846132,half-life of elimination,The mean half-life of elimination was between 5.05 h (total concentration) and 11.9 h (unbound concentration).,Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17846132/),h,11.9,253458,DB02377,Guanine
,17846132,total concentration,The mean half-life of elimination was between 5.05 h (total concentration) and 11.9 h (unbound concentration).,Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17846132/),h,5.05,253459,DB02377,Guanine
,17846132,unbound concentration,The mean half-life of elimination was between 5.05 h (total concentration) and 11.9 h (unbound concentration).,Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17846132/),h,11.9,253460,DB02377,Guanine
,16322991,total systemic clearance,"Typical values of total systemic clearance, central volume of distribution, distributional clearance, and peripheral volume of distribution were 91.6 ml/min, 12.9 l, 14.4 ml/min, and 3.38 l, respectively.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),[ml] / [min],91.6,254215,DB02377,Guanine
,16322991,central volume of distribution,"Typical values of total systemic clearance, central volume of distribution, distributional clearance, and peripheral volume of distribution were 91.6 ml/min, 12.9 l, 14.4 ml/min, and 3.38 l, respectively.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),l,12.9,254216,DB02377,Guanine
,16322991,central volume of distribution,"Typical values of total systemic clearance, central volume of distribution, distributional clearance, and peripheral volume of distribution were 91.6 ml/min, 12.9 l, 14.4 ml/min, and 3.38 l, respectively.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),[ml] / [min],14.4,254217,DB02377,Guanine
,16322991,distributional clearance,"Typical values of total systemic clearance, central volume of distribution, distributional clearance, and peripheral volume of distribution were 91.6 ml/min, 12.9 l, 14.4 ml/min, and 3.38 l, respectively.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),l,12.9,254218,DB02377,Guanine
,16322991,distributional clearance,"Typical values of total systemic clearance, central volume of distribution, distributional clearance, and peripheral volume of distribution were 91.6 ml/min, 12.9 l, 14.4 ml/min, and 3.38 l, respectively.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),[ml] / [min],14.4,254219,DB02377,Guanine
,16322991,peripheral volume of distribution,"Typical values of total systemic clearance, central volume of distribution, distributional clearance, and peripheral volume of distribution were 91.6 ml/min, 12.9 l, 14.4 ml/min, and 3.38 l, respectively.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),l,3.38,254220,DB02377,Guanine
,16322991,terminal elimination half-life,"Based on these parameter estimates, the terminal elimination half-life of pemetrexed was approximately 3.5 h.",Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16322991/),h,3.5,254221,DB02377,Guanine
,10501910,MTD,"The MTD of MTA was 600 mg/m(2), with neutropenia and thrombocytopenia, and cumulative fatigue as the dose-limiting toxicities.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),[mg] / [m],600,254279,DB02377,Guanine
,10501910,half-life,"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),h,3.08,254280,DB02377,Guanine
,10501910,maximum plasma concentration (Cpmax),"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),[μg] / [ml],137,254281,DB02377,Guanine
,10501910,maximum plasma concentration (Cpmax),"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),[min·ml] / [m(2],40.0,254282,DB02377,Guanine
,10501910,clearance (CL),"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),[μg] / [ml],137,254283,DB02377,Guanine
,10501910,area under the curve (AUC),"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),[μg] / [ml],137,254284,DB02377,Guanine
,10501910,area under the curve (AUC),"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),[min·ml] / [m(2],40.0,254285,DB02377,Guanine
,10501910,apparent volume of distribution at steady state (Vdss),"Pharmacokinetic analysis during the first course of treatment at the 600 mg/m(2) dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 microg/ml, 40.0 ml/min per m(2), 266 microg.","A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501910/),μg,266,254286,DB02377,Guanine
,8840412,bioavailability,Penciclovir has excellent bioavailability (77%) after oral administration of 500 mg of famciclovir.,The pharmacological profile of famciclovir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8840412/),%,77,256310,DB02377,Guanine
,8840412,intracellular half-life,"Penciclovir-triphosphate has a prolonged in vitro intracellular half-life of 10 to 20 hours in HSV-1-and HSV-2-infected cells, respectively, and 9 to 14 hours in VZV-infected cells.",The pharmacological profile of famciclovir. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8840412/),h,10 to 20,256311,DB02377,Guanine
,8840412,intracellular half-life,"Penciclovir-triphosphate has a prolonged in vitro intracellular half-life of 10 to 20 hours in HSV-1-and HSV-2-infected cells, respectively, and 9 to 14 hours in VZV-infected cells.",The pharmacological profile of famciclovir. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8840412/),h,9 to 14,256312,DB02377,Guanine
,8840412,intracellular half-life,"In contrast, the in vitro intracellular half-life of acyclovir is substantially shorter at 0.7 and 1 hours in HSV-1- and HSV-2-infected cells, respectively, and 0.8 hours in VZV-infected cells.",The pharmacological profile of famciclovir. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8840412/),h,0.7,256313,DB02377,Guanine
,8840412,intracellular half-life,"In contrast, the in vitro intracellular half-life of acyclovir is substantially shorter at 0.7 and 1 hours in HSV-1- and HSV-2-infected cells, respectively, and 0.8 hours in VZV-infected cells.",The pharmacological profile of famciclovir. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8840412/),h,1,256314,DB02377,Guanine
,8840412,intracellular half-life,"In contrast, the in vitro intracellular half-life of acyclovir is substantially shorter at 0.7 and 1 hours in HSV-1- and HSV-2-infected cells, respectively, and 0.8 hours in VZV-infected cells.",The pharmacological profile of famciclovir. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8840412/),h,0.8,256315,DB02377,Guanine
,19246256,flow-rate,"The chromatographic separation was achieved on a Gemini C18 analytical column using isocratic mobile phase, consisting of 0.1% formic acid and methanol (30:70 v/v), at a flow-rate of 0.8 mL/min.","Stability evaluation and sensitive determination of antiviral drug, valacyclovir and its metabolite acyclovir in human plasma by a rapid liquid chromatography-tandem mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246256/),[ml] / [min],0.8,257783,DB02377,Guanine
,19246256,recovery,"The mean recovery of valacyclovir (92.2%), acyclovir (84.2%) and IS (103.7%) from spiked plasma samples was consistent and reproducible.","Stability evaluation and sensitive determination of antiviral drug, valacyclovir and its metabolite acyclovir in human plasma by a rapid liquid chromatography-tandem mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246256/),%,92.2,257784,DB02377,Guanine
,19246256,recovery,"The mean recovery of valacyclovir (92.2%), acyclovir (84.2%) and IS (103.7%) from spiked plasma samples was consistent and reproducible.","Stability evaluation and sensitive determination of antiviral drug, valacyclovir and its metabolite acyclovir in human plasma by a rapid liquid chromatography-tandem mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246256/),%,84.2,257785,DB02377,Guanine
,19246256,recovery,"The mean recovery of valacyclovir (92.2%), acyclovir (84.2%) and IS (103.7%) from spiked plasma samples was consistent and reproducible.","Stability evaluation and sensitive determination of antiviral drug, valacyclovir and its metabolite acyclovir in human plasma by a rapid liquid chromatography-tandem mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246256/),%,103.7,257786,DB02377,Guanine
,10606085,terminal-phase half-life,"After intravenous administration of DXG, plasma concentrations of the nucleoside declined in a biexponential manner, with a terminal-phase half-life of 0.44 +/- 0.14 hr (mean +/- SD) in rats and 2.3 hr in monkeys.","Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606085/),h,0.44,257817,DB02377,Guanine
,10606085,terminal-phase half-life,"After intravenous administration of DXG, plasma concentrations of the nucleoside declined in a biexponential manner, with a terminal-phase half-life of 0.44 +/- 0.14 hr (mean +/- SD) in rats and 2.3 hr in monkeys.","Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606085/),h,2.3,257818,DB02377,Guanine
,10606085,Total clearance,Total clearance of DXG was 4.28 +/- 0.99 liters/hr/kg in rats and 0.72 liters/hr/kg in monkeys.,"Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606085/),[l] / [h·kg],4.28,257819,DB02377,Guanine
,10606085,Total clearance,Total clearance of DXG was 4.28 +/- 0.99 liters/hr/kg in rats and 0.72 liters/hr/kg in monkeys.,"Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606085/),[l] / [h·kg],0.72,257820,DB02377,Guanine
,10606085,Steady state volume of distribution,Steady state volume of distribution of DXG was 2.30 liters/kg in rats and 1.19 liters/kg in monkeys.,"Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606085/),[l] / [kg],2.30,257821,DB02377,Guanine
,10606085,Steady state volume of distribution,Steady state volume of distribution of DXG was 2.30 liters/kg in rats and 1.19 liters/kg in monkeys.,"Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606085/),[l] / [kg],1.19,257822,DB02377,Guanine
,10606085,half-life,"After intravenous administration of DAPD to rats, prodrug concentrations declined with a half-life of 0.37 +/- 0.11 hr.","Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606085/),h,0.37,257823,DB02377,Guanine
,10606085,half-lives,"The half-lives of DAPD and DXG after intravenous administration determined from urinary excretion data were 0.8 +/- 0.4 and 1.6 +/- 0.2 hr, respectively.","Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606085/),h,0.8,257824,DB02377,Guanine
,10606085,half-lives,"The half-lives of DAPD and DXG after intravenous administration determined from urinary excretion data were 0.8 +/- 0.4 and 1.6 +/- 0.2 hr, respectively.","Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606085/),h,1.6,257825,DB02377,Guanine
,10606085,Oral bioavailability,Oral bioavailability of DAPD was estimated to be approximately 30%.,"Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606085/),%,30,257826,DB02377,Guanine
,8355201,Ki,BzDAG was a potent inhibitor of PNP from calf spleen (Ki = 12 nM).,Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355201/),nM,12,258399,DB02377,Guanine
,8355201,orally bioavailable,Pharmacokinetic analysis of BzDAG in the rat showed it to be 48% orally bioavailable (at a dose of 5 mg/kg).,Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355201/),%,48,258400,DB02377,Guanine
,32661922,zeta potential,"According to results, SA-PMX-Lips were spherical and the particle size was 219.7 ± 4.97 nm with a narrow polydispersity index (PDI) (0.231 ± 0.024) and a positive zeta potential 22.2 ± 0.52 mV.",Preparation and Evaluation of Stearylamine-Bearing Pemetrexed Disodium-Loaded Cationic Liposomes In Vitro and In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32661922/),mv,22.2,258707,DB02377,Guanine
,32661922,EE,Its EE was 92.39 ± 1.94% and DL was 9.15 ± 0.07%.,Preparation and Evaluation of Stearylamine-Bearing Pemetrexed Disodium-Loaded Cationic Liposomes In Vitro and In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32661922/),%,92.39,258708,DB02377,Guanine
,32661922,DL,Its EE was 92.39 ± 1.94% and DL was 9.15 ± 0.07%.,Preparation and Evaluation of Stearylamine-Bearing Pemetrexed Disodium-Loaded Cationic Liposomes In Vitro and In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32661922/),%,9.15,258709,DB02377,Guanine
,32661922,relative uptake rate (Re),"More notably, SA-PMX-Lips could improve the accumulation of drugs in the lungs and the relative uptake rate (Re) was 2.35 in the lungs, which indicated its lung targeting.",Preparation and Evaluation of Stearylamine-Bearing Pemetrexed Disodium-Loaded Cationic Liposomes In Vitro and In Vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32661922/),,2.35,258710,DB02377,Guanine
,8163759,Peak,"Peak and trough concentrations were respectively 16.1 +/- 2.4 and 5.5 +/- 0.5 mg/l, sieving coefficient 0.75-0.95, and volume of distribution at steady state 0.64 +/- 0.09 l/kg, half life (beta phase) 18.6 +/- 1.8 h.",Clinical use of ganciclovir during renal failure and continuous hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8163759/),[mg] / [l],16.1,259272,DB02377,Guanine
,8163759,trough concentrations,"Peak and trough concentrations were respectively 16.1 +/- 2.4 and 5.5 +/- 0.5 mg/l, sieving coefficient 0.75-0.95, and volume of distribution at steady state 0.64 +/- 0.09 l/kg, half life (beta phase) 18.6 +/- 1.8 h.",Clinical use of ganciclovir during renal failure and continuous hemodialysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8163759/),[mg] / [l],5.5,259273,DB02377,Guanine
,8163759,volume of distribution at steady state,"Peak and trough concentrations were respectively 16.1 +/- 2.4 and 5.5 +/- 0.5 mg/l, sieving coefficient 0.75-0.95, and volume of distribution at steady state 0.64 +/- 0.09 l/kg, half life (beta phase) 18.6 +/- 1.8 h.",Clinical use of ganciclovir during renal failure and continuous hemodialysis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8163759/),[l] / [kg],0.64,259274,DB02377,Guanine
,8163759,half life (beta phase),"Peak and trough concentrations were respectively 16.1 +/- 2.4 and 5.5 +/- 0.5 mg/l, sieving coefficient 0.75-0.95, and volume of distribution at steady state 0.64 +/- 0.09 l/kg, half life (beta phase) 18.6 +/- 1.8 h.",Clinical use of ganciclovir during renal failure and continuous hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8163759/),h,18.6,259275,DB02377,Guanine
,30973978,clearance (CL),"The final population parameter estimates and relative standard error for clearance (CL) was 3.3 L/h (10.8), central volume of distribution (V1) was 5.2 L (7.8), peripheral volume of distribution (V2) was 5.9 L (14.5) and intercompartmental clearance (Q) was 6.8 L/h (14.3).",Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30973978/),[l] / [h],3.3,259276,DB02377,Guanine
,30973978,central volume of distribution (V1),"The final population parameter estimates and relative standard error for clearance (CL) was 3.3 L/h (10.8), central volume of distribution (V1) was 5.2 L (7.8), peripheral volume of distribution (V2) was 5.9 L (14.5) and intercompartmental clearance (Q) was 6.8 L/h (14.3).",Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30973978/),l,5.2,259277,DB02377,Guanine
,30973978,peripheral volume of distribution (V2),"The final population parameter estimates and relative standard error for clearance (CL) was 3.3 L/h (10.8), central volume of distribution (V1) was 5.2 L (7.8), peripheral volume of distribution (V2) was 5.9 L (14.5) and intercompartmental clearance (Q) was 6.8 L/h (14.3).",Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30973978/),l,5.9,259278,DB02377,Guanine
,30973978,intercompartmental clearance (Q),"The final population parameter estimates and relative standard error for clearance (CL) was 3.3 L/h (10.8), central volume of distribution (V1) was 5.2 L (7.8), peripheral volume of distribution (V2) was 5.9 L (14.5) and intercompartmental clearance (Q) was 6.8 L/h (14.3).",Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30973978/),[l] / [h],6.8,259279,DB02377,Guanine
,7769276,Oral bioavailability,Oral bioavailability ranged from 2.6% to 7.3%.,"Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7769276/),%,2.6,260512,DB02377,Guanine
,7769276,Oral bioavailability,Oral bioavailability ranged from 2.6% to 7.3%.,"Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7769276/),%,7.3,260513,DB02377,Guanine
,7769276,maximum serum concentration,"The mean maximum serum concentration achieved at 1000 mg every 8 h was 1.11 micrograms/mL, and mean trough level was 0.54 microgram/mL.","Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7769276/),[μg] / [ml],1.11,260514,DB02377,Guanine
,7769276,trough level,"The mean maximum serum concentration achieved at 1000 mg every 8 h was 1.11 micrograms/mL, and mean trough level was 0.54 microgram/mL.","Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7769276/),[μg] / [ml],0.54,260515,DB02377,Guanine
,7769276,time to maximum serum drug concentration,"The time to maximum serum drug concentration was 1.0-2.9 h, with a serum half-life of 3.0-7.3 h, suggesting prolonged oral absorption.","Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7769276/),h,1.0-2.9,260516,DB02377,Guanine
,7769276,serum half-life,"The time to maximum serum drug concentration was 1.0-2.9 h, with a serum half-life of 3.0-7.3 h, suggesting prolonged oral absorption.","Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7769276/),h,3.0-7.3,260517,DB02377,Guanine
,19430790,T (max),"Temozolomide was rapidly absorbed (mean T (max), 2.1 h).",Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19430790/),h,2.1,261133,DB02377,Guanine
,19430790,apparent clearance (CL/F),The mean apparent clearance (CL/F) (96 mL/min/m(2)) was similar to the CL/F for temozolomide alone and was not age- or gender-dependent.,Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19430790/),[min·ml] / [m(2],96,261134,DB02377,Guanine
,8389067,t1/2 beta,"Pharmacokinetic parameters (mean +/- SD) were the following: t1/2 beta 18.9 +/- 2.2 h, Cl 0.42 +/- 0.08 ml/min/kg, Vdss 0.68 +/- 0.10 L/kg.",Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8389067/),h,18.9,261721,DB02377,Guanine
,8389067,Cl,"Pharmacokinetic parameters (mean +/- SD) were the following: t1/2 beta 18.9 +/- 2.2 h, Cl 0.42 +/- 0.08 ml/min/kg, Vdss 0.68 +/- 0.10 L/kg.",Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8389067/),[ml] / [kg·min],0.42,261722,DB02377,Guanine
,8389067,Vdss,"Pharmacokinetic parameters (mean +/- SD) were the following: t1/2 beta 18.9 +/- 2.2 h, Cl 0.42 +/- 0.08 ml/min/kg, Vdss 0.68 +/- 0.10 L/kg.",Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8389067/),[l] / [kg],0.68,261723,DB02377,Guanine
,8389067,clearance of ultrafiltration,At the steady state the clearance of ultrafiltration was 12.9 +/- 1.9 ml/min (or 130 L/week) and the sieving coefficient was 0.84 +/- 0.08 with an average fraction of 89.7 +/- 10.6% of the administered dose removed by CVVHD.,Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8389067/),[ml] / [min],12.9,261724,DB02377,Guanine
,8389067,sieving coefficient,At the steady state the clearance of ultrafiltration was 12.9 +/- 1.9 ml/min (or 130 L/week) and the sieving coefficient was 0.84 +/- 0.08 with an average fraction of 89.7 +/- 10.6% of the administered dose removed by CVVHD.,Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8389067/),,0.84,261725,DB02377,Guanine
,20799743,half-life,"The half-life of εG was found to be 150 days in the liver and lung and 75 days in the kidney, suggesting little or no active repair of this promutagenic adduct.","Development and application of an LC-MS/MS method for the detection of the vinyl chloride-induced DNA adduct N(2),3-ethenoguanine in tissues of adult and weanling rats following exposure to [(13)C(2)]-VC. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20799743/),d,150,261975,DB02377,Guanine
,20799743,half-life,"The half-life of εG was found to be 150 days in the liver and lung and 75 days in the kidney, suggesting little or no active repair of this promutagenic adduct.","Development and application of an LC-MS/MS method for the detection of the vinyl chloride-induced DNA adduct N(2),3-ethenoguanine in tissues of adult and weanling rats following exposure to [(13)C(2)]-VC. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20799743/),d,75,261976,DB02377,Guanine
,9701387,bioavailability,Oral ganciclovir is effective in preventing cytomegalovirus (CMV) disease in HIV-infected patients despite a bioavailability of only 6-9%.,"A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701387/),%,6-9,262338,DB02377,Guanine
,9701387,absolute bioavailability,The absolute bioavailability was similar in patients with or without acute GI-GVHD (7.2 vs. 6.9%).,"A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701387/),%,7.2,262339,DB02377,Guanine
,9701387,absolute bioavailability,The absolute bioavailability was similar in patients with or without acute GI-GVHD (7.2 vs. 6.9%).,"A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701387/),%,6.9,262340,DB02377,Guanine
,9701387,area under the curve [AUC],"At steady state, the extent and rate of absorption of oral ganciclovir were comparable in these same patient subgroups (area under the curve [AUC] = 13.5 and 10.2 mg x hours/L, respectively; time to peak serum ganciclovir concentrations = 5.5 and 3.8 hours, respectively).","A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701387/),[h·mg] / [l],13.5,262341,DB02377,Guanine
,9701387,area under the curve [AUC],"At steady state, the extent and rate of absorption of oral ganciclovir were comparable in these same patient subgroups (area under the curve [AUC] = 13.5 and 10.2 mg x hours/L, respectively; time to peak serum ganciclovir concentrations = 5.5 and 3.8 hours, respectively).","A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701387/),[h·mg] / [l],10.2,262342,DB02377,Guanine
,9701387,time to peak serum ganciclovir concentrations,"At steady state, the extent and rate of absorption of oral ganciclovir were comparable in these same patient subgroups (area under the curve [AUC] = 13.5 and 10.2 mg x hours/L, respectively; time to peak serum ganciclovir concentrations = 5.5 and 3.8 hours, respectively).","A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701387/),h,5.5,262343,DB02377,Guanine
,9701387,time to peak serum ganciclovir concentrations,"At steady state, the extent and rate of absorption of oral ganciclovir were comparable in these same patient subgroups (area under the curve [AUC] = 13.5 and 10.2 mg x hours/L, respectively; time to peak serum ganciclovir concentrations = 5.5 and 3.8 hours, respectively).","A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701387/),h,3.8,262344,DB02377,Guanine
,9428565,half-life of elimination phase,The pharmacokinetic parameters were as follows: half-life of elimination phase 12.6 hrs; total clearance 0.55 mL/min/kg; and volume distribution of steady state 27.07 L.,Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428565/),h,12.6,263102,DB02377,Guanine
,9428565,total clearance,The pharmacokinetic parameters were as follows: half-life of elimination phase 12.6 hrs; total clearance 0.55 mL/min/kg; and volume distribution of steady state 27.07 L.,Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428565/),[ml] / [kg·min],0.55,263103,DB02377,Guanine
,9428565,volume distribution of steady state,The pharmacokinetic parameters were as follows: half-life of elimination phase 12.6 hrs; total clearance 0.55 mL/min/kg; and volume distribution of steady state 27.07 L.,Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428565/),l,27.07,263104,DB02377,Guanine
,9428565,clearance of hemodiafiltration,The clearance of hemodiafiltration was 0.63 mL/min/kg.,Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428565/),[ml] / [kg·min],0.63,263105,DB02377,Guanine
,17264335,steady-state levels,"For up to 14 days, steady-state levels of O6-BG were 0.1 to 0.4 micromol/L, and levels for O6-benzyl-8-oxoguanine were 0.7 to 1.3 micromol/L.",Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17264335/),[μM] / [l],0.1 to 0.4,263465,DB02377,Guanine
,17264335,steady-state levels,"For up to 14 days, steady-state levels of O6-BG were 0.1 to 0.4 micromol/L, and levels for O6-benzyl-8-oxoguanine were 0.7 to 1.3 micromol/L.",Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17264335/),[μM] / [l],0.7 to 1.3,263466,DB02377,Guanine
,32907793,Cmax,"The mean VGCV Cmax was 3.5 μg/mL (range 2-5.3), with no significant variation among individual values, and the values were maintained during treatment.","Efficacy, safety, and pharmacokinetics of oral valganciclovir in patients with congenital cytomegalovirus infection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32907793/),[μg] / [ml],3.5,263483,DB02377,Guanine
,12878501,maximum concentration,"The maximum concentration of acyclovir in serum was reached after 1 to 3 h (mean +/- standard deviation [SD], 27.1 +/- 5.6 micro M), and the minimum concentration in serum was 3.1 +/- 1.1 micro M (mean +/- SD).",Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878501/),μM,27.1,264519,DB02377,Guanine
,12878501,minimum concentration,"The maximum concentration of acyclovir in serum was reached after 1 to 3 h (mean +/- standard deviation [SD], 27.1 +/- 5.6 micro M), and the minimum concentration in serum was 3.1 +/- 1.1 micro M (mean +/- SD).",Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878501/),μM,3.1,264520,DB02377,Guanine
,21076372,apparent clearance,"The final population parameter estimates (95% confidence interval) were as follows: apparent clearance of ganciclovir, 12 L/hr (11.3-12.7 L/hr); volume of distribution, 18.5 L (14.4-22.6 L); and peripheral volume, 44.4 L (40.2-48.6 L).",Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21076372/),[l] / [h],12,264615,DB02377,Guanine
,21076372,volume of distribution,"The final population parameter estimates (95% confidence interval) were as follows: apparent clearance of ganciclovir, 12 L/hr (11.3-12.7 L/hr); volume of distribution, 18.5 L (14.4-22.6 L); and peripheral volume, 44.4 L (40.2-48.6 L).",Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21076372/),l,18.5,264616,DB02377,Guanine
,21076372,peripheral volume,"The final population parameter estimates (95% confidence interval) were as follows: apparent clearance of ganciclovir, 12 L/hr (11.3-12.7 L/hr); volume of distribution, 18.5 L (14.4-22.6 L); and peripheral volume, 44.4 L (40.2-48.6 L).",Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21076372/),l,44.4,264617,DB02377,Guanine
,21076372,area under the concentration time curve,"The pharmacokinetics of ganciclovir were similar between the two dosing groups (100 vs. 200 days), with the majority of patients achieving an area under the concentration time curve in the target therapeutic range (40-60 μg hr/mL).",Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21076372/),[h·μg] / [ml],40-60,264618,DB02377,Guanine
,22339892,Maximum tear famciclovir concentration,Maximum tear famciclovir concentration of 0.305 μg/mL occurred at 2.64 h; elimination half-life was 2.28 h.,Pharmacokinetics of famciclovir and penciclovir in tears following oral administration of famciclovir to cats: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339892/),[μg] / [ml],0.305,265145,DB02377,Guanine
,22339892,elimination half-life,Maximum tear famciclovir concentration of 0.305 μg/mL occurred at 2.64 h; elimination half-life was 2.28 h.,Pharmacokinetics of famciclovir and penciclovir in tears following oral administration of famciclovir to cats: a pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339892/),h,2.28,265146,DB02377,Guanine
,22339892,Maximum tear penciclovir concentration,Maximum tear penciclovir concentration (0.981 μg/mL) occurred 2.25 h following oral administration of famciclovir; elimination half-life was 2.77 h.,Pharmacokinetics of famciclovir and penciclovir in tears following oral administration of famciclovir to cats: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339892/),[μg] / [ml],0.981,265147,DB02377,Guanine
,22339892,elimination half-life,Maximum tear penciclovir concentration (0.981 μg/mL) occurred 2.25 h following oral administration of famciclovir; elimination half-life was 2.77 h.,Pharmacokinetics of famciclovir and penciclovir in tears following oral administration of famciclovir to cats: a pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339892/),h,2.77,265148,DB02377,Guanine
,2847287,distribution half-life (t1/2),"In patients with normal renal function, a biexponential decay of ganciclovir from plasma was observed, with an initial distribution half-life (t1/2) of 0.76 +/- 0.67 hour and a terminal elimination t1/2 of 3.60 +/- 1.40 hours.",Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847287/),h,0.76,265224,DB02377,Guanine
,2847287,terminal elimination t1/2,"In patients with normal renal function, a biexponential decay of ganciclovir from plasma was observed, with an initial distribution half-life (t1/2) of 0.76 +/- 0.67 hour and a terminal elimination t1/2 of 3.60 +/- 1.40 hours.",Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847287/),h,3.60,265225,DB02377,Guanine
,2847287,terminal elimination t1/2,"In patients with renal insufficiency who were receiving 5 mg of ganciclovir/kg, the terminal elimination t1/2 of ganciclovir was markedly increased (11.50 +/- 3.90 hours), as compared with values obtained in patients with normal renal function.",Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847287/),h,11.50,265226,DB02377,Guanine
,11935212,total body clearance,"The total body clearance of SPI-77 varied from 14 to 30 ml/h and was significantly lower than reported clearance values for cisplatin of 20 l/m(2) per h, due to the slow release of cisplatin from the liposomes.","Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11935212/),[ml] / [h],14 to 30,265897,DB02377,Guanine
,11935212,clearance,"The total body clearance of SPI-77 varied from 14 to 30 ml/h and was significantly lower than reported clearance values for cisplatin of 20 l/m(2) per h, due to the slow release of cisplatin from the liposomes.","Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11935212/),[l] / [h·m(2)],20,265898,DB02377,Guanine
,15161693,Plasma clearance,"Plasma clearance of total Pt was 644 +/- 266 ml/h, and the terminal half-life was 116 +/- 46.2 h.",A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15161693/),[ml] / [h],644,266451,DB02377,Guanine
,15161693,terminal half-life,"Plasma clearance of total Pt was 644 +/- 266 ml/h, and the terminal half-life was 116 +/- 46.2 h.",A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15161693/),h,116,266452,DB02377,Guanine
,25037863,MTD,MTD of afatinib was 30 mg in SA and 50 mg in SB.,"A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25037863/),mg,30,266933,DB02377,Guanine
,25037863,MTD,MTD of afatinib was 30 mg in SA and 50 mg in SB.,"A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25037863/),mg,50,266934,DB02377,Guanine
,11483684,specific activity,"[(18)F]FHBG was synthesized with a specific activity of 37,000--444,000 GBq/mmol and a radiochemical purity > 99%.",Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11483684/),[gbq] / [mM],"37,000--444,000",266998,DB02377,Guanine
,7102703,peak acyclovir plasma level,"At the end of a one-hour intravenous infusion (2.5 mg/kg), the mean peak acyclovir plasma level (+/- SD), determined by radioimmunoassay, was 37.5 +/- 24.2 microM (8.4 +/- 5.4 microgram/ml), twice the level found at this dose in patients with normal renal function (NRF).",Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102703/),μM,37.5,267023,DB02377,Guanine
,7102703,peak acyclovir plasma level,"At the end of a one-hour intravenous infusion (2.5 mg/kg), the mean peak acyclovir plasma level (+/- SD), determined by radioimmunoassay, was 37.5 +/- 24.2 microM (8.4 +/- 5.4 microgram/ml), twice the level found at this dose in patients with normal renal function (NRF).",Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102703/),[μg] / [ml],8.4,267024,DB02377,Guanine
,7102703,plasma t 1/2,"The mean plasma t 1/2 during dialysis of 5.4 hours, the extraction ratio of 0.44, and the dialysis clearance for plasma of 113 ml/min indicate that acyclovir is efficiently removed by hemodialysis.",Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102703/),h,5.4,267025,DB02377,Guanine
,7102703,extraction ratio,"The mean plasma t 1/2 during dialysis of 5.4 hours, the extraction ratio of 0.44, and the dialysis clearance for plasma of 113 ml/min indicate that acyclovir is efficiently removed by hemodialysis.",Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102703/),,0.44,267026,DB02377,Guanine
,7102703,clearance for,"The mean plasma t 1/2 during dialysis of 5.4 hours, the extraction ratio of 0.44, and the dialysis clearance for plasma of 113 ml/min indicate that acyclovir is efficiently removed by hemodialysis.",Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102703/),[ml] / [min],113,267027,DB02377,Guanine
less,9408695,Cmin,Doses of oral GAN were increased if Cmin levels were less than 0.5-1.0 microgram/ml.,Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408695/),[μg] / [ml],0.5-1.0,267685,DB02377,Guanine
,29237296,maximal concentration,"Using 60mg as an example, the maximal concentration of LB80331 in plasma is 397 ng/mL.",Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237296/),[ng] / [ml],397,267747,DB02377,Guanine
,29237296,time required to reach maximal concentration,"The time required to reach maximal concentration in plasma and elimination half-life are 2.0 and 3.0 h, respectively.",Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237296/),h,2.0,267748,DB02377,Guanine
,29237296,time required to reach maximal concentration,"The time required to reach maximal concentration in plasma and elimination half-life are 2.0 and 3.0 h, respectively.",Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237296/),h,3.0,267749,DB02377,Guanine
,29237296,elimination half-life,"The time required to reach maximal concentration in plasma and elimination half-life are 2.0 and 3.0 h, respectively.",Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237296/),h,2.0,267750,DB02377,Guanine
,29237296,elimination half-life,"The time required to reach maximal concentration in plasma and elimination half-life are 2.0 and 3.0 h, respectively.",Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237296/),h,3.0,267751,DB02377,Guanine
,10100598,Peak plasma ganciclovir concentrations,Peak plasma ganciclovir concentrations ranged from 18.3 to 20.0 microg/ml and the mean plasma AUC was 1075+/-202 microg/ml x min.,Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100598/),[μg] / [ml],18.3 to 20.0,269005,DB02377,Guanine
,10100598,plasma AUC,Peak plasma ganciclovir concentrations ranged from 18.3 to 20.0 microg/ml and the mean plasma AUC was 1075+/-202 microg/ml x min.,Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100598/),[μg] / [min·ml],1075,269006,DB02377,Guanine
,10100598,distribution half-life (t(1/2)alpha),Disappearance of ganciclovir from the plasma was biexponential with a distribution half-life (t(1/2)alpha) of 18+/-7 min and an elimination half-life (t(1/2)beta) of 109+/-7 min.,Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100598/),min,18,269007,DB02377,Guanine
,10100598,elimination half-life (t(1/2)beta),Disappearance of ganciclovir from the plasma was biexponential with a distribution half-life (t(1/2)alpha) of 18+/-7 min and an elimination half-life (t(1/2)beta) of 109+/-7 min.,Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100598/),min,109,269008,DB02377,Guanine
,10100598,Total body clearance (ClTB),Total body clearance (ClTB) was 9.4+/-1.6 ml/min/kg.,Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100598/),[ml] / [kg·min],9.4,269009,DB02377,Guanine
,10100598,AUC,The mean CSF ganciclovir AUC was 168+/-83 microg/ml x min and the mean peak CSF concentration was 0.7+/-0.3 microg/ml.,Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100598/),[μg] / [min·ml],168,269010,DB02377,Guanine
,10100598,peak CSF concentration,The mean CSF ganciclovir AUC was 168+/-83 microg/ml x min and the mean peak CSF concentration was 0.7+/-0.3 microg/ml.,Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100598/),[μg] / [ml],0.7,269011,DB02377,Guanine
,18083075,m/z,"The tandem mass spectrometer was tuned in the multiple reaction monitoring mode to monitor the m/z 278.1-->234.9 and the m/z 288.1-->133.1 transitions for CDV and the internal standard 9-(2-phosphonylmethoxyethyl)guanine (PMEG), respectively, using negative electrospray ionization.",Quantification of cidofovir in human serum by LC-MS/MS for children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18083075/),,278.1,269172,DB02377,Guanine
,18083075,m/z,"The tandem mass spectrometer was tuned in the multiple reaction monitoring mode to monitor the m/z 278.1-->234.9 and the m/z 288.1-->133.1 transitions for CDV and the internal standard 9-(2-phosphonylmethoxyethyl)guanine (PMEG), respectively, using negative electrospray ionization.",Quantification of cidofovir in human serum by LC-MS/MS for children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18083075/),,234.9,269173,DB02377,Guanine
,18083075,m/z,"The tandem mass spectrometer was tuned in the multiple reaction monitoring mode to monitor the m/z 278.1-->234.9 and the m/z 288.1-->133.1 transitions for CDV and the internal standard 9-(2-phosphonylmethoxyethyl)guanine (PMEG), respectively, using negative electrospray ionization.",Quantification of cidofovir in human serum by LC-MS/MS for children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18083075/),,288.1,269174,DB02377,Guanine
,18083075,m/z,"The tandem mass spectrometer was tuned in the multiple reaction monitoring mode to monitor the m/z 278.1-->234.9 and the m/z 288.1-->133.1 transitions for CDV and the internal standard 9-(2-phosphonylmethoxyethyl)guanine (PMEG), respectively, using negative electrospray ionization.",Quantification of cidofovir in human serum by LC-MS/MS for children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18083075/),,133.1,269175,DB02377,Guanine
,2066845,t 1/2 beta,"The average t 1/2 beta for infants with serum creatinine level less than 1 mg/dl (88 mumol/L) was 5.0 hours, and 15.6 hours for those with serum creatinine level greater than 1 mg/dl.",Acyclovir therapy in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2066845/),h,5.0,269655,DB02377,Guanine
,2066845,t 1/2 beta,"The average t 1/2 beta for infants with serum creatinine level less than 1 mg/dl (88 mumol/L) was 5.0 hours, and 15.6 hours for those with serum creatinine level greater than 1 mg/dl.",Acyclovir therapy in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2066845/),h,15.6,269656,DB02377,Guanine
,11021740,distribution,"The pharmacokinetics of pemetrexed disodium were best characterized by a two-compartment model with initial distribution and terminal elimination half-lives of 0.63 h and 2.73 h, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),h,0.63,269925,DB02377,Guanine
,11021740,terminal elimination half-lives,"The pharmacokinetics of pemetrexed disodium were best characterized by a two-compartment model with initial distribution and terminal elimination half-lives of 0.63 h and 2.73 h, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),h,2.73,269926,DB02377,Guanine
,11021740,central volume (V(c)),"Typical values of central volume (V(c)), distributional CL (Q), and peripheral volume (V(p)) were 11.3 1, 3.21 l/h, and 5.20 l, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),1,11.3,269927,DB02377,Guanine
,11021740,distributional CL (Q),"Typical values of central volume (V(c)), distributional CL (Q), and peripheral volume (V(p)) were 11.3 1, 3.21 l/h, and 5.20 l, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),[l] / [h],3.21,269928,DB02377,Guanine
,11021740,peripheral volume (V(p)),"Typical values of central volume (V(c)), distributional CL (Q), and peripheral volume (V(p)) were 11.3 1, 3.21 l/h, and 5.20 l, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),l,5.20,269929,DB02377,Guanine
,10747829,peak concentration (C(max)),"Mean peak concentration (C(max)) was 4.8 mg/L (0. 96-12.8), mean minimum concentration (C(min)) was 3.6 mg/L (0.78-11. 7) and mean area under the curve (AUC) was 35.4 mg.8 h/L (8-99).",Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10747829/),[mg] / [l],4.8,270446,DB02377,Guanine
,10747829,minimum concentration (C(min)),"Mean peak concentration (C(max)) was 4.8 mg/L (0. 96-12.8), mean minimum concentration (C(min)) was 3.6 mg/L (0.78-11. 7) and mean area under the curve (AUC) was 35.4 mg.8 h/L (8-99).",Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10747829/),[mg] / [l],3.6,270447,DB02377,Guanine
,10747829,area under the curve (AUC),"Mean peak concentration (C(max)) was 4.8 mg/L (0. 96-12.8), mean minimum concentration (C(min)) was 3.6 mg/L (0.78-11. 7) and mean area under the curve (AUC) was 35.4 mg.8 h/L (8-99).",Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10747829/),[8·h·mg] / [l],35.4,270448,DB02377,Guanine
,21300929,PFS,"Median PFS in the ABT-751 arm was 2.3 months versus 1.9 for placebo (P = .819, log-rank) for the intention-to-treat population.",Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21300929/),month,2.3,270565,DB02377,Guanine
,21300929,PFS,"Median PFS in the ABT-751 arm was 2.3 months versus 1.9 for placebo (P = .819, log-rank) for the intention-to-treat population.",Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21300929/),,1.9,270566,DB02377,Guanine
,21107572,initial,"The distribution/elimination of pemetrexed in CSF was best described by a two-compartment model, with initial and terminal half-lives of 0.43 and 1.43 h, respectively.",Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107572/),h,0.43,271252,DB02377,Guanine
,21107572,terminal half-lives,"The distribution/elimination of pemetrexed in CSF was best described by a two-compartment model, with initial and terminal half-lives of 0.43 and 1.43 h, respectively.",Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107572/),h,1.43,271253,DB02377,Guanine
,21107572,maximal concentration,"The predicted maximal concentration in CSF was 588 μM, and high levels of pemetrexed appeared to be maintained for a long time.",Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107572/),μM,588,271254,DB02377,Guanine
,21107572,Area under the curve,"Area under the curve and volume of distribution at steady state were 560 μM h and 1.14 ml, respectively.",Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107572/),h·μM,560,271255,DB02377,Guanine
,21107572,volume of distribution at steady state,"Area under the curve and volume of distribution at steady state were 560 μM h and 1.14 ml, respectively.",Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107572/),ml,1.14,271256,DB02377,Guanine
,8728343,rate constant from the central to the peripheral compartment,"Mean pharmacokinetic parameters obtained included rate constant from the central to the peripheral compartment (KCP,3.1 hr-1), rate constant from the peripheral to the central compartment (KPC, 0.824 hr-1), slope of the volume of distribution to body weight (VS, 0.246 L/kg), and slope of clearance to creatinine clearance (Cl(cr)) and body weight (CLS,0.222L/hr/kg/100 mL/ min Cl(cr).",Nonparametric expectation maximization population modeling of ganciclovir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728343/),1/[h],3.1,271347,DB02377,Guanine
,8728343,rate constant from the peripheral to the central compartment (,"Mean pharmacokinetic parameters obtained included rate constant from the central to the peripheral compartment (KCP,3.1 hr-1), rate constant from the peripheral to the central compartment (KPC, 0.824 hr-1), slope of the volume of distribution to body weight (VS, 0.246 L/kg), and slope of clearance to creatinine clearance (Cl(cr)) and body weight (CLS,0.222L/hr/kg/100 mL/ min Cl(cr).",Nonparametric expectation maximization population modeling of ganciclovir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728343/),1/[h],0.824,271348,DB02377,Guanine
,8728343,volume of distribution,"Mean pharmacokinetic parameters obtained included rate constant from the central to the peripheral compartment (KCP,3.1 hr-1), rate constant from the peripheral to the central compartment (KPC, 0.824 hr-1), slope of the volume of distribution to body weight (VS, 0.246 L/kg), and slope of clearance to creatinine clearance (Cl(cr)) and body weight (CLS,0.222L/hr/kg/100 mL/ min Cl(cr).",Nonparametric expectation maximization population modeling of ganciclovir. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728343/),[l] / [kg],0.246,271349,DB02377,Guanine
,8728343,clearance,Use of NPEM2 led to identification of a subset of patients with CMV retinitis who had a more rapid clearance of ganciclovir of 0.51 to 0.54 L/hr/kg/100 mL/min Cl(cr).,Nonparametric expectation maximization population modeling of ganciclovir. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728343/),[100·h·kg·l·min·ml] / [cl(cr],0.51 to 0.54,271350,DB02377,Guanine
,11422015,CL/F,"For groups A and B combined, final parameter estimates of CL/F and V1/F were 256 +/- 98 l h(-1) and 1320 +/- 470 l, respectively.",Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422015/),[l] / [h],256,272364,DB02377,Guanine
,11422015,V1/F,"For groups A and B combined, final parameter estimates of CL/F and V1/F were 256 +/- 98 l h(-1) and 1320 +/- 470 l, respectively.",Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422015/),l,1320,272365,DB02377,Guanine
,11422015,CL/F,"Final parameter estimates for group C were 118 +/- 108 l h(-1) and 652 +/- 573 l for CL/F and V1/F, respectively.",Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422015/),[l] / [h],118,272366,DB02377,Guanine
,11422015,CL/F,"Final parameter estimates for group C were 118 +/- 108 l h(-1) and 652 +/- 573 l for CL/F and V1/F, respectively.",Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422015/),l,652,272367,DB02377,Guanine
,11422015,V1/F,"Final parameter estimates for group C were 118 +/- 108 l h(-1) and 652 +/- 573 l for CL/F and V1/F, respectively.",Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422015/),l,652,272368,DB02377,Guanine
,7957522,urinary recovery,"Similarly, mean urinary recovery and renal clearance values of penciclovir following famciclovir alone were 56.8% and 27 l.h-1, and when given with allopurinol 59.7% and 27.5 l.h-1, respectively.",Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957522/),%,56.8,272757,DB02377,Guanine
,7957522,urinary recovery,"Similarly, mean urinary recovery and renal clearance values of penciclovir following famciclovir alone were 56.8% and 27 l.h-1, and when given with allopurinol 59.7% and 27.5 l.h-1, respectively.",Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957522/),%,59.7,272758,DB02377,Guanine
,7957522,renal clearance,"Similarly, mean urinary recovery and renal clearance values of penciclovir following famciclovir alone were 56.8% and 27 l.h-1, and when given with allopurinol 59.7% and 27.5 l.h-1, respectively.",Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957522/),[l] / [h],27,272759,DB02377,Guanine
,7957522,renal clearance,"Similarly, mean urinary recovery and renal clearance values of penciclovir following famciclovir alone were 56.8% and 27 l.h-1, and when given with allopurinol 59.7% and 27.5 l.h-1, respectively.",Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957522/),[l] / [h],27.5,272760,DB02377,Guanine
,7957522,Cmax,"Mean Cmax and AUC values of the active metabolite of allopurinol, oxypurinol were 11.2 micrograms.",Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957522/),μg,11.2,272761,DB02377,Guanine
,23313623,Km,"Km and Vmax values of entecavir were 250 μM and 0.83 nmol/mg protein/30s (OAT1) and 23 μM and 1.1 nmol/mg protein/30 s (OAT3), respectively.",OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23313623/),μM,250,273349,DB02377,Guanine
,23313623,Km,"Km and Vmax values of entecavir were 250 μM and 0.83 nmol/mg protein/30s (OAT1) and 23 μM and 1.1 nmol/mg protein/30 s (OAT3), respectively.",OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23313623/),[nM] / [·30s·mg],0.83,273350,DB02377,Guanine
,23313623,Km,"Km and Vmax values of entecavir were 250 μM and 0.83 nmol/mg protein/30s (OAT1) and 23 μM and 1.1 nmol/mg protein/30 s (OAT3), respectively.",OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23313623/),μM,23,273351,DB02377,Guanine
,23313623,Vmax,"Km and Vmax values of entecavir were 250 μM and 0.83 nmol/mg protein/30s (OAT1) and 23 μM and 1.1 nmol/mg protein/30 s (OAT3), respectively.",OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23313623/),[nM] / [·30s·mg],0.83,273352,DB02377,Guanine
,23313623,Vmax,"Km and Vmax values of entecavir were 250 μM and 0.83 nmol/mg protein/30s (OAT1) and 23 μM and 1.1 nmol/mg protein/30 s (OAT3), respectively.",OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23313623/),[nM] / [·30·mg·s],1.1,273353,DB02377,Guanine
,28499946,zeta potential,LDC nanoparticles was found to have particle size 121.9±1.85nm and zeta potential -51.6mV±1.23 and entrapment efficiency 81.0±0.89%.,"Lipid drug conjugate nanoparticle as a potential nanocarrier for the oral delivery of pemetrexed diacid: Formulation design, characterization, ex vivo, and in vivo assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499946/),mv,51.6,273506,DB02377,Guanine
,28499946,entrapment efficiency,LDC nanoparticles was found to have particle size 121.9±1.85nm and zeta potential -51.6mV±1.23 and entrapment efficiency 81.0±0.89%.,"Lipid drug conjugate nanoparticle as a potential nanocarrier for the oral delivery of pemetrexed diacid: Formulation design, characterization, ex vivo, and in vivo assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28499946/),%,81.0,273507,DB02377,Guanine
